Document

0000891293-18-000043.txt : 20180307 0000891293-18-000043.hdr.sgml : 20180307 20180307172718 ACCESSION NUMBER: 0000891293-18-000043 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180307 DATE AS OF CHANGE: 20180307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 18674241 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 10-K 1 cti10k12312017document.htm 10-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)



x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-12465

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)



Washington		91-1533912
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)
3101 Western Avenue, Suite 800 Seattle, WA		98121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (206) 282-7100

Securities registered pursuant to Section 12(b) of the Act:



Title of each class		Name of each exchange on which registered
Common Stock, no par value		The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:

Preferred Stock Purchase Rights

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer ¨		Accelerated filer x

Non-accelerated filer ¨ (Do not check if a smaller reporting company)		Smaller reporting company ¨

		Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No ý

As of June 30, 2017, the aggregate market value of the registrant’s common equity held by non-affiliates was $88,062,209. Shares of common stock held by each executive officer and director and by each person known to the registrant who beneficially owns more than 5% of the outstanding shares of the registrant’s common stock have been excluded in that such persons may under certain circumstances be deemed to be affiliates. This determination of executive officer or affiliate status is not necessarily a conclusive determination for other purposes. The registrant has no non-voting common stock outstanding.

The number of outstanding shares of the registrant’s common stock as of February 28, 2018 was 57,982,860.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement relating to its 2018 annual meeting of shareholders, or the 2018 Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2018 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

CTI BIOPHARMA CORP.

TABLE OF CONTENTS



		Page
PART I
ITEM 1.	BUSINESS	3
ITEM 1A.	RISK FACTORS	25
ITEM 1B.	UNRESOLVED STAFF COMMENTS	43
ITEM 2.	PROPERTIES	43
ITEM 3.	LEGAL PROCEEDINGS	43
ITEM 4.	MINE SAFETY DISCLOSURES	45
PART II
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	46
ITEM 6.	SELECTED FINANCIAL DATA	48
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	50
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	60
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	62
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	102
ITEM 9A.	CONTROLS AND PROCEDURES	102
ITEM 9B.	OTHER INFORMATION	103
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	104
ITEM 11.	EXECUTIVE COMPENSATION	104
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS	104
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	104
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	104
PART IV
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	105
ITEM 16.	FORM 10-K SUMMARY	114
SIGNATURES		114
CERTIFICATIONS

Forward Looking Statements

This Annual Report on Form 10-K and the documents we incorporate by reference herein or therein may contain “forward-looking statements” within the meaning of the United States, or the U.S., federal securities laws. All statements other than statements of historical fact are forward-looking statements, including, without limitation:


•	any statements regarding future operations, plans, expectations, intentions, regulatory filings or approvals;


•	any statements regarding the performance, or likely performance, outcomes or economic benefit of any licensing collaboration or other arrangement;


•	any projections of revenues, operating expenses or other financial terms, and any projections of cash resources, including regarding our potential receipt of future milestone payments under any of our agreements with third parties and expected sales of PIXUVRI;


•	any statements of the plans and objectives of management for future operations or programs;


•	any statements concerning proposed new products;


•	any statements regarding the safety and efficacy or future availability of any of our compounds;


•	any statements regarding our ability to interpret clinical trial data and results or expectations with respect to the potential therapeutic utility of pacritinib and the prevalence of myelofibrosis in the U.S.;


•	any statements on plans regarding proposed or potential clinical trials or new drug filing strategies, timelines or submissions, including expectations with respect to the timing and planned enrollment of PAC203, the timing of PIX306 top-line results, and submission of responses to Day 120 list of questions;


•	any statements regarding the Company’s intent to continue efforts to commercialize PIXUVRI in Europe in partnership with Servier and expand the market potential for PIXUVRI;


•	any statement regarding the Company’s intent to develop and commercialize pacritinib for adult patients with myelofibrosis and potentially additional inactions.


•	any statements regarding the Company’s plans to continue advancing the development of its pipeline candidates through strategic product collaborations or cooperative group and investigator-sponsored trials, as well as the identification and acquisition of additional pipeline opportunities;


•	any significant disruptions in our information technology systems;


•	any statements regarding compliance with the listing standards of the NASDAQ Stock Market;


•	any statements regarding potential future partnerships, licensing arrangements, mergers, acquisitions or other transactions;


•	any statements regarding future economic conditions or performance; and


•	any statements of assumption underlying any of the foregoing.

In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should” or “will” or the negative thereof, variations thereof and similar expressions. Such statements are based on management’s current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from those set forth in the forward-looking statements. In particular, this Annual Report on Form 10-K addresses top-line results regarding data from PERSIST-2, our Phase 3 trial of pacritinib for the treatment of patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter. Meaningful interpretation of PERSIST-2 may not be possible because the pre-specified minimum evaluable patient goal was not met. The statements are based on assumptions about many important factors and information currently available to us to the extent we have thus far had an opportunity to fully and carefully evaluate such information in light of all surrounding facts, circumstances, recommendations and analyses. There can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. We urge you to carefully review the disclosures we make concerning risks and other factors that may affect our business and operating results, including those made under Part I, Item 1, “Business,” Part I, Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Annual Report on Form 10-K and any risk factors contained in subsequent Quarterly Reports on Form 10-Q that we file with the U.S. Securities and Exchange Commission, or the SEC.

We do not intend to update any of the forward-looking statements after the date of this Annual Report on Form 10-K to conform these statements to actual results or changes in our expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this Annual Report on Form 10-K.

In this Annual Report on Form 10-K, all references to “we,” “us,” “our,” the “Company” and “CTI” mean CTI BioPharma Corp. and our subsidiaries, except where it is otherwise made clear.

PART I

Item 1. Business

Overview

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partner, Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, has commercialization rights outside the United States, or the U.S.

PIXUVRI

the first half of 2018. Although we do not have and are not currently pursuing regulatory approval of PIXUVRI in the U.S., we may reevaluate a possible submission strategy in the U.S. based on the data generated from the PIX306 study. Pursuant to our conditional marketing authorization in the E.U., and an extension granted in September 2016, we are required to submit the requisite clinical study report for PIX306 by December 2018.

In April 2017, we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier. Under the Restated Agreement, Servier will have rights to PIXUVRI in all markets except in the U.S. where we will retain the commercialization rights. Previously, Servier had rights to commercialize the drug globally except in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom, or the U.K., and the U.S. Servier paid us €12.0 million in May 2017 and purchased PIXUVRI drug product for an additional €0.9 million in July 2017. In September 2017, we attained a regulatory milestone under the Restated Agreement and recognized a €1.0 million milestone revenue.We are eligible to receive up to €75.0 million in additional sales and regulatory milestone payments as well as royalties on net product sales.

For additional information on our collaboration with Servier, please see the discussion in “License Agreements and Additional Milestone Activities - Servier” below.

Pacritinib

Our lead development candidate, pacritinib, is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia, or AML, myelodysplastic syndrome, or MDS, chronic myelomonocytic leukemia, or CMML, and chronic lymphocytic leukemia, or CLL, due to its inhibition of c-fms, IRAK1, JAK2 and FLT3. We believe pacritinib has the potential to be delivered as a single agent or in combination therapy regimens.

thrombocytopenia on other JAK2 inhibitor therapy; or patients who are intolerant of or whose symptoms are not well controlled (sub-optimally managed) on other JAK2 therapy.

In May 2015, we announced the final results from PERSIST-1, our Phase 3 trial evaluating the efficacy and safety of pacritinib compared to the Best Available Therapy, or BAT, excluding JAK2 inhibitors, which included a broad range of currently utilized treatments, in 327 patients with myelofibrosis regardless of the patients' platelet counts. The study included patients with severe or life-threatening thrombocytopenia. Patients were randomized to receive 400 mg pacritinib once daily or BAT, excluding JAK2 inhibitors. The trial met its primary endpoint of spleen volume reduction, or SVR, (35 percent or greater from baseline to Week 24 by magnetic resonance imaging, or MRI, or computerized tomography, or CT). The most common treatment-emergent adverse events, or AEs, occurring in 20 percent or more of patients treated with pacritinib within 24 weeks, of any grade, were gastrointestinal (generally manageable diarrhea and nausea) and anemia.

In February 2015, we received a recommendation from the Independent Data Monitoring Committee, or IDMC, in place at the time to terminate the PERSIST-1 trial and hold enrollment of new patients in the PERSIST-2 trial. The IDMC’s recommendation was based on non-statistically significant safety concerns, including mortality, in patients on pacritinib, particularly those who crossover after 24 weeks, which crossover potentially confounds evaluation of survival. The IDMC agreed that the recommendation would be only preliminary until we were unblinded to and could review the primary and secondary endpoint data as well as safety results from the PERSIST-1 trial. The IDMC recommendation was reviewed with the PERSIST Steering Committee, comprised of external experts and the study’s principal investigators. who disagreed with the IDMC’s recommendation and expressed the view that the studies should continue as planned. We also asked an independent clinician and a statistician experienced in oversight of clinical trial safety to evaluate the safety profile of pacritinib in the PERSIST-1 trial. Neither was told of the recommendation reached by either the IDMC or the Steering Committee. Both experts agreed with the Steering Committee that the studies could continue. The firm that assembled the IDMC hired a second external independent statistician to review the IDMC’s analyses and recommendation, who also disagreed with the IDMC recommendation and concurred with the other independent experts that the studies need not be terminated nor enrollment held. In June 2015, the IDMC made its recommendation final and we provided to the FDA the information reviewed by the IDMC, the IDMC’s meeting minutes, and the written opinion of the Steering Committee co-chairs, the independent experts, and the second independent statistician. In July 2015, we requested a meeting with the FDA to confirm if we should continue the studies. The FDA assigned the request to a type C meeting. In its written response, the FDA did not mandate any modifications to the studies or place pacritinib on clinical hold at that time, but indicated that it had not yet reviewed the data and noted the difficulty in attempting to draw meaningful conclusions from non-significant results, and that the crossover designs may confound the analysis of survival. We determined that no modifications to the ongoing trials were required. Because we had concerns about the original IDMC’s impartiality, we decided to discharge it, and retained a new IDMC through an independent firm specializing in IDMCs. The newly constituted IDMC met on several occasions and its recommendation was to continue PERSIST-2 as planned.

In December 2015, we submitted the new drug application, or NDA, to the FDA for pacritinib with an indication statement based on the PERSIST-1 trial data.

In February 2016, clinical studies under the investigational new drug, or IND, for pacritinib were placed on a full clinical hold issued by the FDA. A full clinical hold is a suspension of the clinical work requested under the IND application. Under the full clinical hold, all patients on pacritinib at the time were required to discontinue pacritinib immediately and no patients could be enrolled or start pacritinib as initial or crossover treatment. In its written notification, the FDA stated that the reasons for the full clinical hold were that it noted interim overall survival results from the PERSIST-2 Phase 3 trial showing a detrimental effect on survival consistent with the results from PERSIST-1, as well as hemorrhagic/cardiac toxicities. The FDA had earlier put a partial hold on pacritinib on February 4, 2016.

In February 2016, prior to the clinical hold, we completed patient enrollment in the PERSIST-2 Phase 3 clinical trial. Under the full clinical hold, all patients participating in the PERSIST-2 clinical trial discontinued pacritinib treatment.

In August 2016, we announced the top-line results from PERSIST-2, our Phase 3 trial of pacritinib for the treatment of patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter. Three hundred eleven (311) patients were enrolled in the study, which formed the basis for the safety analysis. Two hundred twenty-one (221) patients had a chance to reach Week 24 (the primary analysis time point) at the time the clinical hold was imposed and constituted the intent-to-treat analysis population utilized for the evaluation of efficacy. Results demonstrated that the PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in SVR in patients with myelofibrosis treated with pacritinib compared to BAT, including the approved JAK2 inhibitor ruxolitinib. The co-primary endpoint of reduction of Total Symptom Score, or TSS, was not achieved but trended toward improvement in TSS. There was no significant difference in overall survival across treatment arms, censored at the time of clinical hold. The most common treatment-emergent AEs,

occurring in 20 percent or more of patients treated with pacritinib within 24 weeks, of any grade, were gastrointestinal (generally manageable diarrhea, nausea and vomiting) and hematologic (anemia and thrombocytopenia) and were generally less frequent for twice-daily, or BID, versus once-daily, or QD, administration. Details of the trial were presented in a late-breaking oral session at the American Society of Hematology Annual Meeting in December 2016.

In January 2017, the FDA removed the full clinical hold following review of our complete response submission which included, among other items, final Clinical Study Reports for both PERSIST-1 and 2 trials and a dose-exploration clinical trial protocol that the FDA requested. At that time, we reached agreement with the FDA on the design of a new trial, PAC203, that plans to enroll up to approximately 105 patients with primary myelofibrosis who have failed prior ruxolitinib therapy, and that includes new cardiac entry criteria, to evaluate the dose response relationship for safety and efficacy (SVR at 12 and 24 weeks) of three dose regimens: 100 mg QD, 100 mg BID and 200 mg BID. The 200 mg BID dose regimen was used in PERSIST-2.We enrolled our first patient in PAC203 in July 2017 and expect to complete enrollment in mid 2018. We expect to have interim data from PAC203 by the end of the second quarter of 2018 and topline data in the first quarter of 2019.

The original Marketing Authorization Application, or MAA, for pacritinib was submitted to the European Medicines Agency, or EMA, in February 2016 with an indication statement based on the PERSIST-1 trial data. In its initial assessment report, the Committee for Medicinal Products for Human Use, or CHMP, determined that the original application was not approvable at that point in the review cycle because of major objections in the areas of efficacy, safety (hematological and cardiovascular toxicity) and the overall risk-benefit profile of pacritinib. Subsequent to the filing of the original MAA, data from the second phase 3 trial of pacritinib, PERSIST-2, were reported. These data suggest that pacritinib may show clinical benefit in patients who have failed or are intolerant to ruxolitinib therapy, a population for which there is no approved therapy.

Following discussions with the EMA about how PERSIST-2 data might address the major objections and how to integrate the data into the current application, we withdrew the original MAA, and submitted a new application for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). The new MAA was validated by the EMA in July 2017. Validation confirms that the submission is complete and initiates the centralized review process by the CHMP. The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on E.U. authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 E.U. member states, Norway, Iceland and Liechtenstein.

On January 25, 2018, we were granted a three month extension for submitting our response to the Day 120 List of Questions (D120 LoQ) from the CHMP of the EMA, with regard to the MAA for pacritinib. As a result of the extension, we anticipate submitting our response to the D120 LoQ in May 2018. We primarily requested the extension in order to provide the EMA with new pharmacokinetic analyses that include data from the ongoing phase 2 PAC203 study. The Day 120 LoQ were received by the Company in November 2017 and included Major Objections in areas including efficacy, safety (including hematological, cardiovascular and infectious toxicities) and other concerns including the size of the data set and the pharmacokinetic analyses of the two dosing regimens studied in PERSIST-2. The extension request was submitted following a clarification meeting with the rapporteur and co-rapporteur and members of the EMA. We also plan to address with the EMA deficiencies identified in a January 2018 interim GCP inspection report which concluded that PERSIST-2 was in most aspects conducted in compliance with GCP and internationally accepted ethical standards, but compliance was not verified in the areas of protocol compliance, safety reporting and data integrity, where significant deficiencies were cited.

Other Pipeline Candidates

Tosedostat, is a novel oral, once-daily aminopeptidase inhibitor that has demonstrated significant responses in patients with AML. Enrollment in the randomized Phase 2 cooperative group-sponsored trials in elderly patients with AML (the LI1 trial) was halted in March 2017 after target recruitment had been attained. Following a Data Monitoring Committee meeting in November 2017, the trial Steering Committee decided to not reopen randomization as a sufficient survival benefit had not been demonstrated in patients receiving tosedostat combination therapy.

Our Strategy

Our objective is to become a leader in the acquisition, development and commercialization of novel therapeutics for the treatment of blood-related cancers. The key elements of our strategy to achieve these objectives are to:


•	Commercialize PIXUVRI. Together with Servier, we intend to continue our efforts to build a successful PIXUVRI franchise in Europe as well as other markets. Our partner is currently focused on educating physicians on the unmet medical need and building brand awareness for PIXUVRI among physicians in the countries where PIXUVRI is

available. A successful outcome from the post-authorization trial, PIX306, will enable us to potentially obtain full marketing authorization from the European Commission and expand the market potential for PIXUVRI.


•	Develop Pacritinib in Myelofibrosis and Additional Indications. We intend to develop and commercialize pacritinib for adult patients with myelofibrosis and potentially additional indications.

•

Evaluate Strategic Product Collaborations to Accelerate Development and Commercialization. Where we believe it may be beneficial, we intend to evaluate additional collaborations to broaden and accelerate clinical trial development and potential commercialization of our product candidates. Collaborations have the potential to generate non-equity based operating capital, supplement our own internal expertise and provide us with access to the marketing, sales and distribution capabilities of our collaborators in specific territories.


•	Identify and Acquire Additional Pipeline Opportunities. Our current pipeline is the result of licensing and acquiring assets that we believe were initially undervalued opportunities. We plan to continue to seek out additional product candidates in an opportunistic manner.

Product and Development Portfolio

The following table summarizes our current product and development portfolio as of March 7, 2018:

Oncology Market Overview and Opportunity

According to the American Cancer Society, or ACS, cancer is the second leading cause of death in the U.S., resulting in close to 609,640 deaths annually, or more than 1,670 people per day. Approximately 1.7 million new cases of cancer were expected to be diagnosed in 2018 in the U.S. The most commonly used methods for treating patients with cancer are surgery, radiation and chemotherapy. Patients usually receive a combination of these treatments depending upon the type and extent of their disease.

We believe our expertise in blood-related cancers, together with our ability to identify unique therapies that address unmet medical needs that are potentially less toxic and more effective at treating and curing patients, may fill a significant unmet medical need for cancer patients.

Commercialized Product

PIXUVRI

Overview

PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. In May 2012, the European Commission granted conditional marketing authorization in the E.U., for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL. PIXUVRI is the first approved treatment in the E.U. for patients with multiply relapsed or refractory aggressive B-cell NHL who have failed two or three prior lines of therapy. As part of our conditional marketing authorization in the E.U., we are required to conduct a post-authorization trial, which we refer to as PIX306, comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. In August 2017, we announced the completion of enrollment in the trial. If positive, the results from this trial could support broader indications. Top-line results are event-driven and are expected by the end of the first half of 2018. Although we do not have and are not currently pursuing regulatory approval of PIXUVRI in the U.S., we may reevaluate a possible submission strategy in the U.S. based on the data generated from the PIX306 study. Pursuant to our conditional marketing authorization in the E.U., and an extension granted in September 2016, we are required to submit the requisite clinical study report for PIX306 by December 2018.

PIXUVRI for the Treatment of NHL

We are specifically developing and commercializing PIXUVRI for the treatment of aggressive NHL. NHL is caused by the abnormal proliferation of lymphocytes, which are cells key to the functioning of the immune system. NHL usually originates in lymph nodes and spreads through the lymphatic system. The ACS estimated that there would be 72,240 people diagnosed with NHL in the U.S. and approximately 20,140 people would die from this disease in 2017. The World Health Organization’s International Agency for Research on Cancer’s 2012 GLOBOCAN database estimates that, in the E.U., approximately 79,312 people will be diagnosed with NHL and 30,730 people are estimated to die from NHL annually. NHL is the seventh most common type of cancer. NHL can be broadly classified into two main forms, each with many subtypes; aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly.

Aggressive B-cell NHL is the most common subtype, accounting for about 55 percent of NHL cases. After initial therapy for aggressive NHL with anthracycline-based combination therapy, one-third of patients typically develop progressive disease. Approximately half of these patients are likely to be eligible for intensive second-line treatment and stem cell transplantation, although 50 percent are expected not to respond. For those patients who fail to respond or relapse following second line treatment, treatment options are limited and usually palliative only. PIXUVRI is the first treatment approved in the E.U. for patients with multiply relapsed or refractory aggressive B-cell NHL.

Commercialization of PIXUVRI in the E.U.

In September 2012, we initiated E.U. commercialization of PIXUVRI and in September 2014 we entered into a collaboration arrangement with Servier. In April 2017, we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier. Under the Restated Agreement, Servier will have rights to PIXUVRI in all markets except in the U.S. where we will retain the commercialization rights. Previously, Servier had rights to commercialize the drug globally except in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom, or the U.K., and the U.S. Servier paid us €12.0 million in May 2017 and purchased PIXUVRI drug product for an additional €0.9 million in July 2017. In September 2017, we attained a regulatory milestone under the Restated Agreement and recognized a €1.0 million milestone revenue.We are eligible to receive up to €75.0 million in additional sales and regulatory milestone payments as well as royalties on net product sales.

For additional information on our collaboration with Servier, please see the discussion in “License Agreements and Additional Milestone Activities - Servier.”

As discussed in Part I, Item 1, “Business-Manufacturing, Distribution and Associated Operations,” we utilize third parties for the manufacture, storage and distribution of PIXUVRI, as well as for other associated supply chain operations. Our strategy of utilizing third parties in such manner allows us to direct our resources to the development and commercialization of compounds rather than to the establishment and maintenance of facilities for such operational activities.

Development Candidates

Pacritinib

Development in Myelofibrosis

In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including, but not limited to patients with disease-related thrombocytopenia, patients experiencing treatment-emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant of, or whose symptoms are sub-optimally managed on, other JAK2 therapy. The FDA’s Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Pacritinib was evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis, with one trial in a broad set of patients without limitations on platelet counts, the PERSIST-1 trial; and the other in patients with low platelet counts, the PERSIST-2 trial. Myelofibrosis is a rare blood cancer associated with significantly reduced quality of life and shortened survival. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis, the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia and red blood cell transfusion requirements increase significantly. Among other complications, most patients with myelofibrosis present with enlarged spleens (splenomegaly), as well as many other potentially devastating physical symptoms such as abdominal discomfort, bone pain, feeling full after eating little, severe itching, night sweats and extreme fatigue. Currently patients with very low blood platelets (<50,000/µL) or those ineligible to receive, intolerant of or have insufficient response to the approved JAK1/JAK2 inhibitor have no effective treatment options. Patients have poor survival following discontinuation of therapy with the approved JAK1/JAK2 therapy. We believe pacritinib may offer effective treatment of symptoms for patients following prior exposure to the approved JAK1/JAK2 inhibitor and / or those with thrombocytopenia.

PERSIST-1 was a randomized (2:1), open-label, multi-center Phase 3 trial comparing the efficacy and safety of pacritinib with that of best available therapy other than JAK inhibitors, in 327 patients with myelofibrosis, without exclusion for low platelet counts. The primary endpoint for PERSIST-1 was the proportion of patients achieving a 35 percent or greater reduction in spleen volume from baseline to Week 24 as measured by MRI or CT, when compared with physician-specified BAT, excluding treatment with JAK2 inhibitors. The secondary endpoint was the percentage of patients achieving a 50 percent or greater reduction in Total Symptom Score, or TSS, from baseline to week 24 as measured by tracking specific symptoms on a form, or Patient Reported Outcome, or PRO, instrument. At study entry, 46 percent of patients were thrombocytopenic; 32 percent of patients had platelet counts less than 100,000 per microliter (<100,000/µL); and 16 percent of patients had platelet counts less than 50,000 per microliter (<50,000/µL); normal platelet counts range from 150,000 to 450,000 per microliter. At the time of initiation of the trial, PERSIST-1 utilized the Myeloproliferative Neoplasm Symptom Assessment Form, or MPN-SAF TSS, the PRO instrument developed by Mayo Clinic, to measure TSS reduction. We collaborated with Mayo Clinic and the FDA and developed a modified instrument to be used as the endpoint for pacritinib clinical development. As a result, we amended the PERSIST-1 trial protocol to replace the original MPN-SAF TSS instrument with a new instrument, known as the MPN-SAF TSS 2.0, which is also being used for recording patient-reported outcomes for the PERSIST-2 trial. In connection with this amendment, we increased patient enrollment in the PERSIST-1 study from 270 to 327 patients.

In May 2015, data from PERSIST-1 showed that compared to BAT (exclusive of a JAK inhibitor) pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms meeting the primary endpoint of the trial. Results were presented at a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. Additionally, in June 2015, results from PERSIST-1 PRO and other quality of life measures presented at a late-breaking oral session at the 20th Congress of the European Hematology Association showed significant improvements in symptom score with pacritinib therapy compared to BAT (exclusive of a JAK inhibitor) across the symptoms reported in the presentation.

The following table shows the proportion of patients randomized to pacritinib or BAT who achieved a ≥35% reduction in spleen volume from baseline at Week 24 or up to Week 24 in the intent-to-treat, or ITT, population or evaluable patient population. The greatest difference in treatment arms was observed in evaluable patients with the lowest platelet counts (<50,000/µL platelets) (33.3 percent with pacritinib vs 0 percent with BAT) (p=0.037).

Spleen Volume Reduction of ≥35% at Week 24 by Platelet Levels



	Pacritinib	BAT	p-value
All Platelet Levels
ITT*	19% (n=220)	5% (n=107)	0.0003
Evaluable**	25% (n=168)	6% (n=85)	<0.0001

<100,000/µL platelets
ITT	17% (n=72)	0% (n=34)	0.0086
Evaluable	24% (n=51)	0% (n=24)	0.0072

<50,000/µL platelets
ITT	23% (n=35)	0% (n=16)	0.0451
Evaluable	33% (n=24)	0% (n=11)	0.0370

* ITT - primary analysis included all patients randomized. Patients who missed MRI or CT scans at baseline or at Week 24 were counted as non-responders.

** Evaluable - analysis included patients who had assessment at both baseline and at Week 24.

Results from PERSIST-1 PRO and other quality of life measures showed significant improvements in symptom score with pacritinib therapy compared to BAT (exclusive of a JAK inhibitor) across the symptoms reported in the presentation. Patients treated with pacritinib experienced greater improvement in their disease-related symptoms (ITT patient population: 24.5 percent of pacritinib-treated patients vs 6.5 percent of BAT-treated patients, p<0.0001; evaluable patient population: 40.9 percent of pacritinib-treated patients vs 9.9 percent of BAT-treated patients, p<0.0001).

Additionally, 25 percent of patients treated with pacritinib who were severely anemic and transfusion dependent - requiring at least six units of blood in the 90 days prior to study entry - became transfusion independent, compared to zero patients treated with BAT (p<0.05). Among patients with the lowest baseline platelets (<50,000/µL) who received treatment with pacritinib, a significant increase in platelet counts was observed over time compared to BAT (p=0.003) - with a 35 percent increase in platelet counts from baseline to Week 24.

The most common adverse events, occurring in 10 percent or more of patients treated with pacritinib within 24 weeks, of any grade, were: mild to moderate diarrhea, nausea, anemia, thrombocytopenia, and vomiting. Of the patients treated with pacritinib, 3 discontinued therapy and 13 patients required dose interruption (average one week) for diarrhea. Patients received a daily full dose of pacritinib over the duration of treatment. Gastrointestinal symptoms typically lasted for approximately one week and few patients discontinued treatment due to side effects. There were no Grade 4 gastrointestinal events reported.

In December 2015, primarily based on the results of the PERSIST-1 trial, we submitted a NDA to the FDA, for pacritinib requesting U.S. marketing approval of pacritinib for the treatment of patients with intermediate and high-risk myelofibrosis with low platelet counts of less than 50,000 per microliter (<50,000/µL) for whom there are no approved therapies.

The PERSIST-2 trial was a randomized (2:1), open-label, multi-center registration-directed Phase 3 trial evaluating pacritinib compared to BAT, including the approved JAK inhibitor dosed according to product label, for patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (≤100,000/µL). Patients were randomized to receive 200 mg pacritinib twice daily, 400 mg pacritinib once daily or BAT. In October 2013, we reached an agreement with the FDA on a Special Protocol Assessment, or SPA, for the PERSIST-2 trial regarding the planned design, endpoints and statistical analysis approach of the trial. The SPA is a written agreement between us and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a NDA submission. Under the SPA, the agreed upon co-primary endpoints are the percentage of patients achieving a 35% or greater reduction in spleen volume measured by MRI or CT scan from baseline to Week 24 of treatment and the percentage of patients achieving a TSS reduction of 50 percent or greater using eight key symptoms as measured by the modified MPN-SAF TSS 2.0 diary from baseline to Week 24. The design of PERSIST-1 and PERSIST-2 allowed for patients on the BAT arm to crossover and receive treatment with pacritinib if their disease progresses or after they achieve the 24-week measurement endpoint. Although crossover design

of clinical trials may confound evaluation of survival, such designs are frequently used in cancer studies, and the FDA has approved multiple oncology drugs that utilized crossover design in Phase 3 trials.

In February 2015, we received a recommendation from the Independent Data Monitoring Committee, or IDMC, in place at the time to terminate the PERSIST-1 trial and hold enrollment of new patients in the PERSIST-2 trial. The IDMC’s recommendation was based on non-statistically significant safety concerns, including mortality, in patients on pacritinib, particularly those who crossover after 24 weeks, which crossover potentially confounds evaluation of survival. The IDMC agreed that the recommendation would be only preliminary until we were unblinded to and could review the primary and secondary endpoint data as well as safety results from the PERSIST-1 trial. The IDMC recommendation was reviewed with the PERSIST Steering Committee, comprised of external experts and the study’s principal investigators who disagreed with the IDMC’s recommendation and expressed the view that the studies should continue as planned. We also asked an independent clinician and a statistician experienced in oversight of clinical trial safety to evaluate the safety profile of pacritinib in the PERSIST-1 trial. Neither was told of the recommendation reached by either the IDMC or the Steering Committee. Both experts agreed with the Steering Committee that the studies could continue. The firm that assembled the IDMC hired a second external independent statistician to review the IDMC’s analyses and recommendation, who also disagreed with the IDMC recommendation and concurred with the other independent experts that the studies need not be terminated nor enrollment held. In June 2015, the IDMC made its recommendation final and we provided to the FDA the information reviewed by the IDMC, the IDMC’s meeting minutes, and the written opinion of the Steering Committee co-chairs, the independent experts, and the second independent statistician. In July 2015, we requested a meeting with the FDA to confirm if we should continue the studies. The FDA assigned the request to a type C meeting. In its written response, the FDA did not mandate any modifications to the studies or place pacritinib on clinical hold at that time, but indicated that it had not yet reviewed the data and noted the difficulty in attempting to draw meaningful conclusions from non-significant results, and that the crossover designs may confound the analysis of survival. We determined that no modifications to the ongoing trials were required. Because we had concerns about the original IDMC’s impartiality, we decided to discharge it, and retained a new IDMC through an independent firm specializing in IDMCs. The newly constituted IDMC met on several occasions and its recommendation was to continue PERSIST-2 as planned.

On February 8, 2016, the FDA notified us that a full clinical hold had been placed on pacritinib clinical studies. A full clinical hold is a suspension of the clinical work requested under the investigational new drug, or an IND, application. Under the full clinical hold, all patients on pacritinib at the time were required to discontinue pacritinib immediately and no patients could be enrolled or start pacritinib as initial or crossover treatment. In its written notification, the FDA cited the reasons for the full clinical hold were that it noted interim overall survival results from the PERSIST-2 Phase 3 trial showing a detrimental effect on survival consistent with the results from PERSIST-1. The deaths in PERSIST-2 in pacritinib-treated patients include intracranial hemorrhage, cardiac failure and cardiac arrest. In connection with the full clinical hold, the FDA has recommended that we conduct Phase 1 dose exploration studies of pacritinib in patients with myelofibrosis, submit final clinical study reports, or CSRs, and datasets for PERSIST-1 and PERSIST-2, provide certain notifications, revise relevant statements in the related Investigator’s Brochure and informed consent documents and make certain modifications to protocols. In addition, the FDA recommended that we request a meeting prior to submitting a response to full clinical hold. As a result of the full clinical hold of pacritinib, the SPA agreement is no longer binding for PERSIST-2, and we have withdrawn the NDA.

In February 2016, prior to the clinical hold we completed patient enrollment in the PERSIST-2 Phase 3 clinical trial. Under the full clinical hold, all patients participating in the PERSIST-2 clinical trial discontinued pacritinib treatment.

In August 2016, we announced the top-line results from PERSIST-2, and the detailed results were presented in a late-breaking oral session at the American Society of Hematology Annual Meeting in December 2016. In the PERSIST-2 trial three hundred eleven (311) patients were randomized to receive 200 mg pacritinib BID, 400 mg pacritinib QD or BAT. Two hundred twenty-one (221) patients (74 pacritinib BID; 75 pacritinib QD; 72 BAT) were enrolled at least 24 weeks prior to the full clinical hold and were potentially evaluable for the Week 24 efficacy endpoint (ITT efficacy population). In the ITT efficacy population at study entry, 46 percent (101/221) of patients had platelet counts less than 50,000 per microliter (<50,000/µL), and 59 percent (130/221) were anemic (hemoglobin <10 g/dL). Normal platelet counts range from 150,000 to 450,000 per microliter. The percentage of patients in the ITT efficacy population who received prior ruxolitinib was as follows: 41 percent (31/75) pacritinib QD; 42 percent (31/74) pacritinib BID; and 46 percent (33/72) BAT. Safety analyses were based on all patients exposed to study treatment of any duration.

The co-primary endpoints of the trial were the proportion of patients achieving a 35 percent or greater reduction in spleen volume from baseline to Week 24 as measured by MRI or CT scan and the proportion of patients achieving a TSS reduction of 50 percent or greater using the modified Myeloproliferative Neoplasm Symptom Assessment (MPN-SAF TSS 2.0) diary from baseline to Week 24. The primary objective of the study was to compare pooled pacritinib arms versus BAT

and the secondary objectives were to compare pacritinib BID and QD arms individually to BAT. Study was designed to evaluate its objectives with a sample size of 300. At the time of clinical hold, study enrollment was completed with thre hundred eleven (311) patients randomized, but only two hundred twenty one (221) patients had the potential to be evaluated for efficacy endpoints at Week 24.

The PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in SVR in patients with myelofibrosis treated with pacritinib combining the once- and twice-daily arms compared to BAT. Although the PERSIST-2 trial did not meet the other co-primary endpoint of greater than 50 percent reduction in TSS, the results approached marginal significance compared to BAT. Although secondary objectives could not be evaluated formally due to the study not achieving one of the primary objectives, when the two pacritinib dosing arms were evaluated separately versus BAT, pacritinib given twice daily showed a higher percent of SVR and TSS responses compared to BAT; whereas, pacritinib given once daily showed only a higher percent SVR responses compared to BAT.

Spleen Volume Reduction of ≥35%; Total Symptom Score Reduction of ≥50% at Week 24



	Co-Primary Pacritinib BID + QD (n=149)	Secondary Pacritinib BID (n=74)	Secondary Pacritinib QD (n=75)	BAT (n=72)
Percent of Patients with ≥35% SVR from baseline to Week 24	18% (n=27;p=0.001)	22% (n=16;p=0.001)	15% (n=11;p=0.017)	3% (n=2)
Percent of Patients with ≥50% reduction in TSS from baseline to Week 24	25% (n=37;p=0.079)	32% (n=24;p=0.011)	17% (n=13;p=0.652)	14% (n=10)

A total of 45 percent of the BAT patients randomized received ruxolitinib at some point on the study.

There was no significant difference in overall survival, or OS, across treatment arms, censored at the time of clinical hold. Hazard ratios (95% confidence intervals, or CI) were 0.68 (0.30-1.53) for pacritinib BID versus BAT and 1.18 (0.57-2.44) for pacritinib QD versus BAT. Overall mortality rates at that time were comparable between arms: 9 percent BID versus 14 percent QD and 14 percent BAT.

The most common treatment-emergent AEs, occurring in 20 percent or more of patients treated with pacritinib within 24 weeks, of any grade, were gastrointestinal (generally manageable diarrhea, nausea and vomiting) and hematologic (anemia and thrombocytopenia) and were generally less frequent for BID versus QD administration. The most common serious treatment-emergent AEs (incidence of ≥5 percent reported in any treatment arm irrespective of grade) were anemia, thrombocytopenia, pneumonia and acute renal failure none of which exceeded 8 percent individually in any arm.

In July 2017, we enrolled our first patient in the PAC203 trial which plans to enroll up to approximately 105 patients with primary myelofibrosis who have failed prior ruxolitinib therapy to evaluate the dose response relationship for safety and efficacy (SVR at 12 and 24 weeks) of three dose regimens: 100 mg QD, 100 mg BID and 200 mg BID. The 200 mg BID dose regimen was used in PERSIST-2. We expect to complete enrollment by mid-2018. We expect to have interim data from PAC203 by the end of the second quarter of 2018 and topline data in the first quarter of 2019.

Marketing Authorization Application

The Marketing Authorization Application, or MAA, for pacritinib was submitted to the European Medicines Agency, or EMA, in February 2016 with an indication statement based on the PERSIST-1 trial data. In its initial assessment report, the Committee for Medicinal Products for Human Use, or CHMP, determined that the current application is not approvable at this point in the review cycle because of major objections in the areas of efficacy, safety (hematological and cardiovascular toxicity) and the overall risk-benefit profile of pacritinib. Subsequent to the filing of the MAA, data from the second phase 3 trial of pacritinib, PERSIST-2, were reported. These data suggest that pacritinib may show clinical benefit in patients who

have failed or are intolerant to ruxolitinib therapy, a population for which there is no approved therapy. Following discussions with the EMA about how PERSIST-2 data might address the major objections and how to integrate the data into the current application, we withdrew the original MAA, and submitted a new application for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). The new MAA was validated by the EMA in July 2017. Validation confirms that the submission is complete and initiates the centralized review process by the CHMP. The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on E.U. authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 E.U. member states, Norway, Iceland and Liechtenstein.

On January 25, 2018, we were granted a three-month extension for submitting our response to the Day 120 List of Questions, or D120 LoQ, from the CHMP of the EMA, with regard to the MAA for pacritinib. As a result of the extension, we anticipate submitting our response to the D120 LoQ in May 2018. We primarily requested the extension in order to provide the EMA with new pharmacokinetic analyses that include data from the ongoing phase 2 PAC203 study. The Day 120 LoQ were received by the Company in November 2017 and included Major Objections in areas including efficacy, safety (including hematological, cardiovascular and infectious toxicities) and other concerns including the size of the data set and the pharmacokinetic analyses of the two dosing regimens studied in PERSIST-2. The extension request was submitted following a clarification meeting with the rapporteur and co-rapporteur and members of the EMA. We also plan to address with the EMA deficiencies identified in a January 2018 interim GCP inspection report which concluded that PERSIST-2 was in most aspects conducted in compliance with GCP and internationally accepted ethical standards, but compliance was not verified in the areas of protocol compliance, safety reporting and data integrity, where significant deficiencies were cited.

Development in Other Indications

In December 2014, we announced results of a preclinical analysis of kinase inhibition by pacritinib that demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Pacritinib’s potent inhibition of FLT3, c-fms, IRAK1 and c-kit highlight its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL, some of which are currently being evaluated in ISTs.

In October 2016, we regained worldwide rights for the development and commercialization of pacritinib following termination of the Pacritinib License Agreement with Baxalta. For additional information relating to the termination of the Pacritinib License Agreement, see “License Agreements and Additional Milestone Activities - Baxalta” below.

Tosedostat

Tosedostat, is a novel oral, once-daily aminopeptidase inhibitor that has demonstrated significant responses in patients with AML. It has been evaluated in randomized Phase 2 cooperative group-sponsored trials in elderly patients with AML.

Enrollment in the randomized Phase 2 cooperative group-sponsored trials in elderly patients with AML (the LI1 trial) was halted in March 2017 after target recruitment had been attained. Following a Data Monitoring Committee meeting in November 2017, the trial Steering Committee decided to not reopen randomization as a sufficient survival benefit had not been demonstrated in patients receiving tosedostat combination therapy.

Research and Development Expenses

Research and development is essential to our business. We spent $32.9 million, $65.0 million and $76.6 million in 2017, 2016 and 2015, respectively, on Company-sponsored research and development activities. The development of a product candidate involves inherent risks and uncertainties, including, among other things, that we cannot predict with any certainty the pace of enrollment of our clinical trials. As a result, we are unable to provide the nature, timing and estimated costs of the efforts necessary to complete the development of pacritinib and tosedostat or to complete the post-approval commitment study of PIXUVRI. Further, third parties are conducting clinical trials for tosedostat and pacritinib. Even after a clinical trial is enrolled, preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval and advancement of this compound through the development process. For these reasons, among others, we cannot estimate the date on which clinical development of these product candidates will be completed or when, if ever, we will generate material net cash inflows from PIXUVRI or be able to commence commercialization of pacritinib and tosedostat. For additional information relating to our research and development expenses and associated risks, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations - Years ended December 31, 2017, 2016 and 2015 - Operating costs and expenses - Research and development expenses” and Part I, Item 1A, “Risk Factors.”

License Agreements and Additional Milestone Activities

Servier

In April 2017, we entered into the Restated Agreement with Servier, pursuant to which the Original Agreement with Servier, entered into in September 2014, was amended and restated in its entirety. Under the Original Agreement, we granted Servier an exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products outside of Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the U.K. and the U.S. Under the Original Agreement, we received an upfront payment in October 2014 of €14.0 million (or $17.8 million using the currency exchange rate as of the date we received the funds). In addition, we received a €1.5 million (or $1.7 million upon conversion from euros as of the date we received the funds) milestone payment relating to the attainment of reimbursement approval for PIXUVRI in Spain and a €7.5 million (or $8.0 million upon conversion from euros as of the date we achieved the milestone in December 2016) milestone payment relating to the occurrence of a certain enrollment event in the PIX306 study.

Under the Restated Agreement, we granted Servier an exclusive, sublicensable (subject to certain exceptions) license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions). In accordance with the Restated Agreement, we will transfer to Servier medical affairs and commercialization activities relating to the Licensed Products in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey and the U.K. (collectively, the "Transition Territory"). We are in the process of terminating or assigning certain distributor and wholesaler contracts to Servier in the Transition Territory, and expect the last contract to be terminated in 2018. Each party will be responsible for the manufacture and supply of drug products and substances in its respective territory.

We have obtained conditional marketing authorization in the E.U. to market PIXUVRI for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Under the Restated Agreement, we will transfer our European marketing authorization to Servier upon positive, statistically significant results in an ongoing post-authorization Phase 3 clinical trial, PIX306, unless Servier elects to terminate the Restatement Agreement within thirty (30) days after the positive results.

We received an upfront payment of €12.0 million from Servier, which included €2.0 million for a new milestone previously achieved, and Servier purchased PIXUVRI drug product for an additional €0.9 million in July 2017. Subject to the achievement of certain conditions, the Restated Agreement provides for additional milestone payments from Servier in the aggregate amount of up to €76.0 million, including up to €36.0 million in potential regulatory milestone payments and up to €40.0 million in potential sales milestone payments. In September 2017, we attained a regulatory milestone under the Restated Agreement and recorded a €1.0 million milestone revenue (or $1.2 million using the currency exchange rate as of the date the milestone was achieved).

We are eligible to receive tiered royalty payments ranging from a low-double digit percentage up to a percentage in the low-twenties based on net sales of the Licensed Products, subject to certain reductions of up to mid-double digit percentages under certain circumstances. We will no longer use a joint marketing plan with Servier, and marketing costs will no longer be shared equally; instead Servier will be solely responsible for marketing costs within Europe. Mutually agreed upon

development costs other than PIX306 will continue to be shared equally with Servier, which represents no change to the development cost sharing.

The Restated Agreement also requires an amendment to the trademark license agreement entered into on June 8, 2015 between us and Servier to provide for Servier’s right to use of our trademark PIXUVRI in connection with Licensed Products worldwide, excluding the U.S. (and its territories and possessions). The amendment was executed in October 2017.

Baxalta

In November 2013, we entered into a Development, Commercialization and License Agreement, dated as of November 14, 2013, with Baxter International Inc., or Baxter, for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas, or the Original Pacritinib License Agreement. The Original Pacritinib License Agreement, the rights and obligations to which Baxter had assigned to Baxalta, was amended by the License Amendment, effective June 8, 2015. Under the Original Pacritinib License Agreement, as amended by the License Amendment, or the Pacritinib License Agreement, Baxalta had an exclusive, worldwide (subject to co-promotion rights discussed below), royalty-bearing, non-transferable license (which was sub-licensable under certain circumstances) relating to pacritinib. Licensed products under the Pacritinib License Agreement consisted of products in which pacritinib is an ingredient.

We received an upfront payment of $60.0 million under the Pacritinib License Agreement, which included a $30.0 million investment in our equity. The Pacritinib License Agreement also provided for us to receive potential additional payments of up to $302.0 million upon the successful achievement of certain development and commercialization milestones, comprised of $112.0 million of potential clinical, regulatory and commercial launch milestone payments, and potential additional sales milestone payments of up to $190.0 million. We have received milestone payments of $52.0 million pursuant to the Pacritinib License Agreement.

In June 2015, we entered into the License Amendment. Pursuant to the License Amendment, two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Original Pacritinib License Agreement relating to the PERSIST-2 Milestone and the MAA Milestone. In the first quarter of 2016, we recorded $32.0 million in license and contract revenue upon attainment of these milestones.

In October 2016, we regained worldwide rights for the development and commercialization of pacritinib following termination of the Pacritinib License Agreement with Baxalta. Pursuant to the termination, Baxalta paid us a one-time cash payment in the amount of approximately $10.3 million as reimbursement for certain expenses incurred by us or to be incurred. In exchange, we have agreed to provide a one-time payment to Baxalta, upon the first regulatory approval or any pricing and reimbursement approvals of a product containing pacritinib, in the amount of approximately $10.3 million which represents certain amounts paid by Baxalta for the benefit of the pacritinib program manufacturing efforts. We have also agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of pacritinib unless the transferee/licensee/sublicensee agrees to be bound by the terms of the Asset Return and Termination Agreement with Baxalta.

University of Vermont

We entered into an agreement with the University of Vermont, or UVM, in March 1995, as amended, or the UVM Agreement, which grants us an exclusive sublicensable license for the rights to PIXUVRI. Pursuant to the UVM Agreement, we acquired the rights to make, have made, sell and use PIXUVRI, and we are obligated to make royalty payments to UVM ranging from low single digits to mid-single digits as a percentage of net sales; such royalty expenses are included in Cost of product sold in our consolidated financial statements. The higher royalty rate is payable for net sales in countries where specified UVM licensed patents exist, or where we have obtained orphan drug protection, until such UVM patents or such protection no longer exists. For a period of ten years after the first commercialization of PIXUVRI, the lower royalty rate is payable for net sales in such countries after expiration of the designated UVM patents or loss of orphan drug protection, and in all other countries without such specified UVM patents or orphan drug protection. Unless otherwise terminated, the term of the UVM Agreement continues for the life of the licensed patents in those countries in which a licensed patent exists, and continues for ten years after the first sale of PIXUVRI in those countries where no such patents exist. We may terminate the UVM Agreement, on a country-by-country basis or on a patent-by-patent basis, at any time upon advance written notice. UVM may terminate the UVM Agreement upon advance written notice in the event royalty payments are not made. In addition, either party may terminate the UVM Agreement in the event of an uncured material breach of the UVM Agreement by the other party or in the event of bankruptcy of the other party.

S*BIO

We acquired the compounds SB1518 (which is referred to as “pacritinib”) and SB1578, which inhibit JAK2 and FLT3, from S*BIO in May 2012. Under our agreement with S*BIO, we are required to make milestone payments to S*BIO up to an aggregate amount of $132.5 million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain worldwide net sales thresholds are met in connection with any pharmaceutical product containing or comprising any compound that we acquired from S*BIO for use for specific diseases, infections or other conditions. At our election, we may pay up to 50% of any milestone payments to S*BIO through the issuance of shares of our common stock or shares of our preferred stock convertible into our common stock. In addition, S*BIO will be entitled to receive royalty payments from us at incremental rates in the low single-digits based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis.

Vernalis

We entered into an amended and restated exclusive license agreement with Vernalis (R&D) Limited, or Vernalis, in October 2014, or the Vernalis License Agreement, for the exclusive worldwide right to use certain patents and other intellectual property rights to develop, market and commercialize tosedostat and certain other compounds. Under the Vernalis License Agreement, we have agreed to make tiered royalty payments of no more than a high single-digit percentage of net sales of products containing licensed compounds, with such obligation to continue on a country-by-country basis for the longer of ten years following commercial launch or the expiry of relevant patent claims.

The Vernalis License Agreement will terminate when the royalty obligations expire, although the parties have early termination rights under certain circumstances, including the following: (i) we have the right to terminate, with three months’ notice, upon the belief that the continued development of tosedostat or any of the other licensed compounds is not commercially viable; (ii) Vernalis has the right to terminate in the event of our uncured failure to pay sums due; and (iii) either party has the right to terminate in the event of the other party’s uncured material breach or insolvency.

Gynecologic Oncology Group

We entered into an agreement with the Gynecologic Oncology Group, now part of NRG Oncology, in March 2004, as amended, related to the GOG-0212 trial of Opaxio it is conducting in patients with ovarian cancer. Pursuant to the terms of such agreement, we paid an aggregate of $1.2 million in milestone payments during 2014 based on certain enrollment milestones achieved. In addition, we made a milestone payment of $0.5 million relating to the transfer of final datasets during the second quarter of 2017. The agreement was terminated in May 2017. No further development of Opaxio is planned.

PG-TXL

In November 1998, we entered into an agreement with PG-TXL, as amended in February 2006, or the PG-TXL Agreement, which granted us an exclusive worldwide license for the rights to Opaxio and to all potential uses of PG-TXL’s polymer technology. Pursuant to the PG-TXL Agreement, we acquired the rights to research, develop, manufacture, market and sell anti-cancer drugs developed using this polymer technology. Pursuant to the PG-TXL Agreement, we were obligated to make payments to PG-TXL upon the achievement of certain development and regulatory milestones of up to $14.4 million. The timing of the remaining milestone payments under the PG-TXL Agreement was based on trial commencements and completions for compounds protected by PG-TXL license rights, and regulatory and marketing approval of those compounds by the FDA and the EMA. Additionally, we were required to make royalty payments to PG-TXL based on net sales. Our royalty obligations ranged from low to mid-single digits as a percentage of net sales. In February 2017, we terminated our agreement with PG-TXL and the exclusive worldwide license for rights to Opaxio and certain polymer technology under our agreement with PG-TXL.

Novartis

In January 2014, we entered into a Termination Agreement with Novartis, or the Novartis Termination Agreement, to reacquire the rights to PIXUVRI previously granted to Novartis under our agreement entered into in September 2006, as amended, or the Original Novartis Agreement. Pursuant to the Novartis Termination Agreement, the Original Novartis Agreement was terminated in its entirety, except for certain customary provisions, including those pertaining to confidentiality and indemnification, which survive termination.

Under the Novartis Termination Agreement, we agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of PIXUVRI and Opaxio unless the recipient thereof agrees to be bound by the terms of the Novartis Termination Agreement. We also agreed to provide potential payments to Novartis, including a percentage ranging from the low double-digits to the mid-teens, of any consideration received by us or our affiliates in connection with any transfer, license, sublicense or other grant of rights with respect to intellectual property of PIXUVRI or Opaxio; provided that such payments will not exceed certain prescribed ceilings in the low single-digit millions. Novartis is entitled to receive potential payments of up to $16.6 million upon the successful achievement of certain sales milestones of PIXUVRI and Opaxio. We are also obligated to pay to Novartis tiered low single-digit percentage royalty payments for the first several hundred million dollars in annual net sales, and 10% royalty payments thereafter based on annual net sales of each of PIXUVRI and Opaxio, subject to reduction in the event generic drugs are introduced and sold by a third party, causing the sale of PIXUVRI to fall by a percentage in the high double digits. Royalty payments for PIXUVRI are subject to certain minimum floor percentages in the low single digits. The royalty expenses payable under the Novartis Termination Agreement are included in Cost of product sold in our consolidated financial statements.

Teva Pharmaceutical Industries Ltd.

In June 2005, we entered into an acquisition agreement with Cephalon, Inc., or Cephalon, pursuant to which we divested the compound, TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. Under this agreement, we have the right to receive up to $100 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX. To date, we have received $50.0 million of such potential milestone payments as a result of having achieved certain sales milestones.

Other Agreements

We have several agreements with CROs, third-party manufacturers and distributors that have durations of greater than one year for the development and distribution of certain of our compounds.

Information about Customer and Geographic Concentrations

Information about customer and geographic revenue is set forth in Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 15. Customer and Geographic Concentrations" of this Annual Report on Form 10-K.

Patents and Proprietary Rights

We dedicate significant resources to protecting our intellectual property, which is important to our business. We have filed numerous patent applications in the U.S. and various other countries seeking protection of inventions originating from our research and development, and we have also obtained rights to various patents and patent applications under licenses with third parties and through acquisitions. Patents have been issued on many of these applications. We have pending patent applications or issued patents in the U.S. and foreign countries directed to PIXUVRI, pacritinib, tosedostat and other product candidates. However, the lives of these patents are limited. Patents for the individual products extend for varying periods according to the date of the patent filing or grant and the legal term of patents in the various countries where patent protection is obtained.

Our U.S. and foreign composition of matter patents for pacritinib expire as follows: US patents expire in 2029 (compound) / 2030 (salt); foreign patents expire in 2026 (compound) / 2029 (salt). Pacritinib has orphan drug designation for myelofibrosis in the U.S. and the E.U.

Our various tosedostat-directed patents expire in 2018. Tosedostat has orphan drug designation for acute myeloid leukemia in the U.S. and the E.U.

Each patent may be eligible for future patent term restoration of up to five years under certain circumstances. Also, regulatory exclusivity tied to the protection of clinical data may be complementary to patent protection. During a period of regulatory exclusivity, competitors generally may not use the original applicant’s data as the basis for a generic application. In the U.S., the data protection generally runs for five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication.

In the absence of a patent, we would, to the extent possible, need to rely on unpatented technology, know-how and confidential information. Ultimately, the lack or expiration at any given time of a patent to protect our compounds may allow our competitors to copy the underlying inventions and better compete with us.

The risks and uncertainties associated with our intellectual property, including our patents, are discussed in more detail in Part I, Item 1A, “Risk Factors.”

Manufacturing, Distribution and Associated Operations

Our manufacturing strategy utilizes third party contractors for the procurement and manufacture, as applicable, of raw materials, active pharmaceutical ingredients and finished drug product, as well as for labeling, packaging, storage and distribution of our compounds and associated supply chain operations. As our business continues to expand, we expect that our manufacturing, distribution and related operational requirements will increase correspondingly. Additionally, in October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement. The development and commercialization of a major product candidate like pacritinib without a collaborative partner would significantly increase our manufacturing, distribution and related operational requirements.

Each third party contractor will always undergo a formal qualification process by CTI subject matter experts prior to signing any service agreement and initiating any manufacturing work. We currently have a commercial supply arrangement for PIXUVRI and pacritinib.

Integral to our manufacturing strategy is our quality control and quality assurance program, which includes standard operating procedures and specifications with the goal that our compounds are manufactured in accordance with current Good Manufacturing Practices, or cGMPs, and other applicable global regulations. The cGMP compliance includes strict adherence to regulations for quality control, quality assurance and the maintenance of records and documentation. Manufacturing facilities for products and product candidates must meet cGMP requirements, and commercialized products must have acquired FDA, EMA and any other applicable regulatory approval. In this regard, we expect to continue to rely on contract manufacturers to produce sufficient quantities of our compounds in accordance with cGMPs for use in clinical trials and distribution.

We believe our operational strategy of utilizing qualified outside vendors in the foregoing manner allows us to direct our financial and managerial resources to development and commercialization activities, rather than to the establishment and maintenance of a manufacturing and distribution infrastructure.

Competition

Competition in the pharmaceutical and biotechnology industries is intense. We face competition from a variety of companies focused on developing oncology drugs. We compete with large pharmaceutical companies and with other specialized biotechnology companies. In addition to the specific competitive factors discussed below, new anti-cancer drugs that may be developed and marketed in the future could compete with our various compounds.

With respect to PIXUVRI, while there are no other products approved in the E.U. as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL, there are other agents approved to treat aggressive NHL that could be used in this setting, including both branded and generic anthracyclines as well as mitoxantrone.

With respect to our other investigational candidates, if approved, they may face competition from compounds that are currently approved or may be approved in the future. Pacritinib would compete with Jakafi®, which is marketed by Incyte in the U.S., and potentially other candidates in development that target JAK inhibition to treat cancer such as fedratinib that was recently acquired and now being developed by Celgene. Tosedostat would compete with currently marketed products such as Dacogen®, Vidaza®, Revlimid®, Thalomid® and Clolar®.

Many of our existing or potential competitors have substantially greater financial, technical and human resources than us and may be better equipped to develop, manufacture and market products. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Many of these competitors have products that have been approved or are in development and operate large, well-funded research and development programs.

Companies that complete clinical trials, obtain required regulatory approvals and commence commercial sales of their products before us may achieve a significant competitive advantage if their products work through a similar mechanism as our products and if the approved indications are similar. A number of biotechnology and pharmaceutical companies are developing new products for the treatment of the same diseases being targeted by us. In some instances, such products have already entered late-stage clinical trials or received FDA or European Commission approval. However, cancer drugs with distinctly different mechanisms of action are often used together in combination for treating cancer, allowing several different products to target the same cancer indication or disease type. Such combination therapy is typically supported by clinical trials that demonstrate the advantage of combination therapy over that of a single-agent treatment.

We believe that our ability to compete successfully will be based on our ability to create and maintain scientifically advanced technology, develop proprietary products, attract and retain scientific personnel, obtain patent or other protection for our products, obtain required regulatory approvals and manufacture and successfully market our products, either alone or through outside parties. We will continue to seek licenses with respect to technology related to our field of interest and may face competition with respect to such efforts. See the risk factor, “We face direct and intense competition from our competitors in the biotechnology and pharmaceutical industries, and we may not compete successfully against them.” in Part I, Item 1A, “Risk Factors” of this Annual Report on Form 10-K for additional information regarding the risks and uncertainties we face due to competition in our industry.

Government Regulation

We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. Our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in the E.U. are addressed in a centralized way through the EMA and the European Commission, but country-specific regulation by the competent authorities of the E.U. member states remains essential in many respects.

U.S. Regulation

In the U.S., the FDA regulates drugs under the FDCA and its implementing regulations, through review and approval of NDAs. NDAs require extensive studies and submission of a large amount of data by the applicant.

Drug Development

Preclinical Testing. Before testing any compound in human subjects in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the quality and safety of the product. Animal studies must be performed in compliance with the FDA’s Good Laboratory Practice regulations and the U.S. Department of Agriculture’s Animal Welfare Act.

IND Application. Human clinical trials in the U.S. cannot commence until an IND application is submitted and becomes effective. A company must submit preclinical testing results to the FDA as part of the IND application, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND application becomes effective 30 days following its receipt by the FDA. Once human clinical trials have commenced, the FDA may stop the clinical trials by placing them on “clinical hold” because of concerns about the safety of the product being tested, or for other reasons.

Clinical Trials. Clinical trials involve the administration of the drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA’s bioresearch monitoring regulations and Good Clinical Practice, or GCP, requirements, which establish standards for conducting, recording data from and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND application. In addition, each clinical trial must be reviewed, approved, and conducted under the auspices of an institutional review board, or IRB, at the institution conducting the clinical trial. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with regulations and guidelines for obtaining informed consent from the study subjects, complying with the protocol

and investigational plan, adequately monitoring the clinical trial and timely reporting adverse events. Foreign studies conducted under an IND application must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND application may be submitted in support of an NDA if the study was conducted in accordance with GCP and the FDA is able to validate the data.

A study sponsor is required to submit certain details about active clinical trials and clinical trial results to the National Institutes of Health for public posting on http://clinicaltrials.gov. Human clinical trials typically are conducted in three sequential phases, although the phases may overlap with one another:

•

Phase 1 clinical trials include the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase 1 clinical trials generally are intended to determine the metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.


•	Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population, and are designed to develop data regarding the product’s effectiveness, to determine dose response and the optimal dose range and to gather additional information relating to safety and potential adverse effects.

•

Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained, and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug’s overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug, or the safety, purity, and potency of a biological product, at the proposed dosing regimen.

The sponsoring company, the FDA or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.

The FDA and IND application sponsor may agree in writing on the design and size of clinical trials intended to form the primary basis of an effectiveness claim in an NDA application. This process is known as a SPA. These agreements may not be changed after the clinical trials begin, except in limited circumstances. The existence of a SPA, however, does not assure approval of a product candidate.

Drug Approval

Assuming successful completion of the required clinical testing, the results of the preclinical studies and of the clinical trials, together with other detailed information, including information on the manufacture and composition of the investigational product, are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The testing and approval process requires substantial time, effort and financial resources. Submission of an NDA requires payment of a substantial review user fee to the FDA. The FDA will review the application and may deem it to be inadequate to support commercial marketing, and there can be no assurance that any product approval will be granted on a timely basis, if at all. The FDA may also seek the advice of an advisory committee, typically a panel of clinicians practicing in the field for which the product is intended, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of the advisory committee.

The FDA has various programs, including breakthrough therapy, fast track, priority review and accelerated approval, that are intended to expedite or simplify the process for reviewing drugs and/or provide for approval on the basis of surrogate endpoints. Generally, drugs that may be eligible for one or more of these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that provide meaningful benefit over existing treatments. We cannot be sure that any of our drugs will qualify for any of these programs, or that, if a drug does qualify, the review time will be reduced or the product will be approved.

Before approving a NDA, the FDA usually will inspect the facility or the facilities where the product is manufactured, tested and distributed and will not approve the product unless cGMP compliance is satisfactory. If the FDA evaluates the NDA and the manufacturing facilities as acceptable, the FDA may issue an approval letter, or in some cases, a complete response letter. A complete response letter contains a number of conditions that must be met in order to secure final approval of the NDA. When and if those conditions have been met to the FDA’s satisfaction, the FDA will issue an approval letter. The approval letter authorizes commercial marketing of the drug for specific indications. As a condition of approval, the FDA may

require post-marketing testing and surveillance to monitor the product’s safety or efficacy, or impose other post-approval commitment conditions.

In some circumstances, post-marketing testing may include post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, which are used primarily to gain additional experience from the treatment of patients in the intended population, particularly for long-term safety follow-up. In addition, the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits outweigh the risks. A REMS can include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk mitigation tools.

After approval, certain changes to the approved product, such as adding new indications, making certain manufacturing changes or making certain additional labeling claims, are subject to further FDA review and approval. Obtaining approval for a new indication generally requires that additional clinical trials be conducted.

Post-Approval Requirements

Holders of an approved NDA are required to: (i) report certain adverse reactions to the FDA; (ii) comply with certain requirements concerning advertising and promotional labeling for their products; and (iii) continue to have quality control and manufacturing procedures conform to cGMP after approval. The FDA periodically inspects the sponsor’s records related to safety reporting and/or manufacturing and distribution facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the area of production, quality control and distribution to maintain cGMP compliance. Future FDA inspections may identify compliance issues at manufacturing facilities that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market.

Marketing of prescription drugs is also subject to significant regulation through federal and state agencies tasked with consumer protection and prevention of medical fraud, waste and abuse. After approval in the U.S., we must comply with FDA’s regulation of drug promotion and advertising, including restrictions on off-label promotion, and we comply with federal anti-kickback statutes, limitations on gifts and payments to physicians and reporting of payments to certain third parties, among other requirements.

Failure to comply with applicable U.S. requirements may subject us to administrative or judicial sanctions, such as clinical holds, FDA refusal to approve pending NDAs or supplemental applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.

Non-U.S. Regulation

Before our products can be marketed outside of the U.S., they are subject to regulatory approval similar to that required in the U.S., although the requirements governing the conduct of clinical trials, including additional clinical trials that may be required, product licensing, pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product.

In the E.U., marketing authorizations for medicinal products can be obtained through several different procedures founded on the same basic regulatory process. The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products, medicinal products derived from certain biotechnological processes, advanced therapy medicinal products and certain other new medicinal products containing a new active substance for the treatment of certain diseases. It is optional for certain other products, including medicinal products that are significant therapeutic, scientific or technical innovations, or whose authorization would be in the interest of public or animal health. The centralized procedure allows a company to submit a single application to the EMA which will provide a positive opinion regarding the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European Commission takes a final decision to grant a centralized marketing authorization which is valid in all 28 E.U. Member States and three of the four European Free Trade Association states (Iceland, Liechtenstein and Norway).

Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each E.U. Member State in which the product is to be marketed. One national competent authority selected by the applicant, the Reference Member State, assesses the application for marketing authorization. Following a positive opinion by the competent authority of the Reference Member State the competent authorities of the other E.U. Member States, Concerned Member States are subsequently required to grant marketing authorization for their territory on the basis of this assessment except where grounds of potential serious risk to public health require this authorization to be refused. The mutual recognition procedure is similarly based on the acceptance by the competent authorities of the Concerned Member States of the marketing authorization of a medicinal product by the competent authorities of other Reference Member States. The holder of a national marketing authorization granted by a Reference Member State may submit an application to the competent authority of a Concerned Member State requesting that this authority mutually recognize the marketing authorization delivered by the competent authority of the Reference Member State.

Similar to accelerated approval regulations in the U.S., conditional marketing authorizations can be granted in the E.U. by the European Commission in exceptional circumstances. A conditional marketing authorization can be granted for medicinal products where a number of criteria are fulfilled; i) although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, the benefit/risk balance of the product is positive, ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, iii) unmet medical needs will be fulfilled and iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization must be renewed annually. Under the provisions of the conditional marketing authorization for PIXUVRI, we are required to complete a post-marketing study to further investigate the effects of using PIXUVRI in patients who had received prior treatment with rituximab.

Even if a product receives authorization in the E.U., there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. Individual countries comprising the EU member states, rather than the EU, have jurisdiction across the region over patient reimbursement or pricing matters. Therefore, we will need to expend significant effort and expense to establish and maintain reimbursement arrangements in the various countries comprising the E.U. and may never succeed in obtaining widespread reimbursement arrangements therein.

The national authorities of the individual E.U. Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices and/or reimbursement of medicinal products for human use. Some E.U. Member States adopt policies according to which a specific price or level of reimbursement is approved for the medicinal product. Other E.U. Member States adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements and reference pricing mechanisms.

Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some E.U. Member States. These E.U. Member States include the U.K, France, Germany and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between E.U. Member States.

Post-Approval Regulation

Similarly to the U.S., both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual E.U. Member States both before and after grant of the manufacturing and marketing authorizations. Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with E.U. laws and the related national laws of individual E.U. Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of marketing authorization, may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.

The holder of an E.U. marketing authorization for a medicinal product must also comply with E.U. pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. These rules can impose on central marketing authorization

holders for medicinal products the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies, which may be time consuming and expensive and could impact our profitability. Non-compliance with such obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the product or imposition of financial penalties or other enforcement measures. In the E.U., PIXUVRI's label includes an inverted black triangle, which indicates that it is subject to additional monitoring, as a condition of authorization of PIXUVRI.

The manufacturing process for medicinal products in the E.U. is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable E.U. laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with E.U. cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the E.U. with the intention to import the active pharmaceutical ingredients into the E.U. Similarly, the distribution of medicinal products into and within the E.U. is subject to compliance with the applicable E.U. laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the E.U. Member States.

We and our third-party manufacturers are subject to cGMP, which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by the EMA, the competent authorities of E.U. Member States and other regulatory authorities. The EMA reviews Periodic Safety Update Reports for medicinal products authorized in the E.U. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing marketing authorization for the product be suspended or varied and can advise that the marketing authorization holder be obliged to conduct post-authorization safety studies. The EMA opinion is submitted for approval by the European Commission. Failure by the marketing authorization holder to fulfill the obligations for which the approved opinion provides can undermine the on-going validity of the marketing authorization.

Sales and Marketing Regulations

In the E.U., the advertising and promotion of our products are subject to E.U. Member States’ laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual E.U. Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product’s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. The off-label promotion of medicinal products is prohibited in the E.U.. The applicable laws at E.U. level and in the individual E.U. Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the E.U. could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with health care professionals.

Anti-Corruption Legislation

Our business activities outside of the U.S. are subject to anti-bribery or anti-corruption laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct or rules of other countries in which we operate, including the U.K. Bribery Act of 2010.

Interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct developed at both E.U. level and in the individual E.U. Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the E.U.. Violation of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain E.U. Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her competent professional organization, and/or the competent authorities of the individual E.U. Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Data Privacy and Protection

Data protection laws and regulations have been adopted at E.U. level with related implementing laws in individual E.U. Member States which impose significant compliance obligations. For example, the E.U. Data Protection Directive, as implemented into national laws by the E.U. Member States, imposes strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting.

Furthermore, there is a growth towards the public disclosure of clinical trial data in the E.U. which also adds to the complexity of processing health data from clinical trials. Such public disclosure obligations are provided in the new E.U. Clinical Trials Regulation, EMA disclosure initiatives, and voluntary commitments by industry. Data protection authorities from the different E.U. Member States may interpret the E.U. Data Protection Directive and national laws differently, which adds to the complexity of processing personal data in the E.U., and guidance on implementation and compliance practices are often updated or otherwise revised. Failing to comply with these laws could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results. Apart from exceptional circumstances, the E.U. Data Protection Directive prohibits the transfer of personal data to countries outside of the European Economic Area, that are not considered by the European Commission to provide an adequate level of data protection, including the U.S.

Consequences of Non-Compliance

Failure to comply with applicable requirements may subject us to administrative or judicial sanctions, such as clinical holds, refusal of regulatory authorities to approve or authorize pending product applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.

Environmental Regulation

In connection with our research and development activities, we are subject to federal, state and local laws, rules, regulations and policies, both internationally and domestically, governing the use, generation, manufacture, storage, air emission, effluent discharge, handling, treatment, transportation and disposal of certain materials, biological specimens and wastes and employee safety and health matters. Although we believe that we have complied with these laws, regulations and policies in all material respects and have not been required to take any significant action to correct any noncompliance, we may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Our research and development involves the controlled use of hazardous materials, including, but not limited to, certain hazardous chemicals and radioactive materials. Although we believe that our safety procedures for handling and disposing of such materials comply with applicable law and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability not covered by insurance could exceed our resources. See the risk factor, “We may be subject to claims relating to improper handling, storage or disposal of these materials.” in Part I, Item 1A, “Risk Factors” of this Annual Report on Form 10-K for additional information regarding the risks and uncertainties we face due to the use of hazardous materials.

Employees

As of December 31, 2017, we employed 57 individuals in the U.S., including 1 employee at our majority-owned subsidiary Aequus Biopharma, Inc., or Aequus, and 1 employee in Italy. Our U.S. employees do not have a collective bargaining agreement. Our employee in Italy is subject to a collective bargaining agreement. We believe our relations with our employees are good.

Corporate Information

We were incorporated in Washington in 1991. In May 2014, we changed our name from “Cell Therapeutics, Inc.” to “CTI BioPharma Corp.” We completed our initial public offering in 1997 and our shares are listed on The NASDAQ Capital Market in the U.S. where our symbol is CTIC. On January 24, 2018, we changed our state of incorporation from the State of Washington to the State of Delaware by merging the Company with and into its wholly-owned Delaware subsidiary named CTI Biopharma Corp. and delisted the Company from Borsa Italiana’s Main Market, or MTA. Our principal executive offices are located at 3101 Western Avenue, Suite 800, Seattle, Washington 98121. Our telephone number is (206) 282-7100. Our website address is http://www.ctibiopharma.com. We may post information that is important to investors on our website. However, information found on our website is not incorporated by reference into this Annual Report on Form 10-K. “CTI BioPharma”, “PIXUVRI” and “Opaxio” are our proprietary marks. All other product names, trademarks and trade names referred to in this Annual Report on Form 10-K are the property of their respective owners. We make available free of charge on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after each is electronically filed with, or furnished to, the SEC.

In addition, you may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants, including the Company, that file electronically with the SEC.

Item 1A. Risk Factors

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. The occurrence of any of the risks described below and elsewhere in this document, including the risk that our actual results may differ materially from those anticipated in these forward-looking statements, could materially adversely affect our business, financial condition, liquidity, operating results or prospects and the trading price of our securities. Additional risks and uncertainties that we do not presently know or that we currently deem immaterial may also harm our business, financial condition, operating results and prospects and the trading price of our securities.

Factors Affecting Our Business, Financial Condition, Operating Results and Prospects

We will need to raise additional funds to operate our business, but additional funds may not be available on acceptable terms, or at all. Any inability to raise required capital when needed could harm our liquidity, financial condition, business, operating results and prospects.

We have substantial operating expenses associated with the development of our compounds and the commercialization of PIXUVRI, and we have significant contractual payment obligations. Our available cash, cash equivalents and restricted cash were $43.2 million as of December 31, 2017. In February 2018, we received approximately $64.2 million in net proceeds from the public offering of common stock as discussed in Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 21. Subsequent Events," which is incorporated herein by reference. In addition, we received a $10.0 million milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain of our contractual agreements and our ability to control costs, will be sufficient to fund our operations through the first quarter of 2020. However, cash forecasts and capital requirements are subject to change as a result of a variety of risks and uncertainties. Developments in and expenses associated with our clinical trials and other research and development activities, including the resumption of primary responsibilities for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement in October 2016, acquisitions of compounds or other assets, our ability to generate projected sales of PIXUVRI, any expansion of our sales and marketing organization for PIXUVRI, regulatory approval developments, our ability to consummate appropriate collaborations for development and commercialization activities, our ability to reach milestones triggering payments under applicable contractual arrangements, receive the associated payments, litigation and other disputes, competitive market developments and other unplanned expenses or business developments may consume capital resources earlier than planned. Due to these and other factors, any forecast for the period for which we will have sufficient resources to fund our operations, as well as any other operational or business projection we have disclosed, or may, from time to time, disclose, may fail.

On November 28, 2017, we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, the proceeds of which was partially used to repay in full all outstanding indebtedness under our Loan and Security Agreement, dated March 26, 2013, as amended, with Systems Medicine LLC and Hercules Technology Growth Capital, Inc., or Hercules, (and certain of its affiliates). As of December 31, 2017, we had an outstanding principal balance under our senior secured term loan agreement of $16.0 million. We have an option to borrow an additional $2.0 million through July 31, 2018, subject to the satisfaction of certain conditions, which if borrowed would increase our outstanding principal balance. We are required to make monthly interest only payments for at least 12 months after closing, through November 1, 2018, which period of interest-only payments may be extended to 18 months upon the occurrence of a certain milestone event, in the approximate amount of $0.1 million per month. After the initial 12-month interest-only period, we are required to pay interest plus principal payments for 36 months, in the approximate amount of $0.5 million per month, with the final principal plus interest payment of approximately $0.4 million as well as a back-end fee of $1.4 million on November 1, 2021. These borrowings are secured by a first priority security interest on substantially all of our personal property except our intellectual property and subject to certain other exceptions. In addition, the senior secured term loan agreement requires us to comply with restrictive covenants, including those that limit our operating flexibility and ability to borrow additional funds. A failure to make a required loan payment or an uncured covenant breach could lead to an event of default, and in such case, all amounts then outstanding may become due and payable immediately.

•our ability to raise capital through the issuance of additional shares of our common stock or convertible securities is restricted by the limited number of our residual authorized shares, the potential difficulty of obtaining shareholder approval to increase authorized shares and the restrictive covenants under our senior secured term loan agreement;

•issuance of equity-based securities will dilute the proportionate ownership of existing shareholders;

•our ability to obtain further funds from any potential loan arrangements is limited by our existing senior secured term loan agreement;

•certain financing arrangements may require us to relinquish rights to various assets and/or impose more restrictive terms than any of our existing or past arrangements; and

•we may be required to meet additional regulatory requirements, and we may be subject to certain contractual limitations, which may increase our costs and harm our ability to obtain funding.

For these and other reasons, additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly qualified personnel, refrain from making our contractually required payments when due (including debt payments) and/or be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. Any of these consequences could harm our business, financial condition, operating results and prospects.

We have in the past received and may in the future receive audit reports with an explanatory paragraph on our consolidated financial statements.

Our independent registered public accounting firm included an explanatory paragraph in its reports on our consolidated financial statements for each of the years ended December 31, 2007 through December 31, 2011 and for the years ended December 31, 2014 and 2016 regarding their substantial doubt as to our ability to continue as a going concern. Although our independent registered public accounting firm removed this going concern explanatory paragraph in its report on our December 31, 2017 consolidated financial statements, we expect to continue to need to raise additional financing to fund our operations and satisfy obligations as they become due. The inclusion of a going concern explanatory paragraph in future years may negatively impact the trading price of our common stock and make it more difficult, time consuming or expensive to obtain necessary financing, and we cannot guarantee that we will not receive such an explanatory paragraph in the future.

We expect to continue to incur net losses, and we may never achieve profitability.

We were incorporated in 1991 and have incurred a net operating loss every year since our formation. As of December 31, 2017, we had an accumulated deficit of $2.2 billion, and we expect to continue to incur net losses. As part of our business plan, we will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. There can be no assurances that we will ever achieve profitability.

In order to develop and commercialize pacritinib, we may need to raise additional financing or seek a new collaboration partner for pacritinib.

We have resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement in October 2016, and we are no longer eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta. Because obtaining regulatory approval requires substantial time, effort and financial resources, the termination of this collaborative partnership could negatively impact our ability to successfully develop and commercialize pacritinib. We currently have no commitments or arrangements for any additional financing to fund the development and commercial launch of pacritinib, and we may need to seek additional funding, which may not be available or may not be available on favorable terms. We could also seek another collaborative partnership for the development and commercialization of pacritinib, which may not be available on reasonable terms or at all.

If our development and commercialization collaborations are not successful, or if we are unable to enter into additional collaborations, we may not be able to effectively develop and/or commercialize our compounds, which could have a material adverse effect on our business.

Our business is heavily dependent on the success of our development and commercialization collaborations. In particular, under the Restated Agreement with Servier, we rely heavily on Servier to collaborate with us to develop and commercialize PIXUVRI. As a result of our dependence on our relationship with Servier, the success or commercial viability of PIXUVRI is, to a certain extent, beyond our control. We are subject to a number of specific risks associated with our dependence on our collaborative relationship with Servier, including but not limited to the following: possible disagreements as to the timing, nature and extent of development plans for the respective compound, including clinical trials or regulatory approval strategy; changes in their respective personnel who are key to the collaboration efforts; any changes in their respective business strategies adverse to our interests, whether in connection with a change of control or otherwise; possible disagreements regarding ownership of proprietary rights; the ability to meet our financial and other contractual obligations under the respective agreements; and the possibility that Servier could elect to terminate their agreement with us pursuant to “at-will” termination clauses or breach their agreement with us. Furthermore, the contingent financial returns under our collaboration with Servier depends in large part on the achievement of development and commercialization milestones and the ability to generate applicable product sales to trigger royalty payments. Therefore, our success, and any associated future financial returns to us and our investors, will depend in large part on the performance of Servier. If our existing collaborations fail, or if we do not successfully enter into additional collaborations when needed, we may be unable to further develop and commercialize the applicable compounds, generate revenues to sustain or grow our business or achieve profitability, which would harm our business, financial condition, operating results and prospects.

The regulatory approval process for pacritinib has been subject to delay and uncertainty associated with clinical holds placed on pacritinib clinical trials in February 2016 and the withdrawal of the original MAA in Europe. While the full clinical hold on pacritinib trials has been removed and a new MAA has been validated by the EMA, our dose-exploration trial for pacritinib and further clinical trials for pacritinib could be subject to further delay or we could be prevented from further studying pacritinib or seeking its commercialization.

On February 8, 2016, the FDA notified us that a full clinical hold had been placed on pacritinib and we subsequently withdrew our NDA for pacritinib until we determine next steps. A full clinical hold is a suspension of the clinical work requested under an investigational new drug application. Under the full clinical hold, all patients on pacritinib at the time the hold was placed were required to discontinue pacritinib, and we were not permitted to enroll any new patients or start pacritinib as initial or crossover treatment. In its written notification, the FDA noted interim overall survival results from PERSIST-2 showing a detrimental effect on survival consistent with the results from PERSIST-1, and that deaths in PERSIST-2 in pacritinib-treated patients include intracranial hemorrhage, cardiac failure and cardiac arrest. On January 3, 2017, the full clinical hold was removed. Our complete response submission included, among other items, final Clinical Study Reports for both PERSIST-1 and 2 trials and the dose-exploration clinical trial protocol requested by the FDA. In July 2017, we enrolled the first patient in the PAC203 trial. We plan to enroll up to approximately 105 patients in our PAC203 trial with primary myelofibrosis who have failed prior ruxolitinib therapy to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 or 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in PERSIST-2. The trial is expected to enroll up to 105 patients. We enrolled our first patient in PAC203 in July 2017 and expect to complete enrollment by mid-2018. We expect to have interim data from PAC203 by the end of the second quarter of 2018 and full data in the first quarter of 2019. The results of PAC203 may not address all of the FDA’s concerns regarding appropriate safe and efficacious dosage for pacritinib, and the FDA may again request additional information or require us to pursue new clinical safety trials with changes to, among other things, protocol, study design or sample size.

Further, in the EMA’s initial assessment report regarding our original MAA, the CHMP determined that the current application was not approvable because of major objections in the areas of efficacy, safety (hematological and cardiovascular toxicity) and the overall risk-benefit profile of pacritinib. Subsequent to the filing of the original MAA, data from the second phase 3 trial of pacritinib, PERSIST-2, were reported. These data suggest that pacritinib may show clinical benefit in patients who have failed or are intolerant to ruxolinitib therapy, a population for which there is no approved therapy. Following discussions with the EMA about how PERSIST-2 data might address the major objections and how to integrate the data into the current application, we withdrew our original MAA, and we submitted a new MAA that seeks to address the major objections by including data from PERSIST-2. The new application is for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). The new MAA was validated by the EMA in July 2017. Following discussions with the EMA about how PERSIST-2 data might address the major objections and how to integrate the data into the current application, we withdrew the original MAA, and submitted a new application for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). The new MAA was validated by the EMA in July 2017. Validation confirms that the submission is complete and initiates the centralized review process by the CHMP. The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a

final decision on E.U. authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 E.U. member states, Norway, Iceland and Liechtenstein.

The submission of new marketing applications, complying with any additional requests for information from the FDA or EMA or making any changes to protocol, study design, or sample size may be time-consuming, expensive and delay or prevent our ability to continue to study pacritinib. If we are unable to address any further recommendations, requests, or objections in a manner satisfactory to the FDA or EMA, as applicable, in a timely manner, or at all, we could be delayed or prevented from seeking commercialization of pacritinib. Delays in the commercialization of pacritinib would prevent us from receiving future milestone or royalty payments, and otherwise significantly harm our business.

Compounds that appear promising in research and development may fail to reach later stages of development for a number of reasons, including, among others, that clinical trials may take longer to complete than expected or may not be completed at all, and top-line or preliminary clinical trial data reports may ultimately differ from actual results once existing data are more fully evaluated.

Successful development of anti-cancer and other pharmaceutical products is highly uncertain, and obtaining regulatory approval to market drugs to treat cancer is expensive, difficult and speculative. Compounds that appear promising in research and development may fail to reach later stages of development for several reasons, including, but not limited to:

•delay or failure in obtaining necessary U.S. and international regulatory approvals, or the imposition of a partial or full regulatory hold on a clinical trial;

•difficulties in formulating a compound, scaling the manufacturing process, timely attaining process validation for particular drug products and obtaining manufacturing approval;

•pricing or reimbursement issues or other factors that may make the product uneconomical to commercialize;

•production problems, such as the inability to obtain raw materials or supplies satisfying acceptable standards for the manufacture of our products, equipment obsolescence, malfunctions or failures, product quality/contamination problems or changes in regulations requiring manufacturing modifications;

•inefficient cost structure of a compound compared to alternative treatments;

•obstacles resulting from proprietary rights held by others with respect to a compound, such as patent rights;

•lower than anticipated rates of patient enrollment as a result of factors, such as the number of patients with the relevant conditions, the proximity of patients to clinical testing centers, eligibility criteria for tests and competition with other clinical testing programs;

•preclinical or clinical testing requiring significantly more time than expected, resources or expertise than originally expected and inadequate financing, which could cause clinical trials to be delayed or terminated;

•failure of clinical testing to show potential products to be safe and efficacious, and failure to demonstrate desired safety and efficacy characteristics in human clinical trials;

•suspension of a clinical trial at any time by us, an applicable collaboration partner or a regulatory authority on the basis that the participants are being exposed to unacceptable health risks or for other reasons;

•delays in reaching or failing to reach agreement on acceptable terms with prospective CROs, and trial sites; and

•failure of third parties, such as CROs, academic institutions, collaborators, cooperative groups and/or investigator sponsors, to conduct, oversee and monitor clinical trials and results.

In addition, from time to time, we report top-line data for clinical trials. Such data are based on a preliminary analysis of then-available efficacy and safety data, and such findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Top-line or preliminary data are based on important assumptions, estimations, calculations and information then available to us to the extent we have had, at the time of such reporting, an opportunity to fully and carefully evaluate such information in light of all surrounding facts,

circumstances, recommendations and analyses. As a result, top-line results may differ from future results, or different conclusions or considerations may qualify such results once existing data have been more fully evaluated. In addition, third parties, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular compound and our business in general.

If the development of our compounds is delayed or fails, or if top-line or preliminary clinical trial data reported differ from actual results, our development costs may increase and the ability to commercialize our compounds may be harmed, which could harm our business, financial condition, operating results or prospects.

We or our collaboration partners may not obtain or maintain the regulatory approvals required to develop or commercialize some or all of our compounds.

We are subject to rigorous and extensive regulation by the FDA in the U.S. and by comparable agencies in other jurisdictions, including the EMA in the E.U. Some of our other product candidates are currently in research or development and, other than conditional marketing authorization for PIXUVRI in the E.U., we have not received marketing approval for our compounds. Our products may not be marketed in the U.S. until they have been approved by the FDA and may not be marketed in other jurisdictions until they have received approval from the appropriate foreign regulatory agencies. Each product candidate requires significant research, development and preclinical testing and extensive clinical investigation before submission of any regulatory application for marketing approval. Obtaining regulatory approval requires substantial time, effort and financial resources, and we may not be able to obtain approval of any of our products on a timely basis, or at all. For instance, on February 8, 2016, the FDA placed pacritinib on full clinical hold and the clinical hold was not removed until January 3, 2017. The number, size, design and focus of preclinical and clinical trials that will be required for approval by the FDA, the EMA or any other foreign regulatory agency varies depending on the compound, the disease or condition that the compound is designed to address and the regulations applicable to any particular compound. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval. The FDA, the EMA and other foreign regulatory agencies can delay, limit or deny approval of a compound for many reasons, including, but not limited to:

•a compound may not be shown to be safe or effective;

•the clinical and other benefits of a compound may not outweigh its safety risks;

•clinical trial results may be negative or inconclusive, or adverse medical events may occur during a clinical trial;

•the results of clinical trials may not meet the level of statistical significance required by regulatory agencies for approval;

•such regulatory agencies may interpret data from pre-clinical and clinical trials in different ways than we do;

•such regulatory agencies may not approve the manufacturing process of a compound or determine that a third-party contract manufacturers manufactures a compound in accordance with current good manufacturing practices, or cGMPs;

•a compound may fail to comply with regulatory requirements; or

•such regulatory agencies might change their approval policies or adopt new regulations.

If our compounds are not approved at all or quickly enough to provide net revenues to defray our operating expenses, our business, financial condition, operating results and prospects could be harmed.

In the event that we seek and the FDA does not grant accelerated approval or priority review for a drug candidate, we would experience a longer time to commercialization in the U.S., if commercialized at all, our development costs may increase and our competitive position may be harmed.

We were seeking accelerated approval and requested Priority Review of our NDA for pacritinib. However, on February 8, 2016, the FDA notified us that a full clinical hold had been placed on pacritinib and we subsequently withdrew our NDA for pacritinib. On January 3, 2017, the full clinical hold was removed. In July 2017, we enrolled the first patient in a new trial, PAC203, and we plan to enroll up to approximately 105 patients with primary myelofibrosis who have failed

prior ruxolitinib therapy to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in PERSIST-2.

We may in the future decide to seek accelerated approval pathway for our compounds. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. A surrogate endpoint under an accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. There can be no assurance that the FDA will agree that any endpoint we suggest with respect to any of our drug candidates is an appropriate surrogate endpoint. Furthermore, there can be no assurance that any application will be accepted or that approval will be granted. Even if a product candidate is granted accelerated approval, such accelerated approval is contingent on the sponsor’s agreement to conduct one or more post-approval confirmatory trials. Such confirmatory trial(s) must be completed with due diligence and, in some cases, the FDA may require that the trial(s) be designed and/or initiated prior to approval. Moreover, the FDA may withdraw approval of a product candidate or indication approved under the accelerated approval pathway for a variety of reasons, including if the trial(s) required to verify the predicted clinical benefit of a product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug, or if the sponsor fails to conduct any required post-approval trial(s) with due diligence.

In the event of priority review, the FDA has a goal to (but is not required to) take action on an application within a total of eight months (rather than a goal of twelve months for a standard review). The FDA grants priority review only if it determines that a product treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared to a standard application. The FDA has broad discretion whether to grant priority review, and, while the FDA has granted priority review to other oncology product candidates, our drug candidates may not receive similar designation. Moreover, receiving priority review from the FDA does not guarantee completion of review or approval within the targeted eight-month cycle or thereafter.

A failure to obtain accelerated approval or priority review would result in a longer time to commercialization of the applicable compound in the U.S., if commercialized at all, could increase the cost of development and could harm our competitive position in the marketplace.

Even if our compounds are successful in clinical trials and receive regulatory approvals, we or our collaboration partners may not be able to successfully commercialize them.

The development and ongoing clinical trials for our compounds may not be successful and, even if they are, the resulting products may never be successfully developed into commercial products. Even if we are successful in our clinical trials and in obtaining other regulatory approvals, the respective products may not reach or remain in the market for a number of reasons including:

•they may be found ineffective or cause harmful side effects;

•they may be difficult to manufacture on a scale necessary for commercialization;

•they may experience excessive product loss due to contamination, equipment failure, inadequate transportation or storage, improper installation or operation of equipment, vendor or operator error, inconsistency in yields or variability in product characteristics;

•they may be uneconomical to produce;

•political and legislative changes emerging after the recent election of the President of the United States may make the commercialization of our product candidates more difficult;

•we may fail to obtain reimbursement approvals or pricing that is cost effective for patients as compared to other available forms of treatment or that covers the cost of production and other expenses;

•they may not compete effectively with existing or future alternatives;

•we may be unable to develop commercial operations and to sell marketing rights;

•they may fail to achieve market acceptance; or

•we may be precluded from commercialization of a product due to proprietary rights of third parties.

In particular, with respect to the commercialization of PIXUVRI, we will be heavily dependent on our collaboration partner, Servier. The failure of Servier (or any other applicable collaboration partner) to fulfill its commercialization obligations with respect to a compound, or the occurrence of any of the events in the list above, could adversely affect the commercialization of our products. Additionally, uncertainty and speculation continue regarding the possible repeal of all or a portion of the Patient Protection and Affordable Care Act through legislative action, as well as possible changes to the regulations implemented under the Patient Protection and Affordable Care Act by the Department of Health and Human Services. The uncertainty this causes for the healthcare industry could also adversely affect the commercialization of our products. If we fail to commercialize products or if our future products do not achieve significant market acceptance, we will not likely generate significant revenues or become profitable.

The pharmaceutical business is subject to increasing government price controls and other restrictions on pricing, reimbursement and access to drugs, which could adversely affect our future revenues and profitability.

To the extent our products are developed, commercialized and successfully introduced to market, they may not be considered cost-effective and third-party or government reimbursement might not be available or sufficient. Globally, governmental and other third-party payors are becoming increasingly aggressive in attempting to contain health care costs by strictly controlling, directly or indirectly, pricing and reimbursement and, in some cases, limiting or denying coverage altogether on the basis of a variety of justifications, and we expect pressures on pricing and reimbursement from both governments and private payors inside and outside the U.S. to continue. In the U.S., we are subject to substantial pricing, reimbursement and access pressures from state Medicaid programs, private insurance programs and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Patient Protection and Affordable Care Act instituted comprehensive health care reform, which includes provisions that, among other things, reduce and/or limit Medicare reimbursement and impose new and/or increased taxes. In addition, members of the Trump administration, including the President, have made public statements criticizing pricing practices within the pharmaceutical industry, indicating that they may seek to increase pricing pressures on the pharmaceutical industry.

In almost all European markets, pricing and choice of prescription pharmaceuticals are subject to governmental control. Therefore, the price of our products and their reimbursement in Europe is and will be determined by national regulatory authorities. Reimbursement decisions from one or more of the European markets may impact reimbursement decisions in other European markets. A variety of factors are considered in making reimbursement decisions, including whether there is sufficient evidence to show that treatment with the product is more effective than current treatments, that the product represents good value for money for the health service it provides and that treatment with the product works at least as well as currently available treatments. The continuing efforts of governments and insurance companies, health maintenance organizations and other payors of health care costs, to contain or reduce costs of health care may affect the availability of capital, as well as our future revenues and profitability or those of our potential customers, suppliers and collaborative partners.

We may never be able to generate significant product revenues from the sale of PIXUVRI.

We anticipate that, for at least the next several years, our ability to generate revenues and become profitable will depend, in part, on our ability and that of our collaborator, Servier, to successfully commercialize our only currently marketed product, PIXUVRI. PIXUVRI is not approved for marketing in the U.S., is presently available only in a limited number of countries and is reimbursed in even fewer countries.

In addition, the successful commercialization of PIXUVRI depends heavily on the ability to obtain and maintain favorable reimbursement rates for users of PIXUVRI, as well as on various additional factors, including, without limitation, the ability to:

•obtain an annual renewal of our conditional marketing authorization for PIXUVRI;

•increase demand for and sales of PIXUVRI and obtain greater acceptance of PIXUVRI by physicians and patients;

•establish and maintain agreements with wholesalers and distributors on reasonable terms;

•maintain, and where necessary, enter into additional, commercial manufacturing arrangements with third parties, cost-effectively manufacture necessary quantities and secure distribution, managerial and other capabilities; and

•further develop and maintain a commercial organization to market PIXUVRI.

If we are unable to successfully commercialize PIXUVRI as planned, our business, financial condition, operating results and prospects could be harmed.

Post-approval or authorization regulatory reviews and obligations often result in significant expense and marketing limitations, and any failure to satisfy such ongoing obligations, including, in particular, our post-authorization commitment trial for PIXUVRI, could negatively affect our business, financial condition, operating results or prospects.

Even if a product receives regulatory approval or authorization, as applicable, we are and will continue to be subject to numerous regulations and statutes regulating the manner of obtaining reimbursement for and selling the product, including limitations on the indicated uses for which a product may be marketed. Approved or authorized products, including PIXUVRI, are subject to extensive manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping regulations. These requirements include submissions of safety and other post-marketing information and reports. In addition, such products are subject to ongoing maintenance of product registration and continued compliance with cGMPs, good clinical practices, or GCPs, and good laboratory practices, or GLPs. Further, distribution of products must be conducted in accordance with good distribution practices, or GDPs. The distribution process and facilities of our third-party distributors are subject to, and our wholesale distribution authorization by the UK Medicines and Healthcare Products Regulatory Agency subjects us to, continuing regulation by applicable regulatory authorities with respect to the distribution and storage of products. Regulatory authorities may also impose new restrictions on continued product marketing or may require the withdrawal of a product from the market if adverse events of unanticipated severity or frequency are discovered following approval. In addition, regulatory agencies may impose post-approval/post-authorization clinical trials, such as our ongoing PIX306 trial of PIXUVRI required by the EMA. We cannot predict the outcome of PIX306 or whether we will be able to complete the associated requirements in a timely manner. If we are unable to submit the requisite PIX306 clinical study report by the due date in December 2018 and are unable to obtain an extension of such deadline, or if we are otherwise unable to satisfy all applicable requirements, our conditional marketing authorization for PIXUVRI may be revoked.

Any other failure to comply with applicable regulations could result in warning or untitled letters, product recalls, interruption of manufacturing and commercial supply processes, withdrawal or seizure of products, suspension of an applicable wholesale distribution authorization and/or distribution of products, operating restrictions, injunctions, suspension of licenses, revocation of the applicable product’s approval or authorization, other administrative or judicial sanctions (including civil penalties and/or criminal prosecution) and/or unanticipated related expenditure to resolve shortcomings, which could negatively affect our business, financial condition, operating results or prospects.

We may not be able to maintain our listings on the NASDAQ Capital Market, or the NASDAQ, or trading on the NASDAQ may otherwise be halted or suspended, which may make it more difficult for investors to sell shares of our common stock and consequently may negatively impact the price of our common stock.

We regained compliance in January 2017 with the minimum $1.00 bid price requirement by effecting a 1-for-10 reverse stock split on January 1, 2017, after receiving notice of non-compliance from the NASDAQ in March 2016.

We have in the past and may in the future fail to comply with the NASDAQ requirements. If our common stock ceases to be listed for trading on the NASDAQ for failure to comply with the minimum $1.00 per share closing bid price requirement or for any other reason, it may harm our stock price, increase the volatility of our stock price, decrease the level of trading activity and make it more difficult for investors to buy or sell shares of our common stock. Our failure to maintain a listing on the NASDAQ may constitute an event of default under our senior secured term loan and any future indebtedness, which would accelerate the maturity date of such debt or trigger other obligations. In addition, certain institutional investors that are not permitted to own securities of non-listed companies may be required to sell their shares adversely affecting the market price of our common stock. If we are not listed on the NASDAQ or if our public float falls below $75 million, we will be limited in our ability to file new shelf registration statements on SEC Form S-3 and/or to fully use one or more registration statements on SEC Form S-3. We have relied significantly on shelf registration statements on SEC Form S-3 for most of our financings in recent years, so any such limitations may harm our ability to raise the capital we need. Trading in our common stock has been halted or suspended on the NASDAQ in the past and may also be halted or suspended in the future on the NASDAQ due to market or trading conditions at the discretion of the NASDAQ. Any halt or suspension in the trading in our common stock may negatively impact the market price of our common stock.

We may be unable to obtain a quorum for meetings of our shareholders or obtain requisite shareholder approval and, consequently, be unable to take certain corporate actions, including financing activities.

Failure to meet the requisite quorum or obtain requisite shareholder approval can prevent us from raising capital through equity financing or otherwise taking certain actions that may be in our best interest and that of our shareholders. We have experienced such difficulties in the past.

We are required under the NASDAQ Marketplace Rules to obtain shareholder approval for any issuance of additional equity securities that would comprise more than 20% of the total shares of our common stock outstanding before the issuance of such securities sold at a discount to the greater of book or market value in an offering that is not deemed to be a “public offering” by the NASDAQ Marketplace Rules, as well as under certain other circumstances. We have in the past and may in the future issue additional equity securities that would comprise more than 20% of the total shares of our common stock outstanding in order to fund our operations. However, we might not be successful in obtaining the required shareholder approval for any future issuance that requires shareholder approval pursuant to applicable rules and regulations, particularly in light of difficulties we have had in the past in obtaining a quorum and obtaining the requisite vote. If we are unable to obtain financing or our financing options are limited due to shareholder approval difficulties, such failure may harm our ability to continue operations.

As a result of the foregoing or for other reasons, we may be unable to obtain a quorum at annual or special meetings of shareholders. Even if we are able to obtain a quorum at our shareholder meetings, we may not obtain enough votes to approve matters to be resolved upon at those meetings. Any failure to obtain a quorum or the requisite vote on a proposal in question could harm us.

We will incur a variety of costs for, and may never realize the anticipated benefits of, acquisitions, collaborations or other strategic transactions.

We evaluate and undertake acquisitions, collaborations and other strategic transactions from time to time. The process of negotiating these transactions, as well as integrating any acquisitions and implementing any strategic alliances, may result in operating difficulties and expenditures. In addition, these transactions may require significant management attention that would otherwise be available for ongoing development of our business, whether or not any such transaction is ever consummated. These undertakings could also result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to intangible assets, and we may never realize the anticipated benefits. In addition, following the consummation of a transaction, our results of operations and the market price of our common stock may be affected by factors different from those that affected our results of operations and the market price of our common stock prior to such acquisition. Any of the foregoing consequences resulting from transactions of the type described above could harm our business, financial condition, operating results or prospects.

We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting the use of our products for non-FDA-approved, or off-label, uses.

Our business and future growth depend on the development, ultimate sale and use of products that are subject to FDA, EMA and or other regulatory agencies regulation, clearance and approval. Under the U.S. Federal Food, Drug, and Cosmetic Act and other laws, we are prohibited from promoting our products for off-label uses. This means that in the U.S., we may not make claims about the safety or effectiveness of our products and may not proactively discuss or provide information on the use of our products, except as allowed by the FDA.

Government investigations concerning the promotion of off-label uses and related issues are typically expensive, disruptive and burdensome, generate negative publicity and may result in fines or payments of settlement awards. If our promotional activities are found to be in violation of applicable law or if we agree to a settlement in connection with an enforcement action, we would likely face significant fines and penalties and would likely be required to substantially change our sales, promotion, grant and educational activities.

A failure to comply with the numerous laws and regulations that govern our business, including those related to cross-border conduct, health care fraud and abuse, anti-corruption and false claims and the protection of health information, could result in substantial penalties and prosecution.

We are subject to risks associated with doing business outside of the U.S., which exposes us to complex foreign and U.S. regulations. For example, we are subject to regulations imposed by the Foreign Corrupt Practices Act, or the

FCPA, the Bribery Act 2010 and other anti-corruption laws. These laws generally prohibit U.S. companies and their intermediaries from offering, promising, authorizing or making improper payments to foreign government officials for the purpose of obtaining or retaining business. The SEC and U.S. Department of Justice have increased their enforcement activities with respect to the FCPA. Internal control policies and procedures and employee training and compliance programs that we have implemented to deter prohibited practices may not be effective in prohibiting our employees, contractors or agents from violating or circumventing our policies and the law.

In addition, we are subject to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and federal False Claims Act. There are similar laws in other countries. These laws may impact, among other things, the sales, marketing and education programs for our products. The federal Anti-Kickback Statute prohibits persons from knowingly and willingly soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program. The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Suits filed under the False Claims Act can be brought by any individual on behalf of the government and such individuals, commonly known as “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement. Many states have also adopted laws similar to the federal Anti-Kickback Statute and False Claims Act.

We may also be subject to the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act and their respective implementing regulations, or HIPAA, which established uniform standards for certain “covered entities” (health care providers, health plans and health care clearinghouses) governing the conduct of certain electronic health care transactions and protecting the security and privacy of protected health information. Among other things, HIPAA’s privacy and security standards are directly applicable to “business associates” - independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. In addition to possible civil and criminal penalties for violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney’s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

We are unable to predict whether we could be subject to actions under any of the foregoing or similar laws and regulations, or the impact of such actions. If we were to be found to be in violation of applicable laws or regulations, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government health care reimbursement programs and the curtailment or restructuring of our operations, all of which could have a material adverse effect on our business and results of operations.

We are dependent on third-party service providers for a number of critical operational activities including, in particular, for the manufacture, testing and distribution of our compounds and associated supply chain operations, as well as for clinical trial activities. Any failure or delay in these undertakings by third parties could harm our business.

Our business is dependent on the performance by third parties of their responsibilities under contractual relationships. In particular, we rely heavily on third parties for the manufacture and testing of our compounds. We do not have internal analytical laboratory or manufacturing facilities to allow the testing or production of compounds in compliance with GLP and cGMP. As a result, we rely on third parties to supply us in a timely manner with manufactured products/product candidates. We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. In particular, we depend on third-party manufacturers to conduct their operations in compliance with GLP and cGMP or similar standards imposed by the U.S. and/or applicable foreign regulatory authorities, including the FDA and EMA. Any of these regulatory authorities may take action against a contract manufacturer who violates GLP and cGMP. Failure of our manufacturers to comply with FDA, EMA or other applicable regulations may cause us to curtail or stop the manufacture of such products until we obtain regulatory compliance.

We may not be able to obtain sufficient quantities of our compounds if we are unable to secure manufacturers when needed, or if our designated manufacturers do not have the capacity or otherwise fail to manufacture compounds according to our schedule and specifications or fail to comply with cGMP regulations. In particular, in connection with the transition of the manufacturing of PIXUVRI and pacritinib drug supply to successor vendors, respectively, we could face logistical, scaling or other challenges that may adversely affect supply. Furthermore, in order to ultimately obtain and maintain applicable regulatory approvals, any manufacturers we utilize are required to consistently produce the respective

compounds in commercial quantities and of specified quality or execute fill-finish services on a repeated basis and document their ability to do so, which is referred to as process validation. In order to obtain and maintain regulatory approval of a compound, the applicable regulatory authority must consider the result of the applicable process validation to be satisfactory and must otherwise approve of the manufacturing process. Even if our compound manufacturing processes obtain regulatory approval and sufficient supply is available to complete clinical trials necessary for regulatory approval, there are no guarantees we will be able to supply the quantities necessary to effect a commercial launch of the applicable drug, or once launched, to satisfy ongoing demand. Any compound shortage could also impair our ability to deliver contractually required supply quantities to applicable collaborators, as well as to complete any additional planned clinical trials.

We also rely on third-party service providers for certain warehousing, transportation, sales, order processing, distribution and cash collection services. With regard to the distribution of our compounds, we depend on third-party distributors to act in accordance with GDP, and the distribution process and facilities are subject to continuing regulation by applicable regulatory authorities with respect to the distribution and storage of products.

In addition, we depend on medical institutions and CROs (together with their respective agents) to conduct clinical trials and associated activities in compliance with GCP and in accordance with our timelines, expectations and requirements. To the extent any such third parties are delayed in achieving or fail to meet our clinical trial enrollment expectations, fail to conduct our trials in accordance with GCP or study protocol or otherwise take actions outside of our control or without our consent, our business may be harmed. Furthermore, we conduct clinical trials in foreign countries, subjecting us to additional risks and challenges, including, in particular, as a result of the engagement of foreign medical institutions and foreign CROs, who may be less experienced with regard to regulatory matters applicable to us and may have different standards of medical care.

With regard to certain of the foregoing clinical trial operations and stages in the manufacturing and distribution chain of our compounds, we rely on single vendors. In particular, our current business structure contemplates, at least in the foreseeable future, use of a single commercial supplier for PIXUVRI drug substance. In addition, in the event pacritinib is approved, we are initially preparing to have only one commercial supplier for pacritinib. We may in the future seek to qualify an additional manufacturer of pacritinib, but the process for qualifying a manufacturer can be lengthy and may not occur on a timely basis or at all. The use of single vendors for core operational activities, such as clinical trial operations, manufacturing and distribution, and the resulting lack of diversification, expose us to the risk of a material interruption in service related to these single, outside vendors. As a result, our exposure to this concentration risk could harm our business.

Although we monitor the compliance of our third-party service providers performing the aforementioned services, we cannot be certain that such service providers will consistently comply with applicable regulatory requirements or that they will otherwise timely satisfy their obligations to us. Any such failure and/or any failure by us to monitor their services and to plan for and manage our short and long term requirements underlying such services could result in shortage of the compound, delays in or cessation of clinical trials, failure to obtain or revocation of product approvals or authorizations, product recalls, withdrawal or seizure of products, suspension of an applicable wholesale distribution authorization and/or distribution of products, operating restrictions, injunctions, suspension of licenses, other administrative or judicial sanctions (including civil penalties and/or criminal prosecution) and/or unanticipated related expenditures to resolve shortcomings. Such consequences could have a significant impact on our business, financial condition, operating results or prospects.

If we are unable to recruit, retain, integrate and motivate senior management, other key personnel and directors, or if such persons are unable to perform effectively, our business could suffer.

Our future success depends, in part, on our ability to continue to attract and retain senior management, other key personnel and directors to enable the execution of our business plan and to identify and pursue new opportunities. Additionally, our productivity and the quality of our operations are dependent on our ability to integrate and train our new personnel quickly and effectively. In February 2017, we announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer effective March 2017, and also in September 2017, we announced the appointment of Bruce J. Seeley as Executive Vice President, Chief Operating Officer and David H. Kirske as Chief Financial Officer. Leadership transitions and management changes can be difficult to manage and may create uncertainty or disruption to our business or increase the likelihood of turnover in our other officers and employees. We may not be able to effectively manage our transition to a new president and chief executive officer.

Directors and management of publicly traded corporations are increasingly concerned with the extent of their personal exposure to lawsuits and shareholder claims, as well as governmental, creditor and other claims that may be made against them. Due to these and other reasons, such persons are also becoming increasingly concerned with the availability of

directors and officers liability insurance to pay on a timely basis the costs incurred in defending such claims. We currently carry directors and officers liability insurance. However, directors and officers liability insurance is expensive and can be difficult to obtain. If we are unable to continue to provide directors and officers sufficient liability insurance at affordable rates or at all, or if directors and officers perceive our ability to do so in the future to be limited, it may become increasingly more difficult to attract and retain management and qualified directors to serve on our Board of Directors.

The loss of the services of senior management, other key personnel or directors and/or the inability to timely attract or integrate such persons could significantly delay or prevent the achievement of our development and strategic objectives and may adversely affect our business, financial condition and operating results.

We face direct and intense competition from our competitors in the biotechnology and pharmaceutical industries, and we may not compete successfully against them.

Competition in the oncology market is intense and is accentuated by the rapid pace of technological and product development. We anticipate that we will face increased competition in the future as new companies enter the market. Our competitors in the U.S. and elsewhere are numerous and include, among others, major multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. Specifically:

•In Europe, PIXUVRI faces competition from existing treatments for adults with multiply relapsed or refractory aggressive B-cell NHL. For example, patients are currently being treated with ibrutinib, idelalisib, lenolidimide, bendamustine, oxaliplatin and gemcitabine, although these particular agents do not have regulatory approval in Europe for the foregoing indication. If we were to pursue bringing PIXUVRI to market in the U.S. (which is not currently part of our near-term plan), PIXUVRI would face similar competition.

•If we are successful in bringing pacritinib to market, pacritinib will face competition from the currently approved JAK1/JAK2 inhibitor, Jakafi®.

•If we are successful in bringing tosedostat to market, we will face competition from currently marketed products, such as cytarabine, Dacogen®, Vidaza®, Clolar®, Revlimid® and Thalomid®.

In addition to the specific competitive factors discussed above, new anti-cancer drugs that may be under development or developed and marketed in the future could compete with our various compounds.

Many of our competitors, particularly multinational pharmaceutical companies, either alone or together with their collaborators, have substantially greater financial and technical resources and substantially larger development and marketing teams than us, as well as significantly greater experience than we do in developing, commercializing, manufacturing, marketing and selling products. As a result, products of our competitors might come to market sooner or might prove to be more effective, less expensive, have fewer side effects or be easier to administer than ours. In any such case, sales of PIXUVRI or any potential future product would likely suffer and we might never recoup the significant investments we have made and will continue to make to develop and market these compounds.

If any of our license agreements for intellectual property underlying our compounds are terminated, we may lose the right to develop or market that product.

We have acquired or licensed intellectual property from third parties, including patent applications and patents relating to intellectual property for PIXUVRI, pacritinib and tosedostat. Some of our product development programs depend on our ability to maintain rights under these arrangements. Each licensor has the power to terminate its agreement with us if we fail to meet our obligations under these licenses. We may not be able to meet our obligations under these licenses. If we default under any license agreement, we may lose our right to market and sell any products based on the licensed technology and may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. Bankruptcy may result in the termination of agreements pursuant to which we license certain intellectual property rights.

If we are unable to in-license or acquire additional product candidates, our future product portfolio and potential profitability could be harmed.

One component of our business strategy is the in-licensing and acquisition of drug compounds developed by other pharmaceutical and biotechnology companies or academic research laboratories. PIXUVRI, pacritinib and tosedostat have all been in-licensed or acquired from third parties. Competition for new promising compounds and commercial products can

be intense. If we are not able to identify future in-licensing or acquisition opportunities and enter into arrangements on acceptable terms, our future product portfolio and potential profitability could be harmed.

We hold rights under numerous patents that we have acquired or licensed or that protect inventions originating from our research and development, and the expiration of any of these patents may allow our competitors to copy the inventions that are currently protected.

Our various tosedostat-directed patents expire in 2018. Tosedostat has orphan drug designation for acute myeloid leukemia in the U.S. and the E.U.

If we fail to adequately protect our intellectual property, our competitive position and the potential for long-term success could be harmed.

Development and protection of our intellectual property are critical to our business. If we do not adequately protect our intellectual property, competitors may be able to practice our technologies. Our success depends in part on our ability to:

•obtain and maintain patent protection for our products or processes both in the U.S. and other countries;

•protect trade secrets; and

•prevent others from infringing on our proprietary rights.

The patent position of pharmaceutical and biotechnology firms, including ours, generally is highly uncertain and involves complex legal and factual questions. The U.S. Patent and Trademark Office has not established a consistent policy regarding the breadth of claims that it will allow in biotechnology patents. If it allows broad claims, the number and cost of patent interference proceedings in the U.S. and the risk of infringement litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the value of our rights under our patents, licenses and patent applications may also decrease. Patent applications in which we have rights may never issue as patents, and the claims of any issued patents may not afford meaningful protection for our technologies or products. In addition, patents issued to us or our licensors may be challenged and subsequently narrowed, invalidated or circumvented. Litigation, interference proceedings or other governmental proceedings that we may become involved in with respect to our proprietary technologies or the proprietary technology of others could result in substantial cost to us.

We also rely upon trade secrets, proprietary know-how and continuing technological innovation to remain competitive. Third parties may independently develop such know-how or otherwise obtain access to our technology. While

we require our employees, consultants and corporate partners with access to proprietary information to enter into confidentiality agreements, these agreements may not be honored.

Patent litigation is widespread in the biotechnology industry, and any patent litigation could harm our business.

Costly litigation might be necessary to protect a patent position or to determine the scope and validity of third-party proprietary rights, and we may not have the required resources to pursue any such litigation or to protect our patent rights. Any adverse outcome in litigation with respect to the infringement or validity of any patents owned by third parties could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using a product or technology. With respect to our in-licensed patents, if we attempt to initiate a patent infringement suit against an alleged infringer, it is possible that our applicable licensor will not participate in or assist us with the suit, and as a result, we may not be able to effectively enforce the applicable patents against the alleged infringers.

We may be unable to obtain or protect our intellectual property rights and we may be liable for infringing upon the intellectual property rights of others, which may cause us to engage in costly litigation and, if unsuccessful, could cause us to pay substantial damages and prohibit us from selling our products.

At times, we may monitor patent filings for patents that might be relevant to some of our products and product candidates in an effort to guide the design and development of our products to avoid infringement, but may not have conducted an exhaustive search. We may not be able to successfully challenge the validity of third-party patents and could be required to pay substantial damages, possibly including treble damages, for past infringement and attorneys’ fees if it is ultimately determined that our products infringe such patents. Further, we may be prohibited from selling our products before we obtain a license, which, if available at all, may require us to pay substantial royalties.

Moreover, third parties may challenge the patents that have been issued or licensed to us. We do not believe that PIXUVRI, pacritinib or any of the other compounds we are currently developing infringe upon the rights of any third parties nor do we believe that they are materially infringed upon by third parties; however, there can be no assurance that our technology will not be found in the future to infringe upon the rights of others or be infringed upon by others. In such a case, others may assert infringement claims against us, and should we be found to infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties’ patent rights. In addition to any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property, enter into royalty agreements or redesign our compounds so as not to utilize this intellectual property, each of which may prove to be uneconomical or otherwise impossible. Conversely, we may not always be able to successfully pursue our claims against others that infringe upon our technology and the technology exclusively licensed from any third parties. Thus, the proprietary nature of our technology or technology licensed by us may not provide adequate protection against competitors.

Even if infringement claims against us are without merit, or if we challenge the validity of issued patents, lawsuits take significant time, may, even if resolved in our favor, be expensive and divert management attention from other business concerns. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations.

The illegal distribution and sale by third parties of counterfeit versions of a product or stolen product could have a negative impact on our reputation and business.

Third parties might illegally distribute and sell counterfeit or unfit versions of a product that do not meet our rigorous manufacturing and testing standards. A patient who receives a counterfeit or unfit product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit product sold under our brand name. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.

We may owe additional amounts for VAT related to our operations in Europe.

Our European operations are subject to the VAT which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was $4.8 million and $4.4 million as of December 31, 2017 and December 31, 2016, respectively. On April 14, 2009, December 21, 2009 and June 25, 2010, the ITA issued notices of assessment to CTI (Europe) based on the ITA’s audit of CTI (Europe)’s VAT returns for the years 2003, 2005, 2006 and 2007. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services

performed by CTI (Europe). The assessments, including interest and penalties, for the years 2003, 2006 and 2007 are €0.5 million, €2.5 million and €0.8 million, respectively. While we are defending ourselves against the assessments both on procedural grounds and on the merits of the case, there can be no assurances that we will be successful in such defense. The 2005 VAT assessment was decided in favor of the Company by the Italian Supreme Court, with no further potential liabilities for the Company. Further information pertaining to these cases can be found in Part I, Item 3, "Legal Proceedings," and is incorporated by reference herein. If the final decision of the Italian Supreme Court is unfavorable to us, or if, in the interim, the ITA were to make a demand for payment and we were to be unsuccessful in suspending collection efforts, we may be requested to pay to the ITA an amount up to €3.9 million or approximately $4.7 million converted using the currency exchange rate as of December 31, 2017, plus collection fees, notification expenses and additional interest for the period lapsed between the date in which the assessments were issued and the date of effective payment.

We are currently subject to certain regulatory and legal proceedings, and may in the future be subject to additional proceedings and/or allegations of wrong-doing, which could harm our financial condition and operating results.

We are currently, and may in the future be, subject to regulatory matters and legal claims, including possible securities, derivative, consumer protection and other types of proceedings pursued by individuals, entities or regulatory bodies. As described in Part I, Item 3, "Legal Proceedings," we are currently in the process of supplying documents in response to a subpoena from the SEC in connection with an investigation into potential federal securities law violations. Litigation is subject to inherent uncertainties, and we have had and may in the future have unfavorable rulings and settlements. Adverse outcomes may result in significant monetary damages or injunctive relief against us. It is possible that our financial condition and operating results could be harmed in any period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable. If an unfavorable ruling were to occur in any of the legal proceedings we are or may be subject to, our business, financial condition, operating results and prospects could be harmed. The ultimate outcome of litigation and other claims is subject to inherent uncertainties, and our view of these matters may change in the future.

We cannot predict with certainty the eventual outcome of pending litigation. In addition, negative publicity resulting from any allegations of wrong-doing could harm our business, regardless of whether the allegations are valid or whether there is a finding of liability. Furthermore, we may have to incur substantial time and expense in connection with such lawsuits and management’s attention and resources could be diverted from operating our business as we respond to the litigation. Our insurance is subject to high deductibles and there is no guarantee that the insurance will cover any specific claim that we currently face or may face in the future, or that it will be adequate to cover all potential liabilities and damages. In the event of negative publicity resulting from allegations of wrong-doing and/or an adverse outcome under any currently pending or future lawsuit, our business could be materially harmed.

If we fail to maintain effective internal controls over financial reporting, we may not be able to accurately report our financial results, which could adversely effect on investor confidence, our business and the trading prices of our securities.

If we fail to maintain the adequacy of our internal controls, we may be unable to provide financial information in a timely and reliable manner within the time periods required for our financial reporting under SEC rules and regulations. Internal controls over financial reporting may not prevent or detect misstatements or omissions in our financial statements because of their inherent limitations, including the possibility of human error, the circumvention or overriding of controls or fraud. We have recently implemented a reduction in force, which may result in changes to occur in our internal controls over financial reporting. The changes could relate to different employees performing internal control activities than those who have previously performed those activities or revisions to our actual control activities as we evaluate the appropriate internal control structure after our workforce reduction. A changing internal control environment increases the risk that our system of internal controls is not designed effectively or that internal control activities will not occur as designed. The occurrence of or failure to remediate a significant deficiency material weakness may adversely affect our reputation and business and the market price of shares of our common stock.

Our net operating losses may not be available to reduce future income tax liability.

We have substantial tax loss carryforwards for U.S. federal income tax purposes, but our ability to use such carryforwards to offset future income or tax liability is limited under section 382 of the Internal Revenue Code of 1986, as amended, as a result of prior changes in the stock ownership of the Company. Moreover, future changes in the ownership of our stock, including those resulting from issuance of shares of our common stock upon exercise of outstanding warrants, may further limit our ability to use our net operating losses.

Due to the fact that we have European branches and subsidiaries conducting operations, together with the fact that we are party to certain contractual arrangements denoting monetary amounts in foreign currencies, we are subject to risk regarding currency exchange rate fluctuations.

We are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars for financial reporting purposes. The carrying value of the assets and liabilities, as well as the reported amounts of revenues and expenses, in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. Any expansion of our commercial operations in Europe (including with regard to sales of PIXUVRI) may increase our exposure to fluctuations in foreign currency exchange rates. In addition, certain of our contractual arrangements, such as the Restated Agreement with Servier, denote monetary amounts in foreign currencies, and consequently, the ultimate financial impact to us from a U.S. dollar perspective is subject to significant uncertainty. Furthermore, the referendum in the United Kingdom in June 2016, in which the majority of voters voted in favor of an exit from the European Union has resulted in increased volatility in the global financial markets and caused severe volatility in global currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against the euro. Changes in the value of the U.S. dollar as compared to foreign currencies (in particular, the euro) might have an adverse effect on our reported operating results and financial condition.

We may be unable to obtain the raw materials necessary to produce a particular product or product candidate.

We may not be able to purchase the materials necessary to produce a particular product or product candidate in adequate volume and quality. If any raw material required to produce a product or product candidate is insufficient in quantity or quality, if a supplier fails to deliver in a timely fashion or at all or if these relationships terminate, we may not be able to qualify and obtain a sufficient supply from alternate sources on acceptable terms, or at all.

Because there is a risk of product liability associated with our compounds, we face potential difficulties in obtaining insurance, and if product liability lawsuits were to be successfully brought against us, our business may be harmed.

Our business exposes us to potential product liability risks inherent in the testing, manufacturing, marketing and sale of human pharmaceutical products. In particular, as a result of the commercialization of PIXUVRI, our risk with respect to potential product liability has increased. If our insurance covering a compound is not maintained on acceptable terms or at all, we might not have adequate coverage against potential liabilities. Our inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or limit the commercialization of any products we develop. A successful product liability claim could also exceed our insurance coverage and could harm our financial condition and operating results.

We may be subject to claims relating to improper handling, storage or disposal of hazardous materials.

Our research and development activities involve the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations, both internationally and domestically, governing the use, manufacture, storage, handlings, treatment, transportation and disposal of such materials and certain waste products and employee safety and health matters. Although we believe that our safety procedures for handling and disposing of such materials comply with applicable law and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated completely. In the event of such an accident, we could be held liable for any damages that result and any such liability not covered by insurance could exceed our resources. Compliance with environmental, safety and health laws and regulations may be expensive, and current or future environmental regulations may impair our research, development or production efforts.

We depend on sophisticated information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business.

We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. Any such successful attacks could result in the theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent. We have invested in our systems and the protection of our data to reduce the risk of an intrusion or interruption, and we monitor our systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns. If we fail to maintain or protect our information

technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems, we could have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues or suffer other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.

Risks Related to the Securities Markets

Shares of our common stock are subordinate to existing and any future indebtedness and to any preferred stock we may issue.

Shares of our common stock rank junior to our existing indebtedness, including under our senior secured term loan agreement and any future indebtedness we may incur, as well as to all creditor claims and other non-equity claims against us and our assets available to satisfy claims on us, including claims in a bankruptcy or similar proceeding. Our senior secured term loan agreement restricts, and any future indebtedness and preferred stock may restrict, payment of dividends on our common stock. Shares of our common stock will also rank junior to any shares of our preferred stock that we may issue in the future.

Additionally, unlike indebtedness, where principal and interest customarily are payable on specified due dates, in the case of our common stock, (i) dividends are payable only when and if declared by our Board of Directors or a duly authorized committee of our Board of Directors and (ii) as a corporation, we are restricted to making dividend payments and redemption payments out of legally available assets. We have never paid a dividend on our common stock and have no current intention to pay dividends in the future. Furthermore, our common stock places no restrictions on our business or operations or on our ability to incur indebtedness or engage in any transactions, subject only to the voting rights available to our shareholders generally.

The market price of shares of our common stock is extremely volatile, which may affect our ability to raise capital in the future and may subject the value of your investment in our securities to sudden decreases.

The market price for securities of biopharmaceutical and biotechnology companies, including ours, historically has been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. For example, during the 12-month period ended February 28, 2018, our stock price ranged from a low of $2.45 to a high of $4.65. Fluctuations in the market price or liquidity of our common stock may harm the value of your investment in our common stock. Factors that may have an impact, which, depending on the circumstances, could be significant, on the market price and marketability of our securities include:

•announcements by us or others of results of clinical trials and regulatory actions, such as the imposition of a clinical trial hold;

•announcements by us or others of serious adverse events that have occurred during administration of our products to patients;

•announcements by us or others relating to our ongoing development and commercialization activities;

•halting or suspension of trading in our common stock on the NASDAQ;

•announcements of technological innovations or new commercial therapeutic products by us, our collaborative partners or our present or potential competitors;

•our issuance of debt or equity securities, which we expect to pursue to generate additional funds to operate our business, or any perception from time to time that we will issue such securities;

•our quarterly operating results;

•liquidity, cash position or financing needs;

•developments or disputes concerning patent or other proprietary rights;

•developments in relationships with collaborative partners;

•acquisitions or divestitures;

•our ability to realize the anticipated benefits of our compounds;

•litigation and government proceedings;

•adverse legislation, including changes in governmental regulation;

•third-party reimbursement policies;

•changes in securities analysts’ recommendations;

•short selling of our securities;

•changes in health care policies and practices;

•a failure to achieve previously announced goals and objectives as or when projected; and

•general economic and market conditions.

Anti-takeover provisions in our charter documents, in our shareholder rights agreement, or rights plan, under Delaware law and in other applicable instruments could make removal of incumbent management or an acquisition of us, which may be beneficial to our shareholders, more difficult.

Provisions of our certificate of incorporation and bylaws may have the effect of deterring or delaying attempts by our shareholders to remove or replace management, to commence proxy contests or to effect changes in control. These provisions include:

•elimination of cumulative voting in the election of directors;

•procedures for advance notification of shareholder nominations and proposals;

•the ability of our Board of Directors to amend our bylaws without shareholder approval; and

•the ability of our Board of Directors to issue shares of preferred stock without shareholder approval upon the terms and conditions and with the rights, privileges and preferences as our Board of Directors may determine.

Pursuant to our rights plan, an acquisition of 20% or more of our common stock by a person or group, subject to certain exceptions, could result in the exercisability of the preferred stock purchase right accompanying each share of our common stock (except those held by a 20% shareholder, which become null and void), thereby entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. The existence of our rights plan could have the effect of delaying, deterring or preventing a third party from making an acquisition proposal for us and may inhibit a change in control that some, or a majority, of our shareholders might believe to be in their best interest or that could give our shareholders the opportunity to realize a premium over the then-prevailing market prices for their shares.

In addition, as a Delaware corporation, we are subject to Delaware’s anti-takeover statute, which imposes restrictions on some transactions between a corporation and certain interested shareholders. Other existing provisions applicable to us that could have an anti-takeover effect include our executive employment agreements and certain provisions of our outstanding equity-based compensatory awards that allow for acceleration of vesting in the event of a change in control.

The foregoing provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

We currently lease approximately 66,000 square feet of space at 3101 Western Avenue in Seattle, Washington. The lease commenced in May 2012 and expires in April 2022. Approximately 44,000 square feet of space at this address has been subleased commencing December 2017 and ending April 2022. We also lease approximately 4,700 square feet of warehouse space in Seattle, Washington under a lease expiring in May 2018. We believe our existing and planned facilities are adequate to meet our present requirements. We anticipate that additional space will be available, when needed, on commercially reasonable terms.

Item 3. Legal Proceedings

In April 2009, December 2009 and June 2010, the Italian Tax Authority, or the ITA, issued notices of assessment to CTI - Sede Secondaria, or CTI (Europe), based on the ITA’s audit of CTI (Europe)’s value added tax, or VAT, returns for the years 2003, 2005, 2006 and 2007. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). The assessments, including interest and penalties, for the years 2003, 2005, 2006 and 2007 are €0.5 million, €5.5 million, €2.5 million and €0.8 million, respectively. We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We have appealed against all the assessments. As better detailed below, three different procedures have started before the Italian tax courts:

(i)2003 VAT, currently pending before the Supreme Court;

(ii)2005 VAT, decided in favor of CTI with no further potential liabilities for the Company; and

(iii)2006 and 2007 VAT (joined by the judge).

We are defending ourselves against the assessments in the pending procedures (those under (i) and (ii) above) both on procedural grounds and on the merits of the case, although we can make no assurances regarding the ultimate outcome of these cases. If the final decision of the Italian Supreme Court is unfavorable to us, or if, in the interim, the ITA were to make a demand for payment and we were to be unsuccessful in suspending collection efforts, we may be requested to pay the ITA an amount up to €3.9 million or approximately $4.7 million converted using the currency exchange rate as of December 31, 2017, plus collection fees, notification expenses and additional interest for the period lapsed between the date in which the assessments were issued and the date of effective payment. Following is a summary of the status of the legal proceedings surrounding each respective VAT year return at issue:

•2003 VAT. In September 2011, the Provincial Tax Court issued decision no. 229/3/2011, which (i) fully accepted the merits of our appeal, (ii) declared that no penalties can be imposed against us, and (iii) found the ITA liable to pay us €10,000, as partial refund of the legal expenses we incurred for our appeal. In October 2012, the ITA appealed this decision. In June 2013, the Regional Tax Court issued decision no. 119/50/13, which accepted the appeal of the ITA and reversed the previous decision of the Provincial Tax Court. We believe that such decision has not carefully taken into account our arguments and the documentation we filed, and therefore appealed such decision in front of the Supreme Court both on procedural grounds and on the merits of the case in January 2014. In January 2014 the Company was provided a notice of payment with which the ITA requested the advance payment of €0.4 million of VAT, interest and penalties. We paid such amount in March 2014.

•2005 VAT. In January 2011, the Provincial Tax Court issued decision No. 4/2010 which (i) partially accepted our appeal and declared that no penalties can be imposed against us, (ii) confirmed the right of the ITA to reassess the VAT (plus interest) in relation to the transactions identified in the 2005 notice of assessment and (iii) repealed the suspension of the notice of deposit payment. Both the ITA and the Company appealed to the higher court against the decision. In October 2012, the Regional Tax Court issued decision no. 127/31/2012, which (i) fully accepted the merits of our appeal and (ii) confirmed that no penalties can be imposed against us. In April 2013, the ITA appealed the decision to the Italian Supreme Court. On January 30, 2018, the Italian Supreme Court issued decision No. 02250/2018 which (i) rejected the appeal of the ITA, (ii) confirmed decision of the Regional Tax Court which ruled fully in our favor, and (iii) due to the novelty of the arguments at stake, compensated the legal expenses incurred by the parties. ITA may not use any ordinary mean of appeal against the Supreme Court decision.

•2006 VAT. In October 2011, the Provincial Tax Court issued decision no. 276/21/2011 (jointly with the 2007 VAT case) in which it (i) fully accepted the merits of our appeal, (ii) declared that no penalties can be imposed against us, and (iii) found that for the 2006 and 2007 VAT cases the ITA was liable to pay us €10,000 as partial refund of the legal expenses incurred for the appeal. In December 2011, the ITA appealed this decision to the Regional Tax Court. On April 16, 2013, the Regional Tax Court issued decision no. 57/35/13 (jointly with the 2007 VAT case) in which it fully rejected the merits of the ITA’s appeal, declared that no penalties can be imposed against us, and found the ITA liable to pay us €12,000, as partial refund of the legal expenses we incurred for this appeal. In November 2013, the ITA appealed the decision to the Supreme Court.

•2007 VAT. In October 2011, the Provincial Tax Court issued decision no. 276/21/2011 (jointly with the 2006 VAT case described above) in which the Provincial Tax Court (i) fully accepted the merits of our appeal, (ii) declared that no penalties can be imposed against us, and (iii) found that for the 2006 and 2007 VAT cases the ITA was liable to pay us €10,000 as partial refund of the legal expenses incurred for the appeal. In December 2011, the ITA appealed this decision to the Regional Tax Court. On April 16, 2013, the Regional Tax Court issued decision no. 57/35/13 (jointly with the 2006 VAT case) in which it fully rejected the merits of the ITA’s appeal, declared that no penalties can be imposed against us, and found the ITA liable to pay us €12,000, as partial refund of the legal expenses we incurred for this appeal. In November 2013, the ITA appealed the decision to the Supreme Court.

No hearing has been fixed yet for the 2003 and consolidated 2006/2007 VAT cases.

Securities and Exchange Commission Subpoena

We previously disclosed that we had received a subpoena from the SEC in January 2016. We believe that the SEC is seeking to determine whether there have been possible violations of the antifraud and certain other provisions of the federal securities laws related to the Company's disclosures concerning, among other things, the clinical test results of pacritinib. The SEC Staff's letter sent with the subpoena stated that the investigation is a fact-finding inquiry, and the investigation and subpoena do not mean that the SEC has concluded that we or anyone else has violated any law. We are cooperating with this investigation, which is ongoing.

In re CTI BioPharma Corp. Securities Litigation

On February 10, 2016 and February 12, 2016, class action lawsuits entitled Ahrens v. CTI BioPharma Corp. et al., Case No. 1:16-cv-01044 and McGlothlin v. CTI BioPharma Corp. et al., Case No. C16-216, respectively, were filed in the United States District Court for the Southern District of New York and the United States District Court for the Western District of Washington, respectively, on behalf of shareholders that purchased or acquired the Company’s securities pursuant to our September 24, 2015 public offering and/or shareholders who otherwise acquired our stock between March 4, 2014 and February 9, 2016, inclusive. The complaints assert claims against the Company and certain of our current and former directors and officers for violations of the federal securities laws under Sections 11 and 15 of the Securities Act of 1933, as amended, or the Securities Act, and Sections 10 and 20 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, Plaintiffs’ Securities Act claims allege that the Company’s Registration Statement and Prospectus for the September 24, 2015 public offering contained materially false and misleading statements and failed to disclose certain material adverse facts about the Company’s business, operations and prospects, including with respect to the clinical trials and prospects for pacritinib. Plaintiffs’ Exchange Act claims allege that the Company’s public disclosures were knowingly or recklessly false and misleading or omitted material adverse facts, again with a primary focus on the clinical trials and prospects for pacritinib. On May 2, 2016, the Company filed a motion to transfer the Ahrens case to the United States District Court for the Western District of Washington. The motion was unopposed and granted by the court on May 19, 2016. On June 3, 2016, the parties filed a joint motion to consolidate the McGlothlin case with the Ahrens case in order to proceed as a single consolidated proceeding. On June 13, 2016, the court granted the motion to consolidate with the action being captioned In re CTI BioPharma Corp. Securities Litigation, Master File No. 2:16-cv-00216-RSL. On September 2, 2016, the court appointed Lead Plaintiffs and Lead Counsel. On September 28, 2016, the court entered a scheduling order, as revised by order entered December 8, 2016, setting November 8, 2016 as the deadline to file a consolidated class action complaint and deadlines for briefing defendants’ motion to dismiss. Briefing concluded on February 22, 2017. The consolidated class action complaint asserts claims similar to those asserted in the initial complaints, although it no longer asserts claims relating to the September 24, 2015 public offering, but adds claims relating to the Company’s October 27, 2015 and December 4, 2015 public offerings. On July 26, 2017, we received a written offer for the global resolution and settlement of the consolidated action in exchange for cash payment of $20.0 million. The Company had insurance coverage related to this matter that covered $18.0 million of the claim. In August 2017, we agreed in principle to the terms of the settlement and submitted the terms and proposed class notice to the court for its

preliminary approval. On October 24, 2017, the court granted preliminary approval, and on February 1, 2018, the court fully and finally approved the settlement and dismissed all claims against the Company with prejudice.

Wei v. James A. Bianco, et al.; England v. James A Bianco, et al; Nahar v. James A. Bianco, et al.; Hill v. James A. Bianco, et al.

On March 14, 2016, a Company shareholder filed the first of four similar derivative lawsuits on behalf of the Company seeking damages for alleged harm to the Company caused by certain current and former officers and directors. The first suit, Wei v. James A. Bianco, et al., 16-2-05818-3, was filed in King County Superior Court, Washington. A second suit, England v. James A. Bianco, et al., 16-2-14422-5, was filed in King County Superior Court, Washington, on June 16, 2016. Two additional derivative suits, Nahar v. James A. Bianco, et al., 2:16-cv-0756, and Hill v. James A. Bianco, et al., 2:16-cv-1250, were filed in the United States District Court for the Western District of Washington on May 24, 2016 and August 9, 2016, respectively. The four suits raise similar allegations and seek similar relief against certain current and former officers and directors, including James A. Bianco, Louis A. Bianco, Jack W. Singer, Bruce J. Seeley, John H. Bauer, Phillip M. Nudelman, Reed V. Tuckson, Karen Ignagni, Richard L. Love, Mary O. Mundinger and Frederick W. Telling. Consistent with the requirements of a derivative action, the Company is named in each suit as a nominal defendant against which no monetary relief is sought. The complaints generally allege claims of: (1) breach of fiduciary duty; (2) abuse of control; (3) gross mismanagement; and (4) waste of corporate assets and (5) unjust enrichment (receiving compensation that was unjust in light of the alleged conduct). Each claim is based on the assertion that the Company made materially false and misleading statements and omitted material information from its disclosures about pacritinib and its safety. Plaintiffs in none of the suits made a pre-suit demand on the current Board to investigate whether to pursue claims against officers or directors, instead claiming demand is excused because the named defendants lack independence, are not disinterested because they lack impartiality, received and want to continue to receive their compensation, have longstanding personal and business relationships, and cannot evaluate a demand since they are facing personal liability. Each of plaintiffs’ suits requested the court to award the Company the damages allegedly sustained as a result of the conduct and to direct the Company and the individual defendants to reform and improve the Company’s corporate governance to avoid future damages. On March 29, 2017 during mediation, the parties to the derivative suits reached an agreement in principle to settle all four suits subject to Board and court approvals. Subject to the terms and conditions in the settlement agreement and court approval, CTI has agreed to adopt certain corporate governance reforms relating to, among other things, the content of CTI-retained independent data monitoring committee charters; engagement if an independent expert or entity to conduct yearly audits of compliance with Good Clinical Practices; the creation of a risk compliance officer position; certain improvements to CTI’s Audit Committee, including the requirement that the Audit Committee review CTI’s periodic public reports to facilitate proper disclosure of risks and risk factors; establishment of an internal audit function that will monitor the Company’s adherence to its policies and procedures, including those related to identification and disclosure of drug candidate safety issues; continuing-education requirements for members of the Board; and improvements to CTI’s nominating committee, compensation committee, and clawback policy. CTI also agreed not to object to an attorneys’ fee application by plaintiffs’ counsel of up to $0.8 million collectively, subject to the terms and conditions in the settlement agreement and court approval. There is no admission of liability or any wrongdoing by any of the individual defendants or CTI. On September 25, 2017, the King County Superior Court entered an order substituting Kevin Hammond for former Lead Plaintiff Gang Wei and Maurio Eley for former Lead Plaintiff Michael England, and the two case captions were amended as reflected above. The parties filed settlement-approval papers on October 26, 2017. On November 21, 2017, the Court preliminarily approved the settlement, and on January 31, 2018, the Court fully and finally approved the settlement and dismissed all claims against the Company and the individual defendants with prejudice.

In connection with the securities litigation and four derivative lawsuits described above, after taking into account our existing insurance coverage, we recorded $2.2 million of settlement expense in Selling, general and administrative expenses in our consolidated statement of operations for the year ended December 31, 2017.

In addition to the items discussed above, we are from time to time subject to legal proceedings and claims arising in the ordinary course of business.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

Our common stock is currently traded under the symbol “CTIC” on the NASDAQ Capital Market. The following table sets forth, for the periods indicated, the high and low reported sales prices per share of our common stock as reported on the NASDAQ Capital Market.



	High		Low
2016
First Quarter	$	13.20	$	2.51
Second Quarter	$	5.80	$	3.07
Third Quarter	$	4.58	$	3.16
Fourth Quarter	$	5.80	$	3.60
2017
First Quarter	$	6.48	$	3.87
Second Quarter	$	4.52	$	2.70
Third Quarter	$	3.84	$	3.07
Fourth Quarter	$	3.45	$	2.45

On February 28, 2018, the last reported sale price of our common stock on the NASDAQ Capital Market was $4.02 per share. As of February 28, 2018, there were 132 shareholders of record of our common stock.

Dividend Policy

We have never declared or paid cash dividends on our common stock and do not currently anticipate declaring or paying cash dividends on our common stock in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance operations. Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future prospects, contractual restrictions and other factors that our Board of Directors may deem relevant.

Sales of Unregistered Securities

Not applicable.

Stock Repurchases in the Fourth Quarter

The following table sets forth information with respect to purchases of our common stock during the three months ended December 31, 2017:



Period	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
October 1 – October 31, 2017	6,799	$	3.31	—	—
November 1 – November 30, 2017	345	$	2.79	—	—
December 1 – December 31, 2017	775	$	2.63	—	—
Total	7,919	$	3.22	—	—


(1)	Represents purchases of shares in connection with satisfying tax withholding obligations on the vesting of restricted stock awards to employees and not pursuant to a publicly announced plan or program.

Stock Performance Graph

The following graph sets forth the cumulative total shareholder return of our common stock with the cumulative total return of the NASDAQ Stock Index (U.S.) and the NASDAQ Pharmaceutical Index for the five years ended December 31, 2017. The graph assumes $100 was invested in our common stock at the close of market on December 31, 2012. Stockholder return over the indicated period should not be considered indicative of future stockholder returns.

The actual returns shown on the graph above are as follows:



	12/31/2012		12/31/2013		12/31/2014		12/31/2015		12/30/2016		12/29/2017
CTI BioPharma Corp.	$	100.00	$	146.92	$	181.54	$	94.62	$	31.35	$	20.62
NASDAQ Stock Index (U.S.)	$	100.00	$	133.48	$	150.12	$	150.84	$	170.46	$	206.91
NASDAQ Pharmaceutical Index	$	100.00	$	135.68	$	165.28	$	174.27	$	172.37	$	205.33

The stock performance graph shall not be deemed soliciting material or to be filed with the SEC or subject to Regulation 14A or 14C under the Securities Exchange Act of 1934 or to the liabilities of Section 18 of the Exchange Act, nor shall it be incorporated by reference into any past or future filing under the Securities Act of 1933 or the Exchange Act, except to the extent we specifically request that it be treated as soliciting material or specifically incorporate it by reference into a filing under the Securities Act of 1933 or the Exchange Act.

Item 6. Selected Financial Data

The data set forth below should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and notes thereto appearing at Item 8 of this Annual Report on Form 10-K.



	Year ended December 31,
	2017			2016			2015			2014			2013
	(In thousands, except per share data)
Consolidated Statements of Operations Data:
Revenues:
Product sales, net(1)	$	853		$	4,127		$	3,472		$	6,909		$	2,314
License and contract revenue(2)	24,293			53,278			12,644			53,168			32,364
Total revenues	25,146			57,405			16,116			60,077			34,678
Operating costs and expenses:
Cost of product sold(1)	364			1,377			1,940			895			137
Research and development	32,866			64,961			76,627			64,596			33,624
Selling, general and administrative	31,435			45,306			53,962			56,241			42,443
Acquired in-process research and development(3)	—			—			—			21,859			—
Other operating (income) expense, net	—			(5,077		)	253			2,719			—
Total operating costs and expenses, net	64,665			106,567			132,782			146,310			76,204
Loss from operations	(39,519		)	(49,162		)	(116,666		)	(86,233		)	(41,526		)
Non-operating income (expense):
Interest expense	(1,872		)	(2,614		)	(2,104		)	(1,947		)	(1,026		)
Amortization of debt discount and issuance costs	(163		)	(214		)	(390		)	(729		)	(513		)
Foreign exchange gain (loss)	817			(484		)	(703		)	(4,435		)	61
Other non-operating expense	(94		)	(479		)	(900		)	(885		)	(546		)
Total non-operating expense, net	(1,312		)	(3,791		)	(4,097		)	(7,996		)	(2,024		)
Net loss before noncontrolling interest	(40,831		)	(52,953		)	(120,763		)	(94,229		)	(43,550		)
Noncontrolling interest	161			944			1,341			862			807
Net loss attributable to CTI	(40,670		)	(52,009		)	(119,422		)	(93,367		)	(42,743		)
Deemed dividends on preferred stock	(4,350		)	—			(3,200		)	(2,625		)	(6,900		)
Net loss attributable to common shareholders	$	(45,020	)	$	(52,009	)	$	(122,622	)	$	(95,992	)	$	(49,643	)
Basic and diluted net loss per common share(4)	$	(1.24	)	$	(1.86	)	$	(6.51	)	$	(6.46	)	$	(4.35	)
Shares used in calculation of basic and diluted net loss per common share(4)	36,445			27,948			18,837			14,853			11,419



	Year ended December 31,
	2017			2016			2015			2014			2013
	(In thousands)
Consolidated Balance Sheets Data:
Cash, cash equivalents and restricted cash	$	43,218		$	44,002		$	128,182		$	70,933		$	71,639
Working capital	27,666			15,178			62,566			44,165			60,446
Total assets	54,886			63,843			144,197			92,122			93,464
Current portion of long-term debt(5)	444			7,949			37,371			9,014			3,155
Long-term debt, less current portion(5)	13,575			11,311			19,124			8,198			9,893
Other liabilities	5,469			3,615			4,141			5,882			5,657
Common stock purchase warrants	—			—			—			1,445			13,461
Accumulated deficit	(2,195,346		)	(2,150,326		)	(2,098,317		)	(1,975,695		)	(1,879,703		)
Total shareholders’ equity	16,090			7,757			47,413			38,478			42,758

(1) The amounts relate to commercial sales of PIXUVRI.

(2) The amounts primarily relate to license and development services revenue recognized in connection with the Pacritinib License Agreement, the Servier Original Agreement and the Servier Restated Agreement as well as payments received from Teva upon achievement of sales-based milestones. See Part II, Item 8 "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 11. Collaboration, Licensing and Milestone Agreements" for additional information.

(3) The amount in 2014 represents the purchase of certain assets from Chroma Therapeutics Limited. These purchased assets had not reached technological feasibility at the time of acquisition and were therefore expensed to Acquired in-process research and development.

(4) The net loss per share calculation, including the number of shares used in basic and diluted net loss per share, has been adjusted to reflect a one-for-ten reverse stock split on January 1, 2017.

(5) These amounts relate to our senior secured term loan agreements. Also included in 2015 is milestone advance received from Baxalta in June 2015 which obligation was satisfied during the first quarter of 2016. See Part II, Item 8 "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt" for additional information.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Key Highlights

Select fiscal year 2017 highlights include:

Research and Development

In August 2017, enrollment was completed in the PIX306 Phase 3 trial of PIXUVRI® (pixantrone). The PIX306 trial is evaluating PIXUVRI combined with rituximab in comparison to that of rituximab combined with gemcitabine in patients with aggressive B-cell NHL. PIXUVRI has previously been granted conditional marketing authorization from the European Commission for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell NHL. The trial is being conducted as a post-authorization requirement of conditional marketing authorization. If positive, the results from this trial could support broader indications. Top-line results are expected by the end of the first half of 2018.

In July 2017, the first patient was enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. PAC203 is designed to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in the Phase 3 PERSIST-2 trial of pacritinib in patients with myelofibrosis. The trial is expected to enroll up to approximately 105 patients. We expect to complete enrollment by mid-2018. We expect to have interim data from PAC203 by the end of the second quarter of 2018 and topline data in the first quarter of 2019.

In July 2017, the EMA validated the MAA for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). Validation confirms that the submission is complete and initiates the centralized review process by the EMA's Committee for Medicinal Products for Human Use.

In April 2017, we announced the expansion of the existing license and development collaboration agreement with Servier for PIXUVRI®. Under the expanded agreement, Servier will have rights to PIXUVRI in all markets except in the U.S. where we will retain the commercialization rights. Servier paid us €12.0 million in May 2017 and purchased PIXUVRI drug product for an additional €0.9 million in July 2017. We are eligible to receive up to €75.0 million in additional sales and regulatory milestone payments as well as royalties on net product sales.

Management and Board of Directors

Management

In September 2017, we announced the promotion of David Kirske as Chief Financial Officer, or CFO, of the Company. Mr. Kirske joined the Company earlier in 2017 and served as the Principal Financial and Accounting Officer prior to being appointed CFO. Mr. Kirske leads CTI BioPharma’s finance, accounting and investor relations teams. Prior to his appointment, Mr. Kirske was an independent chief financial officer consultant since January 2013. As a consultant, he has provided financial management services to public and emerging growth private companies primarily in the biotechnology industry, as well as in the technology and manufacturing industries. Mr. Kirske's financial management experience includes overseeing finance, accounting, operations, and capitalization, in both debt and equity. Prior to his time as a consultant, Mr. Kirske served as Vice President and CFO of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporate Controller for F-5 Networks and Redhook Brewery where he managed both corporate and international entities, and was part of the management teams that led and executed each company’s successful initial public offerings. Earlier in his career, he held a controllership position at Cray Computer. Mr. Kirske holds a B.A. in Business Administration from the University of Puget Sound.

In September 2017, we announced the promotion of Bruce Seeley to Chief Operating Officer of the Company. Mr. Seeley joined the Company in 2015 and served as the Chief Commercial and Administrative Officer and Secretary prior to being appointed Chief Operating Officer. Mr. Seeley has more than 25 years of global commercial experience and a proven track record of successfully launching products in various markets and regulatory environments. Most recently, Mr. Seeley was Senior Vice President and General Manager of Diagnostics at NanoString Technologies Inc., overseeing the launch of the diagnostic product PROSIGNA® for early stage breast cancer. Previously, he was Executive Vice President of Commercial at Seattle Genetics where he built and led the commercial organization, including marketing, sales and managed markets, and successfully launched Seattle Genetic's first product, ADCETRIS®, a targeted therapy for lymphoma. He also previously held key leadership positions in marketing at Genentech (now a member of the Roche Group), where he led the launch of HERCEPTIN® in adjuvant breast cancer. Earlier in his career he held various commercial roles at Aventis Pharmaceuticals Inc. (a part of Sanofi) and Bristol-Myers Squibb Co. Mr. Seeley received a B.A. in Sociology from the University of California at Los Angeles.

In February 2017, we announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer, or CEO, and member of the Company's Board of Directors effective March 20, 2017. Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the U.S. and Europe. Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies. Prior to consulting, Dr. Craig was Chief Medical Officer, or CMO, and Executive Vice President of Development at Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012, Dr. Craig was CMO and Senior Vice President of Chemgenex Pharmaceuticals Ltd. Dr. Craig is a Member of the Royal College of Physicians in the United Kingdom, or U.K., and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor's and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an MBA from the Open Business School in the U.K. Dr. Craig recently served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas.

Board of Directors

In July 2017, Laurent Fischer, M.D. was appointed to the Board of Directors, and in September 2017 he was appointed Chairman of the Board. Dr. Fischer has more than 20 years of experience in developing and commercializing novel medicines in the biopharmaceutical industry and currently serves as liver therapeutic area head at Allergan following its acquisition of Tobira Therapeutics in 2016.

In June 2017, David Parkinson, M.D. was appointed to the Board of Directors. Dr. Parkinson has significant experience in oncology clinical development and is currently President and Chief Executive Officer of Essa Pharmaceuticals, Inc. He and has also served as a venture partner at New Enterprise Associates, Inc., or NEA, since 2012, moving into the role of venture advisor to NEA in 2016.

In January 2017, Michael Metzger was appointed to the Board of Directors. Mr. Metzger has extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years. Mr. Metzger is currently President and Chief Operating Officer of Syndax Pharmaceuticals, Inc., a publicly traded immuno-oncology biopharmaceutical company. He has served in executive and senior management positions at Regado Biosciences, Mersana Therapeutics, Forest Laboratories and Onconova Therapeutics.

Financial summary

Our revenues are generated from a combination of PIXUVRI sales and collaboration and license agreements. Collaboration revenues reflect the earned amount of upfront payments and milestone payments under our product collaborations. Total revenues were $25.1 million, $57.4 million and $16.1 million for the years ended December 31, 2017, 2016 and 2015, respectively. Our loss from operations was $39.5 million, $49.2 million and $116.7 million for the years ended December 31, 2017, 2016 and 2015, respectively. Our results of operations may vary substantially from year to year and from quarter to quarter and, as a result, you should not rely on them as being indicative of our future performance.

See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 11. Collaboration, Licensing and Milestone Agreements" for further information relating to our collaboration agreements.

As of December 31, 2017, we had cash, cash equivalents and restricted cash of $43.2 million.

Results of Operations

Years ended December 31, 2017, 2016 and 2015

Product sales, net. Prior to April 2017 when we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier, we sold PIXUVRI primarily through a limited number of wholesale distributors. Servier is currently responsible for distribution of PIXUVRI in countries other than the U.S. (and its territories and possessions.) We generally record product sales upon receipt of the product by the health care provider or distributor at which time title and risk of loss pass.

Gross sales is defined as our contracted reimbursement price in each country. Gross sales from PIXUVRI for the years ended December 31, 2017, 2016 and 2015 were $1.0 million, $4.2 million and $3.5 million, respectively. Product sales, net represents gross sales, net of provisions for distributor discounts, estimated government-mandated discounts and rebates, trade discounts and estimated product returns. After these provisions, product sales, net from PIXUVRI were $0.9 million, $4.1 million and $3.5 million for the years ended December 31, 2017, 2016 and 2015, respectively.

The provision for product returns relates to a limited right of return or replacement that we offer to certain customers. Distributor discounts, return and rebates were $0.1 million during the year ended December 31, 2017. There was no material activity related to distributor discounts, returns and rebates during the years ended December 31, 2016 and 2015, and no material balances recorded as of December 31, 2017 and 2016.

The decrease in product sales, net for the year ended December 31, 2017 from the same period in 2016 was primarily related to the Restated Agreement with Servier in April 2017 under which Servier assumed commercialization rights to PIXUVRI in all markets except in the U.S. The increase in product sales, net of $0.7 million for the year ended December 31, 2016 compared to the year ended December 31, 2015 was primarily due to pricing and volume variances between the periods presented, partially offset by a decline in the average exchange rate of the British pound for our pound-denominated sales.

License and contract revenue. License and contract revenue was as follows (in thousands):



		Years ended December 31,
		2017		2016		2015
Servier	Milestone and license revenue	$	12,665	$	7,998	$	1,702
	Development services revenue	1,098		639		103
	Royalty revenue	530		204		24
	Total Servier	14,293		8,841		1,829

Teva	Milestones revenue	10,000		—		10,000
	Total Teva	10,000		—		10,000

Baxalta	Milestone and license revenue	—		32,000		—
	Development services revenue	—		12,437		815
	Total Baxalta	—		44,437		815

Total license and contract revenue		$	24,293	$	53,278	$	12,644

Servier

In April 2017, in connection with the execution of the Restated Agreement with Servier, we allocated and recorded $11.5 million and $1.3 million of the upfront payment received to license revenue and deferred revenue, respectively. The Restated Agreement with Servier amended and restated in its entirety the Exclusive License and Collaboration Agreement, or the Original Agreement, entered into in September 2014. The remaining deferred revenue balance as of the date of the Restated Agreement relating to the upfront payment under the Original Agreement was $0.6 million, which, along with the $1.3 million of deferred revenue allocated from the Restated Agreement as mentioned above, will be recognized as revenue based upon a proportional performance method.

During the year ended December 31, 2017, we recorded a €1.0 million milestone revenue (or $1.2 million upon conversion from euros as of the date we achieved the milestone) relating to the attainment of a certain regulatory milestone under the Restated Agreement. During the year ended December 31, 2016, we recorded a €7.5 million milestone revenue (or $8.0 million upon conversion from euros as of the date we achieved the milestone) relating to the attainment of a certain

enrollment event in connection with our PIX306 study. During the year ended December 31, 2015, we received a €1.5 million milestone payment (or $1.7 million upon conversion from euros as of the date we received the funds) relating to the attainment of reimbursement approval for PIXUVRI in Spain.

License and contract revenue for the years ended December 31, 2017, 2016 and 2015 includes $0.6 million, $0.1 million and $0.1 million, respectively, of development services revenue recognized from the upfront payments we received in connection with the execution of the Restated Agreement in 2017 and the Original Agreement in September 2014. In addition, we recorded revenue of $0.4 million for the reimbursement of expenses related to commercialization transition

under the Restated Agreement during the year ended December 31, 2017. There were no such revenues during the years ended December 31, 2016 and 2015.

In February 2016, we entered into an agreement with one of Servier's affiliates whereby we were to conduct a pharmacokinetic sub-study on behalf of Servier in conjunction with our ongoing clinical trial, PIX-306. During the years ended December 31, 2017 and 2016, $0.1 million and $0.5 million, respectively, of expense reimbursements in relation to this study was included in development services revenue. There was no such revenue during the year ended December 31, 2015. We expect to receive no such development services revenue in future periods as the pharmacokinetic sub-study was completed in September 2017.

Teva

For each of the years ended December 31, 2017 and 2015, we received $10.0 million in milestone payments upon the achievement of worldwide net sales milestones of TRISENOX. We did not receive a milestone payment during the year ended December 31, 2016.

Baxalta

In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement. As such, we are no longer eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta. For additional information relating to the Pacritinib License Agreement, see Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note11. Collaboration, Licensing and Milestone Agreements."

During the year ended December 31, 2016, we recorded milestone revenue of $32.0 million for achievement of the PERSIST-2 Milestone and the MAA Milestone under the Pacritinib License Agreement. We received the cash advance for these milestone payments in the second quarter of 2015; it was accounted for as long-term debt until the achievement of the associated milestones in the first quarter of 2016. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt," for further details. No milestone payments were received during 2015 under the Pacritinib License Agreement.

During the year ended December 31, 2016, we recorded $11.4 million of development services revenue relating to the reimbursable development costs from Baxalta under the terms of the Pacritinib License Agreement. No such revenue was recorded during the same period in 2015.

The license and contract revenue under the Pacritinib License Agreement for the years ended December 31, 2016 and 2015 also included $1.0 million and $0.8 million, respectively, of development services revenue which was recognized based on a proportional performance method from the allocated upfront payment we received in connection with the execution of the Pacritinib License Agreement in 2013.

Operating costs and expenses

Cost of product sold. Cost of product sold is related to sales of PIXUVRI and includes royalty expenses payable under

the agreement with University of Vermont and the Novartis Termination Agreement.

Cost of product sold was $0.4 million, $1.4 million and $1.9 million for the years ended December 31, 2017, 2016 and 2015, respectively. Royalty expenses were $0.3 million, $0.2 million and $0.2 million for the same periods.

The decrease in cost of product sold for the year ended December 31, 2017 compared to 2016 was primarily a result of the Restated Agreement we entered into with Servier in April 2017 whereby Servier assumed responsibility for the manufacture and supply of drug products and substances in its respective territories. For additional information, see Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note11. Collaboration, Licensing and Milestone Agreements."

The decrease in cost of product sold by $0.5 million for the year ended December 31, 2016 compared to 2015 was primarily due to a reduction in reserve for excess obsolete or unsalable inventory between periods. Based on assessment of shelf lives and net realizable value of the product, reserves of $0.7 million and $1.3 million were recorded during the years ended December 31, 2016 and 2015, respectively. There was no reserve recorded during the year ended December 31, 2017.

Research and development expenses. Our research and development expenses for compounds under development and preclinical development were as follows (in thousands):



	Years ended December 31,
	2017			2016		2015
Compounds under development:
PIXUVRI	$	7,419		$	12,009	$	14,465
Pacritinib	13,135			32,150		36,152
Opaxio	(18		)	98		626
Tosedostat	(3		)	1,587		920
Operating expenses	12,286			18,494		23,212
Research and preclinical development	47			623		1,252
Total research and development expenses	$	32,866		$	64,961	$	76,627

Costs for our compounds include external direct expenses such as principal investigator fees, charges from contract research organizations, or CROs, and contract manufacturing fees incurred for preclinical, clinical, manufacturing and regulatory activities associated with preparing the compounds for submissions of NDAs or similar regulatory filings to the FDA, the EMA or other regulatory agencies outside the U.S. and Europe, as well as upfront license fees for acquired technology. Subsequent to receiving a positive opinion for conditional approval of PIXUVRI in the E.U. from the EMA’s CHMP, costs associated with commercial batch production, quality control, stability testing, and certain other manufacturing costs of PIXUVRI were capitalized as inventory. Operating expenses include personnel costs and an allocation of occupancy, depreciation and amortization expenses associated with developing these compounds. Research and preclinical development costs primarily include costs associated with external laboratory services associated with the compound under development by Aequus Biopharma, Inc. We are not able to capture the total cost of each compound because we do not allocate operating expenses to all of our compounds. External direct costs incurred by us as of December 31, 2017 were $127.8 million for PIXUVRI (excluding costs prior to our 2004 merger with Novuspharma S.p.A, formerly a public pharmaceutical company located in Italy), $128.3 million for pacritinib (excluding costs for pacritinib prior to our acquisition of certain assets from S*BIO in May 2012 and $29.1 million of in-process research and development expenses associated with the acquisition of certain assets from S*BIO), $228.0 million for Opaxio and $13.9 million for tosedostat (excluding costs for tosedostat prior to our co-development and license agreement with Chroma Therapeutics Limited, or Chroma, in 2011 and $21.9 million of inprocess research and development expenses associated with the acquisition of certain assets from Chroma).

Research and development expenses decreased to $32.9 million for the year ended December 31, 2017 compared to $65.0 million for the year ended December 31, 2016. The decrease of $32.1 million was primarily attributed to to a $19.0 million decrease in pacritinib development costs as a result of the full clinical hold, a $4.6 million reduction of PIXUVRI trial costs and medical affairs and manufacturing activities in the E.U., a $1.6 million decrease in tosedostat drug manufacturing and development costs, a $6.2 million decrease in operating expenses associated with supporting our research and development efforts primarily due to a decline in personnel and a $0.7 million decrease in other development costs.

Research and development expenses decreased to $65.0 million for the year ended December 31, 2016 compared to $76.6 million for the year ended December 31, 2015. The decrease of $11.6 million was primarily attributed to a decrease in pacritinib development costs as a result of the full clinical hold, a reduction of PIXUVRI medical affairs and manufacturing activities in the E.U. and a decrease in operating expenses associated with supporting our research and development efforts primarily due to a decline in personnel.

Regulatory agencies, including the FDA and EMA, regulate many aspects of a product candidate’s life cycle, including research and development and preclinical and clinical testing. We will need to commit significant time and resources to develop our current and any future product candidates. Our product candidates pacritinib and tosedostat are currently in clinical development, and our product PIXUVRI, which is currently being commercialized in parts of Europe, is undergoing a post-authorization trial. Many drugs in human clinical trials fail to demonstrate the desired safety and efficacy characteristics. We are unable to provide the nature, timing and estimated costs of the efforts necessary to complete the development of pacritinib

and tosedostat, and to complete the post-authorization PIX306 trial of PIXUVRI, because, among other reasons, we cannot predict with any certainty the pace of patient enrollment of our clinical trials, which is a function of many factors, including the availability and proximity of patients with the relevant condition and the availability of the compounds for use in the applicable trials. We rely on third parties to conduct clinical trials, which may result in delays or failure to complete trials if the third parties fail to perform or meet applicable standards. Even after a clinical trial is enrolled, preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval and advancement of this compound through the development process. We or regulatory authorities may suspend clinical trials at any time on the basis that the participants are being exposed to unacceptable health risks. For example, on February 8, 2016, the FDA placed a full clinical hold on pacritinib. Even if our drugs progress successfully through initial human testing in clinical trials, they may fail in later stages of development. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks in advanced clinical trials, even after reporting promising results in earlier trials. For these reasons, among others, we cannot estimate the date on which clinical development of our product candidates will be completed, if ever, or when we will generate material net cash inflows from PIXUVRI or be able to begin commercializing pacritinib, tosedostat or Opaxio to generate material net cash inflows. In order to generate revenue from these compounds, our product candidates need to be developed to a stage that will enable us to commercialize, sell or license related marketing rights to third parties.

We also enter into collaboration agreements for the development and commercialization of our product candidates. We cannot control the amount and timing of resources our collaborators devote to product candidates, which may also result in delays in the development or marketing of products. Because of these risks and uncertainties, we cannot accurately predict when or whether we will successfully complete the development of our product candidates or the ultimate product development cost.

The risks and uncertainties associated with completing development on schedule and the consequences to operations, financial position and liquidity if the project is not timely completed are discussed in more detail in our risk factors, which can be found in Part I, Item 1A, “Risk Factors.”

Selling, general and administrative expenses. Selling, general and administrative expenses were $31.4 million for the year ended December 31, 2017 compared to $45.3 million for the year ended December 31, 2016 and $54.0 million for the year ended December 31, 2015.

The decrease in 2017 from 2016 was primarily due to decreases of $11.2 million in personnel costs, $0.7 million in travel costs, $0.2 million in professional fees for marketing initiatives related to our drug candidate, pacritnib, $0.4 million in pacritnib promotional costs previously shared with our collaboration partner, Baxalta, $0.4 million in other professional services associated with PIXUVRI, $1.6 million in legal fees, $0.3 million in general administrative costs and $0.3 million in other expenses. These decreases were offset by $1.2 million primarily related to a loss associated with the December 2017 sublease of approximately 44,000 square feet of our office space.

The decrease between 2015 and 2016 was primarily due to decreases in consulting and other professional service costs for PIXUVRI of $4.8 million, professional fees for marketing initiatives related to our drug candidate, pacritnib, of $2.2 million, administrative and travel costs of $2.1 million, primarily due to pacritnib being placed on full clinical hold by the FDA in February 2016, recruiting and other general and administrative consulting fees of $1.9 million, and personel costs of $0.5 million. Offsetting these decreases were $1.4 million in pacritinib promotional costs previously shared with our collaboration partner, Baxalta, and a $1.8 million increase in legal fees.

Other operating (income) expense, net. Other net operating income of $5.1 million for the year ended December 31, 2016 includes a gain of $5.9 million on termination of the Pacritinib License Agreement with Baxalta as well as a $0.8 million expense payable to Novartis as a result of a certain enrollment event achieved in December 2016 under the Original Agreement with Servier. Other operating expense of $0.3 million for the year ended December 31, 2015 relates to payments made to Novartis as a result of the milestone achieved under the same agreement in February 2015 relating to the reimbursement approval for PIXUVRI in Spain. There was no other operating expense or income for the year ended December 31, 2017. Certain payments are required under the Novartis Termination Agreement. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 11. Collaboration, Licensing and Milestone Agreements" for further details.

Non-operating income and expenses

Interest expense. Interest expense is primarily related to our senior secured term loans and was $1.9 million, $2.6 million and $2.1 million for the years ended December 31, 2017, 2016 and 2015, respectively. Interest expense decreased by $0.7 million between 2016 and 2017 primarily due to the declining principal balance and refinancing of our senior secured term

loan. Interest expense increased by $0.5 million between 2016 and 2015 primarily due to the additional principal amounts of our senior secured term loan funded in June 2015 and December 2015. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt" for further details.

Amortization of debt discount and issuance costs. Amortization of debt discount and issuance costs for the years ended December 31, 2017, 2016 and 2015 was primarily related to our senior secured term loans.

Foreign exchange gain (loss). The foreign exchange gain was $0.8 million for the year ended December 31, 2017, and the foreign exchange loss was $0.5 million and $0.7 million for the years ended December 31, 2016 and 2015, respectively. The variances were due to fluctuations in foreign currency exchange rates, primarily related to operations in our European branches and subsidiaries denominated in foreign currencies.

Other non-operating expense. Other non-operating expense of $0.1 million for the year ended December 31, 2017 primarily relates to a loss on debt extinguishment in connection with the repayment of senior secured term loan from Hercules. Other non-operating expense of $0.5 million for the year ended December 31, 2016 primarily represents the other-than-temporary impairment recognized on our available-for-sale securities during the first quarter of 2016. Other non-operating expense of $0.9 million for the year ended December 31, 2015 was primarily related to a $1.2 million loss on debt extinguishment in connection with our entry into an amendment to our senior secured term loan agreement, partially offset by the fair value adjustment of the warrant liability. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt" for further details.

Deemed dividends on preferred stock. Deemed dividends on preferred stock, approximately $4.4 million and $3.2 million for the years ended December 31, 2017 and 2015, respectively, were related to issuances of our preferred stock. There were no deemed dividends on preferred stock for the year ended December 31, 2016. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 8. Preferred Stock" for further details.

Liquidity and Capital Resources

Cash, cash equivalents and restricted cash. As of December 31, 2017, we had $43.2 million in cash, cash equivalents and restricted cash.

Net cash used in operating activities. Net cash used in operating activities totaled $39.3 million, $76.7 million and $95.2 million for the years ended December 31, 2017, 2016 and 2015, respectively. The decrease in net cash used in operating activities for the year ended December 31, 2017 as compared to the same period in 2016 was primarily due to the decrease in research and development and selling, general and administrative expenses, and an increase in license and contract revenue receipts. The decrease in net cash used in operating activities for the year ended December 31, 2016 as compared to the same period in 2015 was primarily due to increased receipts from license and contract revenue and decreases in spending for research and development and selling, general and administrative expenses, as well as timing of cash payments related to operating activities between the two periods.

Net cash used in investing activities. Net cash used in investing activities totaled $38,000, $0.1 million and $0.1 million for the years ended December 31, 2017, 2016 and 2015, respectively and primarily relates to purchases of property and equipment.

Net cash provided by (used in) financing activities. Net cash provided by financing activities totaled $39.0 million and $152.0 million for the years ended December 31, 2017 and 2015, respectively. Net cash used in financing activities was $7.4 million for the year ended December 31, 2016.

Net cash provided by financing activities for the year ended December 31, 2017 was primarily due to the issuance of our Series N-3 preferred stock in June 2017 and the proceeds of our senior secured term loan with Silicon Valley Bank, or SVB, partially offset by the repayment of our senior secured term loan with Hercules.

Net cash used in financing activities for the year ended December 31, 2016 was primarily due to principal repayments made under the Loan and Security Agreement, or the Loan Agreement, with Hercules as well as the payment of a fee required under the Loan Agreement to Hercules.

Net cash provided by financing activities for the year ended December 31, 2015 was primarily due to the acceleration of the two milestone payments received in the aggregate amount of $32.0 million from Baxalta pursuant to the Pacritinib License Amendment discussed above, as well as due to issuances of common stock, preferred stock and long-term debt. We received

$15.1 million in net proceeds from the issuance of our common stock in September 2015. We received $46.7 million in net proceeds from the issuance of our Series N-1 preferred stock in October 2015. We received $52.8 million in net proceeds from the issuance of our Series N-2 preferred stock in December 2015. In June 2015, we entered into the Third Amendment to the Loan Agreement with Hercules, under which we received a total of $5.8 million. Further, we borrowed an additional $5.0 million in December 2015 under the Fourth Amendment to the Loan Agreement. These receipts were offset by repayments to Hercules of $4.7 million made during the six months ended June 30, 2015.

See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 8. Preferred Stock and Note 7. Long-term Debt", which are incorporated herein by reference, for further details.

In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement. We currently have no commitments or arrangements for any additional financing to fund the development and commercial launch of pacritinib, and we may need to seek additional funding. The development and commercialization of a major product candidate like pacritinib without a collaborative partner will require a substantial amount of our time and financial resources, and as a result, we could experience a decrease in our liquidity and a new demand on our capital resources. For additional information relating to the Pacritinib License Agreement, see Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 11. Collaboration, Licensing and Milestone Agreements." which is incorporated herein by reference.

Capital Resources

We have prepared our consolidated financial statements assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations through the first quarter of 2020. However, we have incurred net losses since inception and expect to generate losses for the foreseeable future, primarily due to research and development costs for PIXUVRI, pacritinib, and tosedostat. Because of our reacquisition of worldwide rights for pacritinib, we are no longer be eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta, and losses related to research and development for pacritinib will increase. We have historically funded our operations through equity financings, borrowings and funds obtained under product collaborations, any or all of which may not be available to us in the future.

As of December 31, 2017, our available cash, cash equivalents and restricted cash totaled $43.2 million. We had an outstanding principal balance under our senior secured term loan agreement of $16.0 million. In February 2018, we received approximately $64.2 million in net proceeds from the public offering of common stock as discussed in Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 21. Subsequent Events," which is incorporated herein by reference. In addition, we received a $10.0 million milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia.

Financial resource forecasts are subject to change as a result of a variety of risks and uncertainties. Changes in manufacturing, developments in and expenses associated with our clinical trials and the other factors identified under “Capital Requirements” below may consume capital resources earlier than planned. Additionally, we may not receive anticipated milestone payments or achieve projected net sales from PIXUVRI. Due to these and other factors, the foregoing forecast for the period for which we will have sufficient resources to fund our operations may fail.

Capital Requirements

We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection.

Our future capital requirements will depend on many factors, including:


•	developments in and expenses associated with our research and development activities;


•	acquisitions of compounds or other assets;


•	changes in manufacturing;


•	ability to generate sales of PIXUVRI in the U.S.;


•	regulatory approval developments;


•	ability to execute appropriate collaborations for development and commercialization activities;


•	ability to reach milestones triggering payments under certain of our contractual arrangements;


•	litigation and other disputes;


•	competitive market developments; and


•	other unplanned business developments.

The following table includes information relating to our contractual obligations as of December 31, 2017 (in thousands):



Contractual Obligations	Payments Due by Period
	Total		Less than 1 Year		1-3 Years		4-5 Years		More than 5 Years
Operating leases:
Facilities (1)	$	11,051	$	2,487	$	5,116	$	3,448	$	—
Long-term debt (2)	16,000		444		10,667		4,889		—
Interest on long-term debt (2)	2,696		1,039		1,484		173		—
Purchase commitments (3)	3,349		3,349		—		—		—
Other obligations (4)	2,876		1,436		—		1,440		—
	$	35,972	$	8,755	$	17,267	$	9,950	$	—


(1)	In December 2017, we entered into an agreement to sublease approximately 44,000 square feet of our office space. Rental proceeds under this sublease are excluded from contractual obligations and expected to be $0.8 million in fiscal year 2018, $1.4 million in fiscal year 2019, $1.4 million in fiscal year 2020, $1.5 million in fiscal year 2021, and $0.5 million fiscal year 2022.

(2)

Long-term debt includes the principal payable of $16.0 million under our senior secured term loan. The interest rate on our senior secured term loan floats at a rate per annum equal to the greater of 2.50% above the prime rate and 6.75%. The amounts presented for interest payments in future periods assume a prime rate of 4.50%. See Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt" for further details.

(3)

Purchase commitments include obligations related to manufacturing supply, insurance and other purchase commitments. In addition, we have entered into certain clinical trial contracts that are not reflected in the table above as amounts under these contracts, which could be material, are not readily determinable. We anticipate the timing of payments under these contracts to range from less than one year to more than 3 years.


(4)	Other obligations include $1.4 million in severance payments and a $1.4 million back-end fee due to SVB upon repayment of our senior secured term loan.

Certain of our licensing agreements obligate us to pay a royalty on net sales of products utilizing licensed compounds. Such royalties are dependent on future product sales and are not provided for in the table above as they are not estimable. See Part I, Item 1, “Business - License Agreements and Additional Milestone Activities” for additional information.

Additional Milestone Activities

In connection with our development and commercialization activities, we have entered into a number of agreements pursuant to which we have agreed to make milestone payments upon certain development, sales-based and other milestone events; assume certain development and other expenses; and pay designated royalties on sales, including the UVM Agreement, the S*BIO Agreement and the Novartis Termination Agreement. In particular, we pay royalties on PIXUVRI net sales pursuant to each of the UVM Agreement and the Novartis Termination Agreement. These agreements are discussed in more detail in Part I, Item 1, “Business - License Agreements and Additional Milestone Activities .”

Impact of Inflation

In the opinion of management, inflation has not had a material effect on our operations including selling prices, capital expenditures and operating expenses.

Critical Accounting Estimates

Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the U.S. in the preparation of our consolidated financial statements. We evaluate our estimates and judgments on an on-going basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following estimates are the most critical to us, in that they are important to the portrayal of our consolidated financial statements and require our subjective or complex judgment in the preparation of our consolidated financial statements

Contingencies

We are currently involved in various claims and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may revise our estimates. These revisions in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.

Revenue Recognition

Our license and collaboration agreements may contain multiple elements as evaluated under ASC 605-25, Revenue Recognition—Multiple-Element Arrangements, including grants of licenses to know-how and patents relating to our product candidates as well as agreements to provide research and development services, regulatory services, manufacturing and commercialization services. Each deliverable under the agreement is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has standalone value to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. This evaluation requires subjective determinations and requires us to make judgments about the selling price of the individual elements and whether such elements are separable from the other aspects of the contractual relationship. Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by us. The assessment of multiple element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. If we determine that the license does not have standalone value separate from the research and development services, the license and the services are combined as one unit of accounting and upfront payments are recorded as deferred revenue in the balance sheet and are recognized as revenue over the estimated performance period that is consistent with the term of performance obligations contained in the collaboration agreement. When standalone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property is delivered.

Our license and collaboration agreements may also contain milestone payments that become due to us upon achievements of certain milestones. Under the milestone method, we recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is an event (1) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (2) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be

achieved and (3) that would result in additional payments being due to us. A milestone payment is considered substantive when the consideration payable to us for each milestone (1) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (2) relates solely to our past performance and (3) is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables.

Share-based Compensation Expense

Share-based compensation expense for all share-based payment awards made to employees and directors is recognized and measured based on estimated fair values. For option valuations, we have elected to utilize the Black-Scholes valuation method in order to estimate the fair value of options on the date of grant. The risk-free interest rate is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our share-based awards are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our share-based awards, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry. These assumptions underlying the Black-Scholes valuation model involve management’s best estimates.

For more complex awards, such as our long-term performance awards, or the Long-Term Performance Awards, discussed in the Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 12. Share-Based Compensation" contained herein, we employ a Monte Carlo simulation model to calculate estimated grant-date fair value. For the Long-Term Performance Awards, the average present value is calculated based upon the expected date the award will vest, or the event date, the expected stock price on the event date and the expected current shares outstanding on the event date. The event date, stock price and the shares outstanding are estimated using the Monte Carlo simulation model, which is based on assumptions by management, including the likelihood of achieving milestones and potential future financings. These assumptions impact the fair value of the equity-based award and the expense that will be recognized over the life of the award.

Generally accepted accounting principles for share-based compensation also require that we recognize compensation expense for only the portion of awards expected to vest. Therefore, we apply an estimated forfeiture rate that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, adjustments to compensation expense may be required in future periods. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.

Going Concern

Our financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Recently Issued and Adopted Accounting Pronouncements

For a description of recently issued and adopted accounting pronouncements, including the expected effects on our results of operations and financial condition, refer to Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 1. Description of Business and Summary of Significant Accounting Policies," which is incorporated herein by reference.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Foreign Exchange Market Risk

We are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars for financial reporting purposes. The carrying value of the assets and liabilities held in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. In addition, certain of our contractual arrangements, such as the Restated Agreement with Servier, denote monetary amounts in foreign currencies, and consequently, the ultimate financial impact to us from a U.S. dollar perspective is subject to significant uncertainty. Changes in the value of the U.S. dollar as compared to applicable foreign currencies (in particular, the euro) might have an adverse effect on our reported results of operations and financial condition. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. As of December 31, 2017, we had a net asset balance, excluding intercompany payables and receivables, in our European branches and subsidiaries denominated in euros. If the euro were to weaken 20 percent against the dollar, our net asset balance would decrease by approximately $1.5 million as of this date.

Interest Rate Risk

Our senior secured term loan bears interest at variable rates. Based on the outstanding principal balance under such loan at December 31, 2017 of $16.0 million, a hypothetical increase of 1.0 percent in interest rates would result in additional interest expense of $0.4 million over the next twelve months. For a detailed discussion of our senior secured term loan, including a discussion of the applicable interest rate, refer to the Part II, Item 8, "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 7. Long-term Debt."

Item 8. Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS



	Page
Reports of Marcum LLP, Independent Registered Public Accounting Firm	63
Consolidated Balance Sheets	65
Consolidated Statements of Operations	66
Consolidated Statements of Comprehensive Loss	67
Consolidated Statements of Shareholders’ Equity	68
Consolidated Statements of Cash Flows	69
Notes to Consolidated Financial Statements	71

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

CTI BioPharma Corp.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of CTI BioPharma Corp. (the “Company”) as of December 31, 2017 and 2016, the related consolidated statements of operations, comprehensive loss, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and financial statement schedule listed in the Index at Item 15(a)(ii) (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2017, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated March 7, 2018, expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2005.

San Francisco, CA

March 7, 2018

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL CONTROL OVER FINANCIAL REPORTING

To the Shareholders and Board of Directors of

CTI BioPharma Corp.

Opinion on Internal Control over Financial Reporting

We have audited CTI BioPharma Corp.'s (the “Company”) internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets as of December 31, 2017 and 2016 and the related consolidated statements of operations, comprehensive loss, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and financial statement schedule listed in the Index at Item 15(a)(ii), of the Company and our report dated March 7, 2018 expressed an unqualified opinion on those financial statements and financial statement schedule.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Management Annual Report on Internal Control over Financial Reporting”. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.

/s/ Marcum LLP

Marcum LLP

San Francisco, CA

March 7, 2018

CTI BIOPHARMA CORP.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)



	December 31, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	27,218		$	44,002
Restricted cash	16,000			—
Accounts receivable	4			378
Receivable from collaborative arrangements	1,278			7,778
Inventory, net	550			1,525
Prepaid expenses and other current assets	1,874			2,141
Total current assets	46,924			55,824
Property and equipment, net	2,365			3,023
Other assets	5,597			4,996
Total assets	$	54,886		$	63,843

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	2,588		$	7,227
Accrued expenses	13,890			24,765
Current portion of deferred revenue	912			103
Current portion of long-term debt	444			7,949
Other current liabilities	1,424			602
Total current liabilities	19,258			40,646
Deferred revenue, less current portion	494			514
Long-term debt, less current portion	13,575			11,311
Other liabilities	5,469			3,615
Total liabilities	38,796			56,086
Commitments and contingencies
Shareholders' equity:
Preferred stock, no par value:
Authorized shares - 33,333
Series N-3 Preferred Stock, $2,000 stated value per share, 22,500 shares designated, 575 and 0 shares issued and outstanding as of December 31, 2017 and 2016, respectively	1,090			—
Common stock, no par value:
Authorized shares - 81,500,000 and 41,500,000 at December 31, 2017 and 2016, respectively
Issued and outstanding shares - 42,969,494 and 28,228,602 at December 31, 2017 and 2016, respectively	2,222,341			2,170,300
Accumulated other comprehensive loss	(6,272		)	(6,655		)
Accumulated deficit	(2,195,346		)	(2,150,326		)
Total CTI shareholders' equity	21,813			13,319
Noncontrolling interest	(5,723		)	(5,562		)
Total shareholders' equity	16,090			7,757
Total liabilities and shareholders' equity	$	54,886		$	63,843

See accompanying notes.

CTI BIOPHARMA CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)



	Year Ended December 31,
	2017			2016			2015
Revenues:
Product sales, net	$	853		$	4,127		$	3,472
License and contract revenue	24,293			53,278			12,644
Total revenues	25,146			57,405			16,116
Operating costs and expenses:
Cost of product sold	364			1,377			1,940
Research and development	32,866			64,961			76,627
Selling, general and administrative	31,435			45,306			53,962
Other operating (income) expense, net	—			(5,077		)	253
Total operating costs and expenses, net	64,665			106,567			132,782
Loss from operations	(39,519		)	(49,162		)	(116,666		)
Non-operating expense:
Interest expense	(1,872		)	(2,614		)	(2,104		)
Amortization of debt discount and issuance costs	(163		)	(214		)	(390		)
Foreign exchange gain (loss)	817			(484		)	(703		)
Other non-operating expense	(94		)	(479		)	(900		)
Total non-operating expense, net	(1,312		)	(3,791		)	(4,097		)
Net loss before noncontrolling interest	(40,831		)	(52,953		)	(120,763		)
Noncontrolling interest	161			944			1,341
Net loss attributable to CTI	(40,670		)	(52,009		)	(119,422		)
Deemed dividends on preferred stock	(4,350		)	—			(3,200		)
Net loss attributable to common shareholders	$	(45,020	)	$	(52,009	)	$	(122,622	)
Basic and diluted net loss per common share	$	(1.24	)	$	(1.86	)	$	(6.51	)
Shares used in calculation of basic and diluted net loss per common share	36,445			27,948			18,837

See accompanying notes.

CTI BIOPHARMA CORP.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)



	Year Ended December 31,
	2017			2016			2015
Net loss before noncontrolling interest	$	(40,831	)	$	(52,953	)	$	(120,763	)
Other comprehensive income (loss):
Foreign currency translation adjustments	(3,927		)	947			2,160
Unrealized foreign exchange gain (loss) on intercompany balance	4,303			(1,162		)	(2,585		)
Other-than-temporary impairment on available-for-sale securities	—			520			—
Net unrealized income (loss) on securities available-for-sale	7			(8		)	(28		)
Other comprehensive income (loss)	383			297			(453		)
Comprehensive loss	(40,448		)	(52,656		)	(121,216		)
Comprehensive loss attributable to noncontrolling interest	161			944			1,341
Comprehensive loss attributable to CTI	$	(40,287	)	$	(51,712	)	$	(119,875	)

See accompanying notes.

CTI BIOPHARMA CORP.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(In thousands)



											Accumulated Other									Total
	Preferred Stock					Common Stock					Comprehensive			Accumulated			Noncontrolling			Shareholders'
	Shares		Amount			Shares		Amount			Income (Loss)			Deficit			Interest			Equity
Balance at December 31, 2014	—		$	—		17,676		$	2,023,949		$	(6,499	)	$	(1,975,695	)	$	(3,277	)	$	38,478
Issuance of common stock, net of issuance costs	—		—			1,000		15,147			—			—			—			15,147
Issuance of Series N-1 preferred stock, net of issuance costs	50.0		46,611																	46,611
Conversion of Series N-1 preferred stock to common stock	(50.0	)	(46,611		)	4,000		46,611			—			—			—			—
Value of beneficial conversion features related to preferred stock	—		—			—		3,200			—			—			—			3,200
Issuance of Series N-2 preferred stock, net of issuance costs	55.0		52,409			—		—			—			—			—			52,409
Conversion of Series N-2 preferred stock to common stock	(55.0	)	(52,409		)	5,000		52,409			—			—			—			—
Expiry of exercise price provision features related to common stock purchase warrant	—		—			—		150			—			—			—			150
Equity-based compensation	—		—			393		14,828			—			—			—			14,828
Stock option exercises	—		—			8		156			—			—			—			156
Noncontrolling interest	—		—			—		—			—			—			(1,341		)	(1,341		)
Expiry of mezzanine equity	—		—			—		1,445			—			—			—			1,445
Other	—		—			(31	)	(595		)	—			—			—			(595		)
Deemed dividends on preferred stock	—		—			—		—			—			(3,200		)	—			(3,200		)
Net loss for the year ended December 31, 2015	—		—			—		—			—			(119,422		)	—			(119,422		)
Other comprehensive loss	—		—			—		—			(453		)	—			—			(453		)
Balance at December 31, 2015	—		$	—		28,046		$	2,157,300		$	(6,952	)	$	(2,098,317	)	$	(4,618	)	$	47,413
Equity-based compensation	—		—			207		13,324			—			—			—			13,324
Noncontrolling interest	—		—			—		—			—			—			(944		)	(944		)
Other	—		—			(24	)	(324		)	—			—			—			(324		)
Net loss for the year ended December 31, 2016	—		—			—		—			—			(52,009		)	—			(52,009		)
Other comprehensive income	—		—			—		—			297			—			—			297
Balance at December 31, 2016	—		$	—		28,229		$	2,170,300		$	(6,655	)	$	(2,150,326	)	$	(5,562	)	$	7,757
Issuance of Series N-3 preferred stock, net of issuance costs	22.5		42,669			—		—			—			—			—			42,669
Conversion of Series N-3 preferred stock to common stock	(21.9	)	(41,579		)	14,616		41,579			—			—			—			—
Value of beneficial conversion features related to preferred stock	—		—			—		4,350			—			—			—			4,350
Issuance of warrants	—		—			—		470			—			—			—			470
Equity-based compensation	—		—			150		5,746			—			—			—			5,746
Noncontrolling interest	—		—			—		—			—			—			(161		)	(161		)
Other	—		—			(26	)	(104		)	—			—			—			(104		)
Deemed dividends on preferred stock	—		—			—		—			—			(4,350		)	—			(4,350		)
Net loss for the year ended December 31, 2017	—		—			—		—			—			(40,670		)	—			(40,670		)
Other comprehensive income	—		—			—		—			383			—			—			383
Balance at December 31, 2017	0.6		$	1,090		42,969		$	2,222,341		$	(6,272	)	$	(2,195,346	)	$	(5,723	)	$	16,090

See accompanying notes.

CTI BIOPHARMA CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)



	Year Ended December 31,
	2017			2016			2015
Operating activities
Net loss before noncontrolling interest	$	(40,831	)	$	(52,953	)	$	(120,763	)
Adjustments to reconcile net loss to net cash used in operating activities:
Baxalta milestone revenue	—			(32,000		)	—
Share-based compensation expense	5,746			13,324			14,828
Depreciation and amortization	717			831			990
Loss on debt extinguishment	163			—			1,211
Loss on sublease	1,584			—			—
Provision for bad debts	—			1,735			—
Reserve for excess, obsolete or unsalable inventory	—			692			1,326
Other-than-temporary impairment on available-for-sale securities	—			520			—
Noncash interest expense	163			214			390
Noncash rent benefit	(648		)	(467		)	(409		)
Change in value of warrant liability	—			—			(232		)
Other	(18		)	—			—
Changes in operating assets and liabilities:
Accounts receivable	402			(156		)	1,555
Receivable from collaborative arrangements	6,579			(9,476		)	—
Inventory	1,120			567			(402		)
Prepaid expenses and other current assets	326			1,609			(402		)
Other assets	63			355			826
Accounts payable	(4,730		)	(3,025		)	4,368
Accrued expenses	(11,096		)	2,620			2,426
Deferred revenue	790			(1,071		)	(918		)
Other liabilities	374			1			3
Total adjustments	1,535			(23,727		)	25,560
Net cash used in operating activities	(39,296		)	(76,680		)	(95,203		)
Investing activities
Purchases of property and equipment	(49		)	(137		)	(78		)
Other	11			—			—
Net cash used in investing activities	(38		)	(137		)	(78		)
Financing activities
Proceeds from issuance of Series 21 preferred stock, net of issuance costs	—			—			(227		)
Proceeds from common stock offering, net of issuance costs	—			—			15,147
Proceeds from issuance of Series N-1 preferred stock, net of issuance costs	—			(37		)	46,653
Proceeds from issuance of Series N-2 preferred stock, net of issuance costs	—			(277		)	52,800
Proceeds from issuance of Series N-3 preferred stock, net of issuance costs	42,669			—			—
Proceeds from Baxalta milestone advance, net of issuance costs	—			—			31,922
Proceeds from Silicon Valley Bank debt, net of issuance costs	15,971			—			—
Proceeds from Hercules debt, net of issuance costs	—			—			10,820
Repayment of Hercules debt	(19,548		)	(5,452		)	(4,659		)
Payment of a Hercules fee	—			(1,275		)	—
Payment of tax withholding obligations related to stock compensation	(87		)	(355		)	(604		)
Other	(26		)	30			165
Net cash provided by (used in) financing activities	38,979			(7,366		)	152,017
Effect of exchange rate changes on cash and cash equivalents	(429		)	3			513
Net (decrease) increase in cash, cash equivalents and restricted cash	(784		)	(84,180		)	57,249
Cash, cash equivalents and restricted cash at beginning of year	44,002			128,182			70,933
Cash, cash equivalents and restricted cash at end of year	$	43,218		$	44,002		$	128,182

See accompanying notes.

CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)

(In thousands)



	Year Ended December 31,
	2017		2016		2015
Supplemental disclosure of cash flow information
Cash paid during the period for interest	$	1,970	$	4,446	$	2,067

Supplemental disclosure of noncash financing and investing activities
Conversion of Series N-1 preferred stock to common stock	$	—	$	—	$	46,611
Conversion of Series N-2 preferred stock to common stock	$	—	$	—	$	52,409
Conversion of Series N-3 preferred stock to common stock	$	41,579	$	—	$	—
Repayment and issuance of Hercules debt	$	—	$	—	$	13,815
Baxalta milestone advance - earned in lieu of repayment	$	—	$	32,000	$	—
Debt issuance costs included in accounts payable and accrued expenses	$	79	$	—	$	—

See accompanying notes.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business and Summary of Significant Accounting Policies

CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,” the “Company” and “CTI”, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating

pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partners Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, have commercialization rights outside the United States, or the U.S.

We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, or the U.S., the European Medicines Agency, or the EMA, in the European Union, or the E.U., and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include CTI Life Sciences Limited, or CTILS. We also retain ownership of our branch, CTI BioPharma Corp.- Sede Secondaria, or CTI (Europe) which has ceased operations. Systems Medicine LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in December 2017.

As of December 31, 2017, we also had an approximately 60% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.

All intercompany transactions and balances are eliminated in consolidation.

Reverse Stock Split

On January 1, 2017, we effected a one-for-ten reverse stock split, or the Stock Split. Unless otherwise noted, all impacted amounts included in the consolidated financial statements and notes thereto have been retroactively adjusted for the Stock Split. Unless otherwise noted, impacted amounts include shares of common stock authorized and outstanding, share issuances and cancellations, shares underlying warrants and stock options, shares reserved, conversion prices of convertible securities, exercise prices of warrants and options, and loss per share. Additionally, the Stock Split impacted preferred stock authorized (but not outstanding because there were no shares of preferred stock outstanding as of the time of the Stock Split).

Liquidity

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement with Baxalta Incorporated and its affiliates, or Baxalta, and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of December 31, 2017, we had an accumulated deficit of $2.2 billion, and we expect to incur net losses for the foreseeable future.

Our available cash, cash equivalents and restricted cash were $43.2 million as of December 31, 2017. In February 2018, as discussed in Note 21. Subsequent Events, we completed the public offering of common stock and received approximately $64.2 million in net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses. In addition, we received a $10.0 million milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations at least through the next twelve months from the date these financial statements were issued. We previously disclosed that we had substantial doubt about our ability to continue as a going concern, which was primarily due to lack of liquidity. This has since been alleviated as a result of the proceeds we received from the public offering of common stock as well as the milestone payment.

We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying consolidated consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, and excess and obsolete inventory, recording share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, and determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates.

Certain Risks, Uncertainties and Concentrations

Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.

We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.

Additionally, see Note 15. Customer and Geographic Concentrations for further concentration disclosure.

Cash and Cash Equivalents

We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value. We had no cash equivalents as of December 31, 2017.

Restricted Cash

Restricted cash represents a legally restricted deposit held as a compensating balance against our senior secured term loan with Silicon Valley Bank, or SVB. Pursuant to the loan and security agreement entered into with SVB in November 2017, we were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million at all times prior to the occurrence of an event relating to the delivery to SVB of duly executed signatures to a control agreement from Bank of America with respect to all of our accounts maintained with Bank of America. In January 2018, we obtained a waiver from SVB for such requirement and as a result, we no longer have restrictions placed on the cash balance. See Note 7. Long-term Debt for further details regarding our senior secured term loan with SVB.

The following table provides reconciliations of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.



	December 31, 2017		December 31, 2016		December 31, 2015
Cash and cash equivalents	$	27,218	$	44,002	$	128,182
Restricted cash	16,000		—		—
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	43,218	$	44,002	$	128,182

Receivables from Collaborative Arrangements

Our receivables from collaborative arrangements relate to amounts payable or reimbursable to us under the terms of collaborative arrangements with our partners. The receivable balance as of December 31, 2017 relates primarily to the sale of PIXUVRI drug product to Servier. The receivable balance as of December 31, 2016 relates primarily to a milestone receivable from Servier for the attainment of a certain enrollment event in December 2016 in connection with our PIX306 study. Receivables from collaborative arrangements are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable. During the year ended December 31, 2016, we recorded $1.7 million in bad debt expense related to disputed invoices under the collaborative arrangement with Baxalta. We had no allowance for doubtful accounts from collaborative arrangements as of December 31, 2017 and 2016.

Value Added Tax Receivable

Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was approximately $4.8 million and $4.4 million as of December 31, 2017 and 2016, respectively, of which $4.7 million and $4.1 million was included in other assets and $0.1 million and $0.3 million was included in prepaid expenses and other current assets as of December 31, 2017 and 2016, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of December 31, 2017, the VAT receivable related to operations in Italy was approximately $4.8 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.

Inventory

We carry inventory at the lower of cost or net realizable value. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the distribution of PIXUVRI. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We review our inventories on a quarterly basis for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsalable inventory, the value is written down to the net realizable value. We had a reserve of $1.4 million and $1.5 million related to excess, obsolete or unsalable inventory as of December 31, 2017 and 2016, respectively, which was included in Inventory, net. Inventory, net as of December 31, 2017 is comprised of bulk active pharmaceutical ingredient which we expect to be salable to Servier under the terms of the Restated Agreement and to future emerging markets.

Property and Equipment

Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of 10 years or the term of the applicable lease.

Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.

Leases

We analyze leases at the inception of each agreement for classification as either an operating or capital lease. Certain of our lease agreement terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense equal to the amount of total minimum lease payments on a straight-line basis over the term of the lease. A deferred liability recognized in connection with the December 2017 sublease arrangement is amortized over the term of the sublease as a reduction of rent expense.

Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.

Level 3 - Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

At December 31, 2017 and 2016, the carrying value of financial instruments such as receivables and payables approximated their fair values due to their short-term maturities. The carrying value of our long-term debt approximated its fair value at December 31, 2017 and 2016 based on borrowing rates for similar loans and maturities.

Contingencies

We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 11. Collaboration, Licensing and Milestone Agreements and Note 18. Legal Proceedings for further information regarding our current gain and loss contingencies.

Revenue Recognition

We currently have conditional marketing authorization for PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred

revenue until such time that all criteria under the provision are met.

Product Sales

PIXUVRI was sold primarily through a limited number of wholesale distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary. As of April 2017, Servier has the

exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note 11. Collaboration, Licensing and Milestone Agreements for further details.

Collaboration Agreements

We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with Accounting Standards Codification, or ASC, 605-25, Revenue Recognition—Multiple-Element Arrangements. If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Upon the completion of the performance obligation, such amounts will be recognized as revenue when collectability is reasonably assured.

The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

Milestone payments under collaboration agreements are generally aggregated into three categories for reporting purposes: (1) development milestones, (2) regulatory milestones and (3) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable (1) upon submission for marketing approval with the FDA or with the regulatory authorities of other countries, and (2) upon receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.

At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (1) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.

We follow ASC 605-25, Revenue Recognition – Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the accounting for reimbursement arrangements under collaborative research and development and commercialization agreements.

Cost of Product Sold

Cost of product sold includes third-party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes allowances, if any, for excess inventory that may expire and become unsalable.

Research and Development Expenses

Research and development costs are expensed as incurred in accordance with the FASB ASC 730, Research and Development. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.

Foreign Currency Translation and Transaction Gains and Losses

We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.

The intercompany balance due from CTILS is considered to be of a long-term nature. An unrealized foreign exchange gain of $4.3 million and unrealized foreign exchange losses of $1.2 million and $2.6 million were recorded in the cumulative foreign currency translation adjustment account for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017 and 2016, the intercompany balance due from CTILS was €26.2 million and €29.7 million, respectively (or $31.4 million and $31.2 million upon conversion from euros as of December 31, 2017 and 2016, respectively).

Income Taxes

We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

Net Loss per Share

Basic net loss per common share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect.

Recently Adopted Accounting Standards

In April 2015, the FASB issued a new accounting standard which changes the presentation of debt issuance costs in financial statements. Under the new standard, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The accounting standard is effective for annual reporting periods beginning after December 15, 2015 and interim periods beginning after December 15, 2016. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In July 2015, the FASB issued new accounting guidance on simplifying the measurement of inventory which requires

that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2016. The adoption of this standard did not have a material impact on our consolidated financial statements.

In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The adoption of this guidance did not have an impact on our consolidated financial statements.

In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period and to provide related footnote disclosures in certain circumstances. The accounting standard is effective for annual reporting periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard in the fourth quarter of 2016 did not have a material impact on our consolidated financial statements.

In March 2016, the FASB issued new accounting guidance for employee share-based payments accounting. The accounting standard primarily affects the accounting for forfeitures, minimum statutory tax withholding requirements, and income tax effects related to share-based payments at settlement (or expiration). The accounting guidance is effective for annual reporting periods beginning after December 15, 2016 (including interim periods within those periods). We have historically maintained a full valuation allowance against deferred tax assets. The adoption of this standard in the first quarter of 2017 did not have a material impact on our consolidated financial statements, and we will continue to estimate expected forfeitures.

In November 2016, the FASB issued accounting guidance which amends ASC 230, Statement of Cash Flows, to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments require that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Consequently, transfers between cash and restricted cash will not be presented as a separate line item in the operating, investing or financing sections of the cash flow statement. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. The early adoption is permitted. The adoption of this standard did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In May 2014, the FASB issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five-step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. We will adopt the new standard in the first quarter 2018 using the modified retrospective method. We have completed the impact on our customer contracts and do not expect the implementation of ASU 2014-09 to have a material quantitative impact on our consolidated financial statements. Under the new standard, such customer arrangements will be accounted for as variable consideration, which may result in revenue being recognized earlier provided we can reliably estimate the ultimate price expected to be realized from the customer. In addition, we do not expect a material cumulative effect adjustment to Retained earnings upon adoption of the standard on January 1, 2018. Adoption of the new standard will also result in additional revenue-related disclosures in the footnotes to our consolidated financial statements.

In February 2016, the FASB issued a new accounting guidance on accounting for leases which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018. Early adoption is permitted. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.

In August 2016, the FASB issued an amendment to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows with the objective of reducing diversity in practice regarding eight types of cash flows. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of this standard to have a material impact on our statement of cash flows.

Reclassifications

Certain prior year items have been reclassified to conform to current year presentation.

2. Inventory

The components of PIXUVRI inventories consisted of the following as of December 31, 2017 and 2016 (in thousands):



	2017			2016
Finished goods	$	394		$	477
Work-in-process	1,523			2,558
Inventory, gross	$	1,917		$	3,035
Reserve for excess, obsolete or unsalable inventory	$	(1,367	)	$	(1,510	)
Inventory, net	$	550		$	1,525

3. Property and Equipment

Property and equipment are composed of the following as of December 31, 2017 and 2016 (in thousands):



	2017			2016
Furniture and office equipment	$	4,552		$	6,521
Leasehold improvements	5,168			5,106
Lab equipment	209			201
	9,929			11,828
Less: accumulated depreciation and amortization	(7,564		)	(8,805		)
Property and equipment, net	$	2,365		$	3,023

Depreciation expense for the years ended December 31, 2017, 2016 and 2015 was $0.7 million, $0.8 million and $1.0 million, respectively.

4. Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2017 and 2016 (in thousands):



	2017		2016
Clinical and investigator-sponsored trial expenses	$	5,019	$	7,303
Employee compensation and related expenses	4,432		6,364
Manufacturing expenses	2,637		7,616
Legal expenses	537		1,037
Selling expenses	143		136
Insurance financing	575		888
Interest expenses	93		2
Other	454		1,419
Total accrued expenses	$	13,890	$	24,765

5. Leases

Lease Agreements

In January 2012, we entered into an operating lease agreement with Selig Holdings Company LLC to lease approximately 66,000 square feet of office space in Seattle, Washington for a term of 120 months, commencing May 1, 2012. We have two five-year options to extend the term of the lease at a market rate determined according to the lease. The initial rent amount was based on $27.00 per square foot per annum, but no payments were due during the initial five months of the lease term. Rent increases three percent over the prior year’s amount for each year thereafter for the duration of the lease. In addition, we were provided an allowance of $3.3 million for certain tenant improvements made by us.

In December 2017, we entered into an agreement to sublease approximately 44,000 square feet of our Seattle office space. No payments are due through May 2018, after which monthly rent is due through the sublease termination date in April 2022. Monthly sublease rent increases by a minor amount each January 1. In connection with the sublease, we recognized a loss and a deferred liability of $1.6 million, representing future rental payments plus related expenses in excess of the future sublease payments to be received. The loss was recorded in Selling, general and administrative expense during the year ended December 31, 2017. Other current liabilities and Other liabilities in the consolidated balance sheet include $0.8 million and $0.6 million, respectively, related to the sublease agreement as of December 31, 2017 .

Rent expense, net of sublease-related income of $0.1 million for the year ended December 31, 2017, amounted to $1.6 million, $2.0 million and $2.0 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Future Minimum Lease Payments

Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at December 31, 2017 were as follows (in thousands):



	Operating		Sublease
	Leases		Rentals		Net
2018	$	2,487	$	771	$	1,716
2019	2,532		1,365		1,167
2020	2,584		1,410		1,174
2021	2,580		1,454		1,126
2022	868		499		369
Thereafter	—		—		—
Total minimum lease commitments	$	11,051	$	5,499	$	5,552

6. Other Liabilities

Other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):



	2017		2016
Deferred rent, less current portion	$	3,050	$	3,011
Other long-term obligations	2,419		604
Total other liabilities	$	5,469	$	3,615

Deferred rent, less current portion as of December 31, 2017 and 2016 includes amounts related to incentives for rent holidays and leasehold improvements associated with our operating lease for office space. In addition, deferred rent, less current portion as of December 31, 2017 includes $0.6 million of deferred liability related to the sublease of Seattle office space as discussed in Note 5. Leases.

Other long-term obligations as of December 31, 2017 include a fee in the amount of $1.4 million payable to Silicon Valley Bank. See Note 7, Long-term Debt, for additional information.

7. Long-term Debt

Silicon Valley Bank

In November 2017, we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, for a senior secured term loan of up to $18.0 million. The first $16.0 million of the term loan was funded in November 2017, and the remaining $2.0 million is available at our option at any time from the occurrence of the Milestone Event (as defined below) through July 31, 2018, subject to the satisfaction of certain conditions. The loan proceeds were used to repay in full all outstanding indebtedness under the Loan and Security Agreement with Hercules as discussed below and to fund our general business requirements. We were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million under the terms of Loan and Security Agreement, and as such, $16.0 million of our cash was legally restricted as of December 31, 2017 and held as a compensating balance against the term loan. The restriction was subsequently removed in January 2018. See Note 1. Description of Business and Summary of Significant Accounting Policies for further details regarding restricted cash.

The Milestone Event is defined as our receipt of evidence satisfactory to SVB, in its sole but reasonable discretion, that we have received a positive opinion from the EMA for our pacritinib product.

The term loan is repayable over 36 months after an initial interest-only period of at least 12 months after closing, which will be extended to 18 months upon the occurrence of the Milestone Event. The interest rate on the term loan floats at a rate per annum equal to the greater of 2.5 percent above the prime rate and 6.75 percent. We may elect to prepay some or all of the loan balance at any time subject to a prepayment fee. A fee in the amount of 9 percent of the total principal amount funded to us is payable to SVB on the date on which the term loan is paid or becomes due and payable in full. Such fee in the amount of $1.4 million was included in Other liabilities in the consolidated balance sheet as of December 31, 2017. The loan obligations are secured by a first priority security interest on substantially all of our personal property except our intellectual property, and subject to certain other exceptions.

In addition, we issued warrants to SVB and Life Science Loans II, LLC, pursuant to a participation arrangement among SVB, Loan Manager II, LLC and Life Science Loans II, LLC, to purchase up to 190,140 shares of our common stock. Warrants underlying 169,014 shares of our common stock are initially exercisable at any time prior to November 28, 2027. Warrants underlying 21,126 shares of our common stock will become exercisable when the remaining $2.0 million of the term loan is funded to us. The initial exercise price of the warrants is $2.84 per share of our common stock.

In connection with the Loan and Security Agreement, we recorded debt discount and debt issuance costs of $1.9 million and $0.1 million, respectively, of which $1.9 million and $0.1 million was unamortized as of December 31, 2017, respectively. The outstanding principal balance on the term loan was $16.0 million as of December 31, 2017.

Hercules

In March 2013, we entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules, providing for a senior secured term loan of up to $15.0 million. In March 2014, we entered into a First Amendment to the Loan Agreement, which modified certain terms applicable to the loan balance then-outstanding of $15.0 million and provided us with the option to borrow an additional $5.0 million.

In June 2015, we entered into a Third Amendment to the Loan Agreement, or the Third Amendment. Under the Third Amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million, inclusive of the principal balance outstanding immediately prior to closing of the Third Amendment of $13.8 million, or collectively, the Term Loan Borrowings. We drew $6.2 million upon closing of the Third Amendment, resulting in a then-outstanding principal balance of $20.0 million under the Term Loan Borrowings. The remaining $5.0 million was available for borrowing at our option through June 30, 2016, subject to certain conditions. In connection with the Third Amendment, we paid a commitment fee of $15,000 and a facility charge of $0.3 million. The provision under the Loan Agreement requiring us to pay a fee to Hercules of $1.3 million on the date of repayment of the borrowings thereunder was amended pursuant to the Third Amendment, such that the fee was paid in October 2016.

In connection with the Third Amendment, we issued a warrant to Hercules to purchase shares of common stock. The warrant is exercisable for five years from the date of issuance for 29,239 shares of common stock at an initial exercise price of $17.10 per share. The warrant did not meet the considerations necessary for equity classification under the applicable authoritative guidance. As such, we determined that the warrant was a liability instrument with changes in fair value recognized through earnings at each reporting period. The warrant was categorized as Level 2 in the fair value hierarchy as the significant inputs used in determining fair value were considered observable market data. As of the issuance date, we estimated the fair value of the warrant to be $0.4 million. Upon expiry of the exercise price adjustment provision in December 2015, the then-estimated fair value of the warrant of $0.2 million was reclassified from liability to equity.

The modified terms under the Third Amendment were considered substantially different as compared to the terms of the Loan Agreement immediately prior to the Third Amendment, pursuant to ASC 470-50, Modification and Extinguishment. As such, the Third Amendment was accounted for as a debt extinguishment, resulting in a loss on debt extinguishment of $1.2 million, which is included in Other non-operating expense for the year ended December 31, 2015.

In December 2015, we entered into a Fourth Amendment to the Loan Agreement, or the Fourth Amendment, pursuant to which Hercules funded the remaining $5.0 million term loan available under the facility, resulting in a then-outstanding principal balance of $25.0 million.

In November 2017, we repaid the then-outstanding principal balance of $14.3 million in full, using the proceeds from the the Loan and Security Agreement with SVB as discussed above. Accordingly, among other things, (1) all obligations under the Loan Agreement and all related documents have been paid, satisfied, released and discharged in full, (2) all unfunded commitments to make credit extensions or financial accommodations to us or any other person under the Loan Agreement have been automatically and irrevocably terminated, and (3) our obligations under the Loan Agreement and all related documents have been automatically and irrevocably terminated (other than with respect to customary provisions and agreements that are expressly specified to survive the termination). Upon full repayment of the principal in November 2017, we wrote-off the then-unamortized debt discount balance of $0.1 million to a loss on debt extinguishment, which was recorded in Other non-operating expense for the year ended December 31, 2017.

Baxalta

In November 2013, we entered into a Development, Commercialization and License agreement, or the Pacritinib License Agreement, with Baxter International Inc., or Baxter, for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxalta has been assigned Baxter’s rights and obligations under the Pacritinib License Agreement. In June 2015, we entered into the First Amendment to the Pacritinib License Agreement, or the Pacritinib License Amendment, pursuant to which two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Pacritinib License Agreement relating to the following: the $12.0 million development milestone payment payable in connection with the regulatory submission of the Marketing Authorization Application, or the MAA, to the EMA with respect to pacritinib, or the MAA Milestone, and the $20.0 million development milestone payment payable in connection with the first treatment dosing of the 300th patient enrolled per the protocol in PERSIST-2, or the PERSIST-2 Milestone. Under the Pacritinib License Amendment, each of the two milestone advances bore interest at an annual rate of 9% until the earlier of the date of the first occurrence of the respective milestone or the date that the respective advance plus accrued interest was repaid in full. In January 2016 and February 2016, we successfully achieved the $20.0 million PERSIST-2 Milestone and the $12.0 million MAA Milestone, respectively, which were recorded in License and contract revenue for the year ended December 31, 2016.

See Note 11. Collaboration, Licensing and Milestone Agreements for further details regarding our agreements with Baxalta.

8. Preferred Stock

Series N-1 Preferred Stock

In October 2015, in an underwritten public offering, we issued 50,000 shares of Series N-1 convertible preferred stock, or Series N-1 Preferred Stock, for gross proceeds of $50.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $3.4 million, including $3.0 million in underwriting commissions and discounts.

Each share of Series N-1 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-1 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-1 Preferred Stock. The Series N-1 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-1 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law.

In October 2015, all 50,000 shares of Series N-1 Preferred Stock were converted into 4.0 million shares of common stock at a conversion price of $12.50 per share. During the year ended December 31, 2015, we recognized $3.2 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-1 Preferred Stock.

Series N-2 Preferred Stock

In December 2015, in an underwritten public offering, we issued 55,000 shares of Series N-2 Preferred Stock for gross proceeds of $55.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.6 million, including $2.2 million in underwriting commissions and discounts.

Each share of Series N-2 Preferred Stock was convertible at the option of the holder (subject to a limited exception) and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-2 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-2 Preferred Stock. The Series N-2 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-2 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law.

In December 2015, all 55,000 shares of Series N-2 Preferred Stock were converted into 5.0 million shares of common stock at a conversion price of $11.00 per share. There was no beneficial conversion feature on Series N-2 Preferred Stock.

Series N-3 Preferred Stock

In June 2017, in an underwritten public offering, we issued 22,500 shares of Series N-3 Preferred Stock for gross proceeds of $45.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.3 million. BVF Partners L.P., or BVF, an existing shareholder of the Company, was one of our investors in this offering. See

Note 17. Related Party Transactions for further details.

Each share of Series N-3 Preferred Stock is convertible at the option of the holder (subject to a limited exception) and is entitled to a liquidation preference equal to the initial stated value of $2,000 per share, plus any declared and unpaid dividends, and any other payments that may be due on such shares, before any distribution of assets may be made to holders of capital stock ranking junior to the Series N-3 Preferred Stock. The Series N-3 Preferred Stock is not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-3 Preferred Stock has no voting rights, except as otherwise expressly provided in the articles of amendment to amended and restated articles of incorporation of CTI or as otherwise required by law.

In June 2017, 21,925 shares of Series N-3 Preferred Stock were converted into 14.6 million shares of common stock at a conversion price of $3.00 per share. For the year ended December 31, 2017, we recognized $4.4 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-3 Preferred Stock. There were 575 shares of Series N-3 Preferred Stock outstanding as of December 31, 2017.

In February 2018, 575 shares of Series N Preferred Stock owned by certain affiliates of BVF Partners L.P., or collectively, BVF, along with 8.0 million shares of our common stock owned by BVF were exchanged for 12,575 shares of Series O Preferred Stock. See Note 17. Related Party Transactions for further details.

9. Common Stock

Common Stock Authorized

In April 2016, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from 31.5 million to 41.5 million.

In May 2017, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from 41.5 million to 81.5 million.

Common Stock Issued

In September 2015, we entered into a subscription agreement with BVF pursuant to which we issued to BVF an aggregate of 1.0 million shares of common stock at a purchase price per share of $15.70. The shares of common stock were offered directly to BVF without a placement agent or underwriter. The net proceeds from the offering, after deducting offering expenses, were approximately $15.1 million.

Common Stock Reserved

A summary of common stock reserved for issuance is as follows as of December 31, 2017 (in thousands):



Equity incentive plans	5,920
Option agreement with Adam R. Craig	1,120
Common stock purchase warrants	219
Series N-3 convertible preferred stock	383
Employee stock purchase plan	184
Total common stock reserved	7,826

Warrants

Warrants to purchase up to 29,239 shares of our common stock with an exercise price of $17.10 per share, issued in connection with the Third Amendment to the Loan Agreement with Hercules in June 2015, were outstanding as of December 31, 2017.

Warrants to purchase up to 190,140 shares of our common stock with an exercise price of $2.84 per share, issued in connection with the Loan and Security Agreement with SVB, were outstanding as of December 31, 2017.

See Note 7. Long-term Debt for additional information concerning our warrants.

10. Other Comprehensive Loss

Total accumulated other comprehensive loss consisted of the following (in thousands):



	Net Unrealized Gain (Loss) and Impairment on Available-For-Sale Securities			Foreign Currency Translation Adjustments			Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance			Accumulated Other Comprehensive Loss
December 31, 2016	$	(6	)	$	(2,902	)	$	(3,747	)	$	(6,655	)
Current period other comprehensive income (loss)	7			(3,927		)	4,303			383
December 31, 2017	$	1		$	(6,829	)	$	556		$	(6,272	)

In the first quarter of 2016, we recognized an other-than-temporary impairment on available-for-sale securities of $0.5 million in our consolidated statement of operations. The value of available-for-sale securities of $13,500 was included in Prepaid expenses and other current assets as of December 31, 2016. We had no available-for-sale securities as of December 31, 2017.

11. Collaboration, Licensing and Milestone Agreements

Servier

In September 2014, we entered into an Exclusive License and Collaboration Agreement, or the Original Agreement, with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively, Servier. In April 2017, we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier, pursuant to which the Original Agreement was amended and restated in its entirety.

Under the Restated Agreement, we granted Servier an exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions).

In May 2017, we received a non-refundable, non-creditable upfront cash payment of €12.0 million under the terms of the Restated Agreement. This amount included a €2.0 million payment for a milestone relating to EMA approval of an additional third-party manufacturer of PIXUVRI, which was not included in the Original Agreement and was deemed achieved at the time

of the Restated Agreement. Subject to the achievement of certain conditions, the Restated Agreement provides for additional milestone payments of up to €76.0 million: up to €36.0 million in potential regulatory milestone payments (which includes a €1.0 million payment for a regulatory milestone achieved in September 2017 as discussed below), and up to €40.0 million in potential sales-based milestone payments. We have determined that all the regulatory milestones, other than the €2.0 million milestone mentioned above, are substantive due to significant uncertainty involved in each milestone, and will be recognized as revenue upon achievement of the respective milestones, assuming all other revenue recognition criteria are met. We have also determined that the sales-based milestone payments are contingent consideration and will be recognized as revenue in the period in which the respective revenue recognition criteria are met.

We are eligible to receive tiered royalty payments on net sales of products containing PIXUVRI, ranging from a low double-digit percentage up to a percentage in the low twenties, subject to certain reductions of up to mid-double-digit percentages under certain circumstances. Royalties are subject to expiration upon certain events, including upon expiration of exclusivity rights to products containing PIXUVRI in the respective country.

Under the Restated Agreement, with the exception of the conclusion of the PIX306 trial and certain other services,

Servier will be responsible for development, commercialization and manufacturing activities within its territory. We entered into a commercialization transition plan whereby we transferred to Servier medical affairs and commercialization activities relating to the Licensed Products in Israel, Turkey, Germany, Austria, the United Kingdom, Denmark, Finland, Norway and Sweden, or collectively, the Transition Territory. Upon completion of the commercialization transition plan, we terminated or assigned certain distributor and wholesaler contracts to Servier in the Transition Territory. Each party is responsible for the manufacture and supply of drug products and substances in their respective territories. We record reimbursements received from Servier for their portion of operating expenses we pay on their behalf as revenue and the full amount of costs as operating expenses in the statements of operations.

The Restated Agreement will expire on a country-by-country basis upon the expiration of the royalty terms in the countries in the Servier territory, at which time all licenses granted to Servier would become perpetual and royalty-free. Each party may terminate the Restated Agreement in the event of an uncured repudiatory breach of the other party’s obligations. Subject to applicable notification periods, Servier may terminate the Restated Agreement on a country-by-country basis upon 30 days’ written notice in the event of (1) certain safety or public health issues relating to the Licensed Product, (2) suspension or withdrawal of marketing authorizations and (3) without cause. In the event of a termination prior to the expiration date, rights granted to Servier will terminate, subject to certain exceptions.

Pursuant to accounting guidance under ASC 605-25 Revenue Recognition - Multiple-Element Arrangements, we identified the following non-contingent deliverables with standalone value at the inception of the Restated Agreement:

• a license with respect to the development and commercialization of PIXUVRI

• development services

• joint committee obligations

• regulatory responsibilities

• commercialization responsibilities

• manufacturing and supply responsibilities

The license deliverable has standalone value because it is sublicensable and can be used for its intended purpose without the receipt of the remaining deliverables. The service deliverables have standalone value because these services are not proprietary in nature, and other vendors could provide the same services in order to derive value from the license. Further, there is no general right of return associated with these deliverables. As such, the deliverables meet the criteria for separation and qualify as separate units of accounting.

We determined that the value of the joint committee obligations and the regulatory, commercial, and manufacturing and supply responsibilities were insignificant. These deliverables have been combined with the development services and included as “Other services” in the table below.

We allocated the arrangement consideration of $12.8 million (€12.0 million converted into U.S. dollars using the

currency exchange rate as of the date of the Restated Agreement) based on the percentage of the relative selling price of each

unit of accounting as follows (in thousands):



License	$	11,487
Development and other services	1,348
Total upfront payment	$	12,835

We estimated the selling price of the license using the income approach that values the license by discounting direct cash flow expected to be generated over the remaining life of the license, net of cash flow adjustments related to working capital.The estimates and assumptions include, but are not limited to, estimated market opportunity, expected market share, and

contractual royalty rates. We estimated the selling price of the development services deliverable, which includes personnel costs as well as third-party costs for applicable services and supplies, by discounting estimated expenditures for services to the date of the Restated Agreement. We concluded that a change in the key assumptions used to determine the best estimate of the selling price for the license deliverable would not have a significant effect on the allocation of the arrangement consideration.

During the year ended December 31, 2017, we recognized $11.5 million of consideration allocated to the license as revenue upon delivery of the license and the satisfaction of the remaining revenue recognition criteria. The $1.3 million consideration allocated to development and other services was recorded as deferred revenue. During the year ended December 31, 2017, $0.5 million of other services consideration was recognized as revenue; the remaining $1.4 million is included in deferred revenue in the consolidated balance sheet as of December 31, 2017.

In September 2017, we attained a regulatory milestone under the Restated Agreement and recognized a €1.0 million milestone revenue (or $1.2 million using the currency exchange rate as of the date the milestone was achieved).

Of the potential milestone payments under the Original Agreement, we received a €1.5 million (or $1.7 million upon conversion from euros as of the date we received the funds) milestone payment in February 2015 relating to the attainment of reimbursement approval for PIXUVRI in Spain. In December 2016, we recorded €7.5 million in milestone revenue (or $8.0 million upon conversion from euros as of the date we achieved the milestone) relating to the attainment of a certain enrollment event in connection with our PIX306 study. This was included in Receivable from collaborative arrangements as of December 2016, and we received the funds in January 2017. These milestone revenues were accounted for under the milestone method of accounting since this milestone was determined to be substantive at the inception of the arrangement.

Other operating (income) expense, net for the years ended December 31, 2015 and December 31, 2016, includes $0.3 million and $0.8 million, respectively, for payments made to Novartis International Pharmaceutical Ltd. in connection with the milestone payments received in February 2015 and January 2017, respectively, as discussed above.

In February 2016, we entered into an agreement with one of Servier's affiliates whereby we conduct the pharmacokinetic sub-study on behalf of Servier in conjunction with our ongoing clinical trial, PIX-306. During the years ended December 31, 2017 and 2016, $0.1 million and $0.5 million, respectively, of expense reimbursements in relation to this study was included in development services revenue. There was no such revenue during the year ended December 31, 2015. We expect to receive no such development services revenue in future periods as the pharmacokinetic sub-study was completed in September 2017.

Teva

Pursuant to an acquisition agreement entered into with Cephalon, Inc., or Cephalon, in June 2005, we have the right to receive up to $100.0 million in payments upon achievement of specified sales and development milestones related to TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. As of December 31, 2017, we have received $40.0 million of such potential milestone payments as a result of having achieved certain sales milestones. For each of the years ended December 31, 2017 and 2015, we received $10.0 million from Teva upon the achievement of worldwide net sales milestones of TRISENOX, which was included in license and contract revenue. We received no milestone payment from Teva during the year ended December 31, 2016. In February 2018, we received a $10.0 million milestone payment related to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. The achievement of the remaining milestones is uncertain at this time.

Baxalta

In November 2013, we entered into the Pacritinib License Agreement with Baxter for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxter assigned its rights and obligations under the Pacritinib License Agreement to Baxalta. Under the Pacritinib License Agreement, we granted to Baxter

an exclusive, worldwide (subject to our certain co-promotion rights in the U.S.), royalty-bearing, non-transferable, and (under certain circumstances outside of the U.S.) sub-licensable license to our know-how and patents relating to pacritinib. We received an upfront payment of $60.0 million upon execution of the Pacritinib License Agreement, which included an equity investment of $30.0 million to acquire our Series 19 Preferred Stock.

We allocated the fixed and determinable Pacritinib License Agreement consideration of $30.0 million based on the percentage of the relative selling price of each unit of accounting. Of the $30.0 million consideration, $27.3 million was allocated to the license and $2.7 million was allocated to the development services. The amount allocated to development services was initially deferred and recognized as revenue based on a proportional performance method. During the years ended December 31, 2016 and 2015, $1.0 million and $0.8 million, respectively, of development services was recognized as revenue. There was no deferred revenue relating to the development services in the balance sheet as of December 31, 2017 and 2016 due to our entry into the Asset Return and Termination Agreement with Baxalta in October 2016 as discussed below.

Under the Pacritinib License Agreement, we were responsible for all development costs incurred prior to January 1, 2014 as well as up to approximately $96.0 million on or after January 1, 2014 for U.S. and E.U. development costs, subject to potential adjustment in certain circumstances. All development costs exceeding such threshold were generally shared with Baxalta. We recorded development cost reimbursements received from Baxalta as license and contract revenue in the consolidated statements of operations, and we recorded the full amount of development costs as research and development expense. During the year ended December 31, 2016, we recorded $11.4 million of development services revenue relating to reimbursable development costs from Baxalta under the terms of the Pacritinib License Agreement. There was no such revenue recorded during the years ended December 31, 2017 and December 31, 2015.

In June 2015, we entered into the Pacritinib License Amendment to the Pacritinib License Agreement. Pursuant to the Pacritinib License Amendment, two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Pacritinib License Agreement. Refer to the Note 7. Long-term Debt for further details regarding these milestone advances received. During the first quarter of 2016, we achieved these milestones and recorded $32.0 million in license and contract revenue for the year ended December 31, 2016.

In October 2016, we entered into the Asset Return and Termination Agreement (the “Termination Agreement”) with Baxalta. Pursuant to the Termination Agreement, the Pacritinib License Agreement was terminated in its entirety (other than with respect to certain customary provisions that survive termination, including those pertaining to confidentiality and indemnification), the Pacritinib License Agreement has no further force or effect, and all rights and obligations of the Company and Baxalta under the Pacritinib License Agreement were terminated. In connection with this termination, we recorded a gain of $5.9 million which was included in Other operating (income) expense for the year ended December 31, 2016.

In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the Termination Agreement and are no longer eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta. In addition, under the Termination Agreement, we are required to make a milestone payment to Baxalta in the amount of approximately $10.3 million upon the first regulatory approval or any pricing and reimbursement approvals of a product containing pacritinib.

Novartis

In January 2014, we entered into a Termination Agreement, or the Novartis Termination Agreement, with Novartis to reacquire the rights to PIXUVRI and Opaxio, or collectively, the Compounds, previously granted to Novartis under our License and Co-Development Agreement with Novartis, as amended, or the Original Novartis Agreement. Pursuant to the Novartis Termination Agreement, the Original Novartis Agreement was terminated in its entirety, other than with respect to certain customary provisions, including those pertaining to confidentiality and indemnification, which survive termination.

Under the Novartis Termination Agreement, we agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of the Compounds unless the transferee/licensee/sublicensee agrees to be bound by the terms of the Novartis Termination Agreement. We also agreed to provide potential payments to Novartis, including a percentage ranging from the low double-digits to the mid-teens, of any consideration received by us or our affiliates in connection with any transfer, license, sublicense or other grant of rights with respect to intellectual property of the Compounds, provided that such payments would not exceed certain prescribed ceilings in the low-single digit millions. Novartis is entitled to receive potential payments of up to $16.6 million upon the achievement of certain sales milestones of the Compounds. Novartis is also eligible to receive tiered low single-digit percentage royalty payments for the first several hundred million in annual net sales, and ten percent royalty payments thereafter based on annual net sales of each Compound, subject to reduction in the event generic

drugs are introduced and sold by a third party, causing the sale of the Compounds to fall by a percentage in the high double-digits. Notwithstanding the foregoing, royalty payments for the Compounds are subject to certain minimum floor percentages in the low single-digits.

University of Vermont

In March 1995, the University of Vermont, or UVM, entered into an agreement, or the UVM Agreement, which, as amended in March 2000, grants us an exclusive, sublicensable license for the rights to PIXUVRI. Pursuant to the UVM Agreement, we acquired the rights to make, have made, sell and use PIXUVRI. We are obligated to make royalty payments to UVM that range from low-single digits to mid-single digits as a percentage of net sales. The higher royalty rate is payable for net sales in countries where specified UVM licensed patents exist, or where we have obtained orphan drug protection, until such UVM patents or such protection no longer exists. For a period of ten years after first commercialization of PIXUVRI, the lower royalty rate is payable for net sales in such countries after expiration of the designated UVM patents or loss of orphan drug protection, and in all other countries without such specified UVM patents or orphan drug protection. Unless otherwise terminated, the term of the UVM Agreement continues for the life of the licensed patents in those countries in which a licensed patent exists, and continues for ten years after the first sale of PIXUVRI in those countries where no such patents exist. We may terminate the UVM Agreement, on a country-by-country basis or on a patent-by-patent basis, at any time upon advance written notice. UVM may terminate the UVM Agreement upon advance written notice in the event royalty payments are not made. In addition, either party may terminate the UVM Agreement (1) in the event of an uncured material breach of the UVM Agreement by the other party or (2) in the event of bankruptcy of the other party.

S*BIO Pte Ltd.

We acquired the compounds SB1518 (which is referred to as “pacritinib”) and SB1578, which inhibit JAK2 and FLT3, from S*BIO Pte Ltd., or S*BIO, in May 2012. Under our agreement with S*BIO, we are required to make milestone payments to S*BIO up to an aggregate amount of $132.5 million if certain U.S., E.U. and Japanese regulatory approvals are obtained or if certain worldwide net sales thresholds are met in connection with any pharmaceutical product containing or comprising any compound that we acquired from S*BIO for use for specific diseases, infections or other conditions. At our election, we may pay up to 50% of any milestone payments to S*BIO through the issuance of shares of our common stock or shares of our preferred stock convertible into our common stock. S*BIO will also be entitled to receive royalty payments from us at incremental rates in the low single-digits based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis.

Vernalis

The Vernalis License Agreement will terminate when the royalty obligations expire, although the parties have early termination rights under certain circumstances, including the following: (1) we have the right to terminate, with three months’ notice, upon the belief that the continued development of tosedostat or any of the other licensed compounds is not commercially viable, (2) Vernalis has the right to terminate in the event of our uncured failure to pay sums due, and (3) either party has the right to terminate in the event of the other party’s uncured material breach or insolvency.

Gynecologic Oncology Group

We entered into an agreement with the Gynecologic Oncology Group, or GOG, now part of NRG Oncology, in March 2004, as amended, related to the GOG-212 trial of Opaxio in patients with ovarian cancer. Pursuant to the terms of such agreement, we made a milestone payment of $0.5 million relating to the transfer of final datasets during the second quarter of 2017. The agreement was terminated in May 2017. No further development of Opaxio is planned.

PG-TXL

polymer technology. Pursuant to the PG-TXL Agreement, we acquired the rights to research, develop, manufacture, market and sell anti-cancer drugs developed using this polymer technology. Pursuant to the PG-TXL Agreement, we were obligated to make payments to PG-TXL of up to $14.4 million upon the achievement of certain development and regulatory milestones. The timing of the remaining milestone payments under the PG-TXL Agreement was based on trial commencements and completions for compounds protected by PG-TXL license rights, and regulatory and marketing approval of those compounds by the FDA and the EMA. Additionally, we were required to make royalty payments to PG-TXL ranging from low to mid-single digits as a percentage of net sales. In February 2017, we terminated our agreement with PG-TXL and the exclusive worldwide license for rights to Opaxio and certain polymer technology thereunder.

Nerviano Medical Sciences

Under a license agreement entered into with Nerviano Medical Sciences, S.r.l. in October 2006, for brostallicin, we were required to pay up to $80.0 million in milestone payments based on the achievement of certain product development results. In April 2015 we terminated our license agreement with Nerviano Medical Sciences, S.r.l. for brostallicin. No milestone payments were made prior to the termination of the license agreement.

Other Agreements

We have several agreements with contract research organizations, third-party manufacturers, and distributors which have durations of greater than one year for the development and distribution of certain of our compounds.

12. Share-Based Compensation

Share-Based Compensation Expense

Share-based compensation expense for all share-based payment awards made to employees and directors is measured based on the grant-date fair value estimated in accordance with GAAP. We recognize share-based compensation using the straight-line, single-award method based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Share-based compensation is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.

During the years ended December 31, 2017, 2016 and 2015, we recognized share-based compensation expense which consisted of the following types of awards (in thousands):



	2017		2016		2015
Performance rights	$	—	$	575	$	3,155
Restricted stock	1,015		4,199		8,656
Options	4,731		8,550		3,017
Total share-based compensation expense	$	5,746	$	13,324	$	14,828

The following table summarizes share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, which was allocated as follows (in thousands):



	2017		2016		2015
Research and development	$	911	$	2,320	$	3,964
Selling, general and administrative	4,835		11,004		10,864
Total share-based compensation expense	$	5,746	$	13,324	$	14,828

Share-based compensation had a $5.7 million, $13.3 million and $14.8 million effect on our net loss attributable to common shareholders, which resulted in a $(0.16), $(0.48) and $(0.79) effect on basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015, respectively. It had no effect on cash flows from operations or financing activities for the periods presented; however, during the years ended 2017, 2016 and 2015, we repurchased 21,000,

35,000 and 32,000 shares of our common stock totaling $0.1 million, $0.4 million and $0.6 million, respectively, for cash in connection with the vesting of employee restricted stock awards based on taxes owed by employees upon vesting.

As of December 31, 2017, unrecognized compensation cost related to unvested stock options, restricted stock awards and restricted stock units amounted to $9.9 million, which will be recognized over the remaining weighted-average requisite service period of 2.28 years. The unrecognized compensation cost related to unvested options and restricted stock does not include the value of performance-based awards.

For the years ended December 31, 2017, 2016 and 2015, no tax benefits were attributed to share-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.

Stock Plans

In May 2017, the Company's 2017 Equity Incentive Plan, or the 2017 Plan, was approved by the Company's shareholders, and no additional awards will be granted under the 2015 Equity Incentive Plan, or the 2015 Plan.

The Company's 2007 Employee Stock Purchase Plan, as amended and restated in August 2009 and September 2015, or the Purchase Plan, was amended in September 2015 to increase the maximum number of shares of the Company’s common stock authorized for issuance by 0.2 million shares. Refer to Employee Stock Purchase Plan below for further details.

Pursuant to our 2017 Plan, we may grant the following types of incentive awards: (1) stock options, including incentive stock options and non-qualified stock options, (2) stock appreciation rights, (3) restricted stock, (4) restricted stock units and (5) cash awards. The 2017 Plan is administered by the Compensation Committee of our Board, which has the discretion to determine the employees and consultants who shall be granted incentive awards. The Board retained sole authority under the 2017 Plan with respect to non-employee directors’ awards, although the Compensation Committee has authority under its charter to make recommendations to the Board concerning such awards. Options expire 10 years from the date of grant, subject to the recipients continued service to the Company.

As of December 31, 2017, 8.3 million shares were authorized for issuance, of which 24,000 shares of common stock were available for future grants, under the 2017 Plan.

Stock Options

Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:



	Year Ended December 31,
	2017		2016		2015
Risk-free interest rate	1.9	%	1.2	%	1.7	%
Expected dividend yield	None		None		None
Expected life (in years)	5.2		4.0		5.3
Volatility	83	%	75	%	80	%

The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our options are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our options, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.

Our stock price volatility and option lives, both of which impact the fair value of options calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option, involve management’s best estimates. As we recognize compensation expense for only the portion of options expected to vest, we apply estimated forfeiture rates that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.

The following table summarizes stock option activity for all of our stock option plans:



	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (Thousands)
Outstanding at December 31, 2014 (317,400 exercisable)	492,000		$	31.39
Granted	1,149,000		$	13.94
Exercised	(8,000	)	$	13.98
Forfeited	(62,000	)	$	21.70
Cancelled and expired	(12,000	)	$	242.92
Outstanding at December 31, 2015 (436,100 exercisable)	1,559,000		$	17.45
Granted	1,511,000		$	6.43
Exercised	—		$	—
Forfeited	(128,000	)	$	9.07
Cancelled and expired	(136,000	)	$	25.58
Outstanding at December 31, 2016 (1,913,000 exercisable)	2,806,000		$	11.44
Granted	4,450,000		$	3.68
Exercised	—		$	—
Forfeited	(378,000	)	$	6.27
Cancelled and expired	(210,000	)	$	24.33
Outstanding at December 31, 2017	6,668,000		$	6.15	7.0	$	—
Vested or expected to vest at December 31, 2017	6,410,000		$	6.26	6.9	$	9
Exercisable at December 31, 2017	2,500,000		$	9.83	3.2	$	—

The weighted average exercise price of options exercisable at December 31, 2017, 2016 and 2015 was $9.83, $12.58 and $25.71, respectively. The weighted average grant-date fair value of options granted during 2017, 2016 and 2015 was $2.47, $3.01 and $9.17 per option, respectively.

In March 2017, Dr. Adam R. Craig, our President and CEO, was granted stock options to purchase 1.2 million shares of common stock at an exercise price of $4.24 per share. The stock options have a maximum term of ten years and vest in six equal semi-annual installments over the three-year period beginning March 20, 2017, subject to his continued employment through the applicable vesting dates and acceleration under certain circumstances. The stock options were granted in connection with his entering into employment with the Company as President and CEO. A portion of the stock options covering 80,000 shares were granted under the 2015 Plan. The balance of such stock options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

Restricted Stock

We issued 2,000, 270,000 and 570,000 shares of restricted stock awards in 2017, 2016 and 2015, respectively. The weighted average grant-date fair value of restricted stock awards issued during 2017, 2016 and 2015 was $5.78, $5.64 and $20.61, respectively. Additionally, 39,000, 97,000 and 177,000 shares of restricted stock awards were cancelled during 2017, 2016 and 2015, respectively.

The total fair value of restricted stock awards vested during the years ended December 31, 2017, 2016 and 2015 was $0.3 million, $1.3 million and $7.3 million, respectively.

A summary of the status of nonvested restricted stock awards as of December 31, 2017 and changes during the period then ended, is presented below:



	Nonvested Shares		Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2016	183,000		$	12.76
Issued	2,000		$	5.78
Vested	(83,000	)	$	9.43
Forfeited	(39,000	)	$	14.39
Nonvested at December 31, 2017	63,000		$	15.93

We issued 20,000, 187,000 and 46,000 restricted stock units during 2017, 2016 and 2015, respectively, and cancelled 13,000 restricted stock units during 2015. No restricted stock units were cancelled during 2017 or 2016. The weighted average grant-date fair value of restricted stock units issued during 2017, 2016 and 2015 was $4.97, $5.35 and $15.70, respectively. The total fair value of restricted stock units vested during the year ended December 31, 2017 and 2016 was $0.8 million and $0.2 million, respectively. No restricted stock units vested during the year ended December 31, 2015.

A summary of the status of nonvested restricted stock units as of December 31, 2017 and changes during the period then ended, is presented below:



	Nonvested Units		Weighted Average Grant-Date Fair Value Per Unit
Nonvested at December 31, 2016	187,000		$	5.35
Issued	20,000		$	4.97
Vested	(187,000	)	$	5.35
Forfeited	—		$	—
Nonvested at December 31, 2017	20,000		$	4.97

Long-Term Performance Awards

In November 2011, we granted restricted stock units to our executive officers and directors that became effective on January 3, 2012, or the Long-Term Performance Awards, which was subsequently amended in 2013, 2014 and 2015. The Long-Term Performance Awards vest upon achievement of milestone-based performance conditions, including a market-based condition. If one or more of the underlying performance-based conditions were timely achieved, the award recipient would be entitled to receive a number of shares of our common stock (subject to share limits of the 2007 Plan or 2015 Plan, as applicable), determined by multiplying (1) the award percentage corresponding to that particular performance goal by (2) the total number of outstanding shares of our common stock as of the date that the particular performance goal is achieved.

In September 2015, our Board certified completion of the performance condition relating to pacritinib Phase 3 trial result that satisfies the primary point set forth in the statistical plan then in effect and an aggregate of 0.2 million shares vested to our executive officers and directors. We recognized $2.8 million in share-based compensation upon satisfaction of this performance condition during the year ended December 31, 2015.

In December 2015, the Long-Term Performance Awards were modified so that as to any particular performance goal that was achieved after December 23, 2015 and on or before December 31, 2016, the executive officers would be granted a stock option with respect to the number of shares determined under the formula described above (as opposed to receiving or retaining such number of fully-vested shares of our common stock). Each option had an exercise price equal to the closing price of the Company’s common stock on the grant date (which would be the date the Compensation Committee of our Board certifies the performance goal is achieved) and would be scheduled to vest in semi-annual installments over a period of three years following the grant date.

On December 31, 2016, the Long-Term Performance Awards expired.

The fair value of the Long-Term Performance Awards was estimated based on the average present value of the awards to be issued upon achievement of the performance conditions. The average present value was calculated based upon the expected

date the shares of common stock underlying the performance awards will vest, or the event date, the expected stock price on the event date, and the expected shares outstanding as of the event date. The event date, stock price and the shares outstanding were estimated using a Monte Carlo simulation model, which is based on assumptions by management, including the likelihood of achieving the milestones and potential future financings.

We determined the Long-Term Performance Awards with a market-based performance condition had a grant-date fair value of $3.6 million for the executive officers and director participants. We determined that the market-based performance condition had an incremental fair value of $0.8 million on the first modification date in March 2013 and an additional incremental fair value of $1.8 million on the second modification date in January 2014 for the executive officers and director participants, which were recognized in addition to the then-unamortized fair value as of the modification date over the remaining estimated requisite service period. The December 2015 modification discussed above did not result in incremental fair value. In December 2015, we reversed the total share-based compensation expense of $1.0 million, which was previously recorded for awards granted to directors who agreed to forfeit their Long-Term Performance Awards as part of the derivative lawsuit settlement. See Note 18. Legal Proceedings for further information. We recognized $0.6 million and $0.3 million in share-based compensation expense related to the awards with a market-based condition during the years ended December 31, 2016 and 2015, respectively. There was no compensation expense for the year ended December 31, 2017 as the Long-Term Performance Awards expired on December 31, 2016.

Nonemployee Share-Based Compensation

Share-based compensation expense for awards granted to nonemployees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of options and restricted stock awards granted to nonemployees is periodically remeasured as the underlying options or awards vest. The value of the instrument is amortized to expense over the vesting period with final valuation measured on the vesting date. As of December 31, 2017 and 2016, unvested options to acquire approximately 4,400 shares and 11,000 shares of common stock were outstanding, respectively. We reversed compensation expense of $8,000 during the year ended December 31, 2017 and recorded $16,000 during the year ended December 31, 2016. As of December 31, 2015, there were no unvested options or restricted stock outstanding, and no compensation expense was recorded for the year-ended December 31, 2015.

Employee Stock Purchase Plan

Under the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at 85% of the lower of the subscription date fair market value and the purchase date fair market value. There are two six-month offerings per year. Under the Purchase Plan, we issued approximately 4,000, 10,000 and 700 shares of our common stock to employees in the years ended December 31, 2017, 2016 and 2015, respectively. There are 0.2 million shares of common stock authorized under the Purchase Plan and approximately 0.2 million shares are reserved for future purchases as of December 31, 2017.

13. Employee Benefit Plans

Our U.S. employees participate in the CTI BioPharma Corp. 401(k) Plan whereby eligible employees may defer up to 80% of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded $0.3 million related to discretionary matching contributions during the year ended December 31, 2017, and $0.2 million during each of the years ended December 31, 2016 and 2015.

14. Shareholder Rights Plan

In December 2009, our Board approved and adopted a shareholder rights plan, or Rights Plan, in which one preferred stock purchase right was distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI’s common stock outstanding as of, and issued subsequent to January 7, 2010. In 2012, 2015 and 2017, our Board approved certain amendments to the Rights Plan. The Rights Plan expires on December 2, 2018.

Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of two ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of $16.00 per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires 20% or more of our common stock. Upon acquisition of 20% or more of our

common stock, our Board could decide that each right (except those held by a 20% shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. In certain circumstances, including if there are insufficient shares of our common stock to permit the exercise in full of the rights, the holder may receive units of preferred stock, other securities, cash or property, or any combination of the foregoing.

In addition, if we are acquired in a merger or other business combination transaction, each holder of a right (except those held by a 20% shareholder which become null and void) would have the right to receive, upon exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the right. Our Board may redeem the rights for $0.0002 per right or terminate the Rights Plan at any time prior to an acquisition by a person or group holding 20% or more of our common stock.

15. Customer and Geographic Concentrations

We consider our operations to be a single operating segment focused on the development, acquisition and commercialization of novel treatments for cancer. Financial results of this reportable segment are presented in the accompanying consolidated financial statements.

All sales of PIXUVRI during the years presented were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:



	Year Ended December 31,
	2017		2016		2015
Customer A	61	%	60	%	41	%
Customer B	24	%	27	%	42	%
Customer C	13	%	—		—

As of April 2017, Servier has the exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note 11. Collaboration, Licensing and Milestone Agreements for further details.

The following table depicts long-lived assets based on the following geographic locations (in thousands):



	Year Ended December 31,
	2017		2016
United States	$	2,365	$	2,990
Europe	—		33
Total long-lived assets	$	2,365	$	3,023

16. Net Loss Per Share

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, as their inclusion would have an anti-dilutive effect. Accordingly, diluted net loss per share is the same as basic net loss per share.

The computation of net loss per share is as follows (in thousands, except per share amounts):



	Year Ended December 31,
	2017			2016			2015
Net loss attributable to common shareholders	$	(45,020	)	$	(52,009	)	$	(122,622	)
Basic and diluted:
Weighted average shares outstanding	36,569			28,198			19,324
Less weighted average restricted shares outstanding	(124		)	(250		)	(487		)
Shares used in calculation of basic and diluted net loss per common share	36,445			27,948			18,837
Net loss per common share: Basic and diluted	$	(1.24	)	$	(1.86	)	$	(6.51	)

Equity awards, warrants, unvested share rights and other convertible securities aggregating 5.2 million shares, 2.7 million shares and 1.5 million shares for the years ended December 31, 2017, 2016 and 2015, respectively, prior to the application of the treasury stock method, have been excluded from the calculation of diluted net loss per share because they were anti-dilutive.

17. Related Party Transactions

Aequus

We have a majority ownership interest in Aequus. In May 2007, we entered into a license agreement with Aequus

whereby Aequus gained rights to our Genetic Polymer™ technology. We also entered into an agreement to fund Aequus in

exchange for a convertible promissory note.

In March 2017, we and Aequus entered into a License and Promissory Note Termination Agreement and a Note Cancellation Agreement, pursuant to which (1) all of the then-outstanding principal, plus all accrued and unpaid interest, approximately $13.7 million in total, was cancelled and terminated, (2) our license agreement with Aequus was terminated, (3) all obligations to Aequus were terminated with the exception of providing additional funding of up to $347,500 to Aequus, and (4) Aequus agreed to pay us a) 20% of milestone and similar payments, up to a maximum amount of $20.0 million, and b) royalties, on a product-by-product and county-by country basis, of 5% of net sales of certain ACTH Products being developed by Aequus. The additional funding of $347,500 had been provided in full as of September 30, 2017. Payments from Aequus are due the later of (1) expiration of the last to expire valid patent claim that claims the ACTH Product, or (2) ten years from the first commercial sale of the applicable ACTH Product. We have the right to terminate the License and Promissory Note Termination Agreement and require Aequus to assign all ACTH Product related assets to us if Aequus does not file an Investigational New Drug Application for an ACTH Product with the FDA by September 6, 2019.

Jack W. Singer, M.D., our Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer, and Global Head of Translational Medicine, and Frederick W. Telling, Ph.D., a member of our Board, are minority shareholders of Aequus, owning approximately 4.3% and 3.8% of the equity in Aequus as of December 31, 2017, respectively. Dr. Telling is the Chairman of Aequus' Board of Directors. Dr. Singer and Richard Love, a member of our Board, are also members of Aequus’ Board of Directors.

BVF Partners L.P.

In September 2015, as discussed in Note 9. Common Stock, we entered into a subscription agreement with BVF pursuant to which we issued 1.0 million shares of our common stock. Further, as discussed in Note 8. Preferred Stock, we completed underwritten public offerings of 55,000 shares of our Series N-2 Preferred Stock, no par value per share in December 2015 and 22,500 shares of our Series N-3 Preferred Stock, no par value per share in June 2017. BVF purchased 30,000 shares of our Series N-2 Preferred Stock and 6,750 shares of our Series N-3 Preferred Stock in such offerings. BVF converted 30,000 shares of our Series N-2 Preferred Stock and 6,175 shares of our Series N-3 Preferred Stock into approximately 2.7 million shares and 4.1

million shares of our common stock, respectively. Primarily as a result of these transactions, BVF beneficially owned approximately 20.0% and 15.9% of our outstanding common stock as of December 31, 2017 and 2016, respectively. Matthew D. Perry, a member of our Board, is the President of BVF and portfolio manager for the underlying funds managed by the firm.

In connection with the Series N-2 Preferred Stock offering, we entered into a letter agreement with BVF, or the First Letter Agreement, pursuant to which we granted BVF a one-time right, subject to certain conditions, to nominate not more than two individuals to serve as members of our Board, subject to the Board’s consent, which is not to be unreasonably withheld and which consent shall be deemed automatically given with respect to two individuals specified in such Letter Agreement. One of such nominees (the “Independent Nominee”) must (1) qualify as an “independent” director as defined under the applicable rules and regulations of the SEC and the NASDAQ, and (2) must not be considered an “affiliate” of BVF as such term is defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have agreed, for the period hereinafter described and subject to a limited exception, to include the nominated directors in the slate of nominees for election to the Board at each annual or special meeting at which directors are to be elected, recommend that shareholders vote in favor of the election of such nominees and support such nominees for election in a manner no less favorable than how we support our own nominees. This obligation will terminate with respect to: (1) the Independent Nominee, and such Independent Nominee must tender his or her resignation to the Board, if requested, promptly upon BVF ceasing to beneficially own at least 11% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), and (2) each of the Independent Nominee and the other individual nominated by BVF, and each such nominee shall tender his or her resignation to the Board promptly upon the earlier to occur of (a) BVF and its affiliates ceasing to beneficially own at least 5% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), (b) BVF ceasing to beneficially own at least 50% of the shares of the common stock beneficially owned by BVF immediately after consummation of the Series N-2 Preferred Stock offering (on an as-converted basis), (c) the continuation of such nomination right would cause any violation of the applicable listing rules of NASDAQ, (d) such time as BVF informs us in writing that it wishes to terminate the foregoing nomination right, or (e) any breach of the Letter Agreement by BVF.

In connection with the offering of Series N-3 Preferred Stock, we entered into a letter agreement with BVF, or the Second Letter Agreement, and pursuant to the First Letter Agreement and the Second Letter Agreement, we agreed to, upon BVF’s election and subject to any board and committee approvals, exchange shares of common stock purchased by BVF directly from us or underlying convertible preferred stock purchased by BVF directly from us, including the shares of common stock underlying the Series N-3 Preferred Stock, into shares of a convertible non-voting preferred stock with substantially similar terms as the Series N-3 Preferred Stock, including a conversion “blocker” initially set at 9.99% of our common stock. Such right would terminate if at any time BVF’s beneficial ownership of our common stock falls below 5%.

In February 2018, in connection with the public offering of common stock as discussed in Note 21. Subsequent Events, BVF purchased 6.3 million shares of our common stock. In addition, BVF exchanged 8.0 million shares of our common stock owned by BVF and 575 shares of our Series N Preferred Stock owned by BVF for 12,575 shares of our Series O Preferred Stock, pursuant to the letter agreements discussed above as well as an additional exchange agreement executed in February 2018. As a result of these transactions, BVF beneficially owned approximately 12.0% of our common stock as of February 28, 2018.

18. Legal Proceedings

Italian VAT Assessments

In April 2009, December 2009 and June 2010, the Italian Tax Authority, or the ITA, issued notices of assessment to CTI (Europe) based on the ITA’s audit of CTI (Europe)’s VAT returns for the years 2003, 2005, 2006 and 2007, or, collectively, the VAT Assessments. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We are defending ourselves against the assessments both on procedural grounds and on the merits of the case although we can make no assurances regarding the ultimate outcome of these cases. Following is a summary of the status of the legal proceedings surrounding each respective VAT year return at issue:

2003. In June 2013, the Regional Tax Court issued decision no. 119/50/13 in regards to the 2003 VAT assessment, which accepted the appeal of the ITA and reversed the previous decision of the Provincial Tax Court. In January 2014, we appealed such decision to the Italian Supreme Court both on procedural grounds and on the merits of the case. In March 2014, we paid a deposit in respect of the 2013 VAT matter of €0.4 million (or $0.6 million upon conversion from euros as of the date of payment), following the ITA's request for such payment.

2005. In January 2018, the Italian Supreme Court issued decision No. 02250/2018 which (i) rejected the appeal of the ITA, (ii) confirmed the decision of the Regional Tax Court which ruled fully in our favor, and (iii) due to the novelty of the arguments at stake, compensated the legal expenses incurred by the parties. ITA may not use any ordinary means of appeal against the Supreme Court decision.

2006 and 2007. The ITA has appealed to the Italian Supreme Court the decisions of the respective appellate court which were favorable to CTI with respect to the consolidated 2006 and 2007 VAT cases (joined by the judge).

No hearing has been fixed yet for the 2003 and consolidated 2006/2007 VAT cases.

If the final decision of the Italian Supreme Court is unfavorable to us, or if, in the interim, the ITA were to make a demand for payment and we were to be unsuccessful in suspending collection efforts, we may be requested to pay the ITA an amount up to €3.9 million, or approximately $4.7 million converted using the currency exchange rate as of December 31, 2017, plus collection fees, notification expenses and additional interest for the period lapsed between the dates in which the assessments were issued and the date of effective payment. In January 2013, our then remaining deposit for the VAT Assessments was refunded to us.

Lopez & Gilbert v. Nudelman,et al

In July 2014, Joseph Lopez and Gilbert Soper, shareholders of the Company, filed a derivative lawsuit purportedly on behalf of the Company, which is named a nominal defendant, against all current and one past member of our Board of Directors in King County Superior Court in the State of Washington, docketed as Lopez & Gilbert v. Nudelman, et al., Case No. 14-2-18941-9 SEA. The lawsuit alleges that the directors exceeded their authority under the Company's 2007 Equity Incentive Plan, or the Plan, by improperly transferring 4,756,137 shares (or 475,613 shares adjusted for the 1-for-10 reverse stock split effective January 1, 2017) of the Company’s common stock from the Company to themselves. It alleges that the directors breached their fiduciary duties by granting themselves fully vested shares of Company common stock, which the plaintiffs allege were not among the six types of grants authorized by the Plan, and that the non-employee directors were unjustly enriched by these grants. The lawsuit also alleges that from 2011 through 2014, the non-employee members of our Board of Directors granted themselves grossly excessive compensation, and in doing so breached their fiduciary duties and were unjustly enriched. Among other remedies, the lawsuit seeks a declaration that the specified grants of common stock violated the Plan, rescission of the granted shares, disgorgement of the compensation awards to the non-employee directors from 2011 through 2014, disgorgement of all compensation and other benefits received by the defendant directors in the course of their breaches of fiduciary duties, damages, an order for certain corporate reforms and plaintiffs’ costs and attorneys’ fees. Because the complaint is derivative in nature, it does not seek monetary damages from the Company. In September 2014, the director defendants moved to dismiss the complaint. The motion to dismiss was heard on November 21, 2014, and the Court entered an order denying the motion to dismiss on December 5, 2014. Defendants' answer to the complaint was filed on January 13, 2015. On May 13, 2015, the Company (as nominal defendant) and our directors (as individual defendants) entered into a memorandum of understanding to settle the pending lawsuit in King County Superior Court in the State of Washington docketed as Lopez & Gilbert v. Nudelman, et al ., Case No. 14-2-18941-9 SEA, or the Settlement. On December 10, 2015, the court issued an order granting final approval to the Settlement.

The provisions of the Settlement include the following terms:


•	We will cancel, and the non-employee directors will agree to, the rescission of all currently outstanding equity awards that we previously granted to non-employee directors that included performance-based vesting metrics and as to which the performance goals remained unsatisfied as of May 13, 2015;


•	Our current non-employee directors will agree to hold (not transfer or sell or encumber in any way) until September 14, 2015 shares of our stock that they currently own and that we awarded to them during 2011, or at any time after 2011 to the present, and that, at the time of the award by us, was fully-vested and unrestricted;

•

We will cap the total annual compensation provided by us to our non-employee directors for each of 2015 and 2016. Such annual compensation cap for each non-employee director for each of 2015 and 2016 will be at the greater of (i) $375,000 plus, as to our Board Chairman, an additional $100,000, or (ii) the 75th percentile of compensation paid by a group of peer companies to their non-employee directors (and, in the case of our Chairman, the 75th percentile of compensation paid by such peers who have a non-employee director chair of their respective board of directors to such non-employee director chairs). The peer group for these purposes will be selected based on advice from an outside compensation consultant. For purposes of the compensation cap and the peer group comparison, compensation will be determined and measured consistent with the rules under Item 402 of

Regulation S-K under the Securities Exchange Act of 1934, as amended, and based on publicly-available information at the applicable time; and

•

We will implement, if not already implemented, within 90 days following final approval of the Settlement by the court, and maintain until at least the end of calendar year 2017 the following: an annual board discussion of non-employee director compensation philosophy; the use of a compensation consultant to advise the Compensation Committee on material decisions concerning non-employee director compensation issues and compare our non-employee director compensation program to a group of our peers; the use of plain language in our compensation-related public filings; and obtain confirmation from our legal department and outside legal counsel advising on executive compensation matters that any contemplated non-employee director awards do not materially violate the applicable plan or materially fail to comply with applicable law.

In connection with the Settlement, we recorded $0.3 million in attorneys’ fees awarded to plaintiffs (net of existing insurance coverage) in our financial statements for the year-ended December 31, 2015.

Securities and Exchange Commission Subpoena

In re CTI BioPharma Corp. Securities Litigation

Wei v. James A. Bianco, et al.; England v. James A Bianco, et al; Nahar v. James A. Bianco, et al.; Hill v. James A. Bianco, et al.

In addition to the items discussed above, we are from time to time subject to legal proceedings and claims arising in the ordinary course of business.

19. Income Taxes

We file income tax returns in the U.S., Italy and the U.K. A substantial part of our operations takes place in the State of Washington, which does not impose an income tax as that term is defined in ASC 740, Accounting for Income Taxes. As such, our state income tax expense or benefit, if recognized, would be immaterial to our operations. We are not currently under examination by an income tax authority, nor have we been notified that an examination is contemplated.

The U.S. signed into law, on December 22, 2017, tax reform legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017, or the 2017 Tax Act. The 2017 Tax Act significantly revises the U.S. corporate income tax by, among other things, lowering the statutory corporate tax rate from 35% to 21%, eliminating certain deductions, imposing a mandatory one-time tax on accumulated earnings of foreign subsidiaries, introducing new tax regimes, and changing how foreign earnings are subject to U.S. tax. The 2017 Tax Act also enhances and extends through 2026 the option to claim accelerated depreciation deductions on qualified property. We have completed our determination of the accounting implications of the 2017 Tax Act, the impact of which is a $41.3 million reduction in net deferred tax assets to reflect the new statutory rate. The rate adjustment to deferred tax assets, a discrete item for the quarter, is fully offset by a decrease in the valuation allowance: there is therefore

no rate impact to us. In addition, there is no impact to current or deferred taxes related to the one-time deemed repatriation, as our foreign subsidiaries do not have cumulative positive earnings and profits.

Loss before income taxes is attributable to the following tax jurisdictions (in thousands):



	2017			2016			2015
United States	$	(40,180	)	$	(51,856	)	$	(110,831	)
Foreign	(651		)	(1,097		)	(9,932		)
Net loss before income taxes	$	(40,831	)	$	(52,953	)	$	(120,763	)

The reconciliation between our effective tax rate and the income tax rate as of December 31 is as follows:



	2017		2016		2015
Federal income tax rate	34	%	34	%	34	%
Research and development tax credits	3		1		3
Non-deductible executive compensation	—		—		(1	)
Valuation allowance	304		(33	)	(32	)
Foreign tax rate differential	—		—		(3	)
Impact of tax reform	(101	)	—		—
Expired tax attribute carryforwards	(240	)	—		—
Other	—		(2	)	(1	)
Net effective tax rate	—	%	—	%	—	%

The principal components of our deferred tax assets and liabilities were as follows (in thousands):



	December 31,
	2017			2016
Deferred tax assets:
Net operating loss carryforwards	$	21,005		$	108,372
Capitalized research and development	27,540			43,768
Research and development tax credit carryforwards	1,347			7,253
Stock-based compensation	12,842			19,288
Intangible assets	8,117			14,525
Depreciation and amortization	472			626
Other deferred tax assets	2,279			3,721
Total deferred tax assets	73,602			197,553
Less: valuation allowance	(73,310		)	(197,131		)
	292			422
Deferred tax liabilities:
Deductions for tax in excess of financial statements	(292		)	(422		)
Total deferred tax liabilities	(292		)	(422		)
Net deferred tax assets	$	—		$	—

As of December 31, 2017 and 2016, we had U.S. federal net operating loss carryforwards, or the NOL, of approximately $74.8 million and $305.4 million respectively, which are available to reduce future taxable income. We also had U.S. federal tax credits of $1.3 million and $7.3 million as of December 31, 2017 and 2016, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will begin to expire in 2018 and may become subject to annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, or the IRC, of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or future tax liabilities. We have undertaken a formal IRC Section 382 study and the attributes disclosed in this footnote reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years.

At December 31, 2017, the NOL carryforwards in the U.K.,which have an indefinite carryforward period, were approximately $31.2 million.

We maintain a full valuation allowance on our net deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In our valuation, we considered our cumulative loss in recent years and forecasted losses in the near term as significant negative evidence. Based upon a review of the four sources of income identified within ASC 740, we determined that the negative evidence outweighed the positive evidence and that a full valuation allowance on our net deferred tax assets will be maintained. We will continue to assess the realizability of our deferred tax assets going forward and will adjust the valuation allowance as needed. Our valuation allowance decreased by $123.8 million during the year ended December 31, 2017, and increased by $23.2 million and $38.7 million during the years ended December 31, 2016 and 2015, respectively. The reduction in the valuation allowance for 2017 was attributable to the reduction in tax rate due to the 2017 Tax Act as well as the reduction in net operating losses as a result of the 2017 Section 382 analysis.

We adopted ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting, in 2017. Due to the fact that there was no excess tax benefit over book expense related to stock compensation, the adoption had no impact to the deferred tax assets.

We follow the provisions ASC 740, Accounting for Income Taxes, and the guidance related to accounting for uncertainty in income taxes. We determine our uncertain tax positions based on a determination of whether and how much of a tax benefit taken by us in our tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. We are subject to U.S. federal and state, Italian and U.K. income taxes with varying statutes of limitations. Tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2017, we had no unrecognized tax benefits and therefore no accrued interest or penalties related to unrecognized tax benefits. We believe that our income tax filing positions reflected in the various tax returns are more-likely-than not to be sustained on audit and thus there are no anticipated adjustments that would result in a material change to our consolidated financial position, results of operations and cash flows. Therefore, no reserves for uncertain income tax positions have been recorded.

20. Unaudited Quarterly Data

The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
2017
Total revenues (1)	$	754		$	22,225		$	1,705		$	462
Product sales, net	626			227			—			—
Gross profit (2)	493			149			(69		)	(84		)
Net income (loss) attributable to CTI	(19,828		)	5,398			(11,974		)	(14,266		)
Net income (loss) attributable to CTI common shareholders	(19,828		)	1,048			(11,974		)	(14,266		)
Net income (loss) per common share—basic	(0.71		)	0.03			(0.28		)	(0.33		)
Net income (loss) per common share—diluted	(0.71		)	0.03			(0.28		)	(0.33		)
2016
Total revenues (3)	$	36,475		$	7,361		$	4,433		$	9,136
Product sales, net	1,223			975			914			1,015
Gross profit (2)	1,033			815			751			151
Net income (loss) attributable to CTI	3,312			(19,766		)	(29,183		)	(6,372		)
Net income (loss) attributable to CTI common shareholders	3,312			(19,766		)	(29,183		)	(6,372		)
Net income (loss) per common share—basic	0.12			(0.71		)	(1.04		)	(0.23		)
Net income (loss) per common share—diluted	0.12			(0.71		)	(1.04		)	(0.23		)


(1)	Total revenues for the second quarter of 2017 include $11.8 million of license and contract revenue recognized in April 2017 in connection with the Restated Agreement with Servier as well as a $10.0 million milestone payment received

100

from Teva upon the achievement of worldwide net sales milestones of TRISENOX. See Note 11. Collaboration, Licensing and Milestone Agreements for additional information.


(2)	Gross profit is computed by subtracting cost of product sold from net product sales.

(3)

Total revenues for the first quarter of 2016 include $32.0 million in milestone revenue upon achievement of two milestones during the quarter. The payments from Baxalta relating to these milestones were received in 2015. See Note 7. Long-term Debt for additional information. The fourth quarter of 2016 includes $8.0 million in milestone revenue from Servier relating to the attainment of a certain enrollment event in connection with our PIX306 study.

101

21. Subsequent Events

Reincorporation Merger

In January 2018, CTI BioPharma Corp., a Delaware corporation ("CTI DE" or, after giving effect to the Reincorporation Merger (defined below), the “Company”), a wholly owned subsidiary of CTI BioPharma Corp., a Washington corporation (“CTI WA”), entered into an Agreement and Plan of Merger, or the Merger Agreement, with CTI WA, pursuant to which CTI WA would merge with and into CTI DE for the sole purpose of reincorporating CTI WA in the State of Delaware (the “Reincorporation Merger”). The Reincorporation Merger and the Merger Agreement were approved by the Board of CTI WA and by a majority of the votes actually cast by the shareholders entitled to vote at CTI WA’s Special Meeting of Shareholders held on January 24, 2018, or the Effective Date. On the Effective Date, CTI DE and CTI WA effected the Reincorporation Merger, thereby changing the state of incorporation of CTI BioPharma Corp. from the State of Washington to the State of Delaware pursuant to the Merger Agreement. As a result of the Reincorporation Merger, CTI WA ceased to exist as a separate entity.

CTI DE’s common stock, par value $0.001 per share, or the Common Stock, will continue to trade on the NASDAQ. The Company’s trading symbol remains as “CTIC.” In accordance with Rule 12g-3 under the Exchange Act, the shares of Common Stock of the Company were deemed to be registered under Section 12(b) of the Exchange Act as a successor to CTI WA. The Delaware Charter authorizes the same number of shares of the Common Stock and each class of preferred stock of CTI WA, except that all subseries of Series N Preferred Stock are eliminated and reclassified as Series N Preferred Stock and the number of authorized Series N Preferred Stock is reduced to 575. In addition, each share of CTI DE common stock and preferred stock has a par value of $0.001 per share.

The Reincorporation Merger changed the legal domicile of CTI WA, but did not result in any change in the principal offices, business, management, capitalization, assets or liabilities of the Company. By operation of law, the Company succeeded to all of the assets and assumed all of the liabilities of CTI WA. The officers and directors of CTI WA are the officers and directors of the Company. As a result of the Reincorporation Merger, the Company has assumed all of the CTI WA employee benefit plans and stock incentive plans in effect at the Effective Date, including CTI WA’s 2017 Equity Incentive Plan, 2015 Equity Incentive Plan, 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan, or the Stock Plans, and any and all stock options, restricted stock and restricted stock unit awards, and other equity-based awards that are outstanding under any of the Stock Plans or any individual award agreements outside of the Stock Plans. The Company has also assumed CTI WA’s rights plan with Computershare Trust Company, N.A., as rights agent, dated as of December 28, 2009 and amended on August 31, 2012, December 3, 2012, December 1, 2015 and September 22, 2017.

Public Offering of Common Stock

In February 2018, we entered into an underwriting agreement with Leerink Partners LLC acting as sole book-running manager and as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the offer and sale (the “Offering”) of 20.0 million shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Offering closed on February 13, 2018. The price to the public in this Offering was $3.00 per share of Common Stock. The Underwriters exercised in full their option to purchase an additional 3.0 million shares. The net proceeds from this Offering, after deducting underwriting discounts, commissions and other estimated offering expenses, were approximately $64.2 million.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

102

Our management, under the supervision and with the participation of our President and Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Annual Report on Form 10-K. Based upon that evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective.

(b) Management’s Annual Report on Internal Controls

Management of the Company, including its consolidated subsidiaries, is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

As of the end of the Company’s 2017 fiscal year, management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the framework established in “Internal Control—Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Company’s internal control over financial reporting as of December 31, 2017 was effective.

The independent registered public accounting firm of Marcum LLP, as auditors of the Company’s consolidated financial statements, has audited our internal controls over financial reporting as of December 31, 2017, as stated in their report, which appears herein.

There have been no changes to our internal control over financial reporting that occurred during the fourth fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

103

PART III

Item 10. Directors, Executive Officers and Corporate Governance

We have adopted a code of ethics for our senior executive and financial officers (including our principal executive officer and principal financial officer), as well as a code of business conduct and ethics applicable to all officers, directors and employees, or collectively, the "Codes." The Codes are available on our website at http://www.ctibiopharma.com. Any amendments to, or waivers from, the Codes for our executive officers and directors will be posted on our website at http://www.ctibiopharma.com to the extent required by applicable SEC and NASDAQ rules.

The additional information required by this Item is incorporated herein by reference from the Company’s 2018 definitive proxy statement or amendment to this annual report (which will be filed with the SEC within 120 days after December 31, 2017 in connection with the solicitation of proxies for the Company’s 2018 annual meeting of shareholders) (“2018 Proxy Statement”) under the captions “Proposal 1 - Election of Directors,” “Other Information - Executive Officers,” and “Beneficial Ownership Reporting Compliance under Section 16(a) of the Exchange Act.”

Item 11. Executive Compensation

The information required by this Item is incorporated herein by reference from the Company’s 2018 Proxy Statement under the captions “Executive Compensation” and “Director Compensation.”

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

The information required by this Item is incorporated herein by reference from the Company’s 2018 Proxy Statement under the captions “Other Information - Security Ownership of Certain Beneficial Owners and Management” and “Other Information - Equity Compensation Plan Information.”

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference from the Company’s 2018 Proxy Statement under the captions “Other Information - Related Party Transactions Overview,” “Other Information - Certain Transactions with Related Persons” and “Director Attributes and Independence.”

Item 14. Principal Accounting Fees and Services

The information required by this Item is incorporated herein by reference from the Company’s 2018 Proxy Statement under the caption “Proposal 4 - Ratification of the Selection of Independent Auditors.”

104

PART IV

Item 15. Exhibits, Financial Statement Schedules


(a)	Financial Statements and Financial Statement Schedules


(i)	Financial Statements

Reports of Marcum LLP, Independent Registered Public Accounting Firm

Consolidated Balance Sheets

Consolidated Statements of Operations

Consolidated Statements of Comprehensive Loss

Consolidated Statements of Shareholders’ Equity

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements


(ii)	Financial Statement Schedules

Schedule II. Valuation and Qualifying Accounts

Valuation and qualifying accounts include the following (in thousands):



			Additions
				(1)		(2)
	Balance at			Charged to		Charged to						Balance at
	beginning of			costs and		other			(3)			end of
Description	period			expenses		accounts			Deductions			period
Reserve for excess, obsolete or unsalable inventory:
Year ended December 31, 2017	$	1,510		$	—	$	204		$	(347	)	$	1,367
Year ended December 31, 2016	$	1,265		$	692	$	(19	)	$	(428	)	$	1,510
Year ended December 31, 2015	$	—		$	1,326	$	(25	)	$	(36	)	$	1,265

Allowance for doubtful accounts:
Year ended December 31, 2016	$	—		$	1,735	$	—		$	(1,735	)	$	—

(1) We review our inventories on a quarterly basis for impairment and reserves are established when necessary.

(2) We record inventory in euros and we record foreign currency translation gains and losses from recurring measurement of our inventory in Accumulated other comprehensive loss in our consolidated balance sheets.

(3) The amount of reserve is adjusted for the items disposed of during the period.

Refer to the Part II "Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 1. Description of Business and Summary of Significant Accounting Policies" for further details regarding our accounting policy for inventory and foreign currency translation.

All other schedules have been omitted since they are either not required, are not applicable, or the required information is shown in the financial statements or related notes.


(iii)	Exhibits

105



Exhibit Number	Exhibit Description	Location

2.1	Agreement and Plan of Merger, dated January 24, 2018, by and between CTI BioPharma Corp., a Washington corporation, and CTI BioPharma Corp., a Delaware corporation.	Incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed on January 24, 2018.

3.1	Certificate of Incorporation of CTI BioPharma Corp., a Delaware corporation, dated January 24, 2018.	Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on January 24, 2018.

3.2	Bylaws of CTI BioPharma Corp., a Delaware corporation.	Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed on January 24, 2018.

4.1	Shareholder Rights Agreement, dated December 28, 2009, between the Registrant and Computershare Trust Company, N.A.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form 8-A, filed on December 28, 2009.

4.2	First Amendment to Shareholder Rights Agreement, dated as of August 31, 2012, between the Registrant and Computershare Trust Company, N.A., as Rights Agent.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on September 4, 2012.

4.3	Second Amendment to Shareholder Rights Agreement, dated as of December 6, 2012, between the Registrant and Computershare Trust Company, N.A., as Rights Agent.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on December 7, 2012.

4.4	Third Amendment to Shareholder Rights Agreement, dated as of December 1, 2015, between the Registrant and Computershare Trust Company, N.A., as Rights Agent.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on December 1, 2015.

4.5	Fourth Amendment to Shareholder Rights Agreement, dated as of September 22, 2017, between the Registrant and Computershare Trust Company, N.A., as Rights Agent.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on September 26, 2017.

4.6	Specimen Common Stock Certificate.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on February 12, 2018.

4.7	Form of Common Stock Purchase Warrant, dated December 13, 2011.	Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-200452), filed on December 14, 2011.

4.8	Warrant Agreement, dated June 9, 2015, by and between Registrant and Hercules Technology Growth Capital, Inc.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on June 10, 2015.

4.9	Warrant to Purchase Stock, dated November 28, 2017, by and between CTI BioPharma Corp. and Silicon Valley Bank.	Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2017.

106



Exhibit Number	Exhibit Description	Location
4.10	Warrant to Purchase Stock, dated November 28, 2017, by and between CTI BioPharma Corp. and Life Science Loans II, LLC.	Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2017.



10.1	Office Lease, dated as of January 27, 2012, by and between the Registrant and Selig Holdings Company LLC.	Incorporated by reference to Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K, filed on March 8, 2012.

10.2†	Sublease agreement between CTI BioPharma Corp. and Cascadian Therapeutics, Inc.	Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on December 5, 2017.

10.3*	Employment Agreement, dated February 24, 2017, by and between the Registrant and Adam Craig.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 27, 2017.

10.4	Separation and Release Agreement, dated March 13, 2017, by and between the Registrant and Louis A. Bianco.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 13, 2017.

10.5*	Offer Letter, by and between the Registrant and Bruce J. Seeley, dated as of July 2, 2015.	Incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 6, 2015.

10.6*	Compensation Agreement, dated October 20, 2016, by and between the Company and Richard L. Love.	Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on October 24, 2016

10.7*	Stock Option Agreement, dated October 20, 2016, by and between the Company and Richard L. Love.	Incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K, filed on October 24, 2016

10.8*	Employment Agreement, dated February 24, 2017, by and between the Company and Adam Craig.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 27, 2017

10.9*	Form of Severance Agreement for the Registrant’s Executive Officers other than James A. Bianco (as in effect as of January 6, 2015).	Incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K, filed on March 12, 2015.

10.10*	Severance Agreement, dated as of July 27, 2015, between the Registrant and Bruce J. Seeley	Incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K, filed on February 17, 2016.

10.11*	Offer Letter, by and between the Registrant and David Kirske, dated August 1, 2017.	Incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-Q, filed on August 4, 2017.

107



Exhibit Number	Exhibit Description	Location
10.12*	Separation and Release Agreement, by and between the Registrant and Matthew Plunkett, dated August 22, 2017.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 22, 2017

10.13*	Severance Agreement, by and between the Registrant and David Kirske, dated September 25, 2017.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 26, 2017



10.14*	Director Compensation Policy.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 3, 2017.

10.15*	Form of Indemnity Agreement for the Registrant’s Executive Officers and Directors.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on January 24, 2018.

10.16*	2007 Employee Stock Purchase Plan, as amended and restated.	Incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on July 29, 2015.

10.17*	CTI BioPharma Corp. 2015 Equity Incentive Plan, as amended.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 29, 2016.

10.18*	Global Form of 2015 Equity Incentive Plan Restricted Stock Unit Award Agreement.	Incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 5, 2015.

10.19*	Global Form of 2015 Equity Incentive Plan Stock Option Agreement.	Incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 5, 2015.

10.20*	Global Form of 2015 Equity Incentive Plan Stock Bonus Award Agreement.	Incorporated by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 5, 2015.

10.21*	2007 Equity Incentive Plan, as amended and restated.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on October 31, 2014.

10.22*	Form of 2007 Equity Incentive Plan Restricted Stock Award Agreement.	Incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K, filed on March 12, 2015.

10.23*	Global Form of 2007 Equity Incentive Plan Restricted Stock Unit Award Agreement.	Incorporated by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K, filed on March 12, 2015.

108



Exhibit Number	Exhibit Description	Location
10.24*	Global Form of 2007 Equity Incentive Plan Stock Option Agreement.	Incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K, filed on March 12, 2015.

10.25*	Form of 2007 Equity Incentive Plan Restricted Stock Award Agreement for the Registrant’s directors (relating to applicable awards granted prior to December 17, 2014).	Incorporated by reference to Exhibit 10.7 to the Registrant’s Quarterly Report on Form 10-Q, filed on April 26, 2011.

10.26*	Form of 2007 Equity Incentive Plan Restricted Stock Award Agreement (relating to applicable awards granted prior to December 17, 2014).	Incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on October 30, 2013.

10.27*	Form of 2007 Equity Incentive Plan Restricted Stock Award Agreement for employees (relating to applicable awards granted prior to December 17, 2014).	Incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q, filed on April 26, 2011.

10.28*	Form of 2007 Equity Incentive Plan Stock Option Agreement for the Registrant’s directors and officers (relating to applicable awards granted prior to December 17, 2014).	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on October 30, 2013.

10.29*	Form of Stock Award Agreement for grants of fully vested shares under the Registrant’s 2007 Equity Incentive Plan, as amended.	Incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on October 30, 2013.

10.30*	Form of Equity/Long-Term Incentive Award Agreement for James A. Bianco, Louis A. Bianco and Jack W. Singer.	Incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on April 20, 2012.

10.31*	Form of Equity/Long-Term Incentive Award Agreement for Matthew J. Plunkett.	Incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 2, 2013.

10.32*	Amendment to Form of Equity/Long-Term Incentive Award Agreement, dated as of March 21, 2013, for James A. Bianco, Louis A. Bianco, Jack W. Singer and the Registrant’s directors.	Incorporated by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 2, 2013.

10.33*	Amendment to Form of Equity/Long-Term Incentive Award Agreement, dated as of January 30, 2014.	Incorporated by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K, filed on March 4, 2014.

10.34*	Form of Equity/Long-Term Incentive Award Agreement for Bruce J. Seeley.	Incorporated by reference to Exhibit 10.35 to the Registrant’s Annual Report on Form 10-K, filed on February 17, 2016.

10.35*	Form of Amendment to Form of Equity/Long-Term Incentive Award Agreement, dated as of December 23, 2015, for James A. Bianco, Louis A. Bianco and Jack W. Singer.	Incorporated by reference to Exhibit 10.36 to the Registrant’s Annual Report on Form 10-K, filed on February 17, 2016.

109



Exhibit Number	Exhibit Description	Location
10.36*	Form of Amendment to Form of Equity/Long-Term Incentive Award Agreement, dated as of December 23, 2015, for Matthew J. Plunkett and Bruce J. Seeley.	Incorporated by reference to Exhibit 10.37 to the Registrant’s Annual Report on Form 10-K, filed on February 17, 2016.

10.37	2017 Equity Incentive Plan of the Registrant.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Annual Report on Form 8-K, filed on May 16, 2017.



10.38	Acquisition Agreement by and among the Registrant, Cell Technologies, Inc. and Cephalon, Inc., dated June 10, 2005.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 14, 2005.

10.39†	Termination Agreement, effective January 3, 2014, by and among Novartis International Pharmaceutical Ltd. and the Registrant.	Incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on April 29, 2014.

10.40†	Asset Purchase Agreement, dated April 18, 2012, between S*BIO Pte Ltd. and the Registrant.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 24, 2012.

10.41†	Amended and Restated Exclusive License and Collaboration Agreement by and between the Registrant, CTI Life Sciences Limited, Laboratoires Servier and Institut de Recherches Internationales Servier dated as of April 21, 2017.	Incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 3, 2017.

10.42†	Development, Commercialization and License Agreement dated as of November 14, 2013 between the Registrant, Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA.	Incorporated by reference to Exhibit 10.32 to the Registrant’s Annual Report on Form 10-K, filed on March 4, 2014.
10.43†	First Amendment to the Development, Commercialization and License Agreement by and among the Registrant, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH, effective June 8, 2015.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 6, 2015.

10.44	Letter Agreement, dated September 19, 2016, by and between the Company and Baxalta.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 19, 2016.

10.45	Second Letter Agreement, dated October 19, 2016, by and between the Company and Baxalta.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on October 24, 2016

10.46	Asset Return and Termination Agreement, dated October 21, 2016, by and between the Company and Baxalta.	Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on October 24, 2016

10.47	Letter Agreement, dated June 9, 2017, by and between the Registrant and BVF Partners L.P.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 9, 2017

110



Exhibit Number	Exhibit Description	Location

10.48†	Amended and Restated Exclusive License Agreement, dated October 24, 2014, by and between Vernalis (R&D) Ltd. and the Registrant.	Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K/A, filed on November 6, 2014.

10.49†	Manufacturing and Supply Agreement, dated as of April 15, 2014, by and between the Registrant and DSM Fine Chemicals Austria Nfg GmbH & Co KG.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 4, 2014.

10.50†	Amended and Restated Exclusive License and Collaboration Agreement by and between the Company, CTI Life Sciences Limited, Laboratoires Servier and Institut de Recherches Internationales Servier, dated as of April 21, 2017.	Incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 3, 2017.

10.51	Loan and Security Agreement, dated March 26, 2013, by and among the Registrant, Systems Medicine LLC and Hercules Technology Growth Capital, Inc.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2013.

10.52	First Amendment to Loan and Security Agreement, dated March 25, 2014, by and among the Registrant, Systems Medicine LLC and Hercules Technology Growth Capital, Inc.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on April 29, 2014.

10.53	Second Amendment to Loan and Security Agreement, dated October 22, 2014, by and among the Registrant, Systems Medicine LLC, Hercules Technology Growth Capital, Inc. and Hercules Capital Funding Trust 2012-1.	Incorporated by reference to Exhibit 10.48 to Registrant's Annual Report on Form 10-K, filed on March 12, 2015.

10.54	Third Amendment to Loan and Security Agreement, dated June 9, 2015, by and among Hercules Technology Growth Capital, Inc. (and certain of its affiliates), the Registrant and Systems Medicine LLC.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 10, 2015.

111



Exhibit Number	Exhibit Description	Location
10.55	Fourth Amendment to Loan and Security Agreement, dated December 11, 2015, by and among the Registrant, Systems Medicine LLC, Hercules Capital Funding Trust 2014-1 and Hercules Technology Growth Capital, Inc.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on December 11, 2015.

10.56	Fifth Amendment to Loan and Security Agreement, dated August 4, 2017, by and among Hercules Technology Growth Capital, Inc. (and certain of its affiliates), CTI BioPharma Corp. and Systems Medicine LLC.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 7, 2017.

10.57	Loan and Security Agreement, dated November 28, 2017, by and between CTI BioPharma Corp. and Silicon Valley Bank.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2017.

10.58	Waiver Agreement, dated January 19, 2018, by and between Silicon Valley Bank and the Registrant.	Filed herewith.

10.59	Stipulation of Settlement, dated February 13, 2012.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 15, 2012.

10.60	Stipulation of Settlement, dated November 6, 2012.	Incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2013.

10.61	Stipulation of Settlement.	Incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K, filed on October 2, 2015.

10.62	Stipulation of Settlement.	Incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K, filed on December 15, 2017.



Exhibit Number	Exhibit Description	Location
10.63	Letter Agreement, dated December 9, 2015, by and between CTI BioPharma Corp. and BVF Partners L.P.	Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on December 9, 2015.

12.1	Statement Re: Computation of Ratio of Earnings to Fixed Charges.	Filed herewith.

21.1	Subsidiaries of the Registrant.	Filed herewith.

23.1	Consent of Marcum LLP, Independent Registered Public Accounting Firm.	Filed herewith.

24.1	Power of Attorney. Contained in the signature page of this Annual Report on Form 10-K and incorporated herein by reference.	Filed herewith.

31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.

31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.

32	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	Furnished herewith.

101.INS	XBRL Instance	Filed herewith.

101.SCH	XBRL Taxonomy Extension Schema	Filed herewith.

101.CAL	XBRL Taxonomy Extension Calculation	Filed herewith.

101.DEF	XBRL Taxonomy Extension Definition	Filed herewith.

101.LAB	XBRL Taxonomy Extension Labels	Filed herewith.

101.PRE	XBRL Taxonomy Extension Presentation	Filed herewith.

112



*	Indicates management contract or compensatory plan or arrangement.



†	Portions of these exhibits have been omitted pursuant to a request for confidential treatment.

113

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on March 7, 2018.



CTI BioPharma Corp.

By: /s/ Adam R. Craig
Adam R. Craig
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Adam R. Craig and David H. Kirske, and each of them his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendment of post-effective amendment to this Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



Signature	Title	Date
/s/ Laurent Fischer Laurent Fischer, M.D.	Chairman of the Board and Director	March 7, 2018
/s/ Adam R. Craig Adam R. Craig	President and Chief Executive Officer and Director (Principal Executive Officer)	March 7, 2018
/s/ David H. Kirske David H. Kirske	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	March 7, 2018
/s/ Richard L. Love Richard L. Love	Director	March 7, 2018
/s/ Michael A. Metzger Michael A. Metzger	Director	March 7, 2018
/s/ David Parkinson David Parkinson, M.D.	Director	March 7, 2018
/s/ Matthew D. Perry Matthew D. Perry	Director	March 7, 2018
/s/ Frederick W. Telling Frederick W. Telling, Ph.D.	Director	March 7, 2018
/s/ Reed V. Tuckson Reed V. Tuckson, M.D.	Director	March 7, 2018

114

EX-10.58 2 waivertoloanandsecurityagr.htm EXHIBIT 10.58 Exhibit

WAIVER AGREEMENT

This Waiver Agreement (this “Waiver”) is entered into this 19^th day of January, 2018, by and between SILICON VALLEY BANK (“Bank”) and CTI BIOPHARMA CORP., a Washington corporation (“Borrower”) whose address is 3101 Western Avenue, #800, Seattle, Washington 98121.

RECITALS

A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of November 28, 2017 (as the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”).

B. Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.

C. Borrower has requested that Bank waive the requirement under Section 6.12 of the Loan Agreement for Borrower to deliver to Bank duly executed signatures to a Control Agreement from Bank of America with respect to all of Borrower’s accounts maintained with Bank of America on or before January 19, 2018 (per the e-mail extension of Bank) (the “BofA DACA Requirement”).

D. Borrower has requested and Bank has agreed to waive the BofA DACA Requirement under the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

1.Definitions. Capitalized terms used but not defined in this Waiver shall have the meanings given to them in the Loan Agreement.

2. Waiver. Pursuant to the terms of the Loan Agreement, Borrower has transferred the majority of funds maintained by Borrower with Bank of America to accounts of Borrower maintained with Bank, with a remaining balance of Six Hundred Forty-Four Thousand Dollars ($644,000.00) maintained by Borrower with Bank of America during the Transition Period (of which One Hundred Fifty-Two Thousand Dollars ($152,000.00) is cash collateral for a credit card). Notwithstanding the foregoing, prior to Borrower establishing a payment processing account with Oracle Payments, Bank shall permit Borrower to transfer funds to its Bank of America accounts as needed for ordinary current and necessary payments to vendors of Borrower. In connection with this agreement, Bank hereby waives the requirement under Section 6.12 of the Loan Agreement for Borrower to deliver to Bank duly executed signatures to a Control Agreement from Bank of America with respect to all of Borrower’s accounts maintained with Bank of America on or before January 19, 2018 (per the e-mail extension of Bank). Bank’s waiver of Borrower’s compliance with said covenant shall apply

only to the BofA DACA Requirement. Borrower hereby acknowledges and agrees that except as specifically provided herein, nothing in this Section or anywhere in this Waiver shall be deemed or otherwise construed as a waiver by Bank of any of its rights and remedies pursuant to the Loan Documents, applicable law or otherwise.

3. Limitation of Waiver. The waiver set forth in Section 2 above is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.

4. No Defenses of Borrower. In consideration of the foregoing, Borrower hereby acknowledges and agrees that it has no offsets, defenses, causes of action, suits, damages, claims, or counterclaims against Bank, SVB Financial Group, or any of their respective officers, directors, employees, attorneys, representatives, predecessors, successors, and assigns (collectively, the “Bank Released Parties”) with respect to the Obligations, the Loan Documents, the Collateral, any Bank Services Agreement, any contracts, promises, commitments, or other agreements to provide, to arrange for, or to obtain loans or other financial accommodations to or for Borrower, or otherwise, and that if Borrower now has, or ever did have, any offsets, defenses, causes of action, suits, damages, claims, or counterclaims against one or more of the Bank Released Parties, at law or in equity, whether known or unknown, from the beginning of the world through this date and through the time of execution of this Waiver (collectively, the “Released Claims”) all of them are hereby expressly WAIVED and Borrower hereby RELEASES the Bank Released Parties from any liability therefor. Borrower hereby irrevocably agrees to refrain from directly or indirectly asserting any claim or demand or commencing (or causing to be commenced) any suit, action, arbitration or proceeding of any kind, in any court or before any tribunal or arbiter or arbitration panel, against any Bank Released Party as to any of the Released Claims. The foregoing release does not release Bank Released Parties from its ongoing obligations under the Loan Documents.

5. Integration. This Waiver and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Waiver and the Loan Documents merge into this Waiver and the Loan Documents.

6. Counterparts. This Waiver may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

7. Effectiveness. This Waiver shall be deemed effective upon (a) the due execution and delivery to Bank of this Waiver by each party hereto, and (b) Borrower’s payment to Bank of Bank’s legal fees and expenses incurred in connection with this Waiver.

[Signature page follows.]

IN WITNESS WHEREOF, the parties hereto have caused this Waiver to be duly executed and delivered as of the date first written above.



BANK		BORROWER
SILICON VALLEY BANK		CTI BIOPHARMA CORP.
By:	/s/ Derek Scalf	By:	/s/ David Kirske
Name:	Derek Scalf	Name:	David Kirske
Title	Vice President	Title:	Chief Financial Officer

EX-12.1 3 a2017exhibit121ratioofearn.htm EXHIBIT 12.1 Exhibit

Exhibit 12.1

RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated:



	Year ended December 31,
	2017	2016	2015	2014	2013
Ratio of earnings to fixed charges (1)	—	—	—	—	—

(1) Earnings were not sufficient to cover fixed charges for each of the periods indicated. Earnings consist of income (loss) before provision for income taxes plus fixed charges less income (loss) attributable to noncontrolling interest. Fixed charges consist of interest charges, amortization of debt expense and discount related to indebtedness, and that portion of rental payments under operating leases we believe to be representative of interest. Earnings for the years ended December 31, 2017, 2016, 2015, 2014 and 2013, were insufficient to cover fixed charges by $45.0, $52.0, $122.6, $96.0 and $49.6 (in millions), respectively. For this reason, no ratios are provided for these periods.

EX-21.1 4 a2017exhibit21110kfy2017su.htm EXHIBIT 21.1 Exhibit

Exhibit 21.1

Subsidiaries of CTI BioPharma Corp.

Aequus Biopharma, Inc., a Washington corporation and CTI Life Sciences Ltd., a U.K. limited company.

The above paragraph includes all material subsidiaries of CTI BioPharma Corp.

EX-23.1 5 a2017exhibit231accountingf.htm EXHIBIT 23.1 Exhibit

Exhibit 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We consent to the incorporation by reference in the Registration Statement of CTI BioPharma Corp. on Form S-3 (File Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-163479, 333-182330, 333-192748, 333-192749, 333-200453 and 333-221382) and Form S-8 (File Nos. 333-146624, 333-152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611, 333-196510, 333-207176, 333-207177, 333-211006, 333-218946, and 333-218947) of our report dated March 7, 2018, with respect to our audits of the consolidated financial statements and the related consolidated financial statement schedule of CTI BioPharma Corp. as of December 31, 2017 and 2016 and for the years ended December 31, 2017, 2016 and 2015 and our report dated March 7, 2018 with respect to our audit of the effectiveness of internal control over financial reporting of CTI BioPharma Corp. as of December 31, 2017, which reports are included in this Annual Report on Form 10-K of CTI BioPharma Corp. for the year ended December 31, 2017.

/s/ Marcum LLP

Marcum LLP

San Francisco, CA

March 7, 2018

EX-31.1 6 a2017exhibit311sect302cert.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
SECURITIES EXCHANGE ACT OF 1934 RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Adam R. Craig, certify that:

1.I have reviewed this Annual Report on Form 10-K of CTI BioPharma Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions) of internal control over financial reporting:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 7, 2018



By: /s/ Adam R. Craig
Adam R. Craig
President and Chief Executive Officer

EX-31.2 7 a2017exhibit312sect302cert.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
SECURITIES EXCHANGE ACT OF 1934 RULES 13a-14(a) AND 15d-14(a)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David H. Kirske, certify that:

1.I have reviewed this Annual Report on Form 10-K of CTI BioPharma Corp.;

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 7, 2018



By: /s/ David H. Kirske
David H. Kirske
Chief Financial Officer

EX-32 8 a2017exhibit32sect906certc.htm EXHIBIT 32 Exhibit

Exhibit 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

I, Adam R. Craig, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.

A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.



Dated: March 7, 2018	By: /s/ Adam R. Craig
	Adam R. Craig
	President and Chief Executive Officer

I, David H. Kirske, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.



Dated: March 7, 2018	By: /s/ David H. Kirske
	David H. Kirske
	Chief Financial Officer

EX-101.INS 9 ctic-20161231.xml XBRL INSTANCE DOCUMENT 0000891293 2017-01-01 2017-12-31 0000891293 2017-06-30 0000891293 2018-02-28 0000891293 2016-12-31 0000891293 2017-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2017-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2016-12-31 0000891293 2015-01-01 2015-12-31 0000891293 2016-01-01 2016-12-31 0000891293 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000891293 us-gaap:PreferredStockMember 2014-12-31 0000891293 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember us-gaap:PreferredStockMember 2015-01-01 2015-12-31 0000891293 2015-12-31 0000891293 us-gaap:RetainedEarningsMember 2014-12-31 0000891293 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000891293 us-gaap:CommonStockMember 2015-12-31 0000891293 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember us-gaap:PreferredStockMember 2015-01-01 2015-12-31 0000891293 us-gaap:RetainedEarningsMember 2015-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesN3PreferredStockMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000891293 us-gaap:CommonStockMember 2017-12-31 0000891293 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000891293 ctic:SeriesN3PreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0000891293 us-gaap:PreferredStockMember 2017-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2014-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2015-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000891293 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2017-01-01 2017-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000891293 us-gaap:PreferredStockMember 2015-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000891293 us-gaap:CommonStockMember 2014-12-31 0000891293 us-gaap:CommonStockMember 2016-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2016-12-31 0000891293 2014-12-31 0000891293 us-gaap:PreferredStockMember 2016-12-31 0000891293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000891293 us-gaap:RetainedEarningsMember 2016-12-31 0000891293 us-gaap:NoncontrollingInterestMember 2017-12-31 0000891293 us-gaap:RetainedEarningsMember 2017-12-31 0000891293 ctic:BaxaltaMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesTwentyOnePreferredStockMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2016-01-01 2016-12-31 0000891293 ctic:HerculesMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2015-01-01 2015-12-31 0000891293 ctic:BaxaltaMember 2017-01-01 2017-12-31 0000891293 ctic:SiliconValleyBankMember 2016-01-01 2016-12-31 0000891293 ctic:SeriesTwentyOnePreferredStockMember 2016-01-01 2016-12-31 0000891293 ctic:HerculesMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesTwentyOnePreferredStockMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember 2016-01-01 2016-12-31 0000891293 ctic:HerculesMember 2016-01-01 2016-12-31 0000891293 ctic:SiliconValleyBankMember 2015-01-01 2015-12-31 0000891293 ctic:BaxaltaMember 2016-01-01 2016-12-31 0000891293 ctic:SiliconValleyBankMember 2017-01-01 2017-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember 2016-01-01 2016-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember 2017-01-01 2017-12-31 0000891293 ctic:LeerinkPartnersLLCMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-28 0000891293 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2016-12-31 0000891293 us-gaap:MinimumMember us-gaap:EuropeMember 2017-01-01 2017-12-31 0000891293 2017-01-01 0000891293 country:IT 2017-12-31 0000891293 ctic:AequusBiopharmaIncMember us-gaap:AffiliatedEntityMember 2017-12-31 0000891293 ctic:AssetsOtherThanLeaseholdImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000891293 ctic:AssetsOtherThanLeaseholdImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000891293 us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-11-30 0000891293 us-gaap:MinimumMember country:IT 2017-01-01 2017-12-31 0000891293 us-gaap:LeaseholdsAndLeaseholdImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000891293 us-gaap:MaximumMember country:IT 2017-01-01 2017-12-31 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementProductAgreementMember 2018-02-01 2018-02-28 0000891293 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2017-12-31 0000891293 us-gaap:OtherNoncurrentAssetsMember 2017-12-31 0000891293 us-gaap:MaximumMember us-gaap:EuropeMember 2017-01-01 2017-12-31 0000891293 us-gaap:OtherNoncurrentAssetsMember 2016-12-31 0000891293 2017-01-01 2017-01-01 0000891293 us-gaap:FurnitureAndFixturesMember 2016-12-31 0000891293 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000891293 us-gaap:EquipmentMember 2016-12-31 0000891293 us-gaap:EquipmentMember 2017-12-31 0000891293 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2017-12-31 0000891293 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-12-31 0000891293 2017-12-01 2017-12-31 0000891293 2012-01-01 2012-01-31 0000891293 ctic:SubleaseMember 2017-12-31 0000891293 2012-01-31 0000891293 us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-12-31 0000891293 us-gaap:SecuredDebtMember ctic:ThirdAmendmentMember 2015-06-30 0000891293 ctic:ParticipationArrangementMember us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-11-30 0000891293 us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-11-01 2017-11-30 0000891293 ctic:BorrowingAssociatedWithLicenseAgreementMember 2015-06-30 0000891293 ctic:ParticipationArrangementInitialExerciseMember us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-11-30 0000891293 ctic:Persist2MilestoneMember ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:BaxaltaIncorporatedAndAffiliatesMember 2016-01-01 2016-01-31 0000891293 us-gaap:SecuredDebtMember ctic:FourthAmendmentMember 2015-12-01 2015-12-31 0000891293 us-gaap:SecuredDebtMember ctic:ThirdAmendmentMember 2015-05-31 0000891293 us-gaap:SecuredDebtMember ctic:ThirdAmendmentMember 2015-06-01 2015-06-30 0000891293 us-gaap:SecuredDebtMember 2017-11-30 0000891293 ctic:EuropeanMedicinesAgencyMilestoneMember ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:BaxaltaIncorporatedAndAffiliatesMember 2016-02-01 2016-02-29 0000891293 us-gaap:SecuredDebtMember 2017-11-01 2017-11-30 0000891293 us-gaap:SecuredDebtMember ctic:AmendedOriginalLoanMember 2014-03-31 0000891293 ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:BaxaltaIncorporatedAndAffiliatesMember 2015-06-30 0000891293 ctic:ParticipationArrangementLoanFundingContingencyMember us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember 2017-11-30 0000891293 us-gaap:SecuredDebtMember ctic:OriginalLoanMember 2013-03-31 0000891293 us-gaap:SecuredDebtMember ctic:ThirdAmendmentMember 2015-12-31 0000891293 us-gaap:SecuredDebtMember 2014-03-31 0000891293 us-gaap:SecuredDebtMember ctic:FourthAmendmentMember 2015-12-31 0000891293 us-gaap:SecuredDebtMember ctic:LoanAndSecurityAgreementMember ctic:SiliconValleyBankMember us-gaap:PrimeRateMember 2017-11-01 2017-11-30 0000891293 us-gaap:SecuredDebtMember ctic:ThirdAmendmentMember 2015-01-01 2015-12-31 0000891293 ctic:SeriesNDashTwoPreferredStockMember 2015-12-01 2015-12-31 0000891293 ctic:SeriesNDashOnePreferredStockMember 2015-10-01 2015-10-31 0000891293 2017-06-01 2017-06-30 0000891293 ctic:UnderwriterMember ctic:SeriesNDashOnePreferredStockMember 2015-10-01 2015-10-31 0000891293 ctic:BVFPartnersL.P.Member ctic:SeriesOPreferredStockMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-28 0000891293 ctic:SeriesNDashTwoPreferredStockMember 2015-12-31 0000891293 ctic:SeriesN3PreferredStockMember 2017-06-01 2017-06-30 0000891293 ctic:UnderwriterMember ctic:SeriesNDashTwoPreferredStockMember 2015-12-01 2015-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-28 0000891293 ctic:SeriesNDashOnePreferredStockMember 2015-10-31 0000891293 ctic:BVFPartnersL.P.Member ctic:SeriesNPreferredStockMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-28 0000891293 ctic:SeriesN3PreferredStockMember 2017-06-30 0000891293 2017-04-30 0000891293 ctic:BVFPartnerMember us-gaap:AffiliatedEntityMember 2015-09-01 2015-09-30 0000891293 ctic:ThirdAmendmentMember us-gaap:WarrantMember 2017-12-31 0000891293 2017-05-31 0000891293 2016-04-30 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember 2015-09-01 2015-09-30 0000891293 ctic:PlacementAgentMember us-gaap:WarrantMember 2017-12-31 0000891293 ctic:BVFPartnerMember us-gaap:AffiliatedEntityMember 2015-09-30 0000891293 2016-03-31 0000891293 ctic:EmployeeStockPurchasePlanMember 2017-12-31 0000891293 ctic:EquityIncentivePlansMember 2017-12-31 0000891293 us-gaap:EmployeeStockOptionMember us-gaap:ChiefExecutiveOfficerMember 2017-12-31 0000891293 us-gaap:WarrantMember 2017-12-31 0000891293 2016-01-01 2016-03-31 0000891293 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000891293 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000891293 ctic:UnrealizedForeignExchangeGainLossOnIntercompanyBalanceMember 2017-12-31 0000891293 ctic:UnrealizedForeignExchangeGainLossOnIntercompanyBalanceMember 2017-01-01 2017-12-31 0000891293 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000891293 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000891293 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000891293 ctic:UnrealizedForeignExchangeGainLossOnIntercompanyBalanceMember 2016-12-31 0000891293 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000891293 ctic:ServierMember 2017-05-01 2017-05-31 0000891293 ctic:BaxterMember us-gaap:UpFrontPaymentArrangementMember us-gaap:CollaborativeArrangementProductAgreementMember 2013-11-01 2013-11-30 0000891293 ctic:ProductsBMember ctic:NovartisInternationalPharmaceuticalLtdMember us-gaap:CollaborativeArrangementProductAgreementMember 2014-01-01 2014-01-31 0000891293 ctic:ServierMember ctic:OtherServicesMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-12-31 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementMember 2017-09-01 2017-09-30 0000891293 ctic:BaxterMember ctic:PacritinibLicenseAgreementMember 2017-01-01 2017-12-31 0000891293 ctic:NervianoMedicalSciencesMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-03-31 0000891293 ctic:BaxterMember us-gaap:UpFrontPaymentArrangementMember ctic:SeriesNineteenPreferredStockMember us-gaap:CollaborativeArrangementProductAgreementMember 2013-11-01 2013-11-30 0000891293 ctic:AgreementSevenMember 2017-12-31 0000891293 ctic:ServierMember ctic:OtherServicesMember us-gaap:CollaborativeArrangementMember 2017-05-31 0000891293 ctic:BaxterMember us-gaap:CollaborativeArrangementProductAgreementMember 2014-01-01 2014-01-01 0000891293 ctic:ServierMember ctic:LicenseServicesMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-12-31 0000891293 ctic:BaxterMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:BaxterMember ctic:LicenseMember us-gaap:CollaborativeArrangementProductAgreementMember 2013-11-01 2013-11-30 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementMember 2017-05-31 0000891293 ctic:ServierMember us-gaap:UpFrontPaymentArrangementMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-02-01 2015-02-28 0000891293 ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:AssetReturnandTerminationAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:BaxterMember ctic:DevelopmentAndLicenseAgreementMember us-gaap:CollaborativeArrangementProductAgreementMember 2013-11-01 2013-11-30 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-01-01 2017-12-31 0000891293 ctic:BaxterMember ctic:PacritinibLicenseAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:PacritinibLicenseAgreementMember 2015-06-30 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-12-01 2016-12-31 0000891293 ctic:AgreementSevenMember 2012-05-31 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-12-31 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementMember 2017-05-01 2017-05-31 0000891293 ctic:BaxterMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-12-31 0000891293 ctic:PGTXLMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-12-31 0000891293 ctic:ProductsBMember ctic:NovartisInternationalPharmaceuticalLtdMember us-gaap:CollaborativeArrangementProductAgreementMember 2014-01-31 0000891293 ctic:NervianoMedicalSciencesMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-12-31 0000891293 ctic:BaxterMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-12-31 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-12-31 0000891293 ctic:BaxterMember ctic:DevelopmentServicesMember us-gaap:CollaborativeArrangementProductAgreementMember 2013-11-30 0000891293 ctic:BorrowingAssociatedWithLicenseAgreementMember ctic:AssetReturnandTerminationAgreementMember 2017-12-31 0000891293 ctic:ServierMember ctic:OtherServicesMember us-gaap:CollaborativeArrangementMember 2017-12-31 0000891293 ctic:PacritinibLicenseAgreementMember 2016-01-01 2016-12-31 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-06-01 2017-12-31 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-01-01 2017-12-31 0000891293 ctic:GynecologicOncologyGroupMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-04-01 2017-06-30 0000891293 ctic:BaxterMember ctic:PacritinibLicenseAgreementMember 2015-01-01 2015-12-31 0000891293 ctic:BaxterMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-12-31 0000891293 ctic:ProductsCMember ctic:CephalonIncMember us-gaap:CollaborativeArrangementProductAgreementMember 2015-01-01 2015-12-31 0000891293 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000891293 us-gaap:RestrictedStockMember 2016-12-31 0000891293 us-gaap:RestrictedStockMember 2017-12-31 0000891293 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000891293 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000891293 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000891293 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000891293 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0000891293 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-12-31 0000891293 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0000891293 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000891293 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0000891293 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000891293 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000891293 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0000891293 ctic:EmployeeStockPurchasePlanMember us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2017-01-01 2017-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2015-12-01 2015-12-31 0000891293 us-gaap:EmployeeStockOptionMember us-gaap:ChiefExecutiveOfficerMember 2017-03-01 2017-03-31 0000891293 ctic:EmployeeStockPurchasePlanMember us-gaap:EmployeeStockMember 2017-12-31 0000891293 ctic:VestedRestrictedStockMember 2016-01-01 2016-12-31 0000891293 us-gaap:EmployeeStockOptionMember ctic:TwoThousandAndSevenEquityIncentiveStockPlanMember 2017-01-01 2017-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2015-01-01 2015-12-31 0000891293 ctic:LongTermPerformanceAwardsMember 2015-12-01 2015-12-31 0000891293 ctic:EmployeeStockPurchasePlanMember us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000891293 ctic:VestedRestrictedStockMember 2017-01-01 2017-12-31 0000891293 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000891293 ctic:EmployeeStockPurchasePlanMember us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000891293 ctic:LongTermPerformanceAwardsMember 2015-09-01 2015-09-30 0000891293 ctic:VestedRestrictedStockMember 2015-01-01 2015-12-31 0000891293 us-gaap:EmployeeStockMember 2015-09-30 0000891293 ctic:NonemployeeStockOptionMember 2016-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2013-03-01 2013-03-31 0000891293 us-gaap:EmployeeStockOptionMember ctic:StockOptionPlan2015Member us-gaap:ChiefExecutiveOfficerMember 2017-03-01 2017-03-31 0000891293 ctic:TwoThousandAndSevenEquityIncentiveStockPlanMember 2017-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2015-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2017-12-31 0000891293 ctic:NonemployeeStockOptionMember 2017-12-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2014-01-01 2014-01-31 0000891293 ctic:LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember 2016-01-01 2016-12-31 0000891293 ctic:LongTermPerformanceAwardsMember 2015-01-01 2015-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2014-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2016-12-31 0000891293 us-gaap:EmployeeStockOptionMember 2015-12-31 0000891293 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0000891293 us-gaap:PerformanceSharesMember 2016-01-01 2016-12-31 0000891293 us-gaap:PerformanceSharesMember 2015-01-01 2015-12-31 0000891293 ctic:RightsPlanMember 2009-12-01 2009-12-31 0000891293 ctic:RightsPlanMember 2009-12-31 0000891293 ctic:RightsPlanMember ctic:SeriesZZPreferredStockMember 2009-12-31 0000891293 us-gaap:EuropeMember 2016-12-31 0000891293 country:US 2017-12-31 0000891293 us-gaap:EuropeMember 2017-12-31 0000891293 country:US 2016-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerBMember 2015-01-01 2015-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerBMember 2017-01-01 2017-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerAMember 2017-01-01 2017-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerAMember 2016-01-01 2016-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerAMember 2015-01-01 2015-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerCMember 2016-01-01 2016-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerCMember 2015-01-01 2015-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerCMember 2017-01-01 2017-12-31 0000891293 us-gaap:SalesRevenueGoodsNetMember us-gaap:CustomerConcentrationRiskMember ctic:CustomerBMember 2016-01-01 2016-12-31 0000891293 ctic:AequusBiopharmaIncMember ctic:LicenseAndPromissoryNoteTerminationAndNoteCancellationAgreementsMember us-gaap:AffiliatedEntityMember 2017-03-01 2017-03-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember 2016-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember 2015-12-01 2015-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember 2017-01-01 2017-12-31 0000891293 ctic:AequusBiopharmaIncMember ctic:JackW.SingerM.D.Member us-gaap:ExecutiveVicePresidentMember 2017-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember ctic:SeriesNDashTwoPreferredStockMember 2015-12-01 2015-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember ctic:SeriesN3PreferredStockMember 2017-06-01 2017-06-30 0000891293 ctic:BVFPartnersL.P.Member us-gaap:MinimumMember us-gaap:AffiliatedEntityMember ctic:SeriesN3PreferredStockMember 2017-06-01 2017-06-30 0000891293 ctic:AequusBiopharmaIncMember ctic:LicenseAndPromissoryNoteTerminationAndNoteCancellationAgreementsMember us-gaap:AffiliatedEntityMember 2017-03-31 0000891293 ctic:AequusBiopharmaIncMember ctic:FrederickW.TellingPh.D.Member us-gaap:DirectorMember 2017-12-31 0000891293 ctic:AequusBiopharmaIncMember ctic:LicenseAndPromissoryNoteMember us-gaap:ConvertibleDebtMember us-gaap:AffiliatedEntityMember 2017-03-01 2017-03-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:MaximumMember us-gaap:AffiliatedEntityMember ctic:SeriesN3PreferredStockMember 2017-06-01 2017-06-30 0000891293 ctic:BVFPartnersL.P.Member us-gaap:AffiliatedEntityMember 2017-12-31 0000891293 ctic:BVFPartnersL.P.Member us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2018-02-28 0000891293 ctic:ValueAddedTaxAssessmentsMember 2017-12-31 0000891293 ctic:TwoThousandAndSevenEquityIncentivePlanMember 2016-01-01 2016-12-31 0000891293 ctic:TwoThousandAndSevenEquityIncentivePlanMember 2014-07-01 2014-07-31 0000891293 ctic:SecuritiesLitigationMember 2017-07-26 2017-07-26 0000891293 ctic:TwoThousandAndSevenEquityIncentivePlanMember 2015-01-01 2015-12-31 0000891293 ctic:DerivativeLawsuitsMember 2017-01-01 2017-12-31 0000891293 ctic:ValueAddedTaxAssessmentsMember 2014-03-01 2014-03-31 0000891293 ctic:DerivativeLawsuitsMember 2017-03-29 2017-03-29 0000891293 country:GB 2017-12-31 0000891293 2017-07-01 2017-09-30 0000891293 2016-04-01 2016-06-30 0000891293 2016-10-01 2016-12-31 0000891293 2017-01-01 2017-03-31 0000891293 2017-10-01 2017-12-31 0000891293 2017-04-01 2017-06-30 0000891293 2016-07-01 2016-09-30 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2017-04-01 2017-06-30 0000891293 ctic:ServierMember us-gaap:CollaborativeArrangementProductAgreementMember 2016-10-01 2016-12-31 0000891293 ctic:AgreementOneMember 2016-01-01 2016-03-31 0000891293 ctic:TevaPharmaceuticalIndustriesLtd.Member us-gaap:CollaborativeArrangementProductAgreementMember 2017-04-01 2017-06-30 0000891293 ctic:LeerinkPartnersLLCMember us-gaap:SubsequentEventMember 2018-02-13 2018-02-13 0000891293 ctic:SeriesNPreferredStockMember us-gaap:SubsequentEventMember 2018-01-31 0000891293 us-gaap:SubsequentEventMember 2018-01-31 0000891293 ctic:LeerinkPartnersLLCMember us-gaap:SubsequentEventMember 2018-02-13 0000891293 us-gaap:InventoryValuationReserveMember 2014-12-31 0000891293 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2017-01-01 2017-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2015-01-01 2015-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2016-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2015-12-31 0000891293 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2017-12-31 0000891293 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000891293 us-gaap:InventoryValuationReserveMember 2016-01-01 2016-12-31 iso4217:EUR utreg:sqft xbrli:pure ctic:Option iso4217:USD utreg:sqft iso4217:USD xbrli:shares xbrli:shares iso4217:USD iso4217:USD ctic:right ctic:grant ctic:member_of_board 7303000 5019000 2000 93000 136000 143000 0 0 30000000 P5Y 2 150000 150000 60000000 1500000 1700000 12000000 80000000.0 14400000.0 10300000 132500000.0 16600000.0 100000000.0 76000000 36000000 40000000 0.0999 0.05 0.09 P18M P12M P36M 43768000 27540000 0 800000 0 11400000 1000000 500000 0 100000 0.00 0.00 -2.40 -0.01 0.00 0.00 27.00 66000 44000 7616000 2637000 500000 0 32000000 0 409000 467000 648000 0.5 0.05 0.11 100000 0 0 369000 1126000 1174000 1167000 5552000 1716000 0 2 300000 1348000 0.03 0.5 P10Y 0 0 79000 0 46653000 52800000 -227000 0 -37000 -277000 0 42669000 0 0 0 P5Y P5Y P3Y P3M 7778000 1278000 0.0002 2 20000000 0.2 0.10 0.05 13815000 0 0 96000000 0.2 3600000 6 -0.79 -0.48 -0.16 0 16000 -8000 475613 3000000 11.00 3.0 12.50 1445000 1445000 -1600000 0 0 -1584000 41300000 3300000 2200000 3000000 2600000 3400000 2300000 12835000 400000 600000 3200000 3200000 4350000 4350000 false --12-31 FY 2017 2017-12-31 10-K 0000891293 57982860 Yes Accelerated Filer 88062209 CTI BIOPHARMA CORP No No CTIC

7227000

2588000

378000

4000

888000

575000

24765000

13890000

1037000

537000

8805000

7564000

-6655000

-3747000

-6000

-2902000

-6272000

556000

1000

-6829000

25560000

-23727000

1535000

390000

214000

163000

1500000

2700000

5200000

63843000

54886000

55824000

46924000

128182000

44002000

27218000

70933000

128182000

44002000

43218000

43200000

57249000

-84180000

-784000

17.10

2.84

17.1

2.84

0.0002

29239

190140

29239

169014

21126

190140

29239

190140

200000

7826000

1120000

184000

200000

5920000

383000

219000

0.001

31500000

41500000

81500000

41500000

81500000

28228602

42969494

28228602

42969494

2170300000

2222341000

16000000

-119875000

-51712000

-40287000

-1341000

-944000

-161000

-121216000

-52656000

-40448000

0.41

0.42

0.00

0.60

0.27

0.00

0.61

0.24

0.13

46611000

52409000

41579000

30000

55000

50000

6175

21925

575

8000000

1940000

1377000

364000

132782000

106567000

64665000

0.025

20000000

25000000

13800000

15000000.0

32000000

1300000

1400000

0.09

0.0675

1900000

100000

1900000

5000000

100000

422000

292000

3011000

3050000

1400000

2700000

1300000

103000

912000

1600000

600000

514000

494000

500000

14525000

8117000

197553000

73602000

422000

292000

108372000

21005000

3721000

2279000

626000

472000

7253000

1347000

19288000

12842000

197131000

73310000

422000

292000

200000

300000

0.80

1000000

990000

831000

800000

700000

717000

400000

200000

0.12

-0.71

-1.04

-0.23

-0.71

0.03

-0.28

-0.33

-6.51

-1.86

-1.24

0.12

-0.71

-1.04

-0.23

-0.71

0.03

-0.28

-0.33

513000

3000

-429000

0.00

0.34

-0.32

-0.33

3.04

0.00

-1.01

-0.03

0.00

-0.01

-0.02

0.00

-0.03

-0.01

-0.03

6364000

4432000

9900000

P2Y3M10D

13700000

-232000

-703000

-484000

817000

-2600000

-1200000

4300000

5900000

-1211000

-1200000

-163000

1033000

815000

751000

151000

493000

149000

-69000

-84000

-110831000

-51856000

-40180000

-9932000

-1097000

-651000

4368000

-3025000

-4730000

-1555000

156000

-402000

2426000

2620000

-11096000

9476000

-6579000

-918000

-1071000

790000

402000

-567000

-1120000

-826000

-355000

-63000

3000

1000

374000

402000

-1609000

-326000

18000000

2104000

2614000

1872000

2067000

4446000

1970000

477000

394000

3035000

1917000

1525000

550000

1500000

1510000

1367000

1400000

2558000

1523000

1326000

692000

P5Y

P120M

5499000

499000

1454000

771000

1410000

1365000

56086000

38796000

63843000

54886000

40646000

19258000

12000000

20000000

12644000

53278000

32000000

11800000

24293000

27300000

11487000

10000000

16000000

15000

15000000.0

5000000.0

25000000

18000000

2000000

800000

20000000

2200000

7949000

444000

11311000

13575000

3900000

4700000

-5562000

-5723000

0.159

0.200

0.1195

0.038

0.043

0.60

-1341000

-944000

-161000

152017000

-7366000

38979000

-78000

-137000

-38000

-95203000

-76680000

-39296000

-119422000

3312000

-19766000

-29183000

-6372000

-52009000

-19828000

5398000

-11974000

-14266000

-40670000

-1341000

-944000

-161000

-122622000

3312000

-19766000

-29183000

-6372000

-52009000

-19828000

1048000

-11974000

-14266000

-45020000

-4097000

-3791000

-1312000

375000

300000

800000

-116666000

-49162000

-39519000

11051000

2487000

868000

2580000

2584000

2532000

2000000

1600000

100000

305400000

74800000

31200000

1419000

454000

4996000

5597000

-2585000

-1162000

4303000

-28000

-8000

7000

2160000

947000

-3927000

-453000

297000

383000

4303000

7000

383000

-3927000

500000

520000

602000

1424000

800000

3615000

5469000

600000

18000

-900000

-479000

-94000

-253000

5077000

604000

2419000

520000

300000

-11000

1275000

604000

355000

87000

78000

137000

49000

3200000

4350000

4400000

4350000

1000

2000

1000

0.001

22500

33333

575

1090000

2141000

13500

1874000

64200000

15147000

55000000

50000000

45000000

15100000

5000000

6200000

16000000

165000

30000

-26000

31922000

10820000

15971000

-120763000

-52953000

-40831000

11828000

201000

6521000

5106000

9929000

209000

4552000

5168000

3023000

2990000

33000

2365000

P5Y

P3Y

P10Y

1735000

1700000

347500

31200000

29700000

26200000

31400000

14300000

4659000

5452000

19548000

76627000

64961000

32866000

16000000

-2150326000

-2195346000

-2200000000

7500000

8000000

2000000

1200000

1000000

40000000

10000000

32000000

8000000

32000000

10000000

12800000

16116000

36475000

7361000

4433000

9136000

57405000

754000

22225000

1705000

462000

25146000

11500000

15.70

3472000

1223000

975000

914000

1015000

4127000

626000

227000

853000

53962000

45306000

31435000

14828000

14800000

2800000

300000

3017000

3155000

8656000

3964000

10864000

13300000

13324000

600000

8550000

575000

4199000

2320000

11004000

5700000

5746000

4731000

1015000

911000

4835000

P3Y

177000

13000

97000

39000

14.39

0.00

570000

46000

270000

187000

2000

20000

20.61

15.70

5.64

5.35

5.78

4.97

183000

187000

63000

20000

12.76

5.35

15.93

4.97

200000

83000

187000

7300000

1300000

200000

300000

800000

9.43

5.35

0.80

0.75

0.83

0.017

0.012

0.019

200000.0

8300000.0

24000

317400

436100

1913000

2500000

25.71

12.58

9.83

12000

136000

210000

62000

128000

378000

1149000

1511000

4450000

4756137

80000

1200000.0

9.17

3.01

2.47

492000

1559000

2806000

6668000

31.39

17.45

11.44

6.15

6.26

9000

6410000

800000

1800000

-1000000

700

10000

4000

13.98

0.00

242.92

25.58

24.33

21.70

9.07

6.27

4.24

13.94

6.43

3.68

P10Y

P5Y3M20D

P4Y0M0D

P5Y2M15D

P3Y2M12D

11000

4400

P7Y0M0D

P6Y10M24D

17676000

28046000

28229000

42969000

600

470000

2700000

5000000

4000000

14600000

4100000

12575

4000000

-50000

5000000

-55000

14616000

-21900

30000

55000

50000

1000000

6750

22500

20000000

6300000

50000

55000

1000000

22500

393000

207000

150000

8000

46611000

-46611000

52409000

-52409000

41579000

-41579000

30000000

15147000

46611000

52409000

15147000

42669000

14828000

13324000

5746000

156000

32000

35000

21000

600000

400000

100000

13319000

21813000

38478000

-6499000

2023949000

-3277000

-1975695000

47413000

-6952000

2157300000

-4618000

-2098317000

7757000

-6655000

2170300000

-5562000

-2150326000

16090000

-6272000

2222341000

-5723000

1090000

-2195346000

0.1

595000

324000

104000

31000

24000

26000

7300000

1300000

100000

38700000

23200000

-123800000

1265000

1510000

1367000

1326000

1735000

692000

-25000

-19000

204000

36000

1735000

428000

347000

4400000

4800000

300000

100000

4100000

4700000

18837000

27948000

36445000

19324000

28198000

36569000

487000

250000

124000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Risks, Uncertainties and Concentrations</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, see Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">15. Customer and Geographic Concentrations</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for further concentration disclosure.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Common Stock</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Authorized</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">April 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from </font><font style="font-family:inherit;font-size:10pt;">31.5 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">41.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from </font><font style="font-family:inherit;font-size:10pt;">41.5 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">81.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Issued</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2015</font><font style="font-family:inherit;font-size:10pt;">, we entered into a subscription agreement with BVF pursuant to which we issued to BVF an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a purchase price per share of </font><font style="font-family:inherit;font-size:10pt;">$15.70</font><font style="font-family:inherit;font-size:10pt;">. The shares of common stock were offered directly to BVF without a placement agent or underwriter. The net proceeds from the offering, after deducting offering expenses, were approximately </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Reserved</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of common stock reserved for issuance is as follows as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity incentive plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option agreement with Adam R. Craig</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock purchase warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series N-3 convertible preferred stock </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock reserved</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">29,239</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$17.10</font><font style="font-family:inherit;font-size:10pt;"> per share, issued in connection with the Third Amendment to the Loan Agreement with Hercules in </font><font style="font-family:inherit;font-size:10pt;">June 2015</font><font style="font-family:inherit;font-size:10pt;">, were outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">190,140</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.84</font><font style="font-family:inherit;font-size:10pt;"> per share, issued in connection with the Loan and Security Agreement with SVB, were outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 7. Long-term Debt for additional information concerning our warrants.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,”  the “Company” and “CTI”, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partners Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, have commercialization rights outside the United States, or the U.S.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, or the U.S., the European Medicines Agency, or the EMA, in the European Union, or the E.U., and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40)</font><font style="font-family:inherit;font-size:10pt;">, our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement with Baxalta Incorporated and its affiliates, or Baxalta, and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$2.2 billion</font><font style="font-family:inherit;font-size:10pt;">, and we expect to incur net losses for the foreseeable future. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our available </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">cash, cash equivalents </font><font style="font-family:inherit;font-size:10pt;">and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">restricted cash </font><font style="font-family:inherit;font-size:10pt;">were </font><font style="font-family:inherit;font-size:10pt;">$43.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. In </font><font style="font-family:inherit;font-size:10pt;">February 2018</font><font style="font-family:inherit;font-size:10pt;">, as discussed in Note 21. Subsequent Events, we completed the public offering of common stock and received approximately </font><font style="font-family:inherit;font-size:10pt;">$64.2 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses. In addition, we received a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations at least through the next twelve months from the date these financial statements were issued. We previously disclosed that we had substantial doubt about our ability to continue as a going concern, which was primarily due to lack of liquidity. This has since been alleviated as a result of the proceeds we received from the public offering of common stock as well as the milestone payment. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying consolidated consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocated the arrangement consideration of </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">€12.0 million</font><font style="font-family:inherit;font-size:10pt;"> converted into U.S. dollars using the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">currency exchange rate as of the date of the Restated Agreement) based on the percentage of the relative selling price of each</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unit of accounting as follows (in thousands):</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">        </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development and other services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total upfront payment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of common stock reserved for issuance is as follows as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity incentive plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option agreement with Adam R. Craig</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock purchase warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series N-3 convertible preferred stock </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock reserved</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides reconciliations of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:288px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Shareholder Rights Plan</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2009, our Board approved and adopted a shareholder rights plan, or Rights Plan, in which </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> preferred stock purchase right was distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI’s common stock outstanding as of, and issued subsequent to January 7, 2010. In 2012, 2015 and 2017, our Board approved certain amendments to the Rights Plan. The Rights Plan expires on </font><font style="font-family:inherit;font-size:10pt;">December 2, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of two ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.00</font><font style="font-family:inherit;font-size:10pt;"> per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> or more of our common stock. Upon acquisition of </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> or more of our common stock, our Board could decide that each right (except those held by a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. In certain circumstances, including if there are insufficient shares of our common stock to permit the exercise in full of the rights, the holder may receive units of preferred stock, other securities, cash or property, or any combination of the foregoing.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, if we are acquired in a merger or other business combination transaction, each holder of a right (except those held by a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> shareholder which become null and void) would have the right to receive, upon exercise, common stock of the acquiring company having a market value equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> times the exercise price of the right. Our Board may redeem the rights for </font><font style="font-family:inherit;font-size:10pt;">$0.0002</font><font style="font-family:inherit;font-size:10pt;"> per right or terminate the Rights Plan at any time prior to an acquisition by a person or group holding </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> or more of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Value Added Tax Receivable</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> was included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other assets</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> was included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">prepaid expenses and other current assets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The collection period of VAT receivable for our European operations ranges from approximately </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. For our Italian VAT receivable, the collection period is approximately </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the VAT receivable related to operations in Italy was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Accrued Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses </font><font style="font-family:inherit;font-size:10pt;">consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical and investigator-sponsored trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation and related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insurance financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,419</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Description of Business and Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,”  the “Company” and “CTI”, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partners Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, have commercialization rights outside the United States, or the U.S.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, or the U.S., the European Medicines Agency, or the EMA, in the European Union, or the E.U., and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include CTI Life Sciences Limited, or CTILS. We also retain ownership of our branch, CTI BioPharma Corp.- Sede Secondaria, or CTI (Europe) which has ceased operations. Systems Medicine LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in December 2017. </font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we also had an approximately </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">noncontrolling interest</font><font style="font-family:inherit;font-size:10pt;"> in the consolidated financial statements.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All intercompany transactions and balances are eliminated in consolidation.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse Stock Split</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2017, we effected a one-for-</font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split, or the Stock Split. Unless otherwise noted, all impacted amounts included in the consolidated financial statements and notes thereto have been retroactively adjusted for the Stock Split. Unless otherwise noted, impacted amounts include shares of common stock authorized and outstanding, share issuances and cancellations, shares underlying warrants and stock options, shares reserved, conversion prices of convertible securities, exercise prices of warrants and options, and loss per share. Additionally, the Stock Split impacted preferred stock authorized (but not outstanding because there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock outstanding as of the time of the Stock Split).</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40)</font><font style="font-family:inherit;font-size:10pt;">, our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement with Baxalta Incorporated and its affiliates, or Baxalta, and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$2.2 billion</font><font style="font-family:inherit;font-size:10pt;">, and we expect to incur net losses for the foreseeable future. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our available </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">cash, cash equivalents </font><font style="font-family:inherit;font-size:10pt;">and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">restricted cash </font><font style="font-family:inherit;font-size:10pt;">were </font><font style="font-family:inherit;font-size:10pt;">$43.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. In </font><font style="font-family:inherit;font-size:10pt;">February 2018</font><font style="font-family:inherit;font-size:10pt;">, as discussed in Note 21. Subsequent Events, we completed the public offering of common stock and received approximately </font><font style="font-family:inherit;font-size:10pt;">$64.2 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses. In addition, we received a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations at least through the next twelve months from the date these financial statements were issued. We previously disclosed that we had substantial doubt about our ability to continue as a going concern, which was primarily due to lack of liquidity. This has since been alleviated as a result of the proceeds we received from the public offering of common stock as well as the milestone payment. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying consolidated consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, and excess and obsolete inventory, recording share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, and determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Risks, Uncertainties and Concentrations</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, see Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">15. Customer and Geographic Concentrations</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for further concentration disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> cash equivalents as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash represents a legally restricted deposit held as a compensating balance against our senior secured term loan with Silicon Valley Bank, or SVB. Pursuant to the loan and security agreement entered into with SVB in November 2017, we were required to maintain unrestricted and unencumbered cash in an amount equal to at least </font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;"> at all times prior to the occurrence of an event relating to the delivery to SVB of duly executed signatures to a control agreement from Bank of America with respect to all of our accounts maintained with Bank of America. In January 2018, we obtained a waiver from SVB for such requirement and as a result, we no longer have restrictions placed on the cash balance. See Note 7. Long-term Debt for further details regarding our senior secured term loan with SVB.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides reconciliations of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:288px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:114px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables from Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our receivables from collaborative arrangements relate to amounts payable or reimbursable to us under the terms of collaborative arrangements with our partners. The receivable balance as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> relates primarily to the sale of PIXUVRI drug product to Servier. The receivable balance as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> relates primarily to a milestone receivable from Servier for the attainment of a certain enrollment event in </font><font style="font-family:inherit;font-size:10pt;">December 2016</font><font style="font-family:inherit;font-size:10pt;"> in connection with our PIX306 study. Receivables from collaborative arrangements are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recorded </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> in bad debt expense related to disputed invoices under the collaborative arrangement with Baxalta. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts from collaborative arrangements as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Value Added Tax Receivable</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> was included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other assets</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> was included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">prepaid expenses and other current assets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The collection period of VAT receivable for our European operations ranges from approximately </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. For our Italian VAT receivable, the collection period is approximately </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the VAT receivable related to operations in Italy was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry inventory at the lower of cost or net realizable value. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the distribution of PIXUVRI. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We review our inventories on a quarterly basis for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsalable inventory, the value is written down to the net realizable value. We had a reserve of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to excess, obsolete or unsalable inventory as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, which was included in</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Inventory, net.</font><font style="font-family:inherit;font-size:10pt;"> Inventory, net as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is comprised of bulk active pharmaceutical ingredient which we expect to be salable to Servier under the terms of the Restated Agreement and to future emerging markets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years or the term of the applicable lease.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We analyze leases at the inception of each agreement for classification as either an operating or capital lease. Certain of our lease agreement terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense equal to the amount of total minimum lease payments on a straight-line basis over the term of the lease. A deferred liability recognized in connection with the December 2017 sublease arrangement is amortized over the term of the sublease as a reduction of rent expense.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 </font><font style="font-family:inherit;font-size:10pt;">– Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 </font><font style="font-family:inherit;font-size:10pt;">- Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 </font><font style="font-family:inherit;font-size:10pt;">- Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of financial instruments such as receivables and payables approximated their fair values due to their short-term maturities. The carrying value of our long-term debt approximated its fair value at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> based on borrowing rates for similar loans and maturities. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">11. Collaboration, Licensing and Milestone Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">and Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">18. Legal Proceedings</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for further information regarding our current gain and loss contingencies.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have conditional marketing authorization for PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Product Sales</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PIXUVRI was sold primarily through a limited number of wholesale distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary. As of April 2017, Servier has the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">11. Collaboration, Licensing and Milestone Agreements</font><font style="font-family:inherit;font-size:10pt;"> for further details.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration Agreements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with Accounting Standards Codification, or ASC, 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">—</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple-Element Arrangements.</font><font style="font-family:inherit;font-size:10pt;"> If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Upon the completion of the performance obligation, such amounts will be recognized as revenue when collectability is reasonably assured.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments under collaboration agreements are generally aggregated into three categories for reporting purposes: (1) development milestones, (2) regulatory milestones and (3) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable (1) upon submission for marketing approval with the FDA or with the regulatory authorities of other countries, and (2) upon receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (1) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition – Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;"> and ASC 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;">, if applicable, to determine the accounting for reimbursement arrangements under collaborative research and development and commercialization agreements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Product Sold</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sold includes third-party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes allowances, if any, for excess inventory that may expire and become unsalable. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred in accordance with the FASB ASC 730, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</font><font style="font-family:inherit;font-size:10pt;">. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Translation and Transaction Gains and Losses</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Foreign Currency Matters.</font><font style="font-family:inherit;font-size:10pt;"> For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intercompany balance due from CTILS is considered to be of a long-term nature. An unrealized foreign exchange gain of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> and unrealized foreign exchange losses of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded in the cumulative foreign currency translation adjustment account for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the intercompany balance due from CTILS was </font><font style="font-family:inherit;font-size:10pt;">€26.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">€29.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively (or </font><font style="font-family:inherit;font-size:10pt;">$31.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;"> upon conversion from euros as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively).</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Share</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect.</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued a new accounting standard which changes the presentation of debt issuance costs in financial statements. Under the new standard, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The accounting standard is effective for annual reporting periods beginning after December 15, 2015 and interim periods beginning after December 15, 2016. The adoption of this guidance did not have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In July 2015, the FASB issued new accounting guidance on simplifying the measurement of inventory which requires</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2016. The adoption of this standard did not have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet</font><font style="font-family:inherit;font-size:9pt;color:#404041;">. </font><font style="font-family:inherit;font-size:10pt;">The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The adoption of this guidance did not have an impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period and to provide related footnote disclosures in certain circumstances. The accounting standard is effective for annual reporting periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard in the fourth quarter of 2016 did not have a material impact on our consolidated financial statements.  </font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued new accounting guidance for employee share-based payments accounting. The accounting standard primarily affects the accounting for forfeitures, minimum statutory tax withholding requirements, and income tax effects related to share-based payments at settlement (or expiration). The accounting guidance is effective for annual reporting periods beginning after December 15, 2016 (including interim periods within those periods). We have historically maintained a full valuation allowance against deferred tax assets. The adoption of this standard in the first quarter of 2017 did not have a material impact on our consolidated financial statements, and we will continue to estimate expected forfeitures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued accounting guidance which amends ASC 230, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows,</font><font style="font-family:inherit;font-size:10pt;"> to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments require that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Consequently, transfers between cash and restricted cash will not be presented as a separate line item in the operating, investing or financing sections of the cash flow statement. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. The early adoption is permitted. The adoption of this standard did not have a material impact on our consolidated financial statements.  </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Recently Issued Accounting Standards</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five-step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. We will adopt the new standard in the first quarter 2018 using the modified retrospective method. We have completed the impact on our customer contracts and do not expect the implementation of ASU 2014-09 to have a material quantitative impact on our consolidated financial statements. Under the new standard, such customer arrangements will be accounted for as variable consideration, which may result in revenue being recognized earlier provided we can reliably estimate the ultimate price expected to be realized from the customer. In addition, we do not expect a material cumulative effect adjustment to Retained earnings upon adoption of the standard on January 1, 2018. Adoption of the new standard will also result in additional revenue-related disclosures in the footnotes to our consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued a new accounting guidance on accounting for leases which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018. Early adoption is permitted. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued an amendment to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows with the objective of reducing diversity in practice regarding eight types of cash flows. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of this standard to have a material impact on our statement of cash flows. </font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year items have been reclassified to conform to current year presentation.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Collaboration Agreements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with Accounting Standards Codification, or ASC, 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">—</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple-Element Arrangements.</font><font style="font-family:inherit;font-size:10pt;"> If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Upon the completion of the performance obligation, such amounts will be recognized as revenue when collectability is reasonably assured.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments under collaboration agreements are generally aggregated into three categories for reporting purposes: (1) development milestones, (2) regulatory milestones and (3) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable (1) upon submission for marketing approval with the FDA or with the regulatory authorities of other countries, and (2) upon receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (1) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition – Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;"> and ASC 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;">, if applicable, to determine the accounting for reimbursement arrangements under collaborative research and development and commercialization agreements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Other Comprehensive Loss</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss) and Impairment on </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-For-Sale Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,902</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,927</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2016, we recognized an other-than-temporary impairment on available-for-sale securities of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations. The value of available-for-sale securities of </font><font style="font-family:inherit;font-size:10pt;">$13,500</font><font style="font-family:inherit;font-size:10pt;"> was included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prepaid expenses and other current assets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale securities as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Share-Based Compensation</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation Expense</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense for all share-based payment awards made to employees and directors is measured based on the grant-date fair value estimated in accordance with GAAP. We recognize share-based compensation using the straight-line, single-award method based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Share-based compensation is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized share-based compensation expense which consisted of the following types of awards (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes share-based compensation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, which was allocated as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation had a </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;"> effect on our net loss attributable to common shareholders, which resulted in a </font><font style="font-family:inherit;font-size:10pt;">$(0.16)</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$(0.48)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(0.79)</font><font style="font-family:inherit;font-size:10pt;"> effect on basic and diluted net loss per common share for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. It had no effect on cash flows from operations or financing activities for the periods presented; however, during the years ended </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we repurchased </font><font style="font-family:inherit;font-size:10pt;">21,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">35,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">32,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock totaling </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for cash in connection with the vesting of employee restricted stock awards based on taxes owed by employees upon vesting.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, unrecognized compensation cost related to unvested stock options, restricted stock awards and restricted stock units amounted to </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">, which will be recognized over the remaining weighted-average requisite service period of </font><font style="font-family:inherit;font-size:10pt;">2.28 years</font><font style="font-family:inherit;font-size:10pt;">. The unrecognized compensation cost related to unvested options and restricted stock does not include the value of performance-based awards. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> tax benefits were attributed to share-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Plans</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company's 2017 Equity Incentive Plan, or the 2017 Plan, was approved by the Company's shareholders, and no additional awards will be granted under the 2015 Equity Incentive Plan, or the 2015 Plan. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's 2007 Employee Stock Purchase Plan, as amended and restated in August 2009 and September 2015, or the Purchase Plan, was amended in September 2015 to increase the maximum number of shares of the Company’s common stock authorized for issuance by </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan </font><font style="font-family:inherit;font-size:10pt;">below for further details.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our 2017 Plan, we may grant the following types of incentive awards: (1) stock options, including incentive stock options and non-qualified stock options, (2) stock appreciation rights, (3) restricted stock, (4) restricted stock units and (5) cash awards. The 2017 Plan is administered by the Compensation Committee of our Board, which has the discretion to determine the employees and consultants who shall be granted incentive awards. The Board retained sole authority under the 2017 Plan with respect to non-employee directors’ awards, although the Compensation Committee has authority under its charter to make recommendations to the Board concerning such awards. Options expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant, subject to the recipients continued service to the Company. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">8.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares were authorized for issuance, of which </font><font style="font-family:inherit;font-size:10pt;">24,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were available for future grants, under the 2017 Plan. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our options are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our options, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stock price volatility and option lives, both of which impact the fair value of options calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option, involve management’s best estimates. As we recognize compensation expense for only the portion of options expected to vest, we apply estimated forfeiture rates that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for all of our stock option plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2014 (317,400 exercisable)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242.92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015 (436,100 exercisable)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,511,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016 (1,913,000 exercisable)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,806,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(210,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,668,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,410,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average exercise price of options exercisable at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$9.83</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$12.58</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$25.71</font><font style="font-family:inherit;font-size:10pt;">, respectively. The weighted average grant-date fair value of options granted during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$2.47</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.01</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9.17</font><font style="font-family:inherit;font-size:10pt;"> per option, respectively.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">March 2017</font><font style="font-family:inherit;font-size:10pt;">, Dr. Adam R. Craig, our President and CEO, was granted stock options to purchase </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$4.24</font><font style="font-family:inherit;font-size:10pt;"> per share. The stock options have a maximum term of ten years and vest in six equal semi-annual installments over the three-year period beginning March 20, 2017, subject to his continued employment through the applicable vesting dates and acceleration under certain circumstances. The stock options were granted in connection with his entering into employment with the Company as President and CEO. A portion of the stock options covering </font><font style="font-family:inherit;font-size:10pt;">80,000</font><font style="font-family:inherit;font-size:10pt;"> shares were granted under the 2015 Plan. The balance of such stock options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued </font><font style="font-family:inherit;font-size:10pt;">2,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">270,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">570,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted stock awards in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The weighted average grant-date fair value of restricted stock awards issued during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$5.78</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.64</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20.61</font><font style="font-family:inherit;font-size:10pt;">, respectively. Additionally, </font><font style="font-family:inherit;font-size:10pt;">39,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">97,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">177,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted stock awards were cancelled during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of restricted stock awards vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of nonvested restricted stock awards as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the period then ended, is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonvested Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant-Date Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">187,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">46,000</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and cancelled </font><font style="font-family:inherit;font-size:10pt;">13,000</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units during </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units were cancelled during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The weighted average grant-date fair value of restricted stock units issued during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$4.97</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.35</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.70</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of restricted stock units vested during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units vested during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of nonvested restricted stock units as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the period then ended, is presented below:</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonvested Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant-Date Fair Value<br clear="none"/>Per Unit</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Term Performance Awards</font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2011, we granted restricted stock units to our executive officers and directors that became effective on January 3, 2012, or the Long-Term Performance Awards, which was subsequently amended in 2013, 2014 and 2015. The Long-Term Performance Awards vest upon achievement of milestone-based performance conditions, including a market-based condition. If one or more of the underlying performance-based conditions were timely achieved, the award recipient would be entitled to receive a number of shares of our common stock (subject to share limits of the 2007 Plan or 2015 Plan, as applicable), determined by multiplying (1) the award percentage corresponding to that particular performance goal by (2) the total number of outstanding shares of our common stock as of the date that the particular performance goal is achieved.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, our Board certified completion of the performance condition relating to pacritinib Phase 3 trial result that satisfies the primary point set forth in the statistical plan then in effect and an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares vested to our executive officers and directors. We recognized </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> in share-based compensation upon satisfaction of this performance condition during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2015</font><font style="font-family:inherit;font-size:10pt;">, the Long-Term Performance Awards were modified so that as to any particular performance goal that was achieved after </font><font style="font-family:inherit;font-size:10pt;">December 23, 2015</font><font style="font-family:inherit;font-size:10pt;"> and on or before </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the executive officers would be granted a stock option with respect to the number of shares determined under the formula described above (as opposed to receiving or retaining such number of fully-vested shares of our common stock). Each option had an exercise price equal to the closing price of the Company’s common stock on the grant date (which would be the date the Compensation Committee of our Board certifies the performance goal is achieved) and would be scheduled to vest in semi-annual installments over a period of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> following the grant date. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2016, the Long-Term Performance Awards expired. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Long-Term Performance Awards was estimated based on the average present value of the awards to be issued upon achievement of the performance conditions. The average present value was calculated based upon the expected date the shares of common stock underlying the performance awards will vest, or the event date, the expected stock price on the event date, and the expected shares outstanding as of the event date. The event date, stock price and the shares outstanding were estimated using a Monte Carlo simulation model, which is based on assumptions by management, including the likelihood of achieving the milestones and potential future financings.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined the Long-Term Performance Awards with a market-based performance condition had a grant-date fair value of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the executive officers and director participants. We determined that the market-based performance condition had an incremental fair value of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> on the first modification date in March 2013 and an additional incremental fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> on the second modification date in January 2014 for the executive officers and director participants, which were recognized in addition to the then-unamortized fair value as of the modification date over the remaining estimated requisite service period. The December 2015 modification discussed above did not result in incremental fair value. In December 2015, we reversed the total share-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was previously recorded for awards granted to directors who agreed to forfeit their Long-Term Performance Awards as part of the derivative lawsuit settlement. See Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">18. Legal Proceedings</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for further information. We recognized </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> in share-based compensation expense related to the awards with a market-based condition during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> compensation expense for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> as the Long-Term Performance Awards expired on December 31, 2016. </font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nonemployee Share-Based Compensation</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense for awards granted to nonemployees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of options and restricted stock awards granted to nonemployees is periodically remeasured as the underlying options or awards vest. The value of the instrument is amortized to expense over the vesting period with final valuation measured on the vesting date. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, unvested options to acquire approximately </font><font style="font-family:inherit;font-size:10pt;">4,400</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">11,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding, respectively. We reversed compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$8,000</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and recorded </font><font style="font-family:inherit;font-size:10pt;">$16,000</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unvested options or restricted stock outstanding, and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> compensation expense was recorded for the year-ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the lower of the subscription date fair market value and the purchase date fair market value. There are two six-month offerings per year. Under the Purchase Plan, we issued approximately </font><font style="font-family:inherit;font-size:10pt;">4,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">10,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">700</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to employees in the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. There are </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized under the Purchase Plan and approximately </font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares are reserved for future purchases as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized share-based compensation expense which consisted of the following types of awards (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. Net Loss Per Share</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, as their inclusion would have an anti-dilutive effect.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Accordingly, diluted net loss per share is the same as basic net loss per share</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The computation of net loss per share is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,009</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(122,622</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,569</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,198</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,324</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less weighted average restricted shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in calculation of basic and diluted net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share: Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity awards, warrants, unvested share rights and other convertible securities aggregating </font><font style="font-family:inherit;font-size:10pt;">5.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares, </font><font style="font-family:inherit;font-size:10pt;">2.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">1.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, prior to the application of the treasury stock method, have been excluded from the calculation of diluted net loss per share because they were anti-dilutive.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19. Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file income tax returns in the U.S., Italy and the U.K. A substantial part of our operations takes place in the State of Washington, which does not impose an income tax as that term is defined in ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes</font><font style="font-family:inherit;font-size:10pt;">. As such, our state income tax expense or benefit, if recognized, would be immaterial to our operations. We are not currently under examination by an income tax authority, nor have we been notified that an examination is contemplated.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. signed into law, on December 22, 2017, tax reform legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017, or the 2017 Tax Act. The 2017 Tax Act significantly revises the U.S. corporate income tax by, among other things, lowering the statutory corporate tax rate from </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">, eliminating certain deductions, imposing a mandatory one-time tax on accumulated earnings of foreign subsidiaries, introducing new tax regimes, and changing how foreign earnings are subject to U.S. tax. The 2017 Tax Act also enhances and extends through 2026 the option to claim accelerated depreciation deductions on qualified property. We have completed our determination of the accounting implications of the 2017 Tax Act, the impact of which is a </font><font style="font-family:inherit;font-size:10pt;">$41.3 million</font><font style="font-family:inherit;font-size:10pt;"> reduction in net deferred tax assets to reflect the new statutory rate. The rate adjustment to deferred tax assets, a discrete item for the quarter, is fully offset by a decrease in the valuation allowance: there is therefore no rate impact to us. In addition, there is no impact to current or deferred taxes related to the one-time deemed repatriation, as our foreign subsidiaries do not have cumulative positive earnings and profits. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes is attributable to the following tax jurisdictions (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(651</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,097</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation between our effective tax rate and the income tax rate as of December 31 is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible executive compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign tax rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of tax reform</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired tax attribute carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;color:#ee2724;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal components of our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,721</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions for tax in excess of financial statements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we had U.S. federal net operating loss carryforwards, or the NOL, of approximately </font><font style="font-family:inherit;font-size:10pt;">$74.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$305.4 million</font><font style="font-family:inherit;font-size:10pt;"> respectively, which are available to reduce future taxable income. We also had U.S. federal tax credits of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and may become subject to annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, or the IRC, of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or future tax liabilities. We have undertaken a formal IRC Section 382 study and the attributes disclosed in this footnote reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the NOL carryforwards in the U.K.,which have an indefinite carryforward period, were approximately </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain a full valuation allowance on our net deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In our valuation, we considered our cumulative loss in recent years and forecasted losses in the near term as significant negative evidence. Based upon a review of the four sources of income identified within ASC 740, we determined that the negative evidence outweighed the positive evidence and that a full valuation allowance on our net deferred tax assets will be maintained. We will continue to assess the realizability of our deferred tax assets going forward and will adjust the valuation allowance as needed. Our valuation allowance decreased by </font><font style="font-family:inherit;font-size:10pt;">$123.8 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$23.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The reduction in the valuation allowance for 2017 was attributable to the reduction in tax rate due to the 2017 Tax Act as well as the reduction in net operating losses as a result of the 2017 Section 382 analysis.</font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation: Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, in 2017. Due to the fact that there was no excess tax benefit over book expense related to stock compensation, the adoption had no impact to the deferred tax assets.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the provisions ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes</font><font style="font-family:inherit;font-size:10pt;">, and the guidance related to accounting for uncertainty in income taxes. We determine our uncertain tax positions based on a determination of whether and how much of a tax benefit taken by us in our tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. We are subject to U.S. federal and state, Italian and U.K. income taxes with varying statutes of limitations. Tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrecognized tax benefits and therefore </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> accrued interest or penalties related to unrecognized tax benefits. We believe that our income tax filing positions reflected in the various tax returns are more-likely-than not to be sustained on audit and thus there are no anticipated adjustments that would result in a material change to our consolidated financial position, results of operations and cash flows. Therefore, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves for uncertain income tax positions have been recorded.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sublease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rentals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,487</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,716</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,584</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">868</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease commitments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,499</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,552</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of nonvested restricted stock units as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the period then ended, is presented below:</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonvested Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant-Date Fair Value<br clear="none"/>Per Unit</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of nonvested restricted stock awards as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the period then ended, is presented below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonvested Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant-Date Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Other Liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other liabilities </font><font style="font-family:inherit;font-size:10pt;">consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,050</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,011</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,419</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, less current portion as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> includes amounts related to incentives for rent holidays and leasehold improvements associated with our operating lease for office space. In addition, deferred rent, less current portion as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> includes </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred liability related to the sublease of Seattle office space as discussed in Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">5. Leases</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term obligations as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> include a fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> payable to Silicon Valley Bank. See Note 7, Long-term Debt, for additional information.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other liabilities </font><font style="font-family:inherit;font-size:10pt;">consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,050</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,011</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,419</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Employee Benefit Plans</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our U.S. employees participate in the CTI BioPharma Corp. 401(k) Plan whereby eligible employees may defer up to </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to discretionary matching contributions during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during each of the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Property and Equipment</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are composed of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,552</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,521</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,929</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,828</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are composed of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,552</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,521</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,929</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,828</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20. Unaudited Quarterly Data</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,828</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,398</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,266</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,828</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,766</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,183</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.04</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues for the second quarter of 2017 include </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;"> of license and contract revenue recognized in April 2017 in connection with the Restated Agreement with Servier as well as a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment received from Teva upon the achievement of worldwide net sales milestones of TRISENOX. See Note 11. Collaboration, Licensing and Milestone Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for additional information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit is computed by subtracting cost of product sold from net product sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues for the first quarter of 2016 include </font><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone revenue upon achievement of two milestones during the quarter. The payments from Baxalta relating to these milestones were received in 2015. See Note 7. Long-term Debt</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for additional information. The fourth quarter of 2016 includes </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone revenue from Servier relating to the attainment of a certain enrollment event in connection with our PIX306 study.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aequus</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a majority ownership interest in Aequus. In </font><font style="font-family:inherit;font-size:10pt;">May 2007</font><font style="font-family:inherit;font-size:10pt;">, we entered into a license agreement with Aequus</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whereby Aequus gained rights to our Genetic Polymer™ technology. We also entered into an agreement to fund Aequus in</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exchange for a convertible promissory note.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">March 2017</font><font style="font-family:inherit;font-size:10pt;">, we and Aequus entered into a License and Promissory Note Termination Agreement and a Note Cancellation Agreement, pursuant to which (1) all of the then-outstanding principal, plus all accrued and unpaid interest, approximately </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> in total, was cancelled and terminated, (2) our license agreement with Aequus was terminated, (3) all obligations to Aequus were terminated with the exception of providing additional funding of up to </font><font style="font-family:inherit;font-size:10pt;">$347,500</font><font style="font-family:inherit;font-size:10pt;"> to Aequus, and (4) Aequus agreed to pay us a) </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of milestone and similar payments, up to a maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, and b) royalties, on a product-by-product and county-by country basis, of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of net sales of certain ACTH Products being developed by Aequus. The additional funding of </font><font style="font-family:inherit;font-size:10pt;">$347,500</font><font style="font-family:inherit;font-size:10pt;"> had been provided in full as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Payments from Aequus are due the later of (1) expiration of the last to expire valid patent claim that claims the ACTH Product, or (2) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years from the first commercial sale of the applicable ACTH Product. We have the right to terminate the License and Promissory Note Termination Agreement and require Aequus to assign all ACTH Product related assets to us if Aequus does not file an Investigational New Drug Application for an ACTH Product with the FDA by </font><font style="font-family:inherit;font-size:10pt;">September 6, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jack W. Singer, M.D., our Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer, and Global Head of Translational Medicine, and Frederick W. Telling, Ph.D., a member of our Board, are minority shareholders of Aequus, owning approximately </font><font style="font-family:inherit;font-size:10pt;">4.3%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.8%</font><font style="font-family:inherit;font-size:10pt;"> of the equity in Aequus as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Dr. Telling is the Chairman of Aequus' Board of Directors. Dr. Singer and Richard Love, a member of our Board, are also members of Aequus’ Board of Directors. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BVF Partners L.P.</font></div><div style="line-height:111%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2015</font><font style="font-family:inherit;font-size:10pt;">, as discussed in Note </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">9. Common Stock</font><font style="font-family:inherit;font-size:10pt;">, we entered into a subscription agreement with BVF pursuant to which we issued </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Further, as discussed in Note 8. Preferred Stock, we completed underwritten public offerings of </font><font style="font-family:inherit;font-size:10pt;">55,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-2 Preferred Stock, no par value per share in </font><font style="font-family:inherit;font-size:10pt;">December 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">22,500</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-3 Preferred Stock, no par value per share in </font><font style="font-family:inherit;font-size:10pt;">June 2017</font><font style="font-family:inherit;font-size:10pt;">. BVF purchased </font><font style="font-family:inherit;font-size:10pt;">30,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-2 Preferred Stock and </font><font style="font-family:inherit;font-size:10pt;">6,750</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-3 Preferred Stock in such offerings. BVF converted </font><font style="font-family:inherit;font-size:10pt;">30,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-2 Preferred Stock and </font><font style="font-family:inherit;font-size:10pt;">6,175</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N-3 Preferred Stock into approximately </font><font style="font-family:inherit;font-size:10pt;">2.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">4.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, respectively. Primarily as a result of these transactions, BVF beneficially owned approximately </font><font style="font-family:inherit;font-size:10pt;">20.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15.9%</font><font style="font-family:inherit;font-size:10pt;"> of our outstanding common stock as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Matthew D. Perry, a member of our Board, is the President of BVF and portfolio manager for the underlying funds managed by the firm. </font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series N-2 Preferred Stock offering, we entered into a letter agreement with BVF, or the First Letter Agreement, pursuant to which we granted BVF a one-time right, subject to certain conditions, to nominate not more than </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> individuals to serve as members of our Board, subject to the Board’s consent, which is not to be unreasonably withheld and which consent shall be deemed automatically given with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> individuals specified in such Letter Agreement. One of such nominees (the “Independent Nominee”) must (1) qualify as an “independent” director as defined under the applicable rules and regulations of the SEC and the NASDAQ, and (2) must not be considered an “affiliate” of BVF as such term is defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have agreed, for the period hereinafter described and subject to a limited exception, to include the nominated directors in the slate of nominees for election to the Board at each annual or special meeting at which directors are to be elected, recommend that shareholders vote in favor of the election of such nominees and support such nominees for election in a manner no less favorable than how we support our own nominees. This obligation will terminate with respect to: (1) the Independent Nominee, and such Independent Nominee must tender his or her resignation to the Board, if requested, promptly upon BVF ceasing to beneficially own at least </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;"> of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), and (2) each of the Independent Nominee and the other individual nominated by BVF, and each such nominee shall tender his or her resignation to the Board promptly upon the earlier to occur of (a) BVF and its affiliates ceasing to beneficially own at least </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), (b) BVF ceasing to beneficially own at least </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the shares of the common stock beneficially owned by BVF immediately after consummation of the Series N-2 Preferred Stock offering (on an as-converted basis), (c) the continuation of such nomination right would cause any violation of the applicable listing rules of NASDAQ, (d) such time as BVF informs us in writing that it wishes to terminate the foregoing nomination right, or (e) any breach of the Letter Agreement by BVF.</font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the offering of Series N-3 Preferred Stock, we entered into a letter agreement with BVF, or the Second Letter Agreement, and pursuant to the First Letter Agreement and the Second Letter Agreement, we agreed to, upon BVF’s election and subject to any board and committee approvals, exchange shares of common stock purchased by BVF directly from us or underlying convertible preferred stock purchased by BVF directly from us, including the shares of common stock underlying the Series N-3 Preferred Stock, into shares of a convertible non-voting preferred stock with substantially similar terms as the Series N-3 Preferred Stock, including a conversion “blocker” initially set at </font><font style="font-family:inherit;font-size:10pt;">9.99%</font><font style="font-family:inherit;font-size:10pt;"> of our common stock. Such right would terminate if at any time BVF’s beneficial ownership of our common stock falls below </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">February 2018</font><font style="font-family:inherit;font-size:10pt;">, in connection with the public offering of common stock as discussed in Note 21. Subsequent Events, BVF purchased </font><font style="font-family:inherit;font-size:10pt;">6.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. In addition, BVF exchanged </font><font style="font-family:inherit;font-size:10pt;">8.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock owned by BVF and </font><font style="font-family:inherit;font-size:10pt;">575</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series N Preferred Stock owned by BVF for </font><font style="font-family:inherit;font-size:10pt;">12,575</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series O Preferred Stock, pursuant to the letter agreements discussed above as well as an additional exchange agreement executed in </font><font style="font-family:inherit;font-size:10pt;">February 2018</font><font style="font-family:inherit;font-size:10pt;">. As a result of these transactions, BVF beneficially owned approximately </font><font style="font-family:inherit;font-size:10pt;">12.0%</font><font style="font-family:inherit;font-size:10pt;"> of our common stock as of </font><font style="font-family:inherit;font-size:10pt;">February 28, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses </font><font style="font-family:inherit;font-size:10pt;">consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical and investigator-sponsored trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation and related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insurance financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,419</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss) and Impairment on </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-For-Sale Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,902</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,927</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal components of our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,372</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,721</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions for tax in excess of financial statements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The computation of net loss per share is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52,009</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(122,622</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,569</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,198</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,324</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less weighted average restricted shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in calculation of basic and diluted net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share: Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation between our effective tax rate and the income tax rate as of December 31 is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible executive compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign tax rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of tax reform</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired tax attribute carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes share-based compensation expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, which was allocated as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,835</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table depicts long-lived assets based on the following geographic locations (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,990</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-lived assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sublease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rentals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,487</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,716</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,584</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">868</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease commitments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,499</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,552</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of PIXUVRI inventories consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,523</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,917</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,035</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for excess, obsolete or unsalable inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,510</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,828</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,398</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,266</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,828</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,766</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,183</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to CTI common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,372</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.04</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share—diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues for the second quarter of 2017 include </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;"> of license and contract revenue recognized in April 2017 in connection with the Restated Agreement with Servier as well as a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment received from Teva upon the achievement of worldwide net sales milestones of TRISENOX. See Note 11. Collaboration, Licensing and Milestone Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for additional information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit is computed by subtracting cost of product sold from net product sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:20px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues for the first quarter of 2016 include </font><font style="font-family:inherit;font-size:10pt;">$32.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone revenue upon achievement of two milestones during the quarter. The payments from Baxalta relating to these milestones were received in 2015. See Note 7. Long-term Debt</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for additional information. The fourth quarter of 2016 includes </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone revenue from Servier relating to the attainment of a certain enrollment event in connection with our PIX306 study. </font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All sales of PIXUVRI during the years presented were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for all of our stock option plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2014 (317,400 exercisable)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242.92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015 (436,100 exercisable)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,559,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,511,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016 (1,913,000 exercisable)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,806,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled and expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(210,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,668,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,410,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II. Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-top:8px;padding-left:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation and qualifying accounts include the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charged to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charged to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">beginning of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">costs and</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">end of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Reserve for excess, obsolete or unsalable inventory:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Year ended December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allowance for doubtful accounts:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:42px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) We review our inventories on a quarterly basis for impairment and reserves are established when necessary. </font></div><div style="line-height:120%;padding-top:8px;padding-left:42px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) We record inventory in euros and we record foreign currency translation gains and losses from recurring measurement of our inventory in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive loss</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:8px;padding-left:42px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) The amount of reserve is adjusted for the items disposed of during the period. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21. Subsequent Events</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reincorporation Merger</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">January 2018</font><font style="font-family:inherit;font-size:10pt;">, CTI BioPharma Corp., a Delaware corporation ("CTI DE" or, after giving effect to the Reincorporation Merger (defined below), the “Company”), a wholly owned subsidiary of CTI BioPharma Corp., a Washington corporation (“CTI WA”), entered into an Agreement and Plan of Merger, or the Merger Agreement, with CTI WA, pursuant to which CTI WA would merge with and into CTI DE for the sole purpose of reincorporating CTI WA in the State of Delaware (the “Reincorporation Merger”). The Reincorporation Merger and the Merger Agreement were approved by the Board of CTI WA and by a majority of the votes actually cast by the shareholders entitled to vote at CTI WA’s Special Meeting of Shareholders held on January 24, 2018, or the Effective Date. On the Effective Date, CTI DE and CTI WA effected the Reincorporation Merger, thereby changing the state of incorporation of CTI BioPharma Corp. from the State of Washington to the State of Delaware pursuant to the Merger Agreement. As a result of the Reincorporation Merger, CTI WA ceased to exist as a separate entity.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CTI DE’s common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share, or the Common Stock, will continue to trade on the NASDAQ. The Company’s trading symbol remains as “CTIC.” In accordance with Rule 12g-3 under the Exchange Act, the shares of Common Stock of the Company were deemed to be registered under Section 12(b) of the Exchange Act as a successor to CTI WA. The Delaware Charter authorizes the same number of shares of the Common Stock and each class of preferred stock of CTI WA, except that all subseries of Series N Preferred Stock are eliminated and reclassified as Series N Preferred Stock and the number of authorized Series N Preferred Stock is reduced to </font><font style="font-family:inherit;font-size:10pt;">575</font><font style="font-family:inherit;font-size:10pt;">. In addition, each share of CTI DE common stock and preferred stock has a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Reincorporation Merger changed the legal domicile of CTI WA, but did not result in any change in the principal offices, business, management, capitalization, assets or liabilities of the Company. By operation of law, the Company succeeded to all of the assets and assumed all of the liabilities of CTI WA. The officers and directors of CTI WA are the officers and directors of the Company. As a result of the Reincorporation Merger, the Company has assumed all of the CTI WA employee benefit plans and stock incentive plans in effect at the Effective Date, including CTI WA’s 2017 Equity Incentive Plan, 2015 Equity Incentive Plan, 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan, or the Stock Plans, and any and all stock options, restricted stock and restricted stock unit awards, and other equity-based awards that are outstanding under any of the Stock Plans or any individual award agreements outside of the Stock Plans. The Company has also assumed CTI WA’s rights plan with Computershare Trust Company, N.A., as rights agent, dated as of December 28, 2009 and amended on August 31, 2012, December 3, 2012, December 1, 2015 and September 22, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Public Offering of Common Stock </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">February 2018</font><font style="font-family:inherit;font-size:10pt;">, we entered into an underwriting agreement with Leerink Partners LLC acting as sole book-running manager and as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the offer and sale (the “Offering”) of </font><font style="font-family:inherit;font-size:10pt;">20.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share (the “Common Stock”). The Offering closed on February 13, 2018. The price to the public in this Offering was </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;"> per share of Common Stock. The Underwriters exercised in full their option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">3.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares. The net proceeds from this Offering, after deducting underwriting discounts, commissions and other estimated offering expenses, were approximately </font><font style="font-family:inherit;font-size:10pt;">$64.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables from Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our receivables from collaborative arrangements relate to amounts payable or reimbursable to us under the terms of collaborative arrangements with our partners.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables from collaborative arrangements are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable.</font></div></div>

EX-101.SCH 10 ctic-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Collaboration, Licensing and Milestone Agreements link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Collaboration, Licensing and Milestone Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Collaboration, Licensing and Milestone Agreements - Allocated Arrangement Consideration (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Collaboration, Licensing and Milestone Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Common Stock - Summary of Common Stock Reserved for Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Customer and Geographic Concentrations link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Customer and Geographic Concentrations - Long-Lived Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Customer and Geographic Concentrations - Product Sales by Major Customers (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Customer and Geographic Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Employee Benefit Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes - Loss Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes - Reconciliation Between Effective and Income Tax Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Legal Proceedings (Detail) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Long-term Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Net Loss Per Share - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Other Comprehensive Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Other Liabilities link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Other Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Preferred Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Property and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Related Party Transactions (Detail) link:presentationLink link:calculationLink link:definitionLink 2122100 - Schedule - Schedule II Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2422401 - Schedule - Schedule II Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Share-Based Compensation - Expense by Types of Awards (Detail) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Share-Based Compensation - Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Share-Based Compensation - Summary of Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Share-Based Compensation - Summary of Status of Nonvested Restricted Stock Awards (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Shareholder Rights Plan link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Shareholder Rights Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Unaudited Quarterly Data link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Unaudited Quarterly Data (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Unaudited Quarterly Data (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 ctic-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 ctic-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 ctic-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Retirement Benefits [Abstract] Employee Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Leases [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Sublease Sublease [Member] Sublease [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Lease agreement area (square feet) Lease Agreement Area Lease agreement area. Lease term Lessee, Operating Lease, Term of Contract Number of options to extend the term Option To Extend Lease Years Option to extend lease years. Extend option term Lessee, Operating Lease, Renewal Term Initial annual rent payments per square foot Initial Lease Annual Rent Payments Per Square Foot Initial rent payments per square foot per annum for the remainder of the first 12 months. Rent payments due in initial five months Operating Leases Future Minimum Payment Due In Five Months Operating leases future minimum payment due in five months. Percentage of annual rent increase Percentage Increases In Monthly Rental Payment Percentage increases in monthly rental payment. Allowance for tenant improvements Tenant Improvements Allowance Allowance for tenant improvements from landlord to tenant. Sublease loss Sublease Income (Loss) Sublease Income (Loss) Deferred liability Deferred Revenue, Leases, Gross Other current liabilities Other Liabilities, Current Other liabilities Other Liabilities, Noncurrent Sublease income Operating Leases, Rent Expense, Sublease Rentals Rent expense, net facilities charges and sublease income Operating Leases, Rent Expense, Net Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Valuation and Qualifying Accounts [Abstract] Schedule II Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Payables and Accruals [Abstract] Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Document And Entity Information [Abstract] Document and entity information. Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Earnings Per Share [Abstract] Anti-dilutive securities excluded from computation of let loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Collaborations [Abstract] Collaborations. Collaboration, Licensing and Milestone Agreements Commitments Disclosure [Text Block] Segment Reporting [Abstract] Customer and Geographic Concentrations Segment Reporting Disclosure [Text Block] Equity [Abstract] Common Stock Common Stock Disclosure [Text Block] Disclosure including description and financial information related to an entity's common stock. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type Award Type [Axis] Equity Award Equity Award [Domain] Performance rights Performance Shares [Member] Restricted stock Restricted Stock [Member] Options Employee Stock Option [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation expense Share-based Compensation Subsequent Event [Table] Subsequent Event [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Leerink Partners LLC Leerink Partners LLC [Member] Leerink Partners LLC [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series N Preferred Stock Series N Preferred Stock [Member] Series N Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock par value (in USD per share) Common Stock, Par or Stated Value Per Share Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Series N preferred stock authorized (in shares) Preferred Stock, Shares Authorized Stock Issued (in shares) Stock Issued During Period, Shares, New Issues Shares issued in public offering (in USD per share) Shares Issued, Price Per Share Option to purchase additional shares (in shares) Shares Issued During Period, Shares, Additional Shares Issued Shares Issued During Period, Shares, Additional Shares Issued Proceeds from common stock offering, net of issuance costs Proceeds from Issuance of Common Stock Quarterly Financial Information Disclosure [Abstract] Schedule of Unaudited Quarterly Financial Information Quarterly Financial Information [Table Text Block] Unaudited Quarterly Data Quarterly Financial Information [Text Block] Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Accumulated Other Comprehensive Income Loss [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Net Unrealized Gain (Loss) and Impairment on Available-For-Sale Securities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance Unrealized Foreign Exchange Gain (Loss) On Intercompany Balance [Member] Unrealized Foreign Exchange Gain (Loss) On Intercompany Balance [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Changes in AOCI [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Current period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Ending Balance Other-than-temporary impairment on available-for-sale securities Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax AFS included in prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Equity incentive plans Equity Incentive Plans [Member] Equity incentive plans. Employee stock purchase plan Employee Stock Purchase Plan [Member] Employee stock purchase plan. Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Chief Executive Officer Chief Executive Officer [Member] Common stock purchase warrants Warrant [Member] Series N-3 convertible preferred stock Series N-3 Preferred Stock [Member] Series N-3 Preferred Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Total common stock reserved (in shares) Common Stock, Capital Shares Reserved for Future Issuance Operating Leases Future Minimum Payments Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating leases, 2018 Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating leases, 2019 Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, 2020 Operating Leases, Future Minimum Payments, Due in Three Years Operating leases, 2021 Operating Leases, Future Minimum Payments, Due in Four Years Operating leases, 2022 Operating Leases, Future Minimum Payments, Due in Five Years Operating leases, Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating leases, Total minimum lease commitments Operating Leases, Future Minimum Payments Due Sublease Rentals Future Payments Receivable Lessor, Operating Lease, Payments, Rolling Maturity [Abstract] Sublease rentals, 2018 Lessor, Operating Lease, Payments to be Received, Next Twelve Months Sublease rentals, 2019 Lessor, Operating Lease, Payments to be Received, Two Years Sublease rentals, 2020 Lessor, Operating Lease, Payments to be Received, Three Years Sublease rentals, 2021 Lessor, Operating Lease, Payments to be Received, Four Years Sublease rentals, 2022 Lessor, Operating Lease, Payments to be Received, Five Years Sublease rentals, Thereafter Lessor, Operating Lease, Payments to be Received, Thereafter Sublease rentals, Total minimum lease commitments Lessor, Operating Lease, Payments to be Received Operating leases, net, 2018 Operating Leases, Future Minimum Payments Due, Next Twelve Months, Net Operating Leases, Future Minimum Payments Due, Next Twelve Months, Net Operating leases, net, 2019 Operating Leases, Future Minimum Payments, Due In Two Years, Net Operating Leases, Future Minimum Payments, Due in Two Years, Net Operating leases, net, 2020 Operating Leases, Future Minimum Payments, Due In Three Years, Net Operating Leases, Future Minimum Payments, Due in Three Years, Net Operating leases, net, 2021 Operating Leases, Future Minimum Payments, Due In Four Years, Net Operating Leases, Future Minimum Payments, Due In Four Years, Net Operating leases, net, 2022 Operating Leases, Future Minimum Payments, Due In Five Years, Net Operating Leases, Future Minimum Payments, Due In Five Years, Net Operating leases, net, Thereafter Operating Leases, Future Minimum Payments, Due Thereafter, Net Operating Leases, Future Minimum Payments, Due Thereafter, Net Operating leases, net, Total minimum lease commitments Operating Leases, Future Minimum Payments Due, Net Operating Leases, Future Minimum Payments Due, Net Deferred tax assets: Components of Deferred Tax Assets [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Capitalized research and development Deferred Tax Assets Capitalized Research And Development Deferred tax assets capitalized research and development. Research and development tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Depreciation and amortization Deferred Tax Assets, Property, Plant and Equipment Other deferred tax assets Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Gross Less: valuation allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance, Total Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Deductions for tax in excess of financial statements Deferred Tax Liabilities, Prepaid Expenses Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax assets Deferred Tax Assets, Net Related Party Transactions [Abstract] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Common Stock Common Stock [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] License And Promissory Note License And Promissory Note [Member] License And Promissory Note [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt Convertible Debt [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Aequus Biopharma, Inc Aequus Biopharma Inc [Member] Aequus Biopharma, Inc Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Executive Vice President Executive Vice President [Member] Member of Board Director [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] License And Promissory Note Termination, And Note Cancellation Agreements License And Promissory Note Termination, And Note Cancellation Agreements [Member] License And Promissory Note Termination, And Note Cancellation Agreements [Member] Jack W. Singer, M.D. Jack W. Singer, M.D. [Member] Jack W. Singer, M.D. [Member] Frederick W. Telling, Ph.D. Frederick W. Telling, Ph.D. [Member] Frederick W. Telling, Ph.D. [Member] BVF Partners, L.P. BVF Partners, L.P. [Member] BVF Partners, L.P. [Member] Series N-2 Preferred Stock Series N Dash Two Preferred Stock [Member] Series N Dash Two Preferred Stock [Member] Series N-3 Preferred Stock Series O Preferred Stock Series O Preferred Stock [Member] Series O Preferred Stock [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Minimum Minimum [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Debt cancelled and terminated Extinguishment of Debt, Amount Amount funded to subsidiary Related Party Transaction, Amounts of Transaction Percent of milestone payments to be received Related Party Transaction, Percentage Of Milestone Payments To Be Received Related Party Transaction, Percentage Of Milestone Payments To Be Received Milestone payments to be received Related Party Transaction, Maximum Amount Of Milestone Payments To Be Received Related Party Transaction, Maximum Amount Of Milestone Payments To Be Received Percentage of royalty payable to net sales Related Party Transaction, Percentage Of Royalty Payable To Net Sales Related Party Transaction, Percentage of royalty payable to net sales. Period from first commercial sale Period From First Commercial Sale Period From First Commercial Sale Percentage of ownership in subsidiary Noncontrolling Interest, Ownership Percentage by Parent Number of shares converted (in shares) Conversion of Stock, Shares Converted Conversion of preferred stock to common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock owned by others, percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Right to elect members of the board Related Party, Agreement, Ability to Nominate Board Members, Maximum Related Party, Agreement, Ability to Nominate Board Members, Maximum EX-101.PRE 14 ctic-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 pipelinefinal.jpg begin 644 pipelinefinal.jpg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end GRAPHIC 16 stockperformancegraph2017.jpg begin 644 stockperformancegraph2017.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1$ 17AI9@ 34T *@ @ ! $[ ( M 2 (2H=I 0 ! (7)R= $ D 0U.H< < @, /@ M FMC M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z&UP;65T83X-"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@' M!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S M+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_ !$( >D"&@,!(@ " M$0$#$0'_Q ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " M 0,# @0#!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1 M\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? M 0 # 0$! 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$ M! ! G< 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ M /I&BBB@ HHHH **** *6KZO9Z%ICW^I/(ENCI&3%"\K,SN$151 68EF4 ' MK61_PGFD?\^?B#_PG-0_^,4>//\ D7;7_L-:5_Z<+>NDH YO_A/-(_Y\_$'_ M (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\ MQBC_ (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S M2/\ GS\0?^$YJ'_QBM?4]9TO1(8YM9U*TT^*6011O=SK$KN>0H+$9/!X]JSK MSQUX1T^Z>VO_ !3HMK<)C=%-J,2,N1D9!;(R"#^- $/_ GFD?\ /GX@_P#" M(-+O(;--]S);WL3Z&@" ME_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)5=;^S?4'L M$NH&O(XQ*]N) 9%0D@,5Z@$@C/M0!A_\)YI'_/GX@_\ ":1 M_P ^?B#_ ,)S4/\ XQ7244 T>35I=+CU6Q?48<>;9K:1_SY M^(/_ G-0_\ C%'_ GFD?\ /GX@_P#":1_P ^?B#_ ,)S4/\ XQ7244 ?\B[:_P#8:TK_ -.%O724 9VKPZU, MD0T*_L+)@3YAO;%[D,.V LL>/UK U73?B#+I%U'8>(M"%RT3"(QZ/+$V['&' M:Y<*?]^S7"Z+8M)Q;:W;/>2/-D^9(H69"H)[EB M&.6 YW-W"V/C8,-_B#0"N>0-"F!(^OVNNCHJI2YI7)BN56.-UM_[)^(4.LZG M87EYILFEFSADM+*2[-O*9"S@I&K. Z[/FQC]W@D9&:DMIIEKK7AFRM/#]U:V M$D5SYMN--=XHT>,(JRE%9%R !M8\# P.E=[14E'%>$[S;\/-1DDL]1A,=UJ# MF&;3YXY6#SR2(5C9 [95U(V@\DCJ"!PFGS:_IVD076F?\))=7-CX=$!FN]$> M.6RGWP;8(4\A?.5MK!B4(_%T"ZG>6=[JMB;>64R03Z M0&MHK<./(DBS NX 0J,4I-8\2V^OMJ$4OB&>.VB403R>'9/.O M8?M"9255@ 3@R\*B.55&!'5O7=2TNPUBQ>RU>QMK^U<@M!=0K*C$'(RK @X/ M-65544*@"JHP !@ 4 >/V7B;Q9J%T;?[1XJL;>>_MA!-<:%NF2%_,$H?_1!& MFW"'^( X)=@2*=?:[XPBOK^*'5?$7E"2^CA*>&RQ41A7A*M]GVDLVY=Q!4ID M ;\25Z_10!YWX/\ $^N:OXXGCO+;78=*FMG:--2TQH%BF5UX4^0FU""VW=([ M$#G:1@U=)\W3_!\6CMX:O+SQ5I9GN(6EL7$$EW\["<7) C(^)]-M5UGQ*-(N&8FXN]"2&7(C#-')FV"HH8 !L#.]P"2 PN M> ?$.M7MTK:K?ZGJ5N\9BEDGT@PQQ3B4K'Y;)$H=616+OED# 8*!@M>BLJNI M5P&5A@@C((JMINEV&CV*66D6-M86J$E8+6%8D4DY.%4 #)YH M4444 %%%% M!7-_#C_DEGA3_L"V?_HA*Z2N;^''_)+/"G_8%L__ $0E '24444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?\B[:_P#8:TK_ -.%O724 %%9VKZY::(L37D5_()20OV+3I[H MC'J(D;;U[XS7(^+OB9'IGAJ6XT*TU 7YF@AB;4M!O8H%\R9$)9F1!P&) +#) MP.^*4FHJ['%.3LCOZ*\O\'_$^_NM4U*R\50^<;>&":"31=%NY?OM*&#A/-Q_ MJQ@DC.3UQ76KXZTEV"BTU_).!GP[?@?F8:BG4C5@IP=TRZE.5*;A-6:.CHKD M=>_M"P\707^F274\/V.1K[3UE=A-&K(-T29PDJ[MPV@;P"IY*LN%%XU7PSI6 ME1:3"==MK]BZ,VIW%S?$BYA\8GPW:: M7975U<2M%8S+?R"%W3)=99#!A&"JV0GF$, IP2#0!WU%<3KFJ7?B+P'IMWII M^R3ZA.FRS:_DM3<8W,81<1C=&Q"9!'4C;T:L6S\/+FR\40:E'93-8P_;;."**\D8W4LRV_ER++Y>&5[<.J/P M8V*C<612%9@*/&4UQ?Z+XPN?MU[9KHL/E6XM+N2WVD0QSM,6C*D_?"\G "-Z MMD ] HKGX+6T7QE ;:\NY&@TT9B.H3/'M+;4=HRY4L3BN>\$7-XG MB(0ZC?W5R;ZVN+NVF%XUQ;7J"6+,JJV&MW7S%4P[=@S\A^_0!Z#16#HUS-%X MGUG1Y)I9X;=8;N%Y6W,@F,F8\]2 8R1G. X'0 5O4 %%/\ L"V? M_HA*Z2N;^''_ "2SPI_V!;/_ -$)0!TE%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% '-^//^1=M?\ L-:5_P"G"WKI*YOQY_R+ MMK_V&M*_].%O724 %5M0TZRU:QDLM5L[>]M)<>9;W,2R1O@@C*L"#R ?PJS1 M0!G:1X=T3P^LHT'1[#3!-@RBRM4A\S&<;MH&<9/7U-:-%% %-M(TUM875FT^ MU.HK%Y*WA@7S@G78'QNV\GC..:IZAX0\-:O(DFJ^'M*OG1/+5KFRCD*KDMM! M93@9)./4DUL44 8;^"/"DEK!;2>&-&>WM@X@B;3XBL0?[^T;<#=WQU[TR\\! M^$K^:>:[\,:-+<7#,\D\FG0N[,W)8EE.3GG)S6_10!A:3X0TS3?"=MX=N4&J MV%LA1%U"&)\J<\%514P 2OW>E67\,: \,,+Z'IK100-;1(;2,K'"PPT:C'"$ M<%1P:U** ,=_"'AJ2.RC?P]I3)IY)LU-E&1;<[OW8V_)R,\8YI^G>%?#VD3B M?2="TRQE6(PB2VLXXV$9;<4RH'RD\XZ9YK5HH YU?AYX*175/"&@J'&U@-,A M&X9!P?EYY /X5:F\(^&[F]FO+CP]I4MU.I66>2RC9Y 4*$,Q7)!0E>>Q(Z5L M44 8@\%>%5LWM%\,Z.+9T$;0BPBV,H8N%*[<$!B6QZDGK5X:3;KJCWT>Y&E@ M\B:)2/+F4'Y2RD=1E@",<-@YP,7:* ,NS\,:!IVGRV&GZ'IMK9SL'EMH+2-( MY&&,%E P3P.3Z"B/PQH$+W+Q:'IJ-=A1<%;2,&8+]T/Q\V,#&>E:E% %.PTR M'3WN9$>26:ZE,LTLIRS'H!Q@!5 [9Y))-RBB@ KF_AQ_R2SPI_P!@6S_] M$)725S?PX_Y)9X4_[ MG_P"B$H Z2BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HJ"]O;?3K">\O9/*MX$,DCX)PH&3P.3]!R:Q(/'.AS>'8]:\R[ M2V=MAC-E,9T;;N(:)5+CY?FSC&TALX(- '145EP^)-*N-<.DP77F787<=L3F M/.T/L\S&POL97V;MVTAL8YIVB^(=,\00RRZ3<-,D9 ):)X]RD95UW ;T8NDKF_'G_(NVO_8:TK_TX6]= M)0 4$@ D\ =36=J_A[1=?6)=>TBPU-823$+VV28(3UQN!QG Z>EQ+Q-(A9HLGD@#:(+[1O M%5M;W0MVTBZA.9UB8/9R!E56D.[#1LS!> I4D$Y4EEAMO&$>D:=!_P )?=C[ M1*[C[3::7<); !V4 OF158[>C."YT)+S7!J%S>7$D)M'M'T]TB:WD M5CEBP*;R3@#&[&!TZYYO5/A9IFJ?V>#J^JP1Z;&JVT>Z&<(RN7W_ +Z)SO.= MK'/S* &S3 F\1>/K.QTFVETJ<_:KB6+;'=:?/A4,RQL).%\DDDJID(RP*@,0 M16E=^.-#L;Z>SNY+V.ZA.!"=-N2\_P VW]R!'F;!//E[L#D\M:M9HR+'-]F6VC$JI*TL8V"'8@1W8@(J@[CNW9--O?A3:3^*&\26^OZS#J MR32302JUL?++@C9N:!F* ,RJ&W;5) H O^*_%[ABDO- M1@9X5BD<(7_UD>,$YR3C ]\UD:#\27EU2WA\07%D+:ZC9;:>RMI66X9;DPB8 M$,V(7&PAC\J[A\[ @G2TWP9?S^ ]&T;6=3FL+S3I4F:73)(Y1(T;[D),L..N M&("#GCD=;GB'P1'XAU&2[DUO4[(R6Z6YBM1!M 602!AOB8YW =\8[4 ++\0? M#\"OY\FH1NDR0&)])NA)O<,4 0Q[B&VL 0,$C )/%12_$WPI!-/%+?W"RVYD M62/^S[@N&CQO4+Y>2R@ARHR=GSXV M6=IOPIL]+O!
(M;DE-Q#3"!'^^ ZDQ[@!R>.:)?'WAR(Q_ MZ=)*DEN+B.2"TFE1U,1F #JA4N8P7\L'?MYQCFN?M_@_96VLP:O%XGU_^TK< ML8KQC:&1<@C!)@^90I90K9"AB !QC3D^&VDS^(AK=U<37%Z\ BN)9;6U+SGR MO*WF3R=Z$KCB-D7C[O)R .NOB3HD.KP:? +Z=Y S221Z;_-S>3VRRAK>QF$5Y6 /(Q]W;VZJ#W;-JQ\ +IEJ]MI_B36[>":V$$R M1O #(5A$*R[O*W(X14P4*C**2#SD ETKQ+DLM.;=8&RE>1)[.6WN(IXY M(P0PDVD K*#@H#WR0:S8?B!'H^LZW;>+K^!(K>]:"P2STRX+NB0QS/N*M(&8 M+*. %.$9L8SML^%OAO8^$]8.H6&K:C,6216MYDMEB)?9N;$<*G),:GKUR>YJ M.[^&D5WJ5]>/XEUM#>R3221(+78IEB$38S!GA%4#)/W03DDD@$_B#QS9Z7K. MEV=M>P!99U%X\MO(8TB:-WXF!$:OA0VTDML^;;CFG0_$WPQ<7S644^H&[7@V M[:/=K)GY3C88LYQ(C$8X5@QX.:K7GPPT^_41W.L:LULQC>YM@T(2ZD2$0%WQ M%G+1 (0I48Y # $5[+X2Z;IT*K8ZQJ-K)%(LUO+:6]E;FWD!&7416ZJ691L8 ML&RA9>C$$ [VN;^''_)+/"G_ &!;/_T0E=(!A0"<^Y[US?PX_P"26>%/^P+9 M_P#HA* .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZW:I>Z%>V MTM@FI1S0LCV;L%$ZD2WNKV+:.WBMW5UFNHHF8^;$Y MW!9#C! SC(-3_P#"+ZO_ -#WX@_[\:?_ /(M'CS_ )%VU_[#6E?^G"WKI* . M$\2^%=>_LJ&:V\0ZYKKVVH65T=.E2PC$ZQ744C#<(8^0J$CYUR0 3CBM?_A* M-7_Z$3Q!_P!_]/\ _DJNDHH YO\ X2C5_P#H1/$'_?\ T_\ ^2J/^$HU?_H1 M/$'_ '_T_P#^2JZ2B@#F_P#A*-7_ .A$\0?]_P#3_P#Y*H_X2C5_^A$\0?\ M?_3_ /Y*KI** .;_ .$HU?\ Z$3Q!_W_ -/_ /DJC_A*-7_Z$3Q!_P!_]/\ M_DJNDHH YO\ X2C5_P#H1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JZ2 MB@#F_P#A*-7_ .A$\0?]_P#3_P#Y*H_X2C5_^A$\0?\ ?_3_ /Y*KI** .;_ M .$HU?\ Z$3Q!_W_ -/_ /DJC_A*-7_Z$3Q!_P!_]/\ _DJNDHH YO\ X2C5 M_P#H1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JZ2B@#F_P#A*-7_ .A$ M\0?]_P#3_P#Y*H_X2C5_^A$\0?\ ?_3_ /Y*KI** .;_ .$HU?\ Z$3Q!_W_ M -/_ /DJC_A*-7_Z$3Q!_P!_]/\ _DJNDHH YO\ X2C5_P#H1/$'_?\ T_\ M^2J/^$HU?_H1/$'_ '_T_P#^2JZ2B@#F_P#A*-7_ .A$\0?]_P#3_P#Y*K(\ M*>"]>T_P9HME=^+]G4]:[NB@#F_^ M$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_ M$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ M )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$ M7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'O MQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ M .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@ M#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U? M_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_? MC3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H M_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ M *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_W MXT__ .1:Z2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1: MZ2B@#F_^$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^ M$7U?_H>_$'_?C3__ )%H_P"$7U?_ *'OQ!_WXT__ .1:Z2B@#F_^$7U?_H>_ M$'_?C3__ )%K-URRUOP]:6=_%XPUB\_XF=C;O;W,%EY@#I**** "BBB@ HHHH **** .;\>?\B[:_ M]AK2O_3A;UTE'9-!@UL:YIZZ7<-LBO)+E$B=LD;0Q(&<@C'7@U-XBM;>]\-ZA;7L-S M/;RP,DJ6F?-*D<[,<[AU&.?3)XKSOP]J\EO\.&_M31[N^:YE-I:W4>AS-)-$ MT**99HD0L HRA.%WB(;0 10!Z5)K&F1:Q%I,NHVB:E-'YL=DTZB9TY^8)G<1 M\IYQC@^E.L-4L-469M,OK:\6WF:"8V\RR".1<;D;!.&&1D'D9KD--M@=8CC\ M.RZY:EK(1WD>H03I!M$"K$ZEUV"4$("(SSE]XR!A_@&"?[0\ZZ?;>YMVA*SP^;Y@4,!N51)&H=//^1=M?\ L-:5_P"G"WKI*XOX MES:Q'HUDNF6%C<0'5=-+O<7KPL)!?0;%"B)P5)P"V00"2 V,'0^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y M#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y M#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y M#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y M#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y M#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/ M_P#@^G_^0Z .DHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z . MDHKF_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DHKF_MWC?_H7 MO#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0Z .DKF_'G_(NVO_ &&M*_\ 3A;T M?;O&_P#T+WA__P 'T_\ \AUA^++OQ5+I=BFJZ-H]M:'6M+\R6VU>6:1?]/@Q MA&MD!YP/O# YYZ$ ] HHHH **** "BBB@ HHHH YOQY_R+MK_P!AK2O_ $X6 M]=)7-^//^1=M?^PUI7_IPMZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ MY_R+MK_V&M*_].%O725S?CS_ )%VU_[#6E?^G"WH Z2BBB@ HHHH **** "B MBB@#F_'G_(NVO_8:TK_TX6]=)7-^//\ D7;7_L-:5_Z<+>NDH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "N;\>?\B[:_\ 8:TK_P!.%O725S?CS_D7;7_L-:5_ MZ<+>@#I**** "BBB@ HHID4L<\*RP2+)&XRKHV0P]010 ^BBB@#F_'G_ "+M MK_V&M*_].%O725S?CS_D7;7_ +#6E?\ IPMZZ2@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *YOQY_R+MK_ -AK2O\ TX6]=)7S;\0?$J7_ (\UZ"WU;4-2C@O8 M6M[+3]6E5(TBMX96D"1N%^1U=LXSO7&&[J]EDGN9])M9)I96+,[F%2S$GDDDDDUOUL8A1110!E>*+>"[\ M)ZI;WEV]E;S6LB2W,:[C"I7!;&""!U.1C&<\5Y7HNH^#F^$OV7Q'!HD=JMR; M6TQF21R>*K9M*NH[[Q$;EO,NG_ -=+IWV#]V_//D-+Y)X^7S2?XMU:_P ,FLFF MN?[!V'3O[.LCI75GHUE%;Z+? M7Z-JNFN9K=X JLM] 0A\R16W,0 , C)&2!DC0_X2C5_^A$\0?]_]/_\ DJCQ MY_R+MK_V&M*_].%O724 (/^_P#I_P#\E4?\)1J__0B>(/\ MO_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ M)5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 M(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 (/^_P#I M_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5' M_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_] M")X@_P"_^G__ "57244 (/^_P#I_P#\E4?\)1J__0B>(/\ MO_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ M)5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 M(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 (/^_P#I M_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5' M_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_] M")X@_P"_^G__ "57244 (/^_P#I_P#\E4?\)1J__0B>(/\ MO_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ M)5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 M(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 (/^_P#I M_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5' M_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_] M")X@_P"_^G__ "55OQ!XMT'PM"CZ]J<%HTG^JA)W2RG.,)&N6^*[Y#D&^;9;QG&#L@7Y5![@Y%=Q;6L%E;);V<$=O!&,)%$@ M55'H .!0!XK/I7Q$\4W#_P#";Z3K266[_CQTN2P\IQ]'N<$'NL@E]B*35O"@ MTRZT^_TC1/%7AZ9I[33'NI[C3KB,1374:/D-)*X.'PH0;00ORXS7N%&_#UGH]M<7%S#9Q^7')0CJ-J%3CK0!LP>)=&N?$5QH5OJ,$FJ6\8DEM@WS*/ MY$C(R!R-RYQD9U*^=F\'>)=$OXHKJPNX5TJ=+JYUNQ!D.PM\TT63N=R"VY3D M@;LA@0'^A+:Y@O;2*ZM)DG@F0/'+&VY74C(((Z@BM*D8Q:Y7&X@^MZE!:E@2D3'=)(! MUVH,LWX T :U(S!%+,0J@9))Z5YP/B)XA\59C^'?AEY8&X75M6/E6W3AE4?$S1?MSZ= MXNZ5R7/TSBMVBB@ HHHH *YOQY_R+MK_V&M*_].%O M725S?CS_ )%VU_[#6E?^G"WH Z2BBB@ HHHH **** "BBB@#F_'G_(NVO_8: MTK_TX6]=)7-^//\ D7;7_L-:5_Z<+>NDH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBFR2)#$TDSK'&@W,[' 4>I- #J*YEO&D-^QB\*6-QKSYQY] MOA+53[SM\I_X!O/M2?V%KNL\^(]:-I >MAHS-"N/1IS^\;ZIY?TH OZMXKTC M1[D6ESX<>HC0%L>Y [D50^T>+-;_P"/6V@\.6C?\M;O;<7; M#VC4^6A]RS^ZUL:3HFF:%;[&"SC8[G\I "[?WF/5C[G)J_0!@6'@S2K6\ M2_O1-J^HQ\K>ZE)YSH?5!]R/_@"J*WZ*P=0\9Z+87CV*7+7^H+UL=/C:XF7_ M 'E0'9]6P/>@#>KC[F&3P)=RZA8QM)X;G=I;ZV0$G3V/+3QK_P \R+NM O^KE98RQW.P<$#/#Q\X7-> ME&S\;3_?UC0K13U6/3)9F_[Z,ZC_ ,=I)I[ =%#-%P(-CXW]:Z..-( MD"1(J*.BJ, 4Z@#FO^$MO9?^/+P?K]QZ%DMX1_Y%E4_I1_;'BR;_ (]O"EO% MZ?;=66/\_+CDKI:* .:SXXG_ (?#]C_P*>ZQ^D>:AO--\:?8+B5?$5I).D;- M'!8Z6L)D8#(4-+*X&3QD\5U=% 'C7A#POXTM-?@>2/6]$-_"[ZU?[]/D$]SD MNL@7=*>K.F HXV@_P#".:Z/N^-M3/\ OV=H?Y0BNDHI)65@.;_L'Q&/ MN^,;@XZ;]/@/YX4?TH_L7Q2/N^+4)_V]+C(_1A7244P.;_LGQ'W_[@DZX_P#)HT?9 M_&XX_M/P^WO_ &=.OZ>>:Z2L&]\<>&K"X-M)J]O-=#K:VF;F;_OW&&;]* (= MGC@<^=X?;V\F=<_CN-&[QPO_ "S\/O\ ]M)UQ^AIO_"4:M>\:)X3U"5>T^HN MEE&?P;,H_P"_=)]A\9ZA_P ?>L:;I$9ZQZ?:FXD'TEE(7_R%0 _SO&X_YE*2NK#3LSRCP;>>-O%SZIH>G>-8+W3]-N%1=3CD MC:1H60% SQ_-(W# X:-L@G>@#I**** "BBB@ HJAK@U(Z!?#0O+_M+R'^R^80%\S'R\D$#GU!'J#7 M":5KVHR_"=[R#6[]M1L9HUE>[MXEN$.4)CDRI1P0^0Z@95EP2?F(!Z517*W] M_J]AXS\R\-RFDM XLX[:2)HIY$C+L)5:+S$<_-M*R%2(^0I^\SP;JFI7%Y+8 MZM?G4)'TVSU/SO*1!$9_-#1*% _=@PY7=N;YCEFQ0!9\>?\ (NVO_8:TK_TX M6]=)7%_$O6K73M&LH+B*^=WU7390;?3YYUVI?0,06C0J&P#A2:1_SY^(/_ M G-0_\ C% '245S?_">:1_SY^(/_":1_SY^(/_ G-0_\ C% '245S?_">:1_SY^(/_"%S(,2W-#TE=+MVZ7NL AB/5;=3N/\ P-HS[4Z/P59W,J7'B6YN M/$%PI#*+XCR$/JL"@1C'8D%O]JC_ (3S2/\ GS\0?^$YJ'_QBJFH?%#PQI%K M]IU5M7L8,X\VYT&^C7/IEH0* .N50BA5 50, =*6N!U#XJ1@QKX?\->(-2$ MR[DNWT>[BM@/=A"S_DAJE_;DVJ\^(=5\20Q'K9Z-X:U&V7'HTQA,I^JE/I0! MV^K^)=&T)D35=0A@FD_U5N"7FE_W(UR[?@#69_;GB'5N-!T V<)Z7FM/Y7XK M N7/T?RZS](UKPCH*O\ V1H>LVSR?ZR5?#.H&24^KN8-S'W)-:?_ GFD?\ M/GX@_P#":H#UM83]DM?IY<9W,/9W<5O:?IMCI M-FMII=G;V5LGW8;>(1H/P'%8G_">:1_SY^(/_"/6@#TBBO#M$\=>([#Q=HRZSK^I:EI M]S<217%LFFQ2LP^SRNI5;>#S"0R+T[9SQ7I)^(&E!B!IOB,^X\.7W/\ Y!KG MP^(AB(>TI['1B,//#S]G4W.G8!E*L 01@@]ZXX$_#V<*>?")G1P596\.7A M# ]01Y==!SG7@@@$'(/0BBO)=/\ B#;>#+B6UET?Q,?#(&ZWFN-%N4.GG.!$ M2RC=$2?D[K]WD8QTS_$VR5#/&K^RZ!+_6F?\+:A_Z$ M?QQ_X(9/\: /0**\[/Q?0'_D0/'A]_[";_XJN<\=_%:6]\(S6MKX:\::"TMQ M;*^I75@]G%;Q^?'O+3!P4!7J92Y4V5%L6D>#KX,!Z>9-#)GZA%K.A65>FJB35^^YI7HNC4=-M.W;8]*)"J2Q &23V MKG[KQYX:MKAK>/58[VY7AK;3T:[E!]"D09A^(KEA'X)F8/J^G>*-;?.Q'(/H1R.HK!@\!:#!X8?0?+O'LY9%E MF8WTPFF57#G 11C.,*HQ@ 5TE% &=;:%96NJR:BANI+ATV?O[V:5$& M/D1V*H3@9*@$]\TW1/#NF>'8)(=(MVACD(R'F>3:JC"HN\G:BCA47"KDX R: MTZ* .;\>?\B[:_\ 8:TK_P!.%O725S?CS_D7;7_L-:5_Z<+>NDH **** "BB MB@ HHHH ***RM:\2:;H7EI>2L]U/G[/9VZ&6><_[$:\D>IZ#N10!JU@:GXMM MK:_?3-(MY=8U9?O6EJ1B'/0RR'Y8Q]3N/9353[!X@\3?-K$SZ#IK?\N%G+FZ ME'I+.O"?[L?/^WVK?TW2['1K%+/2K2&TMTY$<2!1D]2?4GN3R: /(]5^&/BR M76I[V"73IFUJX,MW\S%=/8@#.6.Z9<# &%YP OW?4_#6@6OA;PW9:+8-(\% MG'L5I3EFY))]!R3P.!T& *\^UGXW06NL7]MI.AWMW;:%-*-8E;R\K%&[1$Q M/DMN4MA]N51O4&N@U+Q%K A\W4;S1O!UFPR)=2N4FN"/]T,(T/OND'M5NM*< M5%NZ1*IQC)M+5G92S1V\+RSR+%&@RSNP 4>I)Z5SK>.+&\8Q^&K2[\029QOL M$'D ^\[E8_P#$^UZ4+IGA);-,85M5U".+ _P!V$2_ED?A4%"_8?%FK\W^I6V@VY_Y8::OGSX]Y MI%VCZ"/Z-WJWIO@_1=,O!>I:&ZOQ_P OU[(UQ./I(Y)4>RX'M50Z9XPO?^/O MQ#8ZQLM/E:,_P#;5@(_ M_'JT=+\+:!HC[](T6PLY#R9(+9%=CZE@,D_6M6@#FO[8\5WG_(/\+Q6:G^/5 MM11"/^ 0B7/TW"D&E>+KS_C^\26E@I_@TO3AO7_@6"QT'3;>*9&25([1 )%88 M8-Q\P()SGK6O10!B:=X+\+:/?)>Z3X:TBQNX\A)[:PBCD7(P<,J@C()%;=%% M !1110!'<00W5M);W4230RJ4DCD4,KJ1@@@]017)VD\O@>]ATS4)7E\/7#K% MI]VY+-9,>%@E8_P$X".?]T_PD]A4-W:6]_9S6E["D]O.ACEBD7^Z?FP6ZZ@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *YOQY_P B[:_]AK2O_3A;UTE@#I**** "BB MB@ HHHH **** .;\>?\ (NVO_8:TK_TX6]=)7-^//^1=M?\ L-:5_P"G"WKI M* "BBB@ HHI'=8XV>1@B*"69C@ #N30 M5-2U2QT:Q>\U6[BM+=.#)*P49/0 M#U)[ 1YPVK7.5LT_P!S'S3G_19NI1ZQ M0MPG^])S_L=ZTM+T'2?#4,]S$,2R#==7]W+OFEQW>1N<#TZ#L *Y"\^)]UJE MV]AX-TB>ZF4[6EFA+LA_ZX@C9])GA_&HX? ?B+Q%,ESXNU(1@-N6-]ES(A[% M4*BWC(]?+D8[T$S?ZSZ1+(?:L7_BJ M_%WWH[E[1^SE]-L\?3FYF_'RT;/2NSTKPCHVD77VR&U-Q?XP;Z\D:>)?\ #/M\@OA9^+8]/2_>1Y8[&RN(4&]F.T*MT%PNX@ J>,9S MSGU/1_!OAO0%C&CZ'8VKQJ%$J0*9#@8!+GYF/N236U14QBHMM=2G)O<****H MD**** "BBB@ HHHH **** "BBB@ HHHH **** *]_86NJ:?/8ZC;QW-K<(4E MBD&5=3V-01R" 10!:HKEM*U.[T#5(?#WB.=IUF. MW2]3D/-T ,^5(>@F '7^,#(Y# =30 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 5S?CS_ )%VU_[#6E?^G"WKI*YO MQY_R+MK_ -AK2O\ TX6] '24444 %%%% !1110 4444 ?\B[:_P#8:TK_ -.%O724 %%9&N>*-,\/[4O96DNI%+0V=NOF M32@=2$'11W8X4=R*\TO_ (@77BFZDL=-AO=3P<'2?#TF?H+F_&$C!_NQ'@]7 M(- 'H6H^+(8[Z33=#M9-:U2,XDM[=@([<_\ 3:4_+'].6(Z*:Y'Q%K&@Z9+Y MGQ)UV'4KI64QZ#8@F"-B?E#1]7.>C2D*3T5326/@GQAK%C'::KJEMX1T900N MD^'5Q)M/]^:ZSPWX \,^%,/HVE0I<#.;J7]Y,2>3\[9(R><# ] MJ .4&O?$#Q@H3PWHP\,Z:P 6[O\ "S%?]E2IVD>FQE/&'%7]*^$VG1W)O?$M M_=:Y?2#$C2NR(P[J?F+LO^P[LOH!7?T4 0V=E:Z?:):V%M#:V\8PD,$81%'H M .!4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 4]5TJSUO3);#48O-@E'(S@J0GJCK.C66O:9)8ZC&7B8AE9&VO$X M.5=&'*L#R".AH O45S6B:S>6>I+X=\32*VH[2UG>A=J:A$O5@.BRJ/O)_P " M'!XZ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "N;\>?\B[:_]AK2O_3A;UTEU+4KB6TU MM;47+65MJ,8M$95CBGW@1$LQW,IB;+_*&!'RKS5B/PE9KX@.J2W5U/ES-]DE M*&$3F(0F8 +N#&/*D;MGS,=N234GAWPQ;>'%D\BZNKQWCC@66[96>."($10@ MJHRJ[G(+98EB2QH \E^)_P 0/$<7B+4=#T^.P:VT[4;26*/[')+,_DI!>LY( ME4;01@@+D@8!R0:@C^-FL>,=*M;;0KO0/"TK6Z?;=2UK48H2LI0%Q# 69MN3 M\K,""/0\UU_C_P #6\.K?\);H^I7NF:K>7=E87!B$4L&;+P?X:M=$TMI'MK;=M>4('8LQ8D[%4=3V K.$9IOF=^QX\6_$32_$=S,XDF2?5XHX)&!R"R"0F0CH/,9^.F*]#L_ M'7P]TZTCM=/\4^&;6WC&$A@U"W1$'H%#8%=716A!S?\ PL?P1_T.7A__ ,&D M'_Q5'_"Q_!'_ $.7A_\ \&D'_P 57244 '_\ P:0?_%4?\+'\$?\ M0Y>'_P#P:0?_ !5=)10!S?\ PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ M\&D'_P 57244 '_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5=)10! MS?\ PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 57244 M'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5=)10!S?\ PL?P1_T.7A__ ,&D M'_Q5'_"Q_!'_ $.7A_\ \&D'_P 57244 '_\ P:0?_%4?\+'\$?\ M0Y>'_P#P:0?_ !5=)10!S?\ PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ M\&D'_P 57244 '_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5=)10! MQ6N>+/A[K^F-9WOC+0EPPDBFBU:%9()!]V1&W?*P/?\ Y!(JIX>^*OAPR3Z M7X@\4Z%]LM -M]'?PB"\C/20'=A7X^9,Y!Y&5(->@5S/Q"M_,\%WMW#8W%W? M6*?:++[(=LT4PZ.AP>F22 #E=PPV=I '?\+'\$?]#EX?_P#!I!_\51_PL?P1 M_P!#EX?_ /!I!_\ %5YGX(\?:W'XOTZUO]4.NIKTF&BRJ^2=N3+".BQ@#E?3 M!!W9#>X5I4IRI2Y9$0FIJ\3F_P#A8_@C_H^NY=:TOR[>VOXI)'Q?P$X56 M). "?H*] KF_'G_(NVO_ &&M*_\ 3A;T =)1110 4444 %%%% !1110!S?CS M_D7;7_L-:5_Z<+>NDKF_'G_(NVO_ &&M*_\ 3A;UTE !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 <^? GAC;J 71K9#J,@FN'0%6+@Y#*P.4()+ KC#$MU)-4Q MJ>H^#V$7B*5[_10<1ZN5_>6P["Y [?\ 34#']X+]X]900&!!&0>"#WH :DB2 MQK)$RNC ,K*<@@]"#3JY1]&O_"DC7/A2+[3II):;1"P79ZM;,>$/_3,_(>Q0 MYSN:/K5CKMC]JTV;S$#%)$92DD3CJCH>58=P1F@"_1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !7-^//\ D7;7_L-:5_Z<+>NDKF_'G_(N MVO\ V&M*_P#3A;T =)1110 4444 %%%% !1110!S?CS_ )%VU_[#6E?^G"WK MI*YOQY_R+MK_ -AK2O\ TX6]=)0 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 5@ZQX;-S??VOH=R--UE5"^>$W1W"CHDR<;U]#PR]B.0=ZB@##T;Q(+V\ M;2M6MO[,UF-=S6CON691UDA?CS$_(C(# 5N5GZSH=CKUF+?4(V)C;S(9HV*2 MP..CHXY5AZCZ="16+%K=]X9F2S\72":S=@EOK:J%0D\!;A1Q&_;>/D8_W20I M .JHHZ]** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'G_(NVO\ MV&M*_P#3A;UTE@!&.IYQM8 ZBBN8U3QA_9NNVEA):1P MI):M=3O=RO$RA5+-'$5C:.60*I8IYBD*-PR,D6_#NOSZO)<6^HV*6%Y#'%/Y M*3^=^YE#>6Q.U<-E'!7D KP2,&@"OX\_Y%VU_P"PUI7_ *<+>NDKF_'G_(NV MO_8:TK_TX6]=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EB MCGA>&>-9(I%*NCKE6!X((/44^B@#D_L&I>#?GT2*;4]#'+Z8#NFM!ZVY/WD' M_/(\C^ ]$/0Z9JEEK.GQWNEW*7-O)G#IV(X((Z@@\$'D'@U;KG=3\.31ZA)K M'AB>.QU1\&>-P?L]]CH)5'1L<"0?,.,[@-M '145C:)XC@U::6RN()-/U6W4 M&XL)R-Z#IO4CAT)Z.O'8X.0-F@ HHHH **** "BBB@ HHHH **** "BBB@ K MF_'G_(NVO_8:TK_TX6]=)7-^//\ D7;7_L-:5_Z<+>@#I**** "BBB@ KG?& MWAZ_\2Z$-/T^\LX%>6,W$5_9_:89HPZL05#*<_+QS@C((Y#+T5% '-2>%)[F MWL],O+^*XT6TMUB$,ENQN9'6,IN:'[C1WN+C4K]-0O9 MHXH#.D'DCRH@0@*[FRV7^@5T!()"L"01T()!K0_X5QX(_Z$WP__ ."N#_XFCQY_R+MK_P!A MK2O_ $X6]=)0!S?_ KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$UT ME% '-_\ "N/!'_0F^'__ 5P?_$T?\*X\$?]";X?_P#!7!_\37244 %-(O(M+\8># M/#<;RL([75(])A6WNR>BL-O[J4_W2<-_"3]T>EU#>6=MJ%G+:7T$=S;3*4DB ME0,KJ>H(/6@#!_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)JM MMU/P7_JQ.!TUC?6NIV,-[I]Q'^#6@U#PH\NF+JT[1:A,J!K:-BO$FP_H5#>6=MJ%E-9WT$=Q;3H8Y8I%W*ZG@@CTJHM)IM7%)-JR/+? M'C_4(5NM*UBWU36;:R V:E;6LERZ9_Y92[ 2S@8((R2"-W."W9_\+"\,)_Q] MZBUAZ_VC;2VF/KYJKBMC1]&T_0-+BT[1[5+6TA!V1ID]3DDD\DD\DG))ZU=I MSDI2;BK(44U%)NYFV'B30]5Q_9FLZ?>9Z?9[I),_D36E6;?^'-$U3/\ :>C: M?>9Z_:+5),_F#6;_ ,*^\,)_QZ::;#T_L^YEM,?3RF7%04=)17-_$%5(%SK=M8D]K_-J?RE"T ='7-^//\ D7;7 M_L-:5_Z<+>MBRU?3=37.FZA:W8ZY@F63^1KE/BAX@T[2-$L;>\E8W$FI65RD M$2%Y#%!=12ROM'. B'GU('4@4TFW9 W;<[>BH;.\MM0LH;RQGCN+:=!)%+&V MY74\@@]Q4U( HHHH **** "BBB@#F_'G_(NVO_8:TK_TX6]=)7-^//\ D7;7 M_L-:5_Z<+>NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *" 001D'J*** ,B]$>'-2 M;=J.@:7=-UW36<;G\R*\U\??#Q-#N4USPI! BWKIU)4Y%D\' M^&TTU;E[F1I&GGD/"F1SEMB]$7/0#ZG)))Z"BBI;;=V4E96"BBBD 4444 <\ M?%\)\;_\(Y#874K)$6GNTVF.%\(0I7._D2*=VW:,@9/S;;&B>)[77;B6*WM[ MF !!-!).JA;J$DJ)8\,3MR/X@IY!Q@@G#U;PUJ]]\4=)UNVAL[>ULX9(Y+^* M=TN'B)0_9Y(P,2*6#$$MA=Q(4,H+6O"GAK4-(NHCJ36QBTZP73+'[/(S-)"K M9#R J-K$*@V@L!@G<#X?%=K;J]U>6 M\L%U;2@PW\\*%(YTD8%8W4%BJ$*Q&5)!!! -'_"!Z1_S^>(/_"CU#_X_0!TE M%(/_"CU#_X_0!TE%(/_"CU#_X_0!TE%(/_"CU#_X_0!TE%(/ M_"CU#_X_0!TE%(/_"CU#_X_0!NW M%[;VLUM#<2K')=RF&!3UD<(SE1[[48_@:GKB]2^&FG7E_I,\-_K2I97;3RB3 M7KYV93!+'A"9LHVZ13N&#@,,X8@Z'_"!Z1_S^>(/_"CU#_X_0!TE%(/_"CU#_X_0!TE%(/_"CU#_X_0!TE%(/_"CU#_X_0!TE%(/_"CU#_X_ M0!TE%(/_"CU#_X_0!NI>V[ZA+8I M*IN88DFDB[JCEPK?0F-Q_P !-3UQZ@U_K1@GM+>!$&O7PD#1O, MS%G\[+*1(N%)P"&( W'.A_P@>D?\_GB#_P */4/_ (_0!TE%D?\_GB M#_PH]0_^/T?\('I'_/YX@_\ "CU#_P"/T =)17-_\('I'_/YX@_\*/4/_C]' M_"!Z1_S^>(/_ H]0_\ C] '245S?_"!Z1_S^>(/_"CU#_X_1_P@>D?\_GB# M_P */4/_ (_0!TE%D?\_GB#_PH]0_^/T?\('I'_/YX@_\ "CU#_P"/ MT =)17-_\('I'_/YX@_\*/4/_C]'_"!Z1_S^>(/_ H]0_\ C] &[;WMO=37 M,-O*LDEI*(9U'6-RBN%/OM=3^(J>N+TWX::=9W^K3S7^M,E[=K/$(]>OD95$ M$4>'(FR[;HV.XY."HSA0!H?\('I'_/YX@_\ "CU#_P"/T =)17-_\('I'_/Y MX@_\*/4/_C]'_"!Z1_S^>(/_ H]0_\ C] '245S?_"!Z1_S^>(/_"CU#_X_ M1_P@>D?\_GB#_P */4/_ (_0!TE%D?\_GB#_PH]0_^/T?\('I'_/YX M@_\ "CU#_P"/T =)17-_\('I'_/YX@_\*/4/_C]'_"!Z1_S^>(/_ H]0_\ MC] '245S?_"!Z1_S^>(/_"CU#_X_1_P@>D?\_GB#_P */4/_ (_0!NV5[;ZC MI]O?6,JSVUS$LT,J]'1AE6'L00:GKB] ^&FG:7X;TS3[N_UJ2>TM(H)7@UZ^ MBC9E0*2J+, JY'"@ < 5H?\('I'_/YX@_\ "CU#_P"/T =)17-_\('I'_/Y MX@_\*/4/_C]'_"!Z1_S^>(/_ H]0_\ C] '245S?_"!Z1_S^>(/_"CU#_X_ M1_P@>D?\_GB#_P */4/_ (_0!TE%D?\_GB#_PH]0_^/T?\('I'_/YX M@_\ "CU#_P"/T =)17-_\('I'_/YX@_\*/4/_C]'_"!Z1_S^>(/_ H]0_\ MC] '25S?CS_D7;7_ +#6E?\ IPMZ/^$#TC_G\\0?^%'J'_Q^J>H_#RQGBM38 MWNK":WOK2Z'VO6KRXC(BN(Y6!CDE922$(&0<$@]J .PHHHH **** "BBB@ I M&95&6( R!DGN>!0S*BEG8*!U).*XS6M=AO&OK/5]-@O=&M[@6^HQACYUGG!C MF9?XHSE6W#!3[PSM) !L&\UN'Q #=)9)I$DIA0883+B,L)"^[:02"NW (X.3 MR!KVMS!>V<-U:2K-!/&LD4B'*NK#((/H0:Y^/P_<:A8SZ+XFQJ.FPRHUO7&2!N;!VIG!8XS@?E7#+J">*Y--%]$L#72M+HVL6+$M! M,%)>%E891P%;*G(<*X(&"M &UINMZI#?Q6/B.P\N6XPT5U:1L;="5)\IF8YW MC!^;&T\="=M=%67IUM>W5O:7.OQ1QW]L77;;S,8F.<>9MZ9(&0#NV[B,GDUJ M4 %%%% !1110 4444 %%%% !36.[NR!8 MK2,W(BC+ -(P'.U1EC[*:YC_ $W4=5N+JVM8K#Q/90AXY(W+6VJVQ)VKNXRI M.?>-CD9#?. 6O"/C3^V+K^QM56)-9@MUEE:W8&&8%4.Y#G(.'4E#RN1G@JS= M=56PLX;6U0)9V]HY+2/' !M5W.YR#@9RQ))P,]:M4 %%%% !1110 4444 %% M%% !6/XEO=0M-%:?1(FN)UFC5UBB$K[=X#!5+*"V..2 .IX%)K^LOIBVD=JU MLLMWR[-R)N8@ $!VSG^#WP:^MZ_=V^H"QT MRVM[R9K;[2EL\OEO>(&(D6)NFY1M.#P=Z\KUJAI&CV]U:V\&GVD-WX3OH_/6 MSNE*-I\@((2-2,@;OX#CRRIP<84 '2Z3J0U73UN?L\UJ^YDDMYP \3J<,IP2 M#R.H)!&""0:NU%;6T-G;)!;($B0?*H.??KW.>]2T %%%% !1110 4444 %%% M(S*BEG8*!U).* !F51EB ,@9)[G@5@->ZU;>(?/OO)BTAYA:1PJ,N"0-DS/_ M +3?($ XW D]0,O6M=AO&OK/5]-@O=&M[@6^HQACYUGG!CF9?XHSE6W#!3[P MSM)&WI-EJ,4-SINLF._LH\+;74K9EF0CI(N,;EZ;L_-UP#R0#9HHHH **** M"HKJZALK.:ZNI!%!"ADD=NBJ!DG\JEKG-0.O7-S]OT.96^S-Y)TJX9(HIF#, M':27RW=?EV,FW\00V0 2:K8:=XB.G&_%OJ6CSD2)&ZK)#(^QMC'LRD.>N1N5 M".:SM#TB'4[R9KW1Y;>'30VGVMU+,Z374<;NI#!2-\6 N-^=QW'&"";GA_2] MK"]M#]GTN]1;EM-90PAN-VXLC#A5)Y(&06^88R=W24 %%%% !1110 4444 % M%%% !5:_U&STR!)M0N8[:)Y%B5Y&P"['"C/N34TKM'"[I&9&520BD98XZ#-< MKJ)U:.*;47,6MZ->1,T]A<[(D@@P,>6/++2,RDY1VP3T*]" /U_1+2^NK^YU M.V%YD^)2-7L+QU(U#S5 MAN+:XP6 C1(Q\BE"><@;J &7>G6^DW#ZT-+DU+6X[LQRO!&OG7*2)L1 M6;C]WC83G"J5)X"UO^']"MM&T^!8K6.UE\H!X89G>&$D LD08_(F1T X'%6 M-)M+NUL8QJEREY>A DEPL03> 3MR!WYY(P"22 !P+U !1110 4444 %%%% ! M1110 50EOXKN6]T_3KV$:E;(K-&2"8RPRA8?W3C^>.:35FN)(TLK.X>SFN@0 MEVJ*WEX() # C<5W$9!&5Y!Z'G&TW5[ZY6WO3':ZS8HSZ=K$<@D:9-P5A/&J M( &&W=&,J>JE2HV@%:30]/LDM+'1?#R7::Q 8K]94 B;RW0M)<'',@W2<\L6 M^F5[.PT^WTVW\FT$FTG),LKRLQP!RSDD\ #D]JEAB$,>!C).6(&-S=SCWZU) M0 4444 %%%% !1110 4444 %8D4;F8$':OS@C;N'S=#@#!&2222
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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1

Document and Entity Information - USD ($)
12 Months Ended

Dec. 31, 2017

Feb. 28, 2018

Jun. 30, 2017

Document And Entity Information [Abstract]

Document Type 10-K

Amendment Flag false

Document Period End Date Dec. 31, 2017

Document Fiscal Year Focus 2017

Document Fiscal Period Focus FY

Trading Symbol CTIC

Entity Registrant Name CTI BIOPHARMA CORP

Entity Central Index Key 0000891293

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 57,982,860

Entity Public Float $ 88,062,209

X

- Definition
Document and entity information.
+ References
No definition available.
+ Details

Name: ctic_DocumentAndEntityInformationAbstract

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Current assets:

Cash and cash equivalents $ 27,218 $ 44,002

Restricted cash 16,000 0

Accounts receivable 4 378

Receivable from collaborative arrangements 1,278 7,778

Inventory, net 550 1,525

Prepaid expenses and other current assets 1,874 2,141

Total current assets 46,924 55,824

Property and equipment, net 2,365 3,023

Other assets 5,597 4,996

Total assets 54,886 63,843

Current liabilities:

Accounts payable 2,588 7,227

Accrued expenses 13,890 24,765

Current portion of deferred revenue 912 103

Current portion of long-term debt 444 7,949

Other current liabilities 1,424 602

Total current liabilities 19,258 40,646

Deferred revenue, less current portion 494 514

Long-term debt, less current portion 13,575 11,311

Other liabilities 5,469 3,615

Total liabilities 38,796 56,086

Commitments and contingencies

Shareholders' equity:

Preferred stock, no par value: Authorized shares - 33,333, Series N-3 Preferred Stock, $2,000 stated value per share, 22,500 shares designated, 575 and 0 shares issued and outstanding as of December 31, 2017 and 2016, respectively 1,090 0

Common stock, no par value: Authorized shares - 81,500,000 and 41,500,000 at December 31, 2017 and 2016, respectively, Issued and outstanding shares - 42,969,494 and 28,228,602 at December 31, 2017 and 2016, respectively 2,222,341 2,170,300

Accumulated other comprehensive loss (6,272) (6,655)

Accumulated deficit (2,195,346) (2,150,326)

Total CTI shareholders' equity 21,813 13,319

Noncontrolling interest (5,723) (5,562)

Total shareholders' equity 16,090 7,757

Total liabilities and shareholders' equity $ 54,886 $ 63,843

X

- Definition
Receivables, Reimbursable Expense, Collaborative Arrangement
+ References
No definition available.
+ Details

Name: ctic_ReceivablesReimbursableExpenseCollaborativeArrangement

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of par value plus amounts in excess of par value or issuance value for common stock issued.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStocksIncludingAdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Dec. 31, 2017

Dec. 31, 2016

N-3 Preferred stock authorized (in shares) 33,333 33,333

Common stock authorized (in shares) 81,500,000 41,500,000

Common stock issued (in shares) 42,969,494 28,228,602

Common stock outstanding (in shares) 42,969,494 28,228,602

Series N-3 Preferred Stock

N-3 Preferred stock stated value (in USD per share) $ 2,000 $ 2,000

N-3 Preferred stock designated (in shares) 22,500 22,500

N-3 Preferred stock issued (in shares) 575 0

N-3 Preferred stock outstanding (in shares) 575 0

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockShareSubscriptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Revenues:

Product sales, net $ 853 $ 4,127 $ 3,472

License and contract revenue 24,293 53,278 12,644

Total revenues 25,146 57,405 16,116

Operating costs and expenses:

Cost of product sold 364 1,377 1,940

Research and development 32,866 64,961 76,627

Selling, general and administrative 31,435 45,306 53,962

Other operating (income) expense, net 0 (5,077) 253

Total operating costs and expenses, net 64,665 106,567 132,782

Loss from operations (39,519) (49,162) (116,666)

Non-operating expense:

Interest expense (1,872) (2,614) (2,104)

Amortization of debt discount and issuance costs (163) (214) (390)

Foreign exchange gain (loss) 817 (484) (703)

Other non-operating expense (94) (479) (900)

Total non-operating expense, net (1,312) (3,791) (4,097)

Net loss before noncontrolling interest (40,831) (52,953) (120,763)

Noncontrolling interest 161 944 1,341

Net loss attributable to CTI (40,670) (52,009) (119,422)

Deemed dividends on preferred stock (4,350) 0 (3,200)

Net loss attributable to common shareholders $ (45,020) $ (52,009) $ (122,622)

Basic and diluted net loss per common share (in USD per share) $ (1.24) $ (1.86) $ (6.51)

Shares used in calculation of basic and diluted net loss per common share (in shares) 36,445 27,948 18,837

X

- Definition
Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_PreferredStockDividendsAndOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Statement of Comprehensive Income [Abstract]

Net loss before noncontrolling interest $ (40,831) $ (52,953) $ (120,763)

Other comprehensive income (loss):

Foreign currency translation adjustments (3,927) 947 2,160

Unrealized foreign exchange gain (loss) on intercompany balance 4,303 (1,162) (2,585)

Other-than-temporary impairment on available-for-sale securities 0 520 0

Net unrealized income (loss) on securities available-for-sale 7 (8) (28)

Other comprehensive income (loss) 383 297 (453)

Comprehensive loss (40,448) (52,656) (121,216)

Comprehensive loss attributable to noncontrolling interest 161 944 1,341

Comprehensive loss attributable to CTI $ (40,287) $ (51,712) $ (119,875)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4613674-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a-c)
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Preferred Stock

Common Stock

Accumulated Deficit

Accumulated Other Comprehensive Income (Loss)

Noncontrolling Interest

Series N-1 Preferred Stock

Series N-1 Preferred Stock

Preferred Stock

Series N-1 Preferred Stock

Common Stock

Series N-2 Preferred Stock

Series N-2 Preferred Stock

Preferred Stock

Series N-2 Preferred Stock

Common Stock

Series N-3 Preferred Stock

Series N-3 Preferred Stock

Preferred Stock

Series N-3 Preferred Stock

Common Stock

Beginning Balance (in shares) at Dec. 31, 2014 0 17,676,000

Beginning Balance at Dec. 31, 2014 $ 38,478 $ 0 $ 2,023,949 $ (1,975,695) $ (6,499) $ (3,277)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Stock Issued (in shares) 1,000,000 50,000 55,000

Stock Issued 15,147 $ 15,147 $ 46,611 $ 46,611 $ 52,409 $ 52,409

Conversion of preferred stock to common stock (in shares) (50,000) 4,000,000 (55,000) 5,000,000

Conversion of preferred stock to common stock 0 $ (46,611) $ 46,611 $ 0 $ (52,409) $ 52,409

Value of beneficial conversion features related to preferred stock 3,200 3,200

Expiry of exercise price provision features related to common stock purchase warrant 150 $ 150

Equity-based compensation (in shares) 393,000

Equity-based compensation 14,828 $ 14,828

Stock option exercises (in shares) 8,000

Stock option exercises 156 $ 156

Noncontrolling interest (1,341) (1,341)

Expiry of mezzanine equity 1,445 $ 1,445

Other (in shares) (31,000)

Other (595) $ (595)

Deemed dividends on preferred stock (3,200) (3,200) $ (3,200)

Net loss for the year ended (119,422) (119,422)

Other comprehensive income (loss) (453) (453)

Ending Balance (in shares) at Dec. 31, 2015 0 28,046,000

Ending Balance at Dec. 31, 2015 47,413 $ 0 $ 2,157,300 (2,098,317) (6,952) (4,618)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Equity-based compensation (in shares) 207,000

Equity-based compensation 13,324 $ 13,324

Noncontrolling interest (944) (944)

Other (in shares) (24,000)

Other (324) $ (324)

Deemed dividends on preferred stock 0

Net loss for the year ended (52,009) (52,009)

Other comprehensive income (loss) 297 297

Ending Balance (in shares) at Dec. 31, 2016 0 28,229,000

Ending Balance at Dec. 31, 2016 7,757 $ 0 $ 2,170,300 (2,150,326) (6,655) (5,562)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Stock Issued (in shares) 22,500

Stock Issued $ 42,669 $ 42,669

Conversion of preferred stock to common stock (in shares) (21,900) 14,616,000

Conversion of preferred stock to common stock 0 $ (41,579) $ 41,579

Value of beneficial conversion features related to preferred stock 4,350 4,350

Issuance of warrants 470 $ 470

Equity-based compensation (in shares) 150,000

Equity-based compensation 5,746 $ 5,746

Noncontrolling interest (161) (161)

Other (in shares) (26,000)

Other (104) $ (104)

Deemed dividends on preferred stock (4,350) (4,350) $ (4,400)

Net loss for the year ended (40,670) (40,670)

Other comprehensive income (loss) 383 383

Ending Balance (in shares) at Dec. 31, 2017 600 42,969,000

Ending Balance at Dec. 31, 2017 $ 16,090 $ 1,090 $ 2,222,341 $ (2,195,346) $ (6,272) $ (5,723)

X

- Definition
Common Stock, Expiry of Purchase Warrant Exercise Price Provision Features
+ References
No definition available.
+ Details

Name: ctic_CommonStockExpiryofPurchaseWarrantExercisePriceProvisionFeatures

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Stock expired during period value.
+ References
No definition available.
+ Details

Name: ctic_StockExpiredDuringPeriodValue

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value Of Beneficial Conversion Feature Of Preferred Stock
+ References
No definition available.
+ Details

Name: ctic_ValueOfBeneficialConversionFeatureOfPreferredStock

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683
+ Details

Name: us-gaap_MinorityInterestPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_PreferredStockDividendsAndOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of preferred stock and warrants for common stock issued.
+ References
No definition available.
+ Details

Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of increase (decrease) in shares of stock classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityOtherShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Operating activities

Net loss before noncontrolling interest $ (40,831) $ (52,953) $ (120,763)

Adjustments to reconcile net loss to net cash used in operating activities:

Baxalta milestone revenue 0 (32,000) 0

Share-based compensation expense 5,746 13,324 14,828

Depreciation and amortization 717 831 990

Loss on debt extinguishment 163 0 1,211

Loss on sublease 1,584 0 0

Provision for bad debts 0 1,735 0

Reserve for excess, obsolete or unsalable inventory 0 692 1,326

Other-than-temporary impairment on available-for-sale securities 0 520 0

Noncash interest expense 163 214 390

Noncash rent benefit (648) (467) (409)

Change in value of warrant liability 0 0 (232)

Other (18) 0 0

Changes in operating assets and liabilities:

Accounts receivable 402 (156) 1,555

Receivable from collaborative arrangements 6,579 (9,476) 0

Inventory 1,120 567 (402)

Prepaid expenses and other current assets 326 1,609 (402)

Other assets 63 355 826

Accounts payable (4,730) (3,025) 4,368

Accrued expenses (11,096) 2,620 2,426

Deferred revenue 790 (1,071) (918)

Other liabilities 374 1 3

Total adjustments 1,535 (23,727) 25,560

Net cash used in operating activities (39,296) (76,680) (95,203)

Investing activities

Purchases of property and equipment (49) (137) (78)

Other 11 0 0

Net cash used in investing activities (38) (137) (78)

Financing activities

Proceeds from common stock offering, net of issuance costs 0 0 15,147

Repayment of Hercules debt (19,548) (5,452) (4,659)

Payment of a Hercules fee 0 (1,275) 0

Payment of tax withholding obligations related to stock compensation (87) (355) (604)

Other (26) 30 165

Net cash provided by (used in) financing activities 38,979 (7,366) 152,017

Effect of exchange rate changes on cash and cash equivalents (429) 3 513

Net (decrease) increase in cash, cash equivalents and restricted cash (784) (84,180) 57,249

Cash, cash equivalents and restricted cash at beginning of year 44,002 128,182 70,933

Cash, cash equivalents and restricted cash at end of year 43,218 44,002 128,182

Supplemental disclosure of cash flow information

Cash paid during the period for interest 1,970 4,446 2,067

Supplemental disclosure of noncash financing and investing activities

Repayment and issuance of Hercules debt 0 0 13,815

Baxalta milestone advance - earned in lieu of repayment 0 32,000 0

Debt issuance costs included in accounts payable and accrued expenses 79 0 0

Baxalta

Financing activities

Proceeds from debt, net of issuance costs 0 0 31,922

Silicon Valley Bank

Financing activities

Proceeds from debt, net of issuance costs 15,971 0 0

Hercules

Financing activities

Proceeds from debt, net of issuance costs 0 0 10,820

Series 21 Preferred Stock

Financing activities

Proceeds from issuance of preferred stock, net of issuance costs 0 0 (227)

Series N-1 Preferred Stock

Financing activities

Proceeds from issuance of preferred stock, net of issuance costs 0 (37) 46,653

Supplemental disclosure of noncash financing and investing activities

Conversion of preferred stock to common stock 0 0 46,611

Series N-2 Preferred Stock

Financing activities

Proceeds from issuance of preferred stock, net of issuance costs 0 (277) 52,800

Supplemental disclosure of noncash financing and investing activities

Conversion of preferred stock to common stock 0 0 52,409

Series N-3 Preferred Stock

Financing activities

Proceeds from issuance of preferred stock, net of issuance costs 42,669 0 0

Supplemental disclosure of noncash financing and investing activities

Conversion of preferred stock to common stock $ 41,579 $ 0 $ 0

X

- Definition
Noncash Investing and Financing Activities, Milestone Advance Payment
+ References
No definition available.
+ Details

Name: ctic_NoncashInvestingandFinancingActivitiesMilestoneAdvancePayment

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Noncash Rent Benefit
+ References
No definition available.
+ Details

Name: ctic_NoncashRentBenefit

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Preferred Stock Issuance Costs, Included In Accounts Payable And Accrued Expenses
+ References
No definition available.
+ Details

Name: ctic_PreferredStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of preferred stock, net of issuance costs.
+ References
No definition available.
+ Details

Name: ctic_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Repayment and issuance of debt.
+ References
No definition available.
+ Details

Name: ctic_RepaymentAndIssuanceOfDebt

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sublease Income (Loss)
+ References
No definition available.
+ Details

Name: ctic_SubleaseIncomeLoss

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in receivables arising from the contracting of goods and services, net for uncollectible accounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractReceivablesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4542-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 1C
-URI http://asc.fasb.org/extlink&oid=68049868&loc=SL66093883-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=68049868&loc=SL66093879-108312
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 8B
-URI http://asc.fasb.org/extlink&oid=82897076&loc=SL6284393-111563
+ Details

Name: us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3095-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtExtinguishmentCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 25
-Paragraph 19A
-URI http://asc.fasb.org/extlink&oid=96949009&loc=SL79513924-113897

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3095-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.5)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_BaxaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_SiliconValleyBankMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_HerculesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesTwentyOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1

Description of Business and Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Description of Business and Summary of Significant Accounting Policies
1. Description of Business and Summary of Significant Accounting Policies

CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,”  the “Company” and “CTI”, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating
pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partners Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, have commercialization rights outside the United States, or the U.S.

We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, or the U.S., the European Medicines Agency, or the EMA, in the European Union, or the E.U., and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include CTI Life Sciences Limited, or CTILS. We also retain ownership of our branch, CTI BioPharma Corp.- Sede Secondaria, or CTI (Europe) which has ceased operations. Systems Medicine LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in December 2017.

As of December 31, 2017, we also had an approximately 60% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.

All intercompany transactions and balances are eliminated in consolidation.

Reverse Stock Split

On January 1, 2017, we effected a one-for-ten reverse stock split, or the Stock Split. Unless otherwise noted, all impacted amounts included in the consolidated financial statements and notes thereto have been retroactively adjusted for the Stock Split. Unless otherwise noted, impacted amounts include shares of common stock authorized and outstanding, share issuances and cancellations, shares underlying warrants and stock options, shares reserved, conversion prices of convertible securities, exercise prices of warrants and options, and loss per share. Additionally, the Stock Split impacted preferred stock authorized (but not outstanding because there were no shares of preferred stock outstanding as of the time of the Stock Split).

Liquidity

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement with Baxalta Incorporated and its affiliates, or Baxalta, and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of December 31, 2017, we had an accumulated deficit of $2.2 billion, and we expect to incur net losses for the foreseeable future.

Our available cash, cash equivalents and restricted cash were $43.2 million as of December 31, 2017. In February 2018, as discussed in Note 21. Subsequent Events, we completed the public offering of common stock and received approximately $64.2 million in net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses. In addition, we received a $10.0 million milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations at least through the next twelve months from the date these financial statements were issued. We previously disclosed that we had substantial doubt about our ability to continue as a going concern, which was primarily due to lack of liquidity. This has since been alleviated as a result of the proceeds we received from the public offering of common stock as well as the milestone payment.

We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying consolidated consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, and excess and obsolete inventory, recording share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, and determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates.

Certain Risks, Uncertainties and Concentrations

Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.

We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.

Additionally, see Note 15. Customer and Geographic Concentrations for further concentration disclosure.

Cash and Cash Equivalents

We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value. We had no cash equivalents as of December 31, 2017.

Restricted Cash

Restricted cash represents a legally restricted deposit held as a compensating balance against our senior secured term loan with Silicon Valley Bank, or SVB. Pursuant to the loan and security agreement entered into with SVB in November 2017, we were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million at all times prior to the occurrence of an event relating to the delivery to SVB of duly executed signatures to a control agreement from Bank of America with respect to all of our accounts maintained with Bank of America. In January 2018, we obtained a waiver from SVB for such requirement and as a result, we no longer have restrictions placed on the cash balance. See Note 7. Long-term Debt for further details regarding our senior secured term loan with SVB.

The following table provides reconciliations of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

December 31, 2017

December 31, 2016

December 31, 2015
Cash and cash equivalents
$
27,218

$
44,002

$
128,182

Restricted cash
16,000

—

—

Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows
$
43,218

$
44,002

$
128,182

Receivables from Collaborative Arrangements
Our receivables from collaborative arrangements relate to amounts payable or reimbursable to us under the terms of collaborative arrangements with our partners. The receivable balance as of December 31, 2017 relates primarily to the sale of PIXUVRI drug product to Servier. The receivable balance as of December 31, 2016 relates primarily to a milestone receivable from Servier for the attainment of a certain enrollment event in December 2016 in connection with our PIX306 study. Receivables from collaborative arrangements are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable. During the year ended December 31, 2016, we recorded $1.7 million in bad debt expense related to disputed invoices under the collaborative arrangement with Baxalta. We had no allowance for doubtful accounts from collaborative arrangements as of December 31, 2017 and 2016.

Value Added Tax Receivable

Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was approximately $4.8 million and $4.4 million as of December 31, 2017 and 2016, respectively, of which $4.7 million and $4.1 million was included in other assets and $0.1 million and $0.3 million was included in prepaid expenses and other current assets as of December 31, 2017 and 2016, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of December 31, 2017, the VAT receivable related to operations in Italy was approximately $4.8 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.

Inventory

We carry inventory at the lower of cost or net realizable value. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the distribution of PIXUVRI. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We review our inventories on a quarterly basis for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsalable inventory, the value is written down to the net realizable value. We had a reserve of $1.4 million and $1.5 million related to excess, obsolete or unsalable inventory as of December 31, 2017 and 2016, respectively, which was included in Inventory, net. Inventory, net as of December 31, 2017 is comprised of bulk active pharmaceutical ingredient which we expect to be salable to Servier under the terms of the Restated Agreement and to future emerging markets.

Property and Equipment

Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of 10 years or the term of the applicable lease.

Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.

Leases

We analyze leases at the inception of each agreement for classification as either an operating or capital lease. Certain of our lease agreement terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense equal to the amount of total minimum lease payments on a straight-line basis over the term of the lease. A deferred liability recognized in connection with the December 2017 sublease arrangement is amortized over the term of the sublease as a reduction of rent expense.

Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.

Level 3 - Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

At December 31, 2017 and 2016, the carrying value of financial instruments such as receivables and payables approximated their fair values due to their short-term maturities. The carrying value of our long-term debt approximated its fair value at December 31, 2017 and 2016 based on borrowing rates for similar loans and maturities.

Contingencies

We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 11. Collaboration, Licensing and Milestone Agreements and Note 18. Legal Proceedings for further information regarding our current gain and loss contingencies.

Revenue Recognition

We currently have conditional marketing authorization for PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.

Product Sales
PIXUVRI was sold primarily through a limited number of wholesale distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary. As of April 2017, Servier has the
exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note 11. Collaboration, Licensing and Milestone Agreements for further details.

Collaboration Agreements

We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with Accounting Standards Codification, or ASC, 605-25, Revenue Recognition—Multiple-Element Arrangements. If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Upon the completion of the performance obligation, such amounts will be recognized as revenue when collectability is reasonably assured.

The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

Milestone payments under collaboration agreements are generally aggregated into three categories for reporting purposes: (1) development milestones, (2) regulatory milestones and (3) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable (1) upon submission for marketing approval with the FDA or with the regulatory authorities of other countries, and (2) upon receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.

At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (1) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.

We follow ASC 605-25, Revenue Recognition – Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the accounting for reimbursement arrangements under collaborative research and development and commercialization agreements.

Cost of Product Sold

Cost of product sold includes third-party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes allowances, if any, for excess inventory that may expire and become unsalable.

Research and Development Expenses

Research and development costs are expensed as incurred in accordance with the FASB ASC 730, Research and Development. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.

Foreign Currency Translation and Transaction Gains and Losses

We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.

The intercompany balance due from CTILS is considered to be of a long-term nature. An unrealized foreign exchange gain of $4.3 million and unrealized foreign exchange losses of $1.2 million and $2.6 million were recorded in the cumulative foreign currency translation adjustment account for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017 and 2016, the intercompany balance due from CTILS was €26.2 million and €29.7 million, respectively (or $31.4 million and $31.2 million upon conversion from euros as of December 31, 2017 and 2016, respectively).

Income Taxes

We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

Net Loss per Share

Basic net loss per common share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect.

Recently Adopted Accounting Standards

In April 2015, the FASB issued a new accounting standard which changes the presentation of debt issuance costs in financial statements. Under the new standard, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The accounting standard is effective for annual reporting periods beginning after December 15, 2015 and interim periods beginning after December 15, 2016. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In July 2015, the FASB issued new accounting guidance on simplifying the measurement of inventory which requires
that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2016. The adoption of this standard did not have a material impact on our consolidated financial statements.

In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The adoption of this guidance did not have an impact on our consolidated financial statements.

In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period and to provide related footnote disclosures in certain circumstances. The accounting standard is effective for annual reporting periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard in the fourth quarter of 2016 did not have a material impact on our consolidated financial statements.

In March 2016, the FASB issued new accounting guidance for employee share-based payments accounting. The accounting standard primarily affects the accounting for forfeitures, minimum statutory tax withholding requirements, and income tax effects related to share-based payments at settlement (or expiration). The accounting guidance is effective for annual reporting periods beginning after December 15, 2016 (including interim periods within those periods). We have historically maintained a full valuation allowance against deferred tax assets. The adoption of this standard in the first quarter of 2017 did not have a material impact on our consolidated financial statements, and we will continue to estimate expected forfeitures.

In November 2016, the FASB issued accounting guidance which amends ASC 230, Statement of Cash Flows, to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments require that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Consequently, transfers between cash and restricted cash will not be presented as a separate line item in the operating, investing or financing sections of the cash flow statement. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. The early adoption is permitted. The adoption of this standard did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In May 2014, the FASB issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five-step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. We will adopt the new standard in the first quarter 2018 using the modified retrospective method. We have completed the impact on our customer contracts and do not expect the implementation of ASU 2014-09 to have a material quantitative impact on our consolidated financial statements. Under the new standard, such customer arrangements will be accounted for as variable consideration, which may result in revenue being recognized earlier provided we can reliably estimate the ultimate price expected to be realized from the customer. In addition, we do not expect a material cumulative effect adjustment to Retained earnings upon adoption of the standard on January 1, 2018. Adoption of the new standard will also result in additional revenue-related disclosures in the footnotes to our consolidated financial statements.

In February 2016, the FASB issued a new accounting guidance on accounting for leases which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018. Early adoption is permitted. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.

In August 2016, the FASB issued an amendment to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows with the objective of reducing diversity in practice regarding eight types of cash flows. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of this standard to have a material impact on our statement of cash flows.

Reclassifications

Certain prior year items have been reclassified to conform to current year presentation.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventory
12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventory
2. Inventory

The components of PIXUVRI inventories consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Finished goods
$
394

$
477

Work-in-process
1,523

2,558

Inventory, gross
$
1,917

$
3,035

Reserve for excess, obsolete or unsalable inventory
$
(1,367
)

$
(1,510
)
Inventory, net
$
550

$
1,525

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property and Equipment
12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment
3. Property and Equipment

Property and equipment are composed of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Furniture and office equipment
$
4,552

$
6,521

Leasehold improvements
5,168

5,106

Lab equipment
209

201

9,929

11,828

Less: accumulated depreciation and amortization
(7,564
)

(8,805
)
Property and equipment, net
$
2,365

$
3,023

Depreciation expense for the years ended December 31, 2017, 2016 and 2015 was $0.7 million, $0.8 million and $1.0 million, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accrued Expenses
12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses
4. Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Clinical and investigator-sponsored trial expenses
$
5,019

$
7,303

Employee compensation and related expenses
4,432

6,364

Manufacturing expenses
2,637

7,616

Legal expenses
537

1,037

Selling expenses
143

136

Insurance financing
575

888

Interest expenses
93

2

Other
454

1,419

Total accrued expenses
$
13,890

$
24,765

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1

Leases
12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Leases
5. Leases

Lease Agreements

In January 2012, we entered into an operating lease agreement with Selig Holdings Company LLC to lease approximately 66,000 square feet of office space in Seattle, Washington for a term of 120 months, commencing May 1, 2012. We have two five-year options to extend the term of the lease at a market rate determined according to the lease. The initial rent amount was based on $27.00 per square foot per annum, but no payments were due during the initial five months of the lease term. Rent increases three percent over the prior year’s amount for each year thereafter for the duration of the lease. In addition, we were provided an allowance of $3.3 million for certain tenant improvements made by us.

In December 2017, we entered into an agreement to sublease approximately 44,000 square feet of our Seattle office space. No payments are due through May 2018, after which monthly rent is due through the sublease termination date in April 2022. Monthly sublease rent increases by a minor amount each January 1. In connection with the sublease, we recognized a loss and a deferred liability of $1.6 million, representing future rental payments plus related expenses in excess of the future sublease payments to be received. The loss was recorded in Selling, general and administrative expense during the year ended December 31, 2017. Other current liabilities and Other liabilities in the consolidated balance sheet include $0.8 million and $0.6 million, respectively, related to the sublease agreement as of December 31, 2017 .

Rent expense, net of sublease-related income of $0.1 million for the year ended December 31, 2017, amounted to $1.6 million, $2.0 million and $2.0 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Future Minimum Lease Payments

Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at December 31, 2017 were as follows (in thousands):

Operating

Sublease

Leases

Rentals

Net
2018
$
2,487

$
771

$
1,716

2019
2,532

1,365

1,167

2020
2,584

1,410

1,174

2021
2,580

1,454

1,126

2022
868

499

369

Thereafter
—

—

—

Total minimum lease commitments
$
11,051

$
5,499

$
5,552

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Liabilities
12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Other Liabilities
6. Other Liabilities

Other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Deferred rent, less current portion
$
3,050

$
3,011

Other long-term obligations
2,419

604

Total other liabilities
$
5,469

$
3,615

Deferred rent, less current portion as of December 31, 2017 and 2016 includes amounts related to incentives for rent holidays and leasehold improvements associated with our operating lease for office space. In addition, deferred rent, less current portion as of December 31, 2017 includes $0.6 million of deferred liability related to the sublease of Seattle office space as discussed in Note 5. Leases.

Other long-term obligations as of December 31, 2017 include a fee in the amount of $1.4 million payable to Silicon Valley Bank. See Note 7, Long-term Debt, for additional information.

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1

Long-term Debt
12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Long-term Debt
7. Long-term Debt

Silicon Valley Bank

In November 2017, we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, for a senior secured term loan of up to $18.0 million. The first $16.0 million of the term loan was funded in November 2017, and the remaining $2.0 million is available at our option at any time from the occurrence of the Milestone Event (as defined below) through July 31, 2018, subject to the satisfaction of certain conditions. The loan proceeds were used to repay in full all outstanding indebtedness under the Loan and Security Agreement with Hercules as discussed below and to fund our general business requirements. We were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million under the terms of Loan and Security Agreement, and as such, $16.0 million of our cash was legally restricted as of December 31, 2017 and held as a compensating balance against the term loan. The restriction was subsequently removed in January 2018. See Note 1. Description of Business and Summary of Significant Accounting Policies for further details regarding restricted cash.

The Milestone Event is defined as our receipt of evidence satisfactory to SVB, in its sole but reasonable discretion, that we have received a positive opinion from the EMA for our pacritinib product.

The term loan is repayable over 36 months after an initial interest-only period of at least 12 months after closing, which will be extended to 18 months upon the occurrence of the Milestone Event. The interest rate on the term loan floats at a rate per annum equal to the greater of 2.5 percent above the prime rate and 6.75 percent. We may elect to prepay some or all of the loan balance at any time subject to a prepayment fee. A fee in the amount of 9 percent of the total principal amount funded to us is payable to SVB on the date on which the term loan is paid or becomes due and payable in full. Such fee in the amount of $1.4 million was included in Other liabilities in the consolidated balance sheet as of December 31, 2017. The loan obligations are secured by a first priority security interest on substantially all of our personal property except our intellectual property, and subject to certain other exceptions.

In addition, we issued warrants to SVB and Life Science Loans II, LLC, pursuant to a participation arrangement among SVB, Loan Manager II, LLC and Life Science Loans II, LLC, to purchase up to 190,140 shares of our common stock. Warrants underlying 169,014 shares of our common stock are initially exercisable at any time prior to November 28, 2027. Warrants underlying 21,126 shares of our common stock will become exercisable when the remaining $2.0 million of the term loan is funded to us. The initial exercise price of the warrants is $2.84 per share of our common stock.

In connection with the Loan and Security Agreement, we recorded debt discount and debt issuance costs of $1.9 million and $0.1 million, respectively, of which $1.9 million and $0.1 million was unamortized as of December 31, 2017, respectively. The outstanding principal balance on the term loan was $16.0 million as of December 31, 2017.

Hercules

In March 2013, we entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules, providing for a senior secured term loan of up to $15.0 million. In March 2014, we entered into a First Amendment to the Loan Agreement, which modified certain terms applicable to the loan balance then-outstanding of $15.0 million and provided us with the option to borrow an additional $5.0 million.

In June 2015, we entered into a Third Amendment to the Loan Agreement, or the Third Amendment. Under the Third Amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million, inclusive of the principal balance outstanding immediately prior to closing of the Third Amendment of $13.8 million, or collectively, the Term Loan Borrowings. We drew $6.2 million upon closing of the Third Amendment, resulting in a then-outstanding principal balance of $20.0 million under the Term Loan Borrowings. The remaining $5.0 million was available for borrowing at our option through June 30, 2016, subject to certain conditions. In connection with the Third Amendment, we paid a commitment fee of $15,000 and a facility charge of $0.3 million. The provision under the Loan Agreement requiring us to pay a fee to Hercules of $1.3 million on the date of repayment of the borrowings thereunder was amended pursuant to the Third Amendment, such that the fee was paid in October 2016.

In connection with the Third Amendment, we issued a warrant to Hercules to purchase shares of common stock. The warrant is exercisable for five years from the date of issuance for 29,239 shares of common stock at an initial exercise price of $17.10 per share. The warrant did not meet the considerations necessary for equity classification under the applicable authoritative guidance. As such, we determined that the warrant was a liability instrument with changes in fair value recognized through earnings at each reporting period. The warrant was categorized as Level 2 in the fair value hierarchy as the significant inputs used in determining fair value were considered observable market data. As of the issuance date, we estimated the fair value of the warrant to be $0.4 million. Upon expiry of the exercise price adjustment provision in December 2015, the then-estimated fair value of the warrant of $0.2 million was reclassified from liability to equity.

The modified terms under the Third Amendment were considered substantially different as compared to the terms of the Loan Agreement immediately prior to the Third Amendment, pursuant to ASC 470-50, Modification and Extinguishment. As such, the Third Amendment was accounted for as a debt extinguishment, resulting in a loss on debt extinguishment of $1.2 million, which is included in Other non-operating expense for the year ended December 31, 2015.

In December 2015, we entered into a Fourth Amendment to the Loan Agreement, or the Fourth Amendment, pursuant to which Hercules funded the remaining $5.0 million term loan available under the facility, resulting in a then-outstanding principal balance of $25.0 million.

In November 2017, we repaid the then-outstanding principal balance of $14.3 million in full, using the proceeds from the the Loan and Security Agreement with SVB as discussed above. Accordingly, among other things, (1) all obligations under the Loan Agreement and all related documents have been paid, satisfied, released and discharged in full, (2) all unfunded commitments to make credit extensions or financial accommodations to us or any other person under the Loan Agreement have been automatically and irrevocably terminated, and (3) our obligations under the Loan Agreement and all related documents have been automatically and irrevocably terminated (other than with respect to customary provisions and agreements that are expressly specified to survive the termination). Upon full repayment of the principal in November 2017, we wrote-off the then-unamortized debt discount balance of $0.1 million to a loss on debt extinguishment, which was recorded in Other non-operating expense for the year ended December 31, 2017.

Baxalta

In November 2013, we entered into a Development, Commercialization and License agreement, or the Pacritinib License Agreement, with Baxter International Inc., or Baxter, for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxalta has been assigned Baxter’s rights and obligations under the Pacritinib License Agreement. In June 2015, we entered into the First Amendment to the Pacritinib License Agreement, or the Pacritinib License Amendment, pursuant to which two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Pacritinib License Agreement relating to the following: the $12.0 million development milestone payment payable in connection with the regulatory submission of the Marketing Authorization Application, or the MAA, to the EMA with respect to pacritinib, or the MAA Milestone, and the $20.0 million development milestone payment payable in connection with the first treatment dosing of the 300th patient enrolled per the protocol in PERSIST-2, or the PERSIST-2 Milestone. Under the Pacritinib License Amendment, each of the two milestone advances bore interest at an annual rate of 9% until the earlier of the date of the first occurrence of the respective milestone or the date that the respective advance plus accrued interest was repaid in full. In January 2016 and February 2016, we successfully achieved the $20.0 million PERSIST-2 Milestone and the $12.0 million MAA Milestone, respectively, which were recorded in License and contract revenue for the year ended December 31, 2016.

See Note 11. Collaboration, Licensing and Milestone Agreements for further details regarding our agreements with Baxalta.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1

Preferred Stock
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Preferred Stock
8. Preferred Stock

Series N-1 Preferred Stock

In October 2015, in an underwritten public offering, we issued 50,000 shares of Series N-1 convertible preferred stock, or Series N-1 Preferred Stock, for gross proceeds of $50.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $3.4 million, including $3.0 million in underwriting commissions and discounts.

Each share of Series N-1 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-1 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-1 Preferred Stock. The Series N-1 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-1 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law.

In October 2015, all 50,000 shares of Series N-1 Preferred Stock were converted into 4.0 million shares of common stock at a conversion price of $12.50 per share. During the year ended December 31, 2015, we recognized $3.2 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-1 Preferred Stock.

Series N-2 Preferred Stock

In December 2015, in an underwritten public offering, we issued 55,000 shares of Series N-2 Preferred Stock for gross proceeds of $55.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.6 million, including $2.2 million in underwriting commissions and discounts.

Each share of Series N-2 Preferred Stock was convertible at the option of the holder (subject to a limited exception) and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-2 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-2 Preferred Stock. The Series N-2 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-2 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law.

In December 2015, all 55,000 shares of Series N-2 Preferred Stock were converted into 5.0 million shares of common stock at a conversion price of $11.00 per share. There was no beneficial conversion feature on Series N-2 Preferred Stock.

Series N-3 Preferred Stock

In June 2017, in an underwritten public offering, we issued 22,500 shares of Series N-3 Preferred Stock for gross proceeds of $45.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.3 million. BVF Partners L.P., or BVF, an existing shareholder of the Company, was one of our investors in this offering. See
Note 17. Related Party Transactions for further details.

Each share of Series N-3 Preferred Stock is convertible at the option of the holder (subject to a limited exception) and is entitled to a liquidation preference equal to the initial stated value of $2,000 per share, plus any declared and unpaid dividends, and any other payments that may be due on such shares, before any distribution of assets may be made to holders of capital stock ranking junior to the Series N-3 Preferred Stock. The Series N-3 Preferred Stock is not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-3 Preferred Stock has no voting rights, except as otherwise expressly provided in the articles of amendment to amended and restated articles of incorporation of CTI or as otherwise required by law.

In June 2017, 21,925 shares of Series N-3 Preferred Stock were converted into 14.6 million shares of common stock at a conversion price of $3.00 per share. For the year ended December 31, 2017, we recognized $4.4 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-3 Preferred Stock. There were 575 shares of Series N-3 Preferred Stock outstanding as of December 31, 2017.

In February 2018, 575 shares of Series N Preferred Stock owned by certain affiliates of BVF Partners L.P., or collectively, BVF, along with 8.0 million shares of our common stock owned by BVF were exchanged for 12,575 shares of Series O Preferred Stock. See Note 17. Related Party Transactions for further details.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_PreferredStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1

Common Stock
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Common Stock
9. Common Stock

Common Stock Authorized

In April 2016, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from 31.5 million to 41.5 million.

In May 2017, the Company's Amended and Restated Articles of Incorporation were amended to increase the total number of authorized shares of common stock from 41.5 million to 81.5 million.

Common Stock Issued

In September 2015, we entered into a subscription agreement with BVF pursuant to which we issued to BVF an aggregate of 1.0 million shares of common stock at a purchase price per share of $15.70. The shares of common stock were offered directly to BVF without a placement agent or underwriter. The net proceeds from the offering, after deducting offering expenses, were approximately $15.1 million.

Common Stock Reserved

A summary of common stock reserved for issuance is as follows as of December 31, 2017 (in thousands):
Equity incentive plans
5,920

Option agreement with Adam R. Craig
1,120

Common stock purchase warrants
219

Series N-3 convertible preferred stock
383

Employee stock purchase plan
184

Total common stock reserved
7,826

Warrants

Warrants to purchase up to 29,239 shares of our common stock with an exercise price of $17.10 per share, issued in connection with the Third Amendment to the Loan Agreement with Hercules in June 2015, were outstanding as of December 31, 2017.

Warrants to purchase up to 190,140 shares of our common stock with an exercise price of $2.84 per share, issued in connection with the Loan and Security Agreement with SVB, were outstanding as of December 31, 2017.

See Note 7. Long-term Debt for additional information concerning our warrants.

X

- Definition
Disclosure including description and financial information related to an entity's common stock.
+ References
No definition available.
+ Details

Name: ctic_CommonStockDisclosureTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Comprehensive Loss
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Other Comprehensive Loss
10. Other Comprehensive Loss
Total accumulated other comprehensive loss consisted of the following (in thousands):

Net Unrealized
Gain (Loss) and Impairment on
Available-For-Sale Securities

Foreign
Currency
Translation
Adjustments

Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance

Accumulated
Other
Comprehensive
Loss
December 31, 2016
$
(6
)

$
(2,902
)

$
(3,747
)

$
(6,655
)
Current period other comprehensive income (loss)
7

(3,927
)

4,303

383

December 31, 2017
$
1

$
(6,829
)

$
556

$
(6,272
)

In the first quarter of 2016, we recognized an other-than-temporary impairment on available-for-sale securities of $0.5 million in our consolidated statement of operations. The value of available-for-sale securities of $13,500 was included in Prepaid expenses and other current assets as of December 31, 2016. We had no available-for-sale securities as of December 31, 2017.

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-URI http://asc.fasb.org/topic&trid=2134417
+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration, Licensing and Milestone Agreements
12 Months Ended

Dec. 31, 2017

Collaborations [Abstract]

Collaboration, Licensing and Milestone Agreements
11. Collaboration, Licensing and Milestone Agreements

Servier

In September 2014, we entered into an Exclusive License and Collaboration Agreement, or the Original Agreement, with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively, Servier. In April 2017, we entered into an Amended and Restated Exclusive License and Collaboration Agreement, or the Restated Agreement, with Servier, pursuant to which the Original Agreement was amended and restated in its entirety.

Under the Restated Agreement, we granted Servier an exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions).

In May 2017, we received a non-refundable, non-creditable upfront cash payment of €12.0 million under the terms of the Restated Agreement. This amount included a €2.0 million payment for a milestone relating to EMA approval of an additional third-party manufacturer of PIXUVRI, which was not included in the Original Agreement and was deemed achieved at the time of the Restated Agreement. Subject to the achievement of certain conditions, the Restated Agreement provides for additional milestone payments of up to €76.0 million: up to €36.0 million in potential regulatory milestone payments (which includes a €1.0 million payment for a regulatory milestone achieved in September 2017 as discussed below), and up to €40.0 million in potential sales-based milestone payments. We have determined that all the regulatory milestones, other than the €2.0 million milestone mentioned above, are substantive due to significant uncertainty involved in each milestone, and will be recognized as revenue upon achievement of the respective milestones, assuming all other revenue recognition criteria are met. We have also determined that the sales-based milestone payments are contingent consideration and will be recognized as revenue in the period in which the respective revenue recognition criteria are met.

We are eligible to receive tiered royalty payments on net sales of products containing PIXUVRI, ranging from a low double-digit percentage up to a percentage in the low twenties, subject to certain reductions of up to mid-double-digit percentages under certain circumstances. Royalties are subject to expiration upon certain events, including upon expiration of exclusivity rights to products containing PIXUVRI in the respective country.

Under the Restated Agreement, with the exception of the conclusion of the PIX306 trial and certain other services,
Servier will be responsible for development, commercialization and manufacturing activities within its territory. We entered into a commercialization transition plan whereby we transferred to Servier medical affairs and commercialization activities relating to the Licensed Products in Israel, Turkey, Germany, Austria, the United Kingdom, Denmark, Finland, Norway and Sweden, or collectively, the Transition Territory. Upon completion of the commercialization transition plan, we terminated or assigned certain distributor and wholesaler contracts to Servier in the Transition Territory. Each party is responsible for the manufacture and supply of drug products and substances in their respective territories. We record reimbursements received from Servier for their portion of operating expenses we pay on their behalf as revenue and the full amount of costs as operating expenses in the statements of operations.

The Restated Agreement will expire on a country-by-country basis upon the expiration of the royalty terms in the countries in the Servier territory, at which time all licenses granted to Servier would become perpetual and royalty-free. Each party may terminate the Restated Agreement in the event of an uncured repudiatory breach of the other party’s obligations. Subject to applicable notification periods, Servier may terminate the Restated Agreement on a country-by-country basis upon 30 days’ written notice in the event of (1) certain safety or public health issues relating to the Licensed Product, (2) suspension or withdrawal of marketing authorizations and (3) without cause. In the event of a termination prior to the expiration date, rights granted to Servier will terminate, subject to certain exceptions.

Pursuant to accounting guidance under ASC 605-25 Revenue Recognition - Multiple-Element Arrangements, we identified the following non-contingent deliverables with standalone value at the inception of the Restated Agreement:

• a license with respect to the development and commercialization of PIXUVRI
• development services
• joint committee obligations
• regulatory responsibilities
• commercialization responsibilities
• manufacturing and supply responsibilities

The license deliverable has standalone value because it is sublicensable and can be used for its intended purpose without the receipt of the remaining deliverables. The service deliverables have standalone value because these services are not proprietary in nature, and other vendors could provide the same services in order to derive value from the license. Further, there is no general right of return associated with these deliverables. As such, the deliverables meet the criteria for separation and qualify as separate units of accounting.

We determined that the value of the joint committee obligations and the regulatory, commercial, and manufacturing and supply responsibilities were insignificant. These deliverables have been combined with the development services and included as “Other services” in the table below.

We allocated the arrangement consideration of $12.8 million (€12.0 million converted into U.S. dollars using the
currency exchange rate as of the date of the Restated Agreement) based on the percentage of the relative selling price of each
unit of accounting as follows (in thousands):

License
$
11,487

Development and other services
1,348

Total upfront payment
$
12,835

We estimated the selling price of the license using the income approach that values the license by discounting direct cash flow expected to be generated over the remaining life of the license, net of cash flow adjustments related to working capital.The estimates and assumptions include, but are not limited to, estimated market opportunity, expected market share, and
contractual royalty rates. We estimated the selling price of the development services deliverable, which includes personnel costs as well as third-party costs for applicable services and supplies, by discounting estimated expenditures for services to the date of the Restated Agreement. We concluded that a change in the key assumptions used to determine the best estimate of the selling price for the license deliverable would not have a significant effect on the allocation of the arrangement consideration.

During the year ended December 31, 2017, we recognized $11.5 million of consideration allocated to the license as revenue upon delivery of the license and the satisfaction of the remaining revenue recognition criteria. The $1.3 million consideration allocated to development and other services was recorded as deferred revenue. During the year ended December 31, 2017, $0.5 million of other services consideration was recognized as revenue; the remaining $1.4 million is included in deferred revenue in the consolidated balance sheet as of December 31, 2017.

In September 2017, we attained a regulatory milestone under the Restated Agreement and recognized a €1.0 million milestone revenue (or $1.2 million using the currency exchange rate as of the date the milestone was achieved).

Of the potential milestone payments under the Original Agreement, we received a €1.5 million (or $1.7 million upon conversion from euros as of the date we received the funds) milestone payment in February 2015 relating to the attainment of reimbursement approval for PIXUVRI in Spain. In December 2016, we recorded €7.5 million in milestone revenue (or $8.0 million upon conversion from euros as of the date we achieved the milestone) relating to the attainment of a certain enrollment event in connection with our PIX306 study. This was included in Receivable from collaborative arrangements as of December 2016, and we received the funds in January 2017. These milestone revenues were accounted for under the milestone method of accounting since this milestone was determined to be substantive at the inception of the arrangement.

Other operating (income) expense, net for the years ended December 31, 2015 and December 31, 2016, includes $0.3 million and $0.8 million, respectively, for payments made to Novartis International Pharmaceutical Ltd. in connection with the milestone payments received in February 2015 and January 2017, respectively, as discussed above.

In February 2016, we entered into an agreement with one of Servier's affiliates whereby we conduct the pharmacokinetic sub-study on behalf of Servier in conjunction with our ongoing clinical trial, PIX-306. During the years ended December 31, 2017 and 2016, $0.1 million and $0.5 million, respectively, of expense reimbursements in relation to this study was included in development services revenue. There was no such revenue during the year ended December 31, 2015. We expect to receive no such development services revenue in future periods as the pharmacokinetic sub-study was completed in September 2017.

Teva

Pursuant to an acquisition agreement entered into with Cephalon, Inc., or Cephalon, in June 2005, we have the right to receive up to $100.0 million in payments upon achievement of specified sales and development milestones related to TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. As of December 31, 2017, we have received $40.0 million of such potential milestone payments as a result of having achieved certain sales milestones. For each of the years ended December 31, 2017 and 2015, we received $10.0 million from Teva upon the achievement of worldwide net sales milestones of TRISENOX, which was included in license and contract revenue. We received no milestone payment from Teva during the year ended December 31, 2016. In February 2018, we received a $10.0 million milestone payment related to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. The achievement of the remaining milestones is uncertain at this time.

Baxalta

In November 2013, we entered into the Pacritinib License Agreement with Baxter for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxter assigned its rights and obligations under the Pacritinib License Agreement to Baxalta. Under the Pacritinib License Agreement, we granted to Baxter an exclusive, worldwide (subject to our certain co-promotion rights in the U.S.), royalty-bearing, non-transferable, and (under certain circumstances outside of the U.S.) sub-licensable license to our know-how and patents relating to pacritinib. We received an upfront payment of $60.0 million upon execution of the Pacritinib License Agreement, which included an equity investment of $30.0 million to acquire our Series 19 Preferred Stock.

We allocated the fixed and determinable Pacritinib License Agreement consideration of $30.0 million based on the percentage of the relative selling price of each unit of accounting. Of the $30.0 million consideration, $27.3 million was allocated to the license and $2.7 million was allocated to the development services. The amount allocated to development services was initially deferred and recognized as revenue based on a proportional performance method. During the years ended December 31, 2016 and 2015, $1.0 million and $0.8 million, respectively, of development services was recognized as revenue. There was no deferred revenue relating to the development services in the balance sheet as of December 31, 2017 and 2016 due to our entry into the Asset Return and Termination Agreement with Baxalta in October 2016 as discussed below.

Under the Pacritinib License Agreement, we were responsible for all development costs incurred prior to January 1, 2014 as well as up to approximately $96.0 million on or after January 1, 2014 for U.S. and E.U. development costs, subject to potential adjustment in certain circumstances. All development costs exceeding such threshold were generally shared with Baxalta. We recorded development cost reimbursements received from Baxalta as license and contract revenue in the consolidated statements of operations, and we recorded the full amount of development costs as research and development expense. During the year ended December 31, 2016, we recorded $11.4 million of development services revenue relating to reimbursable development costs from Baxalta under the terms of the Pacritinib License Agreement. There was no such revenue recorded during the years ended December 31, 2017 and December 31, 2015.

In June 2015, we entered into the Pacritinib License Amendment to the Pacritinib License Agreement. Pursuant to the Pacritinib License Amendment, two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Pacritinib License Agreement. Refer to the Note 7. Long-term Debt for further details regarding these milestone advances received. During the first quarter of 2016, we achieved these milestones and recorded $32.0 million in license and contract revenue for the year ended December 31, 2016.

In October 2016, we entered into the Asset Return and Termination Agreement (the “Termination Agreement”) with Baxalta. Pursuant to the Termination Agreement, the Pacritinib License Agreement was terminated in its entirety (other than with respect to certain customary provisions that survive termination, including those pertaining to confidentiality and indemnification), the Pacritinib License Agreement has no further force or effect, and all rights and obligations of the Company and Baxalta under the Pacritinib License Agreement were terminated. In connection with this termination, we recorded a gain of $5.9 million which was included in Other operating (income) expense for the year ended December 31, 2016.

In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the Termination Agreement and are no longer eligible to receive cost sharing or milestone payments for pacritinib’s development from Baxalta. In addition, under the Termination Agreement, we are required to make a milestone payment to Baxalta in the amount of approximately $10.3 million upon the first regulatory approval or any pricing and reimbursement approvals of a product containing pacritinib.

Novartis

In January 2014, we entered into a Termination Agreement, or the Novartis Termination Agreement, with Novartis to reacquire the rights to PIXUVRI and Opaxio, or collectively, the Compounds, previously granted to Novartis under our License and Co-Development Agreement with Novartis, as amended, or the Original Novartis Agreement. Pursuant to the Novartis Termination Agreement, the Original Novartis Agreement was terminated in its entirety, other than with respect to certain customary provisions, including those pertaining to confidentiality and indemnification, which survive termination.

Under the Novartis Termination Agreement, we agreed not to transfer, license, sublicense or otherwise grant rights with respect to intellectual property of the Compounds unless the transferee/licensee/sublicensee agrees to be bound by the terms of the Novartis Termination Agreement. We also agreed to provide potential payments to Novartis, including a percentage ranging from the low double-digits to the mid-teens, of any consideration received by us or our affiliates in connection with any transfer, license, sublicense or other grant of rights with respect to intellectual property of the Compounds, provided that such payments would not exceed certain prescribed ceilings in the low-single digit millions. Novartis is entitled to receive potential payments of up to $16.6 million upon the achievement of certain sales milestones of the Compounds. Novartis is also eligible to receive tiered low single-digit percentage royalty payments for the first several hundred million in annual net sales, and ten percent royalty payments thereafter based on annual net sales of each Compound, subject to reduction in the event generic drugs are introduced and sold by a third party, causing the sale of the Compounds to fall by a percentage in the high double-digits. Notwithstanding the foregoing, royalty payments for the Compounds are subject to certain minimum floor percentages in the low single-digits.

University of Vermont

In March 1995, the University of Vermont, or UVM, entered into an agreement, or the UVM Agreement, which, as amended in March 2000, grants us an exclusive, sublicensable license for the rights to PIXUVRI. Pursuant to the UVM Agreement, we acquired the rights to make, have made, sell and use PIXUVRI. We are obligated to make royalty payments to UVM that range from low-single digits to mid-single digits as a percentage of net sales. The higher royalty rate is payable for net sales in countries where specified UVM licensed patents exist, or where we have obtained orphan drug protection, until such UVM patents or such protection no longer exists. For a period of ten years after first commercialization of PIXUVRI, the lower royalty rate is payable for net sales in such countries after expiration of the designated UVM patents or loss of orphan drug protection, and in all other countries without such specified UVM patents or orphan drug protection. Unless otherwise terminated, the term of the UVM Agreement continues for the life of the licensed patents in those countries in which a licensed patent exists, and continues for ten years after the first sale of PIXUVRI in those countries where no such patents exist. We may terminate the UVM Agreement, on a country-by-country basis or on a patent-by-patent basis, at any time upon advance written notice. UVM may terminate the UVM Agreement upon advance written notice in the event royalty payments are not made. In addition, either party may terminate the UVM Agreement (1) in the event of an uncured material breach of the UVM Agreement by the other party or (2) in the event of bankruptcy of the other party.

S*BIO Pte Ltd.

We acquired the compounds SB1518 (which is referred to as “pacritinib”) and SB1578, which inhibit JAK2 and FLT3, from S*BIO Pte Ltd., or S*BIO, in May 2012. Under our agreement with S*BIO, we are required to make milestone payments to S*BIO up to an aggregate amount of $132.5 million if certain U.S., E.U. and Japanese regulatory approvals are obtained or if certain worldwide net sales thresholds are met in connection with any pharmaceutical product containing or comprising any compound that we acquired from S*BIO for use for specific diseases, infections or other conditions. At our election, we may pay up to 50% of any milestone payments to S*BIO through the issuance of shares of our common stock or shares of our preferred stock convertible into our common stock. S*BIO will also be entitled to receive royalty payments from us at incremental rates in the low single-digits based on certain worldwide net sales thresholds on a product-by-product and country-by-country basis.

Vernalis

We entered into an amended and restated exclusive license agreement with Vernalis (R&D) Limited, or Vernalis, in October 2014, or the Vernalis License Agreement, for the exclusive worldwide right to use certain patents and other intellectual property rights to develop, market and commercialize tosedostat and certain other compounds. Under the Vernalis License Agreement, we have agreed to make tiered royalty payments of no more than a high single-digit percentage of net sales of products containing licensed compounds, with such obligation to continue on a country-by-country basis for the longer of ten years following commercial launch or the expiry of relevant patent claims.

The Vernalis License Agreement will terminate when the royalty obligations expire, although the parties have early termination rights under certain circumstances, including the following: (1) we have the right to terminate, with three months’ notice, upon the belief that the continued development of tosedostat or any of the other licensed compounds is not commercially viable, (2) Vernalis has the right to terminate in the event of our uncured failure to pay sums due, and (3) either party has the right to terminate in the event of the other party’s uncured material breach or insolvency.

Gynecologic Oncology Group

We entered into an agreement with the Gynecologic Oncology Group, or GOG, now part of NRG Oncology, in March 2004, as amended, related to the GOG-212 trial of Opaxio in patients with ovarian cancer. Pursuant to the terms of such agreement, we made a milestone payment of $0.5 million relating to the transfer of final datasets during the second quarter of 2017. The agreement was terminated in May 2017. No further development of Opaxio is planned.

PG-TXL

In November 1998, we entered into an agreement with PG-TXL, as amended in February 2006, or the PG-TXL Agreement, which granted us an exclusive worldwide license for the rights to Opaxio and to all potential uses of PG-TXL’s polymer technology. Pursuant to the PG-TXL Agreement, we acquired the rights to research, develop, manufacture, market and sell anti-cancer drugs developed using this polymer technology. Pursuant to the PG-TXL Agreement, we were obligated to make payments to PG-TXL of up to $14.4 million upon the achievement of certain development and regulatory milestones. The timing of the remaining milestone payments under the PG-TXL Agreement was based on trial commencements and completions for compounds protected by PG-TXL license rights, and regulatory and marketing approval of those compounds by the FDA and the EMA. Additionally, we were required to make royalty payments to PG-TXL ranging from low to mid-single digits as a percentage of net sales. In February 2017, we terminated our agreement with PG-TXL and the exclusive worldwide license for rights to Opaxio and certain polymer technology thereunder.

Nerviano Medical Sciences

Under a license agreement entered into with Nerviano Medical Sciences, S.r.l. in October 2006, for brostallicin, we were required to pay up to $80.0 million in milestone payments based on the achievement of certain product development results. In April 2015 we terminated our license agreement with Nerviano Medical Sciences, S.r.l. for brostallicin. No milestone payments were made prior to the termination of the license agreement.

Other Agreements

We have several agreements with contract research organizations, third-party manufacturers, and distributors which have durations of greater than one year for the development and distribution of certain of our compounds.

X

- Definition
Collaborations.
+ References
No definition available.
+ Details

Name: ctic_CollaborationsAbstract

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation
12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation
12. Share-Based Compensation

Share-Based Compensation Expense

Share-based compensation expense for all share-based payment awards made to employees and directors is measured based on the grant-date fair value estimated in accordance with GAAP. We recognize share-based compensation using the straight-line, single-award method based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Share-based compensation is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.

During the years ended December 31, 2017, 2016 and 2015, we recognized share-based compensation expense which consisted of the following types of awards (in thousands):

2017

2016

2015
Performance rights
$
—

$
575

$
3,155

Restricted stock
1,015

4,199

8,656

Options
4,731

8,550

3,017

Total share-based compensation expense
$
5,746

$
13,324

$
14,828

The following table summarizes share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, which was allocated as follows (in thousands):

2017

2016

2015
Research and development
$
911

$
2,320

$
3,964

Selling, general and administrative
4,835

11,004

10,864

Total share-based compensation expense
$
5,746

$
13,324

$
14,828

Share-based compensation had a $5.7 million, $13.3 million and $14.8 million effect on our net loss attributable to common shareholders, which resulted in a $(0.16), $(0.48) and $(0.79) effect on basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015, respectively. It had no effect on cash flows from operations or financing activities for the periods presented; however, during the years ended 2017, 2016 and 2015, we repurchased 21,000, 35,000 and 32,000 shares of our common stock totaling $0.1 million, $0.4 million and $0.6 million, respectively, for cash in connection with the vesting of employee restricted stock awards based on taxes owed by employees upon vesting.

As of December 31, 2017, unrecognized compensation cost related to unvested stock options, restricted stock awards and restricted stock units amounted to $9.9 million, which will be recognized over the remaining weighted-average requisite service period of 2.28 years. The unrecognized compensation cost related to unvested options and restricted stock does not include the value of performance-based awards.

For the years ended December 31, 2017, 2016 and 2015, no tax benefits were attributed to share-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.

Stock Plans

In May 2017, the Company's 2017 Equity Incentive Plan, or the 2017 Plan, was approved by the Company's shareholders, and no additional awards will be granted under the 2015 Equity Incentive Plan, or the 2015 Plan.

The Company's 2007 Employee Stock Purchase Plan, as amended and restated in August 2009 and September 2015, or the Purchase Plan, was amended in September 2015 to increase the maximum number of shares of the Company’s common stock authorized for issuance by 0.2 million shares. Refer to Employee Stock Purchase Plan below for further details.

Pursuant to our 2017 Plan, we may grant the following types of incentive awards: (1) stock options, including incentive stock options and non-qualified stock options, (2) stock appreciation rights, (3) restricted stock, (4) restricted stock units and (5) cash awards. The 2017 Plan is administered by the Compensation Committee of our Board, which has the discretion to determine the employees and consultants who shall be granted incentive awards. The Board retained sole authority under the 2017 Plan with respect to non-employee directors’ awards, although the Compensation Committee has authority under its charter to make recommendations to the Board concerning such awards. Options expire 10 years from the date of grant, subject to the recipients continued service to the Company.

As of December 31, 2017, 8.3 million shares were authorized for issuance, of which 24,000 shares of common stock were available for future grants, under the 2017 Plan.

Stock Options

Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:

Year Ended December 31,

2017

2016

2015
Risk-free interest rate
1.9
%

1.2
%

1.7
%
Expected dividend yield
None

None

None

Expected life (in years)
5.2

4.0

5.3

Volatility
83
%

75
%

80
%

The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available for U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid dividends on our common stock and do not currently expect to do so in the future. The expected term of options represents the period that our options are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised options. Consideration was given to the contractual terms of our options, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.

Our stock price volatility and option lives, both of which impact the fair value of options calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option, involve management’s best estimates. As we recognize compensation expense for only the portion of options expected to vest, we apply estimated forfeiture rates that we derive from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.

The following table summarizes stock option activity for all of our stock option plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(Thousands)
Outstanding at December 31, 2014 (317,400 exercisable)
492,000

$
31.39

Granted
1,149,000

$
13.94

Exercised
(8,000
)

$
13.98

Forfeited
(62,000
)

$
21.70

Cancelled and expired
(12,000
)

$
242.92

Outstanding at December 31, 2015 (436,100 exercisable)
1,559,000

$
17.45

Granted
1,511,000

$
6.43

Exercised
—

$
—

Forfeited
(128,000
)

$
9.07

Cancelled and expired
(136,000
)

$
25.58

Outstanding at December 31, 2016 (1,913,000 exercisable)
2,806,000

$
11.44

Granted
4,450,000

$
3.68

Exercised
—

$
—

Forfeited
(378,000
)

$
6.27

Cancelled and expired
(210,000
)

$
24.33

Outstanding at December 31, 2017
6,668,000

$
6.15

7.0

$
—

Vested or expected to vest at December 31, 2017
6,410,000

$
6.26

6.9

$
9

Exercisable at December 31, 2017
2,500,000

$
9.83

3.2

$
—

The weighted average exercise price of options exercisable at December 31, 2017, 2016 and 2015 was $9.83, $12.58 and $25.71, respectively. The weighted average grant-date fair value of options granted during 2017, 2016 and 2015 was $2.47, $3.01 and $9.17 per option, respectively.

In March 2017, Dr. Adam R. Craig, our President and CEO, was granted stock options to purchase 1.2 million shares of common stock at an exercise price of $4.24 per share. The stock options have a maximum term of ten years and vest in six equal semi-annual installments over the three-year period beginning March 20, 2017, subject to his continued employment through the applicable vesting dates and acceleration under certain circumstances. The stock options were granted in connection with his entering into employment with the Company as President and CEO. A portion of the stock options covering 80,000 shares were granted under the 2015 Plan. The balance of such stock options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

Restricted Stock

We issued 2,000, 270,000 and 570,000 shares of restricted stock awards in 2017, 2016 and 2015, respectively. The weighted average grant-date fair value of restricted stock awards issued during 2017, 2016 and 2015 was $5.78, $5.64 and $20.61, respectively. Additionally, 39,000, 97,000 and 177,000 shares of restricted stock awards were cancelled during 2017, 2016 and 2015, respectively.

The total fair value of restricted stock awards vested during the years ended December 31, 2017, 2016 and 2015 was $0.3 million, $1.3 million and $7.3 million, respectively.

A summary of the status of nonvested restricted stock awards as of December 31, 2017 and changes during the period then ended, is presented below:

Nonvested Shares

Weighted Average
Grant-Date Fair Value
Per Share
Nonvested at December 31, 2016
183,000

$
12.76

Issued
2,000

$
5.78

Vested
(83,000
)

$
9.43

Forfeited
(39,000
)

$
14.39

Nonvested at December 31, 2017
63,000

$
15.93

We issued 20,000, 187,000 and 46,000 restricted stock units during 2017, 2016 and 2015, respectively, and cancelled 13,000 restricted stock units during 2015. No restricted stock units were cancelled during 2017 or 2016. The weighted average grant-date fair value of restricted stock units issued during 2017, 2016 and 2015 was $4.97, $5.35 and $15.70, respectively. The total fair value of restricted stock units vested during the year ended December 31, 2017 and 2016 was $0.8 million and $0.2 million, respectively. No restricted stock units vested during the year ended December 31, 2015.

A summary of the status of nonvested restricted stock units as of December 31, 2017 and changes during the period then ended, is presented below:

Nonvested Units

Weighted Average
Grant-Date Fair Value
Per Unit
Nonvested at December 31, 2016
187,000

$
5.35

Issued
20,000

$
4.97

Vested
(187,000
)

$
5.35

Forfeited
—

$
—

Nonvested at December 31, 2017
20,000

$
4.97

Long-Term Performance Awards

In November 2011, we granted restricted stock units to our executive officers and directors that became effective on January 3, 2012, or the Long-Term Performance Awards, which was subsequently amended in 2013, 2014 and 2015. The Long-Term Performance Awards vest upon achievement of milestone-based performance conditions, including a market-based condition. If one or more of the underlying performance-based conditions were timely achieved, the award recipient would be entitled to receive a number of shares of our common stock (subject to share limits of the 2007 Plan or 2015 Plan, as applicable), determined by multiplying (1) the award percentage corresponding to that particular performance goal by (2) the total number of outstanding shares of our common stock as of the date that the particular performance goal is achieved.

In September 2015, our Board certified completion of the performance condition relating to pacritinib Phase 3 trial result that satisfies the primary point set forth in the statistical plan then in effect and an aggregate of 0.2 million shares vested to our executive officers and directors. We recognized $2.8 million in share-based compensation upon satisfaction of this performance condition during the year ended December 31, 2015.

In December 2015, the Long-Term Performance Awards were modified so that as to any particular performance goal that was achieved after December 23, 2015 and on or before December 31, 2016, the executive officers would be granted a stock option with respect to the number of shares determined under the formula described above (as opposed to receiving or retaining such number of fully-vested shares of our common stock). Each option had an exercise price equal to the closing price of the Company’s common stock on the grant date (which would be the date the Compensation Committee of our Board certifies the performance goal is achieved) and would be scheduled to vest in semi-annual installments over a period of three years following the grant date.

On December 31, 2016, the Long-Term Performance Awards expired.

The fair value of the Long-Term Performance Awards was estimated based on the average present value of the awards to be issued upon achievement of the performance conditions. The average present value was calculated based upon the expected date the shares of common stock underlying the performance awards will vest, or the event date, the expected stock price on the event date, and the expected shares outstanding as of the event date. The event date, stock price and the shares outstanding were estimated using a Monte Carlo simulation model, which is based on assumptions by management, including the likelihood of achieving the milestones and potential future financings.

We determined the Long-Term Performance Awards with a market-based performance condition had a grant-date fair value of $3.6 million for the executive officers and director participants. We determined that the market-based performance condition had an incremental fair value of $0.8 million on the first modification date in March 2013 and an additional incremental fair value of $1.8 million on the second modification date in January 2014 for the executive officers and director participants, which were recognized in addition to the then-unamortized fair value as of the modification date over the remaining estimated requisite service period. The December 2015 modification discussed above did not result in incremental fair value. In December 2015, we reversed the total share-based compensation expense of $1.0 million, which was previously recorded for awards granted to directors who agreed to forfeit their Long-Term Performance Awards as part of the derivative lawsuit settlement. See Note 18. Legal Proceedings for further information. We recognized $0.6 million and $0.3 million in share-based compensation expense related to the awards with a market-based condition during the years ended December 31, 2016 and 2015, respectively. There was no compensation expense for the year ended December 31, 2017 as the Long-Term Performance Awards expired on December 31, 2016.

Nonemployee Share-Based Compensation

Share-based compensation expense for awards granted to nonemployees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of options and restricted stock awards granted to nonemployees is periodically remeasured as the underlying options or awards vest. The value of the instrument is amortized to expense over the vesting period with final valuation measured on the vesting date. As of December 31, 2017 and 2016, unvested options to acquire approximately 4,400 shares and 11,000 shares of common stock were outstanding, respectively. We reversed compensation expense of $8,000 during the year ended December 31, 2017 and recorded $16,000 during the year ended December 31, 2016. As of December 31, 2015, there were no unvested options or restricted stock outstanding, and no compensation expense was recorded for the year-ended December 31, 2015.

Employee Stock Purchase Plan

Under the Purchase Plan, eligible employees may purchase a limited number of shares of our common stock at 85% of the lower of the subscription date fair market value and the purchase date fair market value. There are two six-month offerings per year. Under the Purchase Plan, we issued approximately 4,000, 10,000 and 700 shares of our common stock to employees in the years ended December 31, 2017, 2016 and 2015, respectively. There are 0.2 million shares of common stock authorized under the Purchase Plan and approximately 0.2 million shares are reserved for future purchases as of December 31, 2017.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1

Employee Benefit Plans
12 Months Ended

Dec. 31, 2017

Retirement Benefits [Abstract]

Employee Benefit Plans
13. Employee Benefit Plans

Our U.S. employees participate in the CTI BioPharma Corp. 401(k) Plan whereby eligible employees may defer up to 80% of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded $0.3 million related to discretionary matching contributions during the year ended December 31, 2017, and $0.2 million during each of the years ended December 31, 2016 and 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1

Shareholder Rights Plan
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Shareholder Rights Plan
14. Shareholder Rights Plan

In December 2009, our Board approved and adopted a shareholder rights plan, or Rights Plan, in which one preferred stock purchase right was distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI’s common stock outstanding as of, and issued subsequent to January 7, 2010. In 2012, 2015 and 2017, our Board approved certain amendments to the Rights Plan. The Rights Plan expires on December 2, 2018.

Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of two ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of $16.00 per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires 20% or more of our common stock. Upon acquisition of 20% or more of our common stock, our Board could decide that each right (except those held by a 20% shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. In certain circumstances, including if there are insufficient shares of our common stock to permit the exercise in full of the rights, the holder may receive units of preferred stock, other securities, cash or property, or any combination of the foregoing.

In addition, if we are acquired in a merger or other business combination transaction, each holder of a right (except those held by a 20% shareholder which become null and void) would have the right to receive, upon exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the right. Our Board may redeem the rights for $0.0002 per right or terminate the Rights Plan at any time prior to an acquisition by a person or group holding 20% or more of our common stock.

X

- Definition
Stockholder rights plan.
+ References
No definition available.
+ Details

Name: ctic_StockholderRightsPlanTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1

Customer and Geographic Concentrations
12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Customer and Geographic Concentrations
15. Customer and Geographic Concentrations

We consider our operations to be a single operating segment focused on the development, acquisition and commercialization of novel treatments for cancer. Financial results of this reportable segment are presented in the accompanying consolidated financial statements.

All sales of PIXUVRI during the years presented were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:

Year Ended December 31,

2017

2016

2015
Customer A
61
%

60
%

41
%
Customer B
24
%

27
%

42
%
Customer C
13
%

—

—

As of April 2017, Servier has the exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note 11. Collaboration, Licensing and Milestone Agreements for further details.

The following table depicts long-lived assets based on the following geographic locations (in thousands):

Year Ended December 31,

2017

2016
United States
$
2,365

$
2,990

Europe
—

33

Total long-lived assets
$
2,365

$
3,023

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1

Net Loss Per Share
12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Loss Per Share
16. Net Loss Per Share

Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, as their inclusion would have an anti-dilutive effect. Accordingly, diluted net loss per share is the same as basic net loss per share.

The computation of net loss per share is as follows (in thousands, except per share amounts):

Year Ended December 31,

2017

2016

2015
Net loss attributable to common shareholders
$
(45,020
)

$
(52,009
)

$
(122,622
)
Basic and diluted:

Weighted average shares outstanding
36,569

28,198

19,324

Less weighted average restricted shares outstanding
(124
)

(250
)

(487
)
Shares used in calculation of basic and diluted net loss per common share
36,445

27,948

18,837

Net loss per common share: Basic and diluted
$
(1.24
)

$
(1.86
)

$
(6.51
)

Equity awards, warrants, unvested share rights and other convertible securities aggregating 5.2 million shares, 2.7 million shares and 1.5 million shares for the years ended December 31, 2017, 2016 and 2015, respectively, prior to the application of the treasury stock method, have been excluded from the calculation of diluted net loss per share because they were anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1

Related Party Transactions
12 Months Ended

Dec. 31, 2017

Related Party Transactions [Abstract]

Related Party Transactions
17. Related Party Transactions

Aequus

We have a majority ownership interest in Aequus. In May 2007, we entered into a license agreement with Aequus
whereby Aequus gained rights to our Genetic Polymer™ technology. We also entered into an agreement to fund Aequus in
exchange for a convertible promissory note.

In March 2017, we and Aequus entered into a License and Promissory Note Termination Agreement and a Note Cancellation Agreement, pursuant to which (1) all of the then-outstanding principal, plus all accrued and unpaid interest, approximately $13.7 million in total, was cancelled and terminated, (2) our license agreement with Aequus was terminated, (3) all obligations to Aequus were terminated with the exception of providing additional funding of up to $347,500 to Aequus, and (4) Aequus agreed to pay us a) 20% of milestone and similar payments, up to a maximum amount of $20.0 million, and b) royalties, on a product-by-product and county-by country basis, of 5% of net sales of certain ACTH Products being developed by Aequus. The additional funding of $347,500 had been provided in full as of September 30, 2017. Payments from Aequus are due the later of (1) expiration of the last to expire valid patent claim that claims the ACTH Product, or (2) ten years from the first commercial sale of the applicable ACTH Product. We have the right to terminate the License and Promissory Note Termination Agreement and require Aequus to assign all ACTH Product related assets to us if Aequus does not file an Investigational New Drug Application for an ACTH Product with the FDA by September 6, 2019.

Jack W. Singer, M.D., our Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer, and Global Head of Translational Medicine, and Frederick W. Telling, Ph.D., a member of our Board, are minority shareholders of Aequus, owning approximately 4.3% and 3.8% of the equity in Aequus as of December 31, 2017, respectively. Dr. Telling is the Chairman of Aequus' Board of Directors. Dr. Singer and Richard Love, a member of our Board, are also members of Aequus’ Board of Directors.

BVF Partners L.P.

In September 2015, as discussed in Note 9. Common Stock, we entered into a subscription agreement with BVF pursuant to which we issued 1.0 million shares of our common stock. Further, as discussed in Note 8. Preferred Stock, we completed underwritten public offerings of 55,000 shares of our Series N-2 Preferred Stock, no par value per share in December 2015 and 22,500 shares of our Series N-3 Preferred Stock, no par value per share in June 2017. BVF purchased 30,000 shares of our Series N-2 Preferred Stock and 6,750 shares of our Series N-3 Preferred Stock in such offerings. BVF converted 30,000 shares of our Series N-2 Preferred Stock and 6,175 shares of our Series N-3 Preferred Stock into approximately 2.7 million shares and 4.1 million shares of our common stock, respectively. Primarily as a result of these transactions, BVF beneficially owned approximately 20.0% and 15.9% of our outstanding common stock as of December 31, 2017 and 2016, respectively. Matthew D. Perry, a member of our Board, is the President of BVF and portfolio manager for the underlying funds managed by the firm.

In connection with the Series N-2 Preferred Stock offering, we entered into a letter agreement with BVF, or the First Letter Agreement, pursuant to which we granted BVF a one-time right, subject to certain conditions, to nominate not more than two individuals to serve as members of our Board, subject to the Board’s consent, which is not to be unreasonably withheld and which consent shall be deemed automatically given with respect to two individuals specified in such Letter Agreement. One of such nominees (the “Independent Nominee”) must (1) qualify as an “independent” director as defined under the applicable rules and regulations of the SEC and the NASDAQ, and (2) must not be considered an “affiliate” of BVF as such term is defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have agreed, for the period hereinafter described and subject to a limited exception, to include the nominated directors in the slate of nominees for election to the Board at each annual or special meeting at which directors are to be elected, recommend that shareholders vote in favor of the election of such nominees and support such nominees for election in a manner no less favorable than how we support our own nominees. This obligation will terminate with respect to: (1) the Independent Nominee, and such Independent Nominee must tender his or her resignation to the Board, if requested, promptly upon BVF ceasing to beneficially own at least 11% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), and (2) each of the Independent Nominee and the other individual nominated by BVF, and each such nominee shall tender his or her resignation to the Board promptly upon the earlier to occur of (a) BVF and its affiliates ceasing to beneficially own at least 5% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), (b) BVF ceasing to beneficially own at least 50% of the shares of the common stock beneficially owned by BVF immediately after consummation of the Series N-2 Preferred Stock offering (on an as-converted basis), (c) the continuation of such nomination right would cause any violation of the applicable listing rules of NASDAQ, (d) such time as BVF informs us in writing that it wishes to terminate the foregoing nomination right, or (e) any breach of the Letter Agreement by BVF.

In connection with the offering of Series N-3 Preferred Stock, we entered into a letter agreement with BVF, or the Second Letter Agreement, and pursuant to the First Letter Agreement and the Second Letter Agreement, we agreed to, upon BVF’s election and subject to any board and committee approvals, exchange shares of common stock purchased by BVF directly from us or underlying convertible preferred stock purchased by BVF directly from us, including the shares of common stock underlying the Series N-3 Preferred Stock, into shares of a convertible non-voting preferred stock with substantially similar terms as the Series N-3 Preferred Stock, including a conversion “blocker” initially set at 9.99% of our common stock. Such right would terminate if at any time BVF’s beneficial ownership of our common stock falls below 5%.

In February 2018, in connection with the public offering of common stock as discussed in Note 21. Subsequent Events, BVF purchased 6.3 million shares of our common stock. In addition, BVF exchanged 8.0 million shares of our common stock owned by BVF and 575 shares of our Series N Preferred Stock owned by BVF for 12,575 shares of our Series O Preferred Stock, pursuant to the letter agreements discussed above as well as an additional exchange agreement executed in February 2018. As a result of these transactions, BVF beneficially owned approximately 12.0% of our common stock as of February 28, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1

Legal Proceedings
12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Legal Proceedings
18. Legal Proceedings

Italian VAT Assessments
In April 2009, December 2009 and June 2010, the Italian Tax Authority, or the ITA, issued notices of assessment to CTI (Europe) based on the ITA’s audit of CTI (Europe)’s VAT returns for the years 2003, 2005, 2006 and 2007, or, collectively, the VAT Assessments. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We are defending ourselves against the assessments both on procedural grounds and on the merits of the case although we can make no assurances regarding the ultimate outcome of these cases. Following is a summary of the status of the legal proceedings surrounding each respective VAT year return at issue:

2003. In June 2013, the Regional Tax Court issued decision no. 119/50/13 in regards to the 2003 VAT assessment, which accepted the appeal of the ITA and reversed the previous decision of the Provincial Tax Court. In January 2014, we appealed such decision to the Italian Supreme Court both on procedural grounds and on the merits of the case. In March 2014, we paid a deposit in respect of the 2013 VAT matter of €0.4 million (or $0.6 million upon conversion from euros as of the date of payment), following the ITA's request for such payment.

2005. In January 2018, the Italian Supreme Court issued decision No. 02250/2018 which (i) rejected the appeal of the ITA, (ii) confirmed the decision of the Regional Tax Court which ruled fully in our favor, and (iii) due to the novelty of the arguments at stake, compensated the legal expenses incurred by the parties. ITA may not use any ordinary means of appeal against the Supreme Court decision.

2006 and 2007. The ITA has appealed to the Italian Supreme Court the decisions of the respective appellate court which were favorable to CTI with respect to the consolidated 2006 and 2007 VAT cases (joined by the judge).

No hearing has been fixed yet for the 2003 and consolidated 2006/2007 VAT cases.
If the final decision of the Italian Supreme Court is unfavorable to us, or if, in the interim, the ITA were to make a demand for payment and we were to be unsuccessful in suspending collection efforts, we may be requested to pay the ITA an amount up to €3.9 million, or approximately $4.7 million converted using the currency exchange rate as of December 31, 2017, plus collection fees, notification expenses and additional interest for the period lapsed between the dates in which the assessments were issued and the date of effective payment. In January 2013, our then remaining deposit for the VAT Assessments was refunded to us.

Lopez & Gilbert v. Nudelman,et al
In July 2014, Joseph Lopez and Gilbert Soper, shareholders of the Company, filed a derivative lawsuit purportedly on behalf of the Company, which is named a nominal defendant, against all current and one past member of our Board of Directors in King County Superior Court in the State of Washington, docketed as Lopez & Gilbert v. Nudelman, et al., Case No. 14-2-18941-9 SEA. The lawsuit alleges that the directors exceeded their authority under the Company's 2007 Equity Incentive Plan, or the Plan, by improperly transferring 4,756,137 shares (or 475,613 shares adjusted for the 1-for-10 reverse stock split effective January 1, 2017) of the Company’s common stock from the Company to themselves. It alleges that the directors breached their fiduciary duties by granting themselves fully vested shares of Company common stock, which the plaintiffs allege were not among the six types of grants authorized by the Plan, and that the non-employee directors were unjustly enriched by these grants. The lawsuit also alleges that from 2011 through 2014, the non-employee members of our Board of Directors granted themselves grossly excessive compensation, and in doing so breached their fiduciary duties and were unjustly enriched. Among other remedies, the lawsuit seeks a declaration that the specified grants of common stock violated the Plan, rescission of the granted shares, disgorgement of the compensation awards to the non-employee directors from 2011 through 2014, disgorgement of all compensation and other benefits received by the defendant directors in the course of their breaches of fiduciary duties, damages, an order for certain corporate reforms and plaintiffs’ costs and attorneys’ fees. Because the complaint is derivative in nature, it does not seek monetary damages from the Company. In September 2014, the director defendants moved to dismiss the complaint. The motion to dismiss was heard on November 21, 2014, and the Court entered an order denying the motion to dismiss on December 5, 2014. Defendants' answer to the complaint was filed on January 13, 2015. On May 13, 2015, the Company (as nominal defendant) and our directors (as individual defendants) entered into a memorandum of understanding to settle the pending lawsuit in King County Superior Court in the State of Washington docketed as  Lopez & Gilbert v. Nudelman, et al ., Case No. 14-2-18941-9 SEA, or the Settlement. On December 10, 2015, the court issued an order granting final approval to the Settlement.

The provisions of the Settlement include the following terms:
•
We will cancel, and the non-employee directors will agree to, the rescission of all currently outstanding equity awards that we previously granted to non-employee directors that included performance-based vesting metrics and as to which the performance goals remained unsatisfied as of May 13, 2015;
•
Our current non-employee directors will agree to hold (not transfer or sell or encumber in any way) until September 14, 2015 shares of our stock that they currently own and that we awarded to them during 2011, or at any time after 2011 to the present, and that, at the time of the award by us, was fully-vested and unrestricted;
•
We will cap the total annual compensation provided by us to our non-employee directors for each of 2015 and 2016. Such annual compensation cap for each non-employee director for each of 2015 and 2016 will be at the greater of (i) $375,000 plus, as to our Board Chairman, an additional $100,000, or (ii) the 75th percentile of compensation paid by a group of peer companies to their non-employee directors (and, in the case of our Chairman, the 75th percentile of compensation paid by such peers who have a non-employee director chair of their respective board of directors to such non-employee director chairs). The peer group for these purposes will be selected based on advice from an outside compensation consultant. For purposes of the compensation cap and the peer group comparison, compensation will be determined and measured consistent with the rules under Item 402 of Regulation S-K under the Securities Exchange Act of 1934, as amended, and based on publicly-available information at the applicable time; and

•
We will implement, if not already implemented, within 90 days following final approval of the Settlement by the court, and maintain until at least the end of calendar year 2017 the following: an annual board discussion of non-employee director compensation philosophy; the use of a compensation consultant to advise the Compensation Committee on material decisions concerning non-employee director compensation issues and compare our non-employee director compensation program to a group of our peers; the use of plain language in our compensation-related public filings; and obtain confirmation from our legal department and outside legal counsel advising on executive compensation matters that any contemplated non-employee director awards do not materially violate the applicable plan or materially fail to comply with applicable law.

In connection with the Settlement, we recorded $0.3 million in attorneys’ fees awarded to plaintiffs (net of existing insurance coverage) in our financial statements for the year-ended December 31, 2015.

Securities and Exchange Commission Subpoena

We previously disclosed that we had received a subpoena from the SEC in January 2016. We believe that the SEC is seeking to determine whether there have been possible violations of the antifraud and certain other provisions of the federal securities laws related to the Company's disclosures concerning, among other things, the clinical test results of pacritinib. The SEC Staff's letter sent with the subpoena stated that the investigation is a fact-finding inquiry, and the investigation and subpoena do not mean that the SEC has concluded that we or anyone else has violated any law. We are cooperating with this investigation, which is ongoing.

In re CTI BioPharma Corp. Securities Litigation

On February 10, 2016 and February 12, 2016, class action lawsuits entitled Ahrens v. CTI BioPharma Corp. et al., Case No. 1:16-cv-01044 and McGlothlin v. CTI BioPharma Corp. et al., Case No. C16-216, respectively, were filed in the United States District Court for the Southern District of New York and the United States District Court for the Western District of Washington, respectively, on behalf of shareholders that purchased or acquired the Company’s securities pursuant to our September 24, 2015 public offering and/or shareholders who otherwise acquired our stock between March 4, 2014 and February 9, 2016, inclusive. The complaints assert claims against the Company and certain of our current and former directors and officers for violations of the federal securities laws under Sections 11 and 15 of the Securities Act of 1933, as amended, or the Securities Act, and Sections 10 and 20 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, Plaintiffs’ Securities Act claims allege that the Company’s Registration Statement and Prospectus for the September 24, 2015 public offering contained materially false and misleading statements and failed to disclose certain material adverse facts about the Company’s business, operations and prospects, including with respect to the clinical trials and prospects for pacritinib. Plaintiffs’ Exchange Act claims allege that the Company’s public disclosures were knowingly or recklessly false and misleading or omitted material adverse facts, again with a primary focus on the clinical trials and prospects for pacritinib. On May 2, 2016, the Company filed a motion to transfer the Ahrens case to the United States District Court for the Western District of Washington. The motion was unopposed and granted by the court on May 19, 2016. On June 3, 2016, the parties filed a joint motion to consolidate the McGlothlin case with the Ahrens case in order to proceed as a single consolidated proceeding. On June 13, 2016, the court granted the motion to consolidate with the action being captioned In re CTI BioPharma Corp. Securities Litigation, Master File No. 2:16-cv-00216-RSL. On September 2, 2016, the court appointed Lead Plaintiffs and Lead Counsel. On September 28, 2016, the court entered a scheduling order, as revised by order entered December 8, 2016, setting November 8, 2016 as the deadline to file a consolidated class action complaint and deadlines for briefing defendants’ motion to dismiss. Briefing concluded on February 22, 2017. The consolidated class action complaint asserts claims similar to those asserted in the initial complaints, although it no longer asserts claims relating to the September 24, 2015 public offering, but adds claims relating to the Company’s October 27, 2015 and December 4, 2015 public offerings. On July 26, 2017, we received a written offer for the global resolution and settlement of the consolidated action in exchange for cash payment of $20.0 million. The Company had insurance coverage related to this matter that covered $18.0 million of the claim. In August 2017, we agreed in principle to the terms of the settlement and submitted the terms and proposed class notice to the court for its preliminary approval. On October 24, 2017, the court granted preliminary approval, and on February 1, 2018, the court fully and finally approved the settlement and dismissed all claims against the Company with prejudice.

Wei v. James A. Bianco, et al.; England v. James A Bianco, et al; Nahar v. James A. Bianco, et al.; Hill v. James A. Bianco, et al.

On March 14, 2016, a Company shareholder filed the first of four similar derivative lawsuits on behalf of the Company seeking damages for alleged harm to the Company caused by certain current and former officers and directors. The first suit, Wei v. James A. Bianco, et al., 16-2-05818-3, was filed in King County Superior Court, Washington. A second suit, England v. James A. Bianco, et al., 16-2-14422-5, was filed in King County Superior Court, Washington, on June 16, 2016. Two additional derivative suits, Nahar v. James A. Bianco, et al., 2:16-cv-0756, and Hill v. James A. Bianco, et al., 2:16-cv-1250, were filed in the United States District Court for the Western District of Washington on May 24, 2016 and August 9, 2016, respectively. The four suits raise similar allegations and seek similar relief against certain current and former officers and directors, including James A. Bianco, Louis A. Bianco, Jack W. Singer, Bruce J. Seeley, John H. Bauer, Phillip M. Nudelman, Reed V. Tuckson, Karen Ignagni, Richard L. Love, Mary O. Mundinger and Frederick W. Telling. Consistent with the requirements of a derivative action, the Company is named in each suit as a nominal defendant against which no monetary relief is sought. The complaints generally allege claims of: (1) breach of fiduciary duty; (2) abuse of control; (3) gross mismanagement; and (4) waste of corporate assets and (5) unjust enrichment (receiving compensation that was unjust in light of the alleged conduct). Each claim is based on the assertion that the Company made materially false and misleading statements and omitted material information from its disclosures about pacritinib and its safety. Plaintiffs in none of the suits made a pre-suit demand on the current Board to investigate whether to pursue claims against officers or directors, instead claiming demand is excused because the named defendants lack independence, are not disinterested because they lack impartiality, received and want to continue to receive their compensation, have longstanding personal and business relationships, and cannot evaluate a demand since they are facing personal liability. Each of plaintiffs’ suits requested the court to award the Company the damages allegedly sustained as a result of the conduct and to direct the Company and the individual defendants to reform and improve the Company’s corporate governance to avoid future damages. On March 29, 2017 during mediation, the parties to the derivative suits reached an agreement in principle to settle all four suits subject to Board and court approvals. Subject to the terms and conditions in the settlement agreement and court approval, CTI has agreed to adopt certain corporate governance reforms relating to, among other things, the content of CTI-retained independent data monitoring committee charters; engagement if an independent expert or entity to conduct yearly audits of compliance with Good Clinical Practices; the creation of a risk compliance officer position; certain improvements to CTI’s Audit Committee, including the requirement that the Audit Committee review CTI’s periodic public reports to facilitate proper disclosure of risks and risk factors; establishment of an internal audit function that will monitor the Company’s adherence to its policies and procedures, including those related to identification and disclosure of drug candidate safety issues; continuing-education requirements for members of the Board; and improvements to CTI’s nominating committee, compensation committee, and clawback policy. CTI also agreed not to object to an attorneys’ fee application by plaintiffs’ counsel of up to $0.8 million collectively, subject to the terms and conditions in the settlement agreement and court approval. There is no admission of liability or any wrongdoing by any of the individual defendants or CTI. On September 25, 2017, the King County Superior Court entered an order substituting Kevin Hammond for former Lead Plaintiff Gang Wei and Maurio Eley for former Lead Plaintiff Michael England, and the two case captions were amended as reflected above. The parties filed settlement-approval papers on October 26, 2017. On November 21, 2017, the Court preliminarily approved the settlement, and on January 31, 2018, the Court fully and finally approved the settlement and dismissed all claims against the Company and the individual defendants with prejudice.

In connection with the securities litigation and four derivative lawsuits described above, after taking into account our existing insurance coverage, we recorded $2.2 million of settlement expense in Selling, general and administrative expenses in our consolidated statement of operations for the year ended ended December 31, 2017.

In addition to the items discussed above, we are from time to time subject to legal proceedings and claims arising in the ordinary course of business.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136
+ Details

Name: us-gaap_LegalMattersAndContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes
12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes
19. Income Taxes

We file income tax returns in the U.S., Italy and the U.K. A substantial part of our operations takes place in the State of Washington, which does not impose an income tax as that term is defined in ASC 740, Accounting for Income Taxes. As such, our state income tax expense or benefit, if recognized, would be immaterial to our operations. We are not currently under examination by an income tax authority, nor have we been notified that an examination is contemplated.

The U.S. signed into law, on December 22, 2017, tax reform legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017, or the 2017 Tax Act. The 2017 Tax Act significantly revises the U.S. corporate income tax by, among other things, lowering the statutory corporate tax rate from 35% to 21%, eliminating certain deductions, imposing a mandatory one-time tax on accumulated earnings of foreign subsidiaries, introducing new tax regimes, and changing how foreign earnings are subject to U.S. tax. The 2017 Tax Act also enhances and extends through 2026 the option to claim accelerated depreciation deductions on qualified property. We have completed our determination of the accounting implications of the 2017 Tax Act, the impact of which is a $41.3 million reduction in net deferred tax assets to reflect the new statutory rate. The rate adjustment to deferred tax assets, a discrete item for the quarter, is fully offset by a decrease in the valuation allowance: there is therefore no rate impact to us. In addition, there is no impact to current or deferred taxes related to the one-time deemed repatriation, as our foreign subsidiaries do not have cumulative positive earnings and profits.

Loss before income taxes is attributable to the following tax jurisdictions (in thousands):

2017

2016

2015
United States
$
(40,180
)

$
(51,856
)

$
(110,831
)
Foreign
(651
)

(1,097
)

(9,932
)
Net loss before income taxes
$
(40,831
)

$
(52,953
)

$
(120,763
)

The reconciliation between our effective tax rate and the income tax rate as of December 31 is as follows:

2017

2016

2015
Federal income tax rate
34
%

34
%

34
%
Research and development tax credits
3

1

3

Non-deductible executive compensation
—

—

(1
)
Valuation allowance
304

(33
)

(32
)
Foreign tax rate differential
—

—

(3
)
Impact of tax reform
(101
)

—

—

Expired tax attribute carryforwards
(240
)

—

—

Other
—

(2
)

(1
)
Net effective tax rate
—
%

—
%

—
%

The principal components of our deferred tax assets and liabilities were as follows (in thousands):

December 31,

2017

2016
Deferred tax assets:

Net operating loss carryforwards
$
21,005

$
108,372

Capitalized research and development
27,540

43,768

Research and development tax credit carryforwards
1,347

7,253

Stock-based compensation
12,842

19,288

Intangible assets
8,117

14,525

Depreciation and amortization
472

626

Other deferred tax assets
2,279

3,721

Total deferred tax assets
73,602

197,553

Less: valuation allowance
(73,310
)

(197,131
)

292

422

Deferred tax liabilities:

Deductions for tax in excess of financial statements
(292
)

(422
)
Total deferred tax liabilities
(292
)

(422
)
Net deferred tax assets
$
—

$
—

As of December 31, 2017 and 2016, we had U.S. federal net operating loss carryforwards, or the NOL, of approximately $74.8 million and $305.4 million respectively, which are available to reduce future taxable income. We also had U.S. federal tax credits of $1.3 million and $7.3 million as of December 31, 2017 and 2016, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will begin to expire in 2018 and may become subject to annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, or the IRC, of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or future tax liabilities. We have undertaken a formal IRC Section 382 study and the attributes disclosed in this footnote reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years.

At December 31, 2017, the NOL carryforwards in the U.K.,which have an indefinite carryforward period, were approximately $31.2 million.

We maintain a full valuation allowance on our net deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In our valuation, we considered our cumulative loss in recent years and forecasted losses in the near term as significant negative evidence. Based upon a review of the four sources of income identified within ASC 740, we determined that the negative evidence outweighed the positive evidence and that a full valuation allowance on our net deferred tax assets will be maintained. We will continue to assess the realizability of our deferred tax assets going forward and will adjust the valuation allowance as needed. Our valuation allowance decreased by $123.8 million during the year ended December 31, 2017, and increased by $23.2 million and $38.7 million during the years ended December 31, 2016 and 2015, respectively. The reduction in the valuation allowance for 2017 was attributable to the reduction in tax rate due to the 2017 Tax Act as well as the reduction in net operating losses as a result of the 2017 Section 382 analysis.

We adopted ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting, in 2017. Due to the fact that there was no excess tax benefit over book expense related to stock compensation, the adoption had no impact to the deferred tax assets.

We follow the provisions ASC 740, Accounting for Income Taxes, and the guidance related to accounting for uncertainty in income taxes. We determine our uncertain tax positions based on a determination of whether and how much of a tax benefit taken by us in our tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. We are subject to U.S. federal and state, Italian and U.K. income taxes with varying statutes of limitations. Tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2017, we had no unrecognized tax benefits and therefore no accrued interest or penalties related to unrecognized tax benefits. We believe that our income tax filing positions reflected in the various tax returns are more-likely-than not to be sustained on audit and thus there are no anticipated adjustments that would result in a material change to our consolidated financial position, results of operations and cash flows. Therefore, no reserves for uncertain income tax positions have been recorded.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1

Unaudited Quarterly Data
12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Data
20. Unaudited Quarterly Data

The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
2017

Total revenues (1)
$
754

$
22,225

$
1,705

$
462

Product sales, net
626

227

—

—

Gross profit (2)
493

149

(69
)

(84
)
Net income (loss) attributable to CTI
(19,828
)

5,398

(11,974
)

(14,266
)
Net income (loss) attributable to CTI common shareholders
(19,828
)

1,048

(11,974
)

(14,266
)
Net income (loss) per common share—basic
(0.71
)

0.03

(0.28
)

(0.33
)
Net income (loss) per common share—diluted
(0.71
)

0.03

(0.28
)

(0.33
)
2016

Total revenues (3)
$
36,475

$
7,361

$
4,433

$
9,136

Product sales, net
1,223

975

914

1,015

Gross profit (2)
1,033

815

751

151

Net income (loss) attributable to CTI
3,312

(19,766
)

(29,183
)

(6,372
)
Net income (loss) attributable to CTI common shareholders
3,312

(19,766
)

(29,183
)

(6,372
)
Net income (loss) per common share—basic
0.12

(0.71
)

(1.04
)

(0.23
)
Net income (loss) per common share—diluted
0.12

(0.71
)

(1.04
)

(0.23
)
(1)
Total revenues for the second quarter of 2017 include $11.8 million of license and contract revenue recognized in April 2017 in connection with the Restated Agreement with Servier as well as a $10.0 million milestone payment received from Teva upon the achievement of worldwide net sales milestones of TRISENOX. See Note 11. Collaboration, Licensing and Milestone Agreements for additional information.
(2)
Gross profit is computed by subtracting cost of product sold from net product sales.
(3)
Total revenues for the first quarter of 2016 include $32.0 million in milestone revenue upon achievement of two milestones during the quarter. The payments from Baxalta relating to these milestones were received in 2015. See Note 7. Long-term Debt for additional information. The fourth quarter of 2016 includes $8.0 million in milestone revenue from Servier relating to the attainment of a certain enrollment event in connection with our PIX306 study.

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-URI http://asc.fasb.org/topic&trid=2126967
+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1

Subsequent Events
12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

Subsequent Events
21. Subsequent Events

Reincorporation Merger

In January 2018, CTI BioPharma Corp., a Delaware corporation ("CTI DE" or, after giving effect to the Reincorporation Merger (defined below), the “Company”), a wholly owned subsidiary of CTI BioPharma Corp., a Washington corporation (“CTI WA”), entered into an Agreement and Plan of Merger, or the Merger Agreement, with CTI WA, pursuant to which CTI WA would merge with and into CTI DE for the sole purpose of reincorporating CTI WA in the State of Delaware (the “Reincorporation Merger”). The Reincorporation Merger and the Merger Agreement were approved by the Board of CTI WA and by a majority of the votes actually cast by the shareholders entitled to vote at CTI WA’s Special Meeting of Shareholders held on January 24, 2018, or the Effective Date. On the Effective Date, CTI DE and CTI WA effected the Reincorporation Merger, thereby changing the state of incorporation of CTI BioPharma Corp. from the State of Washington to the State of Delaware pursuant to the Merger Agreement. As a result of the Reincorporation Merger, CTI WA ceased to exist as a separate entity.

CTI DE’s common stock, par value $0.001 per share, or the Common Stock, will continue to trade on the NASDAQ. The Company’s trading symbol remains as “CTIC.” In accordance with Rule 12g-3 under the Exchange Act, the shares of Common Stock of the Company were deemed to be registered under Section 12(b) of the Exchange Act as a successor to CTI WA. The Delaware Charter authorizes the same number of shares of the Common Stock and each class of preferred stock of CTI WA, except that all subseries of Series N Preferred Stock are eliminated and reclassified as Series N Preferred Stock and the number of authorized Series N Preferred Stock is reduced to 575. In addition, each share of CTI DE common stock and preferred stock has a par value of $0.001 per share.

The Reincorporation Merger changed the legal domicile of CTI WA, but did not result in any change in the principal offices, business, management, capitalization, assets or liabilities of the Company. By operation of law, the Company succeeded to all of the assets and assumed all of the liabilities of CTI WA. The officers and directors of CTI WA are the officers and directors of the Company. As a result of the Reincorporation Merger, the Company has assumed all of the CTI WA employee benefit plans and stock incentive plans in effect at the Effective Date, including CTI WA’s 2017 Equity Incentive Plan, 2015 Equity Incentive Plan, 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan, or the Stock Plans, and any and all stock options, restricted stock and restricted stock unit awards, and other equity-based awards that are outstanding under any of the Stock Plans or any individual award agreements outside of the Stock Plans. The Company has also assumed CTI WA’s rights plan with Computershare Trust Company, N.A., as rights agent, dated as of December 28, 2009 and amended on August 31, 2012, December 3, 2012, December 1, 2015 and September 22, 2017.

Public Offering of Common Stock

In February 2018, we entered into an underwriting agreement with Leerink Partners LLC acting as sole book-running manager and as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the offer and sale (the “Offering”) of 20.0 million shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Offering closed on February 13, 2018. The price to the public in this Offering was $3.00 per share of Common Stock. The Underwriters exercised in full their option to purchase an additional 3.0 million shares. The net proceeds from this Offering, after deducting underwriting discounts, commissions and other estimated offering expenses, were approximately $64.2 million.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1

Schedule II Valuation and Qualifying Accounts
12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts
Schedule II. Valuation and Qualifying Accounts
Valuation and qualifying accounts include the following (in thousands):

Additions

(1)

(2)

Balance at

Charged to

Charged to

Balance at

beginning of

costs and

other

(3)

end of
Description
period

expenses

accounts

Deductions

period
Reserve for excess, obsolete or unsalable inventory:

Year ended December 31, 2017
$
1,510

$
—

$
204

$
(347
)

$
1,367

Year ended December 31, 2016
$
1,265

$
692

$
(19
)

$
(428
)

$
1,510

Year ended December 31, 2015
$
—

$
1,326

$
(25
)

$
(36
)

$
1,265

Allowance for doubtful accounts:

Year ended December 31, 2016
$
—

$
1,735

$
—

$
(1,735
)

$
—

(1) We review our inventories on a quarterly basis for impairment and reserves are established when necessary.
(2) We record inventory in euros and we record foreign currency translation gains and losses from recurring measurement of our inventory in Accumulated other comprehensive loss in our consolidated balance sheets.
(3) The amount of reserve is adjusted for the items disposed of during the period.

X

- Definition
The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ValuationAndQualifyingAccountsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1

Description of Business and Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Description of Business
CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Annual Report on Form 10-K as “we,” “us,” “our,”  the “Company” and “CTI”, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating
pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partners Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, have commercialization rights outside the United States, or the U.S.

We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products requires approval from, and is subject to, ongoing oversight by the Food and Drug Administration, or the FDA, in the United States, or the U.S., the European Medicines Agency, or the EMA, in the European Union, or the E.U., and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.

Principles of Consolidation
Principles of Consolidation

The accompanying consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include CTI Life Sciences Limited, or CTILS. We also retain ownership of our branch, CTI BioPharma Corp.- Sede Secondaria, or CTI (Europe) which has ceased operations. Systems Medicine LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in December 2017.

As of December 31, 2017, we also had an approximately 60% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.

All intercompany transactions and balances are eliminated in consolidation.

Liquidity
Liquidity

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

We will need to continue to conduct research, development, testing and regulatory compliance activities with respect to our compounds and ensure the procurement of manufacturing and drug supply services, the costs of which, together with projected general and administrative expenses, is expected to result in operating losses for the foreseeable future. In October 2016, we resumed primary responsibility for the development and commercialization of pacritinib as a result of the termination of the Pacritinib License Agreement with Baxalta Incorporated and its affiliates, or Baxalta, and are no longer eligible to receive cost sharing or milestone payments for pacritinib's development. We have incurred a net operating loss every year since our formation. As of December 31, 2017, we had an accumulated deficit of $2.2 billion, and we expect to incur net losses for the foreseeable future.

Our available cash, cash equivalents and restricted cash were $43.2 million as of December 31, 2017. In February 2018, as discussed in Note 21. Subsequent Events, we completed the public offering of common stock and received approximately $64.2 million in net proceeds after deducting underwriting discounts, commissions and other estimated offering expenses. In addition, we received a $10.0 million milestone payment from Teva Pharmaceutical Industries Ltd. relating to the achievement of a milestone for FDA approval of TRISENOX for first line treatment of acute promyelocytic leukemia. We believe that our present financial resources, together with payments projected to be received under certain contractual agreements and our ability to control costs, will be sufficient to fund our operations at least through the next twelve months from the date these financial statements were issued. We previously disclosed that we had substantial doubt about our ability to continue as a going concern, which was primarily due to lack of liquidity. This has since been alleviated as a result of the proceeds we received from the public offering of common stock as well as the milestone payment.

We may need to acquire additional funds in order to develop our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly-qualified personnel, be unable to obtain and maintain contracts necessary to continue our operations and at affordable rates with competitive terms, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying consolidated consolidated financial statements do not include adjustments, if any, that may result from the outcome of this uncertainty.

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. For example, estimates include assumptions used in calculating reserves for sales deductions such as rebates and returns of product sold, allowances for credit losses, and excess and obsolete inventory, recording share-based compensation expense, accruals, the allocation of operating expenses, provision for loss contingencies, the fair value of financial instruments, our tax provision and related valuation allowance, and determining the useful lives of fixed assets and potential impairment of long-lived assets. Actual results could differ from those estimates.

Certain Risks, Uncertainties and Concentrations
Certain Risks, Uncertainties and Concentrations

Our results of operations are subject to foreign currency exchange rate fluctuations primarily due to our activity in Europe. We report the results of our operations in U.S. dollars, while the functional currency of our foreign subsidiaries is the euro. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, the reported carrying value of our euro-denominated assets and liabilities that remain in our European branches and subsidiaries will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. We review our foreign currency risk periodically along with hedging options to mitigate such risk.

We source our drug products for clinical trials from a concentrated group of third-party contractors. If we are unable to obtain sufficient quantities of source materials, manufacture or distribute our products to customers from existing suppliers and service providers, or obtain the materials or services from other suppliers, manufacturers or distributors, certain research and development and sales activities may be delayed.

Additionally, see Note 15. Customer and Geographic Concentrations for further concentration disclosure.

Cash, Cash Equivalents, and Restricted Cash
Cash and Cash Equivalents

We consider all highly liquid debt instruments with maturities of three months or less at the time acquired to be cash equivalents. Cash equivalents represent short-term investments consisting of investment-grade corporate and government obligations, carried at cost, which approximates market value. We had no cash equivalents as of December 31, 2017.

Restricted Cash

Restricted cash represents a legally restricted deposit held as a compensating balance against our senior secured term loan with Silicon Valley Bank, or SVB. Pursuant to the loan and security agreement entered into with SVB in November 2017, we were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million at all times prior to the occurrence of an event relating to the delivery to SVB of duly executed signatures to a control agreement from Bank of America with respect to all of our accounts maintained with Bank of America. In January 2018, we obtained a waiver from SVB for such requirement and as a result, we no longer have restrictions placed on the cash balance. See Note 7. Long-term Debt for further details regarding our senior secured term loan with SVB.

Accounts Receivable
Receivables from Collaborative Arrangements
Our receivables from collaborative arrangements relate to amounts payable or reimbursable to us under the terms of collaborative arrangements with our partners.
Receivables from collaborative arrangements are reviewed for collectability whenever circumstances indicate that the carrying amount of the receivable may not be recoverable.

Value Added Tax Receivable
Value Added Tax Receivable

Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable was approximately $4.8 million and $4.4 million as of December 31, 2017 and 2016, respectively, of which $4.7 million and $4.1 million was included in other assets and $0.1 million and $0.3 million was included in prepaid expenses and other current assets as of December 31, 2017 and 2016, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of December 31, 2017, the VAT receivable related to operations in Italy was approximately $4.8 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.

Inventory
Inventory

We carry inventory at the lower of cost or net realizable value. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the distribution of PIXUVRI. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We review our inventories on a quarterly basis for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsalable inventory, the value is written down to the net realizable value.

Property and Equipment
Property and Equipment

Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation commences at the time assets are placed in service. We calculate depreciation using the straight-line method over the estimated useful lives of the assets ranging from three to five years for assets other than leasehold improvements. We amortize leasehold improvements over the lesser of their useful life of 10 years or the term of the applicable lease.

Impairment of Long-lived Assets
Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on fair market values.

Leases
Leases

We analyze leases at the inception of each agreement for classification as either an operating or capital lease. Certain of our lease agreement terms include rent holidays, rent escalation clauses and incentives for leasehold improvements. We recognize deferred rent relating to incentives for rent holidays and leasehold improvements and amortize the deferred rent over the term of the leases as a reduction of rent expense. For rent escalation clauses, we recognize rent expense equal to the amount of total minimum lease payments on a straight-line basis over the term of the lease. A deferred liability recognized in connection with the December 2017 sublease arrangement is amortized over the term of the sublease as a reduction of rent expense.

Fair Value Measurement
Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.

Level 3 - Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

At December 31, 2017 and 2016, the carrying value of financial instruments such as receivables and payables approximated their fair values due to their short-term maturities. The carrying value of our long-term debt approximated its fair value at December 31, 2017 and 2016 based on borrowing rates for similar loans and maturities.

Contingencies
Contingencies

We record liabilities associated with loss contingencies to the extent that we conclude that the occurrence of the contingency is probable and that the amount of the related loss is reasonably estimable. We record income from gain contingencies only upon the realization of assets resulting from the favorable outcome of the contingent event. See Note 11. Collaboration, Licensing and Milestone Agreements and Note 18. Legal Proceedings for further information regarding our current gain and loss contingencies.

Revenue Recognition
Revenue Recognition

We currently have conditional marketing authorization for PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.

Product Sales
PIXUVRI was sold primarily through a limited number of wholesale distributors. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary. As of April 2017, Servier has the
exclusive and sublicensable (subject to certain conditions) royalty-bearing license with respect to the development and commercialization of PIXUVRI for use in pharmaceutical products, or Licensed Products, outside of the U.S. (and its territories and possessions). As a result, we no longer have product sales. See Note 11. Collaboration, Licensing and Milestone Agreements for further details.

Collaboration Agreements
Collaboration Agreements

We evaluate collaboration agreements to determine whether the multiple elements and associated deliverables can be considered separate units of accounting in accordance with Accounting Standards Codification, or ASC, 605-25, Revenue Recognition—Multiple-Element Arrangements. If it is determined that the deliverables under the collaboration agreement are a single unit of accounting, all amounts received or due, including any upfront payments, are recognized as revenue over the performance obligation periods of each agreement. Upon the completion of the performance obligation, such amounts will be recognized as revenue when collectability is reasonably assured.

The assessment of multiple element arrangements requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate point in time, or period of time, that revenue should be recognized. In order to account for these agreements, we identify deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

Milestone payments under collaboration agreements are generally aggregated into three categories for reporting purposes: (1) development milestones, (2) regulatory milestones and (3) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable (1) upon submission for marketing approval with the FDA or with the regulatory authorities of other countries, and (2) upon receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.

At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (1) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.

We follow ASC 605-25, Revenue Recognition – Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the accounting for reimbursement arrangements under collaborative research and development and commercialization agreements.

Cost of Product Sold
Cost of Product Sold

Cost of product sold includes third-party manufacturing costs, shipping costs, contractual royalties, and other costs of PIXUVRI product sold. Cost of product sold also includes allowances, if any, for excess inventory that may expire and become unsalable.

Research and Development Expenses
Research and Development Expenses

Research and development costs are expensed as incurred in accordance with the FASB ASC 730, Research and Development. Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Other types of arrangements with third parties may be fixed fee or fee for service, and may include monthly payments or payments upon completion of milestones or receipt of deliverables. We expense upfront license payments related to acquired technologies that have not yet reached technological feasibility and have no alternative future use.

Foreign Currency Translation and Transaction Gains and Losses
Foreign Currency Translation and Transaction Gains and Losses

We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity, except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.

The intercompany balance due from CTILS is considered to be of a long-term nature.

Income Taxes
Income Taxes

We record a tax provision for the anticipated tax consequences of our results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We provide a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

Net Loss per Share
Net Loss per Share

Basic net loss per common share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period. The calculation of diluted net loss per common share excludes the potential conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock, using the if-converted method, and the potential exercise or vesting of other dilutive securities, such as options, warrants and restricted stock, using the treasury stock method, as their inclusion would have an anti-dilutive effect.

Recently Accounting Standards
Recently Adopted Accounting Standards

In April 2015, the FASB issued a new accounting standard which changes the presentation of debt issuance costs in financial statements. Under the new standard, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The accounting standard is effective for annual reporting periods beginning after December 15, 2015 and interim periods beginning after December 15, 2016. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In July 2015, the FASB issued new accounting guidance on simplifying the measurement of inventory which requires
that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2016. The adoption of this standard did not have a material impact on our consolidated financial statements.

In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The adoption of this guidance did not have an impact on our consolidated financial statements.

In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period and to provide related footnote disclosures in certain circumstances. The accounting standard is effective for annual reporting periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard in the fourth quarter of 2016 did not have a material impact on our consolidated financial statements.

In March 2016, the FASB issued new accounting guidance for employee share-based payments accounting. The accounting standard primarily affects the accounting for forfeitures, minimum statutory tax withholding requirements, and income tax effects related to share-based payments at settlement (or expiration). The accounting guidance is effective for annual reporting periods beginning after December 15, 2016 (including interim periods within those periods). We have historically maintained a full valuation allowance against deferred tax assets. The adoption of this standard in the first quarter of 2017 did not have a material impact on our consolidated financial statements, and we will continue to estimate expected forfeitures.

In November 2016, the FASB issued accounting guidance which amends ASC 230, Statement of Cash Flows, to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments require that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Consequently, transfers between cash and restricted cash will not be presented as a separate line item in the operating, investing or financing sections of the cash flow statement. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods therein. The early adoption is permitted. The adoption of this standard did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In May 2014, the FASB issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five-step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. We will adopt the new standard in the first quarter 2018 using the modified retrospective method. We have completed the impact on our customer contracts and do not expect the implementation of ASU 2014-09 to have a material quantitative impact on our consolidated financial statements. Under the new standard, such customer arrangements will be accounted for as variable consideration, which may result in revenue being recognized earlier provided we can reliably estimate the ultimate price expected to be realized from the customer. In addition, we do not expect a material cumulative effect adjustment to Retained earnings upon adoption of the standard on January 1, 2018. Adoption of the new standard will also result in additional revenue-related disclosures in the footnotes to our consolidated financial statements.

In February 2016, the FASB issued a new accounting guidance on accounting for leases which requires lessees to recognize virtually all of their leases (other than leases that meet the definition of a short-term lease) on the balance sheet. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018. Early adoption is permitted. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.

In August 2016, the FASB issued an amendment to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows with the objective of reducing diversity in practice regarding eight types of cash flows. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of this standard to have a material impact on our statement of cash flows.

Reclassifications
Reclassifications

Certain prior year items have been reclassified to conform to current year presentation.

X

- Definition
Certain risks and uncertainties policy.
+ References
No definition available.
+ Details

Name: ctic_CertainRisksAndUncertaintiesPolicyTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Descriptions of business policy.
+ References
No definition available.
+ Details

Name: ctic_DescriptionsOfBusinessPolicyTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Liquidity Disclosure [Policy Text Block]
+ References
No definition available.
+ Details

Name: ctic_LiquidityDisclosurePolicyTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Value added tax receivable policy.
+ References
No definition available.
+ Details

Name: ctic_ValueAddedTaxPolicyTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for collaborative arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_CollaborativeArrangementAccountingPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249
+ Details

Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84161450&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 50
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68069731&loc=d3e63676-111659

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CostOfSalesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524
+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1

Description of Business and Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides reconciliations of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

December 31, 2017

December 31, 2016

December 31, 2015
Cash and cash equivalents
$
27,218

$
44,002

$
128,182

Restricted cash
16,000

—

—

Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows
$
43,218

$
44,002

$
128,182

X

- Definition
Schedule Of Reconciliation Of Cash And Cash Equivalents, Restricted Cash And Cash Equivalents [Table Text Block]
+ References
No definition available.
+ Details

Name: ctic_ScheduleOfReconciliationOfCashAndCashEquivalentsRestrictedCashAndCashEquivalentsTableTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventory (Tables)
12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Components of Inventories
The components of PIXUVRI inventories consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Finished goods
$
394

$
477

Work-in-process
1,523

2,558

Inventory, gross
$
1,917

$
3,035

Reserve for excess, obsolete or unsalable inventory
$
(1,367
)

$
(1,510
)
Inventory, net
$
550

$
1,525

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property and Equipment (Tables)
12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment
Property and equipment are composed of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Furniture and office equipment
$
4,552

$
6,521

Leasehold improvements
5,168

5,106

Lab equipment
209

201

9,929

11,828

Less: accumulated depreciation and amortization
(7,564
)

(8,805
)
Property and equipment, net
$
2,365

$
3,023

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accrued Expenses (Tables)
12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Summary of Accrued Expenses
Accrued expenses consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Clinical and investigator-sponsored trial expenses
$
5,019

$
7,303

Employee compensation and related expenses
4,432

6,364

Manufacturing expenses
2,637

7,616

Legal expenses
537

1,037

Selling expenses
143

136

Insurance financing
575

888

Interest expenses
93

2

Other
454

1,419

Total accrued expenses
$
13,890

$
24,765

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1

Leases (Tables)
12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Schedule of Future Minimum Operating Lease Payments and Receivables
Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at December 31, 2017 were as follows (in thousands):

Operating

Sublease

Leases

Rentals

Net
2018
$
2,487

$
771

$
1,716

2019
2,532

1,365

1,167

2020
2,584

1,410

1,174

2021
2,580

1,454

1,126

2022
868

499

369

Thereafter
—

—

—

Total minimum lease commitments
$
11,051

$
5,499

$
5,552

Schedule of Future Minimum Operating Lease Payments and Receivables
Future minimum lease commitments for non-cancelable operating leases, net of sublease rentals, at December 31, 2017 were as follows (in thousands):

Operating

Sublease

Leases

Rentals

Net
2018
$
2,487

$
771

$
1,716

2019
2,532

1,365

1,167

2020
2,584

1,410

1,174

2021
2,580

1,454

1,126

2022
868

499

369

Thereafter
—

—

—

Total minimum lease commitments
$
11,051

$
5,499

$
5,552

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Liabilities (Tables)
12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Components of Other Liabilities
Other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):

2017

2016
Deferred rent, less current portion
$
3,050

$
3,011

Other long-term obligations
2,419

604

Total other liabilities
$
5,469

$
3,615

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1

Common Stock (Tables)
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Summary of Common Stock Reserved for Issuance
A summary of common stock reserved for issuance is as follows as of December 31, 2017 (in thousands):
Equity incentive plans
5,920

Option agreement with Adam R. Craig
1,120

Common stock purchase warrants
219

Series N-3 convertible preferred stock
383

Employee stock purchase plan
184

Total common stock reserved
7,826

X

- Definition
Schedule of common stock reserved for future issuance.
+ References
No definition available.
+ Details

Name: ctic_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Comprehensive Loss (Tables)
12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Total Accumulated Other Comprehensive Loss
Total accumulated other comprehensive loss consisted of the following (in thousands):

Net Unrealized
Gain (Loss) and Impairment on
Available-For-Sale Securities

Foreign
Currency
Translation
Adjustments

Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance

Accumulated
Other
Comprehensive
Loss
December 31, 2016
$
(6
)

$
(2,902
)

$
(3,747
)

$
(6,655
)
Current period other comprehensive income (loss)
7

(3,927
)

4,303

383

December 31, 2017
$
1

$
(6,829
)

$
556

$
(6,272
)

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration, Licensing and Milestone Agreements (Tables)
12 Months Ended

Dec. 31, 2017

Collaborations [Abstract]

Allocation of Arrangement Consideration
We allocated the arrangement consideration of $12.8 million (€12.0 million converted into U.S. dollars using the
currency exchange rate as of the date of the Restated Agreement) based on the percentage of the relative selling price of each
unit of accounting as follows (in thousands):

License
$
11,487

Development and other services
1,348

Total upfront payment
$
12,835

X

- Definition
Collaborations.
+ References
No definition available.
+ Details

Name: ctic_CollaborationsAbstract

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of collaborative arrangements revenue recognition.
+ References
No definition available.
+ Details

Name: ctic_ScheduleOfCollaborativeArrangementsRevenueRecognitionTableTextBlock

Namespace Prefix: ctic_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation (Tables)
12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation Expense by Types of Awards
During the years ended December 31, 2017, 2016 and 2015, we recognized share-based compensation expense which consisted of the following types of awards (in thousands):

2017

2016

2015
Performance rights
$
—

$
575

$
3,155

Restricted stock
1,015

4,199

8,656

Options
4,731

8,550

3,017

Total share-based compensation expense
$
5,746

$
13,324

$
14,828

Summary of Share-Based Compensation Expense
The following table summarizes share-based compensation expense for the years ended December 31, 2017, 2016 and 2015, which was allocated as follows (in thousands):

2017

2016

2015
Research and development
$
911

$
2,320

$
3,964

Selling, general and administrative
4,835

11,004

10,864

Total share-based compensation expense
$
5,746

$
13,324

$
14,828

Schedule of Black Scholes Stock Option Pricing Model Weighted Average Assumptions
Fair value for stock options was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:

Year Ended December 31,

2017

2016

2015
Risk-free interest rate
1.9
%

1.2
%

1.7
%
Expected dividend yield
None

None

None

Expected life (in years)
5.2

4.0

5.3

Volatility
83
%

75
%

80
%

Stock Option Activity for All Stock Plans
The following table summarizes stock option activity for all of our stock option plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(Thousands)
Outstanding at December 31, 2014 (317,400 exercisable)
492,000

$
31.39

Granted
1,149,000

$
13.94

Exercised
(8,000
)

$
13.98

Forfeited
(62,000
)

$
21.70

Cancelled and expired
(12,000
)

$
242.92

Outstanding at December 31, 2015 (436,100 exercisable)
1,559,000

$
17.45

Granted
1,511,000

$
6.43

Exercised
—

$
—

Forfeited
(128,000
)

$
9.07

Cancelled and expired
(136,000
)

$
25.58

Outstanding at December 31, 2016 (1,913,000 exercisable)
2,806,000

$
11.44

Granted
4,450,000

$
3.68

Exercised
—

$
—

Forfeited
(378,000
)

$
6.27

Cancelled and expired
(210,000
)

$
24.33

Outstanding at December 31, 2017
6,668,000

$
6.15

7.0

$
—

Vested or expected to vest at December 31, 2017
6,410,000

$
6.26

6.9

$
9

Exercisable at December 31, 2017
2,500,000

$
9.83

3.2

$
—

Summary of Status of Nonvested Restricted Stock Awards and Units
A summary of the status of nonvested restricted stock units as of December 31, 2017 and changes during the period then ended, is presented below:

Nonvested Units

Weighted Average
Grant-Date Fair Value
Per Unit
Nonvested at December 31, 2016
187,000

$
5.35

Issued
20,000

$
4.97

Vested
(187,000
)

$
5.35

Forfeited
—

$
—

Nonvested at December 31, 2017
20,000

$
4.97

A summary of the status of nonvested restricted stock awards as of December 31, 2017 and changes during the period then ended, is presented below:

Nonvested Shares

Weighted Average
Grant-Date Fair Value
Per Share
Nonvested at December 31, 2016
183,000

$
12.76

Issued
2,000

$
5.78

Vested
(83,000
)

$
9.43

Forfeited
(39,000
)

$
14.39

Nonvested at December 31, 2017
63,000

$
15.93

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1

Customer and Geographic Concentrations (Tables)
12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Product Sales from Major Customers
All sales of PIXUVRI during the years presented were in Europe. Product sales from PIXUVRI’s major customers as a percentage of total product sales were as follows:

Year Ended December 31,

2017

2016

2015
Customer A
61
%

60
%

41
%
Customer B
24
%

27
%

42
%
Customer C
13
%

—

—

Long-Lived Assets Based on Geographical Locations
The following table depicts long-lived assets based on the following geographic locations (in thousands):

Year Ended December 31,

2017

2016
United States
$
2,365

$
2,990

Europe
—

33

Total long-lived assets
$
2,365

$
3,023

X

- Definition
Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599
+ Details

Name: us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1

Net Loss Per Share (Tables)
12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Shares
The computation of net loss per share is as follows (in thousands, except per share amounts):

Year Ended December 31,

2017

2016

2015
Net loss attributable to common shareholders
$
(45,020
)

$
(52,009
)

$
(122,622
)
Basic and diluted:

Weighted average shares outstanding
36,569

28,198

19,324

Less weighted average restricted shares outstanding
(124
)

(250
)

(487
)
Shares used in calculation of basic and diluted net loss per common share
36,445

27,948

18,837

Net loss per common share: Basic and diluted
$
(1.24
)

$
(1.86
)

$
(6.51
)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Loss Before Income Taxes
Loss before income taxes is attributable to the following tax jurisdictions (in thousands):

2017

2016

2015
United States
$
(40,180
)

$
(51,856
)

$
(110,831
)
Foreign
(651
)

(1,097
)

(9,932
)
Net loss before income taxes
$
(40,831
)

$
(52,953
)

$
(120,763
)

Reconciliation Between Effective Tax Rate and Income Tax Rate
The reconciliation between our effective tax rate and the income tax rate as of December 31 is as follows:

2017

2016

2015
Federal income tax rate
34
%

34
%

34
%
Research and development tax credits
3

1

3

Non-deductible executive compensation
—

—

(1
)
Valuation allowance
304

(33
)

(32
)
Foreign tax rate differential
—

—

(3
)
Impact of tax reform
(101
)

—

—

Expired tax attribute carryforwards
(240
)

—

—

Other
—

(2
)

(1
)
Net effective tax rate
—
%

—
%

—
%

Significant Components of Deferred Tax Assets and Liabilities
The principal components of our deferred tax assets and liabilities were as follows (in thousands):

December 31,

2017

2016
Deferred tax assets:

Net operating loss carryforwards
$
21,005

$
108,372

Capitalized research and development
27,540

43,768

Research and development tax credit carryforwards
1,347

7,253

Stock-based compensation
12,842

19,288

Intangible assets
8,117

14,525

Depreciation and amortization
472

626

Other deferred tax assets
2,279

3,721

Total deferred tax assets
73,602

197,553

Less: valuation allowance
(73,310
)

(197,131
)

292

422

Deferred tax liabilities:

Deductions for tax in excess of financial statements
(292
)

(422
)
Total deferred tax liabilities
(292
)

(422
)
Net deferred tax assets
$
—

$
—

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of income before income tax between domestic and foreign jurisdictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1

Unaudited Quarterly Data (Tables)
12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Unaudited Quarterly Financial Information
The following table presents summarized unaudited quarterly financial data (in thousands, except per share data):

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
2017

Total revenues (1)
$
754

$
22,225

$
1,705

$
462

Product sales, net
626

227

—

—

Gross profit (2)
493

149

(69
)

(84
)
Net income (loss) attributable to CTI
(19,828
)

5,398

(11,974
)

(14,266
)
Net income (loss) attributable to CTI common shareholders
(19,828
)

1,048

(11,974
)

(14,266
)
Net income (loss) per common share—basic
(0.71
)

0.03

(0.28
)

(0.33
)
Net income (loss) per common share—diluted
(0.71
)

0.03

(0.28
)

(0.33
)
2016

Total revenues (3)
$
36,475

$
7,361

$
4,433

$
9,136

Product sales, net
1,223

975

914

1,015

Gross profit (2)
1,033

815

751

151

Net income (loss) attributable to CTI
3,312

(19,766
)

(29,183
)

(6,372
)
Net income (loss) attributable to CTI common shareholders
3,312

(19,766
)

(29,183
)

(6,372
)
Net income (loss) per common share—basic
0.12

(0.71
)

(1.04
)

(0.23
)
Net income (loss) per common share—diluted
0.12

(0.71
)

(1.04
)

(0.23
)
(1)
Total revenues for the second quarter of 2017 include $11.8 million of license and contract revenue recognized in April 2017 in connection with the Restated Agreement with Servier as well as a $10.0 million milestone payment received from Teva upon the achievement of worldwide net sales milestones of TRISENOX. See Note 11. Collaboration, Licensing and Milestone Agreements for additional information.
(2)
Gross profit is computed by subtracting cost of product sold from net product sales.
(3)
Total revenues for the first quarter of 2016 include $32.0 million in milestone revenue upon achievement of two milestones during the quarter. The payments from Baxalta relating to these milestones were received in 2015. See Note 7. Long-term Debt for additional information. The fourth quarter of 2016 includes $8.0 million in milestone revenue from Servier relating to the attainment of a certain enrollment event in connection with our PIX306 study.

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)-(j)
-URI http://asc.fasb.org/extlink&oid=84173487&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
€ in Millions
1 Months Ended 12 Months Ended 31 Months Ended

Feb. 13, 2018

USD ($)

Jan. 01, 2017

shares

Feb. 28, 2018

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2017

EUR (€)

Dec. 31, 2017

USD ($)

Nov. 30, 2017

USD ($)

Dec. 31, 2016

EUR (€)

Dec. 31, 2016

USD ($)

Dec. 31, 2014

USD ($)

Description Of Business And Significant Accounting Policies [Line Items]

Reverse stock split ratio 0.1

Preferred stock outstanding (in shares) | shares 0

Accumulated deficit $ 2,195,346,000 $ 2,150,326,000

Available cash and cash equivalents $ 128,182,000 43,218,000 44,002,000 $ 70,933,000

Proceeds from common stock offering, net of issuance costs $ 0 $ 0 15,147,000

Milestone payment received 0 32,000,000 0

Cash equivalents 0

Bad debt expense 0 1,735,000 0

Allowance for doubtful accounts from collaborative arrangements 0 0

VAT receivable 4,800,000 4,400,000

Reserve for inventory 1,367,000 1,510,000

Unrealized foreign exchange gain (loss) $ 4,300,000 (1,200,000) $ (2,600,000)

Intercompany balance, due from CTILS, noncurrent € 26.2 31,400,000 € 29.7 31,200,000

Minimum | Assets Other Than Leasehold Improvements

Description Of Business And Significant Accounting Policies [Line Items]

Property and equipment useful life 3 years

Maximum | Assets Other Than Leasehold Improvements

Description Of Business And Significant Accounting Policies [Line Items]

Property and equipment useful life 5 years

Maximum | Leasehold Improvements

Description Of Business And Significant Accounting Policies [Line Items]

Property and equipment useful life 10 years

Europe | Minimum

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, collection period 3 months

Europe | Maximum

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, collection period 5 years

ITALY

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable 4,800,000

ITALY | Minimum

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, collection period 3 years

ITALY | Maximum

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, collection period 5 years

Other Assets

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, non-current 4,700,000 4,100,000

Prepaid Expenses and Other Current Assets

Description Of Business And Significant Accounting Policies [Line Items]

VAT receivable, current 100,000 $ 300,000

Silicon Valley Bank | Secured Debt | Loan and Security Agreement

Description Of Business And Significant Accounting Policies [Line Items]

Unrestricted and unencumbered cash required to be held per agreement $ 16,000,000 $ 16,000,000

Aequus Biopharma, Inc | Affiliated Entity

Description Of Business And Significant Accounting Policies [Line Items]

Interest in majority-owned subsidiary 60.00% 60.00%

Collaborative Arrangement Product Agreement | TRISENOX | Cephalon, Inc

Description Of Business And Significant Accounting Policies [Line Items]

Milestone payment received $ 10,000,000 $ 0 $ 40,000,000

Collaborative Arrangement Product Agreement | Subsequent Event | TRISENOX | Cephalon, Inc

Description Of Business And Significant Accounting Policies [Line Items]

Milestone payment received $ 10,000,000

Leerink Partners LLC | Subsequent Event

Description Of Business And Significant Accounting Policies [Line Items]

Proceeds from common stock offering, net of issuance costs $ 64,200,000 $ 64,200,000

X

- Definition
Allowance for Doubtful Accounts Receivable, Reimbursable Expense, Collaborative Arrangement
+ References
No definition available.
+ Details

Name: ctic_AllowanceforDoubtfulAccountsReceivableReimbursableExpenseCollaborativeArrangement

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of business and significant accounting policies.
+ References
No definition available.
+ Details

Name: ctic_DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Receivable Collection Period
+ References
No definition available.
+ Details

Name: ctic_ReceivableCollectionPeriod

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CompensatingBalanceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.5)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of receivables to be collected from related parties net of obligations owed to related parties after one year or beyond the normal operating cycle, if longer where one party can exercise control or significant influence over another party including, but not limited to, affiliates, owners or officers and their immediate families and pension trusts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedPartyNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ValueAddedTaxReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ValueAddedTaxReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ValueAddedTaxReceivableNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctic_AssetsOtherThanLeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_IT

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_SiliconValleyBankMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_LoanAndSecurityAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_AequusBiopharmaIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ctic_ProductSegmentAxis=ctic_ProductsCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_CephalonIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_LeerinkPartnersLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1

Description of Business and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Accounting Policies [Abstract]

Cash and cash equivalents $ 27,218 $ 44,002 $ 128,182

Restricted cash 16,000 0 0

Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 43,218 $ 44,002 $ 128,182 $ 70,933

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 63 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventory (Detail) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Inventory Disclosure [Abstract]

Finished goods $ 394 $ 477

Work-in-process 1,523 2,558

Inventory, gross 1,917 3,035

Reserve for excess, obsolete or unsalable inventory (1,367) (1,510)

Inventory, net $ 550 $ 1,525

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 64 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property and Equipment (Detail) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Property Plant And Equipment [Line Items]

Property and Equipment, Gross $ 9,929 $ 11,828

Less: accumulated depreciation and amortization (7,564) (8,805)

Property and equipment, net 2,365 3,023

Depreciation expense 717 831 $ 990

Furniture and office equipment

Property Plant And Equipment [Line Items]

Property and Equipment, Gross 4,552 6,521

Leasehold improvements

Property Plant And Equipment [Line Items]

Property and Equipment, Gross 5,168 5,106

Lab equipment

Property Plant And Equipment [Line Items]

Property and Equipment, Gross $ 209 $ 201

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accrued Expenses (Detail) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Payables and Accruals [Abstract]

Clinical and investigator-sponsored trial expenses $ 5,019 $ 7,303

Employee compensation and related expenses 4,432 6,364

Manufacturing expenses 2,637 7,616

Legal expenses 537 1,037

Selling expenses 143 136

Insurance financing 575 888

Interest expenses 93 2

Other 454 1,419

Total accrued expenses $ 13,890 $ 24,765

X

- Definition
Accrued clinical investigator expenses.
+ References
No definition available.
+ Details

Name: ctic_AccruedClinicalInvestigatorExpenses

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued interest expenses.
+ References
No definition available.
+ Details

Name: ctic_AccruedInterestExpenses

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued selling expenses current.
+ References
No definition available.
+ Details

Name: ctic_AccruedSellingExpensesCurrent

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Manufacturing expenses.
+ References
No definition available.
+ Details

Name: ctic_ManufacturingExpenses

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(a))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_AccruedInsuranceCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1

Leases - Additional Information (Detail)
ft² in Thousands
1 Months Ended 12 Months Ended

Dec. 31, 2017

USD ($)

ft²

Jan. 31, 2012

USD ($)

ft²

Option

$ / ft²

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Operating Leased Assets [Line Items]

Lease agreement area (square feet) | ft² 44 66

Lease term 120 months

Number of options to extend the term | Option 2

Extend option term 5 years

Initial annual rent payments per square foot | $ / ft² 27.00

Rent payments due in initial five months $ 0 $ 0 $ 0

Percentage of annual rent increase 3.00%

Allowance for tenant improvements $ 3,300,000

Sublease loss 1,600,000 1,584,000 $ 0 $ 0

Deferred liability 1,600,000 1,600,000

Other current liabilities 1,424,000 1,424,000 602,000

Other liabilities 5,469,000 5,469,000 3,615,000

Sublease income 100,000

Rent expense, net facilities charges and sublease income 1,600,000 $ 2,000,000 $ 2,000,000

Sublease

Operating Leased Assets [Line Items]

Other current liabilities 800,000 800,000

Other liabilities $ 600,000 $ 600,000

X

- Definition
Initial rent payments per square foot per annum for the remainder of the first 12 months.
+ References
No definition available.
+ Details

Name: ctic_InitialLeaseAnnualRentPaymentsPerSquareFoot

Namespace Prefix: ctic_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: duration

X

- Definition
Lease agreement area.
+ References
No definition available.
+ Details

Name: ctic_LeaseAgreementArea

Namespace Prefix: ctic_

Data Type: num:areaItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating leases future minimum payment due in five months.
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentDueInFiveMonths

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Option to extend lease years.
+ References
No definition available.
+ Details

Name: ctic_OptionToExtendLeaseYears

Namespace Prefix: ctic_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage increases in monthly rental payment.
+ References
No definition available.
+ Details

Name: ctic_PercentageIncreasesInMonthlyRentalPayment

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Sublease Income (Loss)
+ References
No definition available.
+ Details

Name: ctic_SubleaseIncomeLoss

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Allowance for tenant improvements from landlord to tenant.
+ References
No definition available.
+ Details

Name: ctic_TenantImprovementsAllowance

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents revenue received, but not recognized for financial reporting purposes. Such deferred revenue may consist of and include amounts paid in advance by lessees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=84165051&loc=d3e45377-112738
+ Details

Name: us-gaap_DeferredRevenueLeasesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesRentExpenseSubleaseRentals1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=ctic_SubleaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1

Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)
$ in Thousands

Dec. 31, 2017

USD ($)

Operating Leases Future Minimum Payments

Operating leases, 2018 $ 2,487

Operating leases, 2019 2,532

Operating leases, 2020 2,584

Operating leases, 2021 2,580

Operating leases, 2022 868

Operating leases, Thereafter 0

Operating leases, Total minimum lease commitments 11,051

Sublease Rentals Future Payments Receivable

Sublease rentals, 2018 771

Sublease rentals, 2019 1,365

Sublease rentals, 2020 1,410

Sublease rentals, 2021 1,454

Sublease rentals, 2022 499

Sublease rentals, Thereafter 0

Sublease rentals, Total minimum lease commitments 5,499

Operating leases, net, 2018 1,716

Operating leases, net, 2019 1,167

Operating leases, net, 2020 1,174

Operating leases, net, 2021 1,126

Operating leases, net, 2022 369

Operating leases, net, Thereafter 0

Operating leases, net, Total minimum lease commitments $ 5,552

X

- Definition
Operating Leases, Future Minimum Payments, Due In Five Years, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments, Due In Four Years, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueInFourYearsNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments, Due in Three Years, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueInThreeYearsNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments, Due in Two Years, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueInTwoYearsNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments Due, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments Due, Next Twelve Months, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueNextTwelveMonthsNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating Leases, Future Minimum Payments, Due Thereafter, Net
+ References
No definition available.
+ Details

Name: ctic_OperatingLeasesFutureMinimumPaymentsDueThereafterNet

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsRollingMaturityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lease payments to be received by lessor for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor in next fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981
+ Details

Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 68 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Liabilities (Detail) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Other Liabilities Disclosure [Abstract]

Deferred rent, less current portion $ 3,050 $ 3,011

Other long-term obligations 2,419 604

Total other liabilities 5,469 $ 3,615

Deferred liability related to sublease execution 600

Silicon Valley Bank | Secured Debt | Loan and Security Agreement

Debt Instrument [Line Items]

Fee amount on term loan $ 1,400

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents revenue received, but not recognized for financial reporting purposes, which is anticipated to be recognized for financial reporting purposes more than one year from the reporting date or one operating cycle, if longer. Such deferred revenue may consist of and include amounts paid in advance by lessees and purchase price adjustments for leases acquired in a business combination or other transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenueLeasesGrossNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherSundryLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_SiliconValleyBankMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_LoanAndSecurityAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1

Long-term Debt (Detail) - USD ($)
1 Months Ended 12 Months Ended

Nov. 30, 2017

Feb. 29, 2016

Jan. 31, 2016

Dec. 31, 2015

Jun. 30, 2015

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

May 31, 2015

Mar. 31, 2014

Mar. 31, 2013

Debt Instrument [Line Items]

Loss on debt extinguishment $ 163,000 $ 0 $ 1,211,000

License and contract revenue 24,293,000 $ 53,278,000 12,644,000

Borrowing Associated With License Agreement

Debt Instrument [Line Items]

Debt instrument stated interest rate percentage 9.00%

Borrowing Associated With License Agreement | Baxalta

Debt Instrument [Line Items]

Debt face amount $ 32,000,000

Borrowing Associated With License Agreement | EMA Milestone | Baxalta

Debt Instrument [Line Items]

License and contract revenue $ 12,000,000

Borrowing Associated With License Agreement | Persist2 Milestone | Baxalta

Debt Instrument [Line Items]

License and contract revenue $ 20,000,000

Secured Debt

Debt Instrument [Line Items]

Debt instrument unamortized discount $ 100,000

Debt face amount $ 15,000,000.0

Repaid principle face amount 14,300,000

Secured Debt | Loan and Security Agreement | Silicon Valley Bank

Debt Instrument [Line Items]

Debt instrument maximum borrowing capacity 18,000,000

Proceeds from line of credit 16,000,000

Remaining borrowing capacity 2,000,000

Legally restricted cash $ 16,000,000 16,000,000

Repayment term 36 months

Interest only period 12 months

Interest only extension period 18 months

Debt instrument stated interest rate percentage 6.75%

Fee payable when loan is paid or payable in full 9.00%

Fee amount on term loan 1,400,000

Debt issuance costs $ 100,000

Debt instrument unamortized discount $ 1,900,000 1,900,000

Debt instrument unamortized issuance cost 100,000

Outstanding principal balance $ 16,000,000

Secured Debt | Loan and Security Agreement | Participation Arrangement | Silicon Valley Bank

Debt Instrument [Line Items]

Number of warrant issued (in shares) 190,140

Warrant exercise price (in USD per share) $ 2.84

Secured Debt | Loan and Security Agreement | Participation Arrangement, Initial Exercise | Silicon Valley Bank

Debt Instrument [Line Items]

Number of warrant issued (in shares) 169,014

Secured Debt | Loan and Security Agreement | Participation Agreement, Loan Funding Contingency | Silicon Valley Bank

Debt Instrument [Line Items]

Number of warrant issued (in shares) 21,126

Secured Debt | Loan and Security Agreement | Prime Rate | Silicon Valley Bank

Debt Instrument [Line Items]

Interest rate above prime rate 2.50%

Secured Debt | Original Loan

Debt Instrument [Line Items]

Debt instrument maximum borrowing capacity $ 15,000,000.0

Secured Debt | Amended Original Loan

Debt Instrument [Line Items]

Debt instrument maximum borrowing capacity $ 5,000,000.0

Secured Debt | Third Amendment

Debt Instrument [Line Items]

Debt instrument maximum borrowing capacity 25,000,000

Proceeds from line of credit 6,200,000

Fee amount on term loan $ 1,300,000

Number of warrant issued (in shares) 29,239

Warrant exercise price (in USD per share) $ 17.10

Debt instrument, outstanding amount $ 20,000,000 $ 13,800,000

Debt instrument unused additional borrowing capacity 5,000,000

Commitment fee 15,000

Facility charge $ 300,000

Warrant exercisable period 5 years

Warrant liability $ 200,000 $ 400,000 200,000

Loss on debt extinguishment 1,200,000

Secured Debt | Fourth Amendment

Debt Instrument [Line Items]

Proceeds from line of credit 5,000,000

Debt instrument, outstanding amount $ 25,000,000 $ 25,000,000

X

- Definition
Class of warrant or right expiration period.
+ References
No definition available.
+ Details

Name: ctic_ClassOfWarrantOrRightExpirationPeriod

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Instrument, Fee Amount, Percentage
+ References
No definition available.
+ Details

Name: ctic_DebtInstrumentFeeAmountPercentage

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Instrument, Interest Only Extension Period
+ References
No definition available.
+ Details

Name: ctic_DebtInstrumentInterestOnlyExtensionPeriod

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Instrument, Interest Only Period
+ References
No definition available.
+ Details

Name: ctic_DebtInstrumentInterestOnlyPeriod

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Instrument, Repayment Term
+ References
No definition available.
+ Details

Name: ctic_DebtInstrumentRepaymentTerm

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Payment of facility charge.
+ References
No definition available.
+ Details

Name: ctic_PaymentOfFacilityCharge

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CompensatingBalanceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredFinanceCostsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the fee for available but unused credit capacity under the credit facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ProceedsFromLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_BorrowingAssociatedWithLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_BaxaltaIncorporatedAndAffiliatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ctic_MilestonePaymentsByMilestoneTypeAxis=ctic_EuropeanMedicinesAgencyMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ctic_MilestonePaymentsByMilestoneTypeAxis=ctic_Persist2MilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_LoanAndSecurityAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=ctic_SiliconValleyBankMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=ctic_ParticipationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=ctic_ParticipationArrangementInitialExerciseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=ctic_ParticipationArrangementLoanFundingContingencyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_OriginalLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_AmendedOriginalLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_ThirdAmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_FourthAmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1

Preferred Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended

Feb. 28, 2018

Jun. 30, 2017

Dec. 31, 2015

Oct. 31, 2015

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Jan. 31, 2018

Jan. 01, 2017

Class of Stock [Line Items]

Number of shares issued in conversion (in shares) 14,600,000

Conversion price (in USD per share) $ 3.0

Dividends and deemed dividends on preferred stock $ 4,350 $ 0 $ 3,200

N-3 Preferred stock outstanding (in shares) 0

Series N-1 Preferred Stock

Class of Stock [Line Items]

Stock Issued (in shares) 50,000

Proceeds from issuance of preferred stock $ 50,000

Underwriting commissions and discounts, and other offering costs $ 3,400

Preferred stock, stated value (in USD per share) $ 1,000

Number of shares converted (in shares) 50,000

Number of shares issued in conversion (in shares) 4,000,000

Conversion price (in USD per share) $ 12.50

Dividends and deemed dividends on preferred stock $ 3,200

Series N-1 Preferred Stock | Underwriters Commissions and Discounts

Class of Stock [Line Items]

Underwriting commissions and discounts $ 3,000

Series N-2 Preferred Stock

Class of Stock [Line Items]

Stock Issued (in shares) 55,000

Proceeds from issuance of preferred stock $ 55,000

Underwriting commissions and discounts, and other offering costs $ 2,600

Preferred stock, stated value (in USD per share) $ 1,000 $ 1,000

Number of shares converted (in shares) 55,000

Number of shares issued in conversion (in shares) 5,000,000

Conversion price (in USD per share) $ 11.00 $ 11.00

Series N-2 Preferred Stock | Underwriters Commissions and Discounts

Class of Stock [Line Items]

Underwriting commissions and discounts $ 2,200

Series N-3 Preferred Stock

Class of Stock [Line Items]

Stock Issued (in shares) 22,500

Proceeds from issuance of preferred stock $ 45,000

Underwriting commissions and discounts, and other offering costs $ 2,300

Preferred stock, stated value (in USD per share) $ 2,000 $ 2,000 $ 2,000

Number of shares converted (in shares) 21,925

Dividends and deemed dividends on preferred stock $ 4,400

N-3 Preferred stock outstanding (in shares) 575 0

Subsequent Event

Class of Stock [Line Items]

Preferred stock, stated value (in USD per share) $ 0.001

Common Stock

Class of Stock [Line Items]

Stock Issued (in shares) 1,000,000

Common Stock | Series N-1 Preferred Stock

Class of Stock [Line Items]

Number of shares issued in conversion (in shares) 4,000,000

Common Stock | Series N-2 Preferred Stock

Class of Stock [Line Items]

Number of shares issued in conversion (in shares) 5,000,000

Common Stock | Series N-3 Preferred Stock

Class of Stock [Line Items]

Number of shares issued in conversion (in shares) 14,616,000

BVF Partners, L.P. | Subsequent Event | Series N Preferred Stock

Class of Stock [Line Items]

Number of shares converted (in shares) 575

BVF Partners, L.P. | Subsequent Event | Series O Preferred Stock

Class of Stock [Line Items]

Number of shares issued in conversion (in shares) 12,575

BVF Partners, L.P. | Common Stock | Subsequent Event

Class of Stock [Line Items]

Stock Issued (in shares) 6,300,000

Number of shares converted (in shares) 8,000,000

X

- Definition
Stock conversion price per share.
+ References
No definition available.
+ Details

Name: ctic_StockConversionPricePerShare

Namespace Prefix: ctic_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Underwriting Commissions and Discounts
+ References
No definition available.
+ Details

Name: ctic_UnderwritingCommissionsandDiscounts

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Underwriting Commissions and Discounts, and Other Offering Costs
+ References
No definition available.
+ Details

Name: ctic_UnderwritingCommissionsandDiscountsandOtherOfferingCosts

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_PreferredStockDividendsAndOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashOnePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=ctic_UnderwriterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_BVFPartnersL.P.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesOPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1

Common Stock - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended

Sep. 30, 2015

Dec. 31, 2017

May 31, 2017

Apr. 30, 2017

Dec. 31, 2016

Apr. 30, 2016

Mar. 31, 2016

Class Of Warrant Or Right [Line Items]

Common stock authorized (in shares) 81,500,000 81,500,000 41,500,000 41,500,000 41,500,000 31,500,000

Warrants outstanding 29,239

Common stock purchase warrants | Third Amendment

Class Of Warrant Or Right [Line Items]

Number of warrant issued (in shares) 29,239

Warrant exercise price (in USD per share) $ 17.1

Common stock purchase warrants | Placement Agent

Class Of Warrant Or Right [Line Items]

Number of warrant issued (in shares) 190,140

Warrant exercise price (in USD per share) $ 2.84

Warrants outstanding 190,140

Affiliates | BVF Partner

Class Of Warrant Or Right [Line Items]

Stock issued, purchase price (in USD per share) $ 15.70

Proceeds from issuance of private placement $ 15.1

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_ThirdAmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=ctic_PlacementAgentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_BVFPartnerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Comprehensive Loss (Detail) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Changes in AOCI [Roll Forward]

Beginning Balance $ (6,655,000)

Current period other comprehensive income (loss) 383,000 $ 297,000 $ (453,000)

Ending Balance (6,272,000) (6,655,000)

Other-than-temporary impairment on available-for-sale securities $ 500,000 0 520,000 $ 0

AFS included in prepaid expenses and other current assets 1,874,000 2,141,000

Net Unrealized Gain (Loss) and Impairment on Available-For-Sale Securities

Changes in AOCI [Roll Forward]

Beginning Balance (6,000)

Current period other comprehensive income (loss) 7,000

Ending Balance 1,000 (6,000)

AFS included in prepaid expenses and other current assets 0 13,500

Foreign Currency Translation Adjustments

Changes in AOCI [Roll Forward]

Beginning Balance (2,902,000)

Current period other comprehensive income (loss) (3,927,000)

Ending Balance (6,829,000) (2,902,000)

Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance

Changes in AOCI [Roll Forward]

Beginning Balance (3,747,000)

Current period other comprehensive income (loss) 4,303,000

Ending Balance $ 556,000 $ (3,747,000)

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=ctic_UnrealizedForeignExchangeGainLossOnIntercompanyBalanceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1

Common Stock - Summary of Common Stock Reserved for Issuance (Detail)
shares in Thousands

Dec. 31, 2017

shares

Class of Stock [Line Items]

Total common stock reserved (in shares) 7,826

Series N-3 convertible preferred stock

Class of Stock [Line Items]

Total common stock reserved (in shares) 383

Common stock purchase warrants

Class of Stock [Line Items]

Total common stock reserved (in shares) 219

Options | Chief Executive Officer

Class of Stock [Line Items]

Total common stock reserved (in shares) 1,120

Equity incentive plans

Class of Stock [Line Items]

Total common stock reserved (in shares) 5,920

Employee stock purchase plan

Class of Stock [Line Items]

Total common stock reserved (in shares) 184

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ctic_EquityIncentivePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ctic_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration, Licensing and Milestone Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended 31 Months Ended

Jan. 01, 2014

USD ($)

Feb. 28, 2018

USD ($)

Sep. 30, 2017

EUR (€)

Sep. 30, 2017

USD ($)

May 31, 2017

EUR (€)

May 31, 2017

USD ($)

Dec. 31, 2016

EUR (€)

Dec. 31, 2016

USD ($)

Feb. 28, 2015

EUR (€)

Feb. 28, 2015

USD ($)

Jan. 31, 2014

USD ($)

Nov. 30, 2013

USD ($)

Dec. 31, 2017

USD ($)

Sep. 30, 2017

USD ($)

Jun. 30, 2017

USD ($)

Mar. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Sep. 30, 2016

USD ($)

Jun. 30, 2016

USD ($)

Mar. 31, 2016

USD ($)

Mar. 31, 2015

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2017

USD ($)

May 31, 2017

USD ($)

Jun. 30, 2015

USD ($)

May 31, 2012

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment received $ 0 $ 32,000,000 $ 0

Total revenues $ 462,000 $ 1,705,000 $ 22,225,000 $ 754,000 $ 9,136,000 $ 4,433,000 $ 7,361,000 $ 36,475,000 25,146,000 57,405,000 16,116,000

Purchase of preferred stock 15,147,000

License and contract revenue 24,293,000 53,278,000 12,644,000

Servier

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License revenue $ 11,487,000

Collaborative Arrangement | Servier

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Consideration received | € € 12,000,000

Milestone payment received € 1,000,000 $ 1,200,000 2,000,000

Contingency milestone payment to be received | € 76,000,000

Potential regulatory milestone payment | € 36,000,000

Potential sales based milestone payment | € € 40,000,000

Total revenues $ 12,800,000

Collaborative Arrangement | Servier | License Services

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Total revenues 11,500,000

Collaborative Arrangement | Servier | Other Services

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Deferred revenue 1,400,000 1,400,000 $ 1,400,000 $ 1,300,000

Other services consideration 500,000

Collaborative Arrangement Product Agreement | Servier

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment received € 7,500,000 $ 8,000,000 8,000,000

Operating expenses 800,000 300,000

Development services revenue 100,000 500,000 0

License and contract revenue 11,800,000

Collaborative Arrangement Product Agreement | Servier | Up-front Payment Arrangement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Consideration received € 1,500,000 $ 1,700,000

Collaborative Arrangement Product Agreement | Cephalon, Inc | TRISENOX

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment received 10,000,000 0 40,000,000

Contingency milestone payment to be received 100,000,000.0 100,000,000.0 100,000,000.0

License revenue 10,000,000

Collaborative Arrangement Product Agreement | Cephalon, Inc | TRISENOX | Subsequent Event

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment received $ 10,000,000

Collaborative Arrangement Product Agreement | Baxter

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Deferred revenue $ 0 0 $ 0 0 0 0

Development services revenue 1,000,000 800,000

Maximum amount allowed for the development costs $ 96,000,000

Collaborative Arrangement Product Agreement | Baxter | Up-front Payment Arrangement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Consideration received $ 60,000,000

Collaborative Arrangement Product Agreement | Baxter | Up-front Payment Arrangement | Series 19 Preferred Stock

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Purchase of preferred stock 30,000,000

Collaborative Arrangement Product Agreement | Baxter | License and Development Services Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Cash consideration received 30,000,000

Collaborative Arrangement Product Agreement | Baxter | License

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License revenue 27,300,000

Collaborative Arrangement Product Agreement | Baxter | Development Services

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Deferred revenue $ 2,700,000

Collaborative Arrangement Product Agreement | Novartis | PIXUVRI

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contingency milestone payment to be made $ 16,600,000.0

Percentage of royalty payable to net sales 10.00%

Collaborative Arrangement Product Agreement | Gynecologic Oncology Group

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestones obligation paid $ 500,000

Collaborative Arrangement Product Agreement | PG-TXL

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contingency milestone payment to be made 14,400,000.0 14,400,000.0 14,400,000.0

Collaborative Arrangement Product Agreement | Nerviano Medical Sciences

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment received $ 0

Contingency milestone payment to be made 80,000,000.0 80,000,000.0 80,000,000.0

Pacritinib License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License and contract revenue 32,000,000

Pacritinib License Agreement | Borrowing Associated With License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Debt outstanding $ 32,000,000

Pacritinib License Agreement | Baxter

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Development services revenue 0 11,400,000 $ 0

Asset Return and Termination Agreement | Borrowing Associated With License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Gain on termination of agreement $ 5,900,000

Contingency milestone payment to be made $ 10,300,000 $ 10,300,000 $ 10,300,000

S_BIO Asset Purchase Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contingency milestone payment to be made $ 132,500,000.0

Milestone payments through the issuance of stock 50.00% 50.00% 50.00%

X

- Definition
Cash consideration received.
+ References
No definition available.
+ Details

Name: ctic_CashConsiderationReceived

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Consideration received.
+ References
No definition available.
+ Details

Name: ctic_ConsiderationReceived

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contingent milestone payment to be made upon achievement of milestone event.
+ References
No definition available.
+ Details

Name: ctic_ContingentMilestonePaymentToBeMade

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contingent milestone payment to be received upon achievement of milestone event.
+ References
No definition available.
+ Details

Name: ctic_ContingentMilestonePaymentToBeReceived

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contingent Milestone Payment To Be Received, Regulatory
+ References
No definition available.
+ Details

Name: ctic_ContingentMilestonePaymentToBeReceivedRegulatory

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contingent Milestone Payment To Be Received, Sales
+ References
No definition available.
+ Details

Name: ctic_ContingentMilestonePaymentToBeReceivedSales

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Development services revenue.
+ References
No definition available.
+ Details

Name: ctic_DevelopmentServicesRevenue

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Milestones obligation paid.
+ References
No definition available.
+ Details

Name: ctic_MilestonesObligationPaid

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage of issuance of common stock related to milestone payments.
+ References
No definition available.
+ Details

Name: ctic_PercentageOfIssuanceOfCommonStockForMilestonePayments

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Related Party Transaction, Percentage of royalty payable to net sales.
+ References
No definition available.
+ Details

Name: ctic_RelatedPartyTransactionPercentageOfRoyaltyPayableToNetSales

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research and development range of possible development expense maximum.
+ References
No definition available.
+ Details

Name: ctic_ResearchAndDevelopmentRangeOfPossibleDevelopmentExpenseMaximum

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously reported as deferred or unearned revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnContractTermination

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=ctic_ServierMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_ServierMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=ctic_LicenseServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=ctic_OtherServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_CephalonIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ctic_ProductSegmentAxis=ctic_ProductsCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_BaxterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNineteenPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=ctic_DevelopmentAndLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=ctic_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=ctic_DevelopmentServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_NovartisInternationalPharmaceuticalLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ctic_ProductSegmentAxis=ctic_ProductsBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_GynecologicOncologyGroupMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_PGTXLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_NervianoMedicalSciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ctic_PacritinibLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_BorrowingAssociatedWithLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ctic_AssetReturnandTerminationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ctic_AgreementSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration, Licensing and Milestone Agreements - Allocated Arrangement Consideration (Detail) - Servier
$ in Thousands
1 Months Ended

May 31, 2017

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

License $ 11,487

Development and other services 1,348

Total upfront payment $ 12,835

X

- Definition
Payment received for development and other services.
+ References
No definition available.
+ Details

Name: ctic_PaymentReceivedForDevelopmentAndOtherServices

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Upfront payment.
+ References
No definition available.
+ Details

Name: ctic_UpfrontPayment

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=ctic_ServierMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Expense by Types of Awards (Detail) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 5,746 $ 13,324 $ 14,828

Performance rights

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense 0 575 3,155

Restricted stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense 1,015 4,199 8,656

Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 4,731 $ 8,550 $ 3,017

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Summary of Expense (Detail) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense $ 5,746 $ 13,324 $ 14,828

Research and development

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense 911 2,320 3,964

Selling, general and administrative

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense $ 4,835 $ 11,004 $ 10,864

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended

Mar. 31, 2017

Dec. 31, 2015

Sep. 30, 2015

Jan. 31, 2014

Mar. 31, 2013

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 5,746,000 $ 13,324,000 $ 14,828,000

Effect on basic and diluted net loss (in USD per share) $ (0.16) $ (0.48) $ (0.79)

Unrecognized compensation cost $ 9,900,000

Recognition period 2 years 3 months 10 days

Tax benefits attributed to share-based compensation expense $ 0 $ 0 $ 0

Shares of common stock reserved for future issuance (in shares) 7,826,000

Weighted average exercise price of options exercisable (in USD per share) $ 25.71 $ 12.58 $ 25.71

Weighted average fair value of options granted (in USD per share) $ 2.47 $ 3.01 $ 9.17

Unvested options to acquire shares of common stock, outstanding (in shares) 0 0

Compensation expense related to nonemployee stock options and restricted stock awards $ (8,000) $ 16,000 $ 0

2007 Equity Incentive Stock Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares authorized for issuance (in shares) 8,300,000.0

Shares available for future grants (in shares) 24,000

Employee stock purchase plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock reserved for future issuance (in shares) 184,000

Options | Chief Executive Officer

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock reserved for future issuance (in shares) 1,120,000

Options granted in period (in shares) 1,200,000.0

Exercise price of options granted (in USD per share) $ 4.24

Options | Chief Executive Officer | Stock Option Plan, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Options granted in period (in shares) 80,000

Employee stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock reserved for future issuance (in shares) 200,000

Employee stock | Employee stock purchase plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock reserved for future issuance (in shares) 200,000

Shares authorized for issuance (in shares) 200,000.0

Shares issued in period (in shares) 4,000 10,000 700

Vested Restricted Stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Repurchased shares of common stock (in shares) 21,000 35,000 32,000

Repurchased shares of common stock $ 100,000 $ 400,000 $ 600,000

Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 4,731,000 $ 8,550,000 $ 3,017,000

Weighted average exercise price of options exercisable (in USD per share) $ 9.83

Exercise price of options granted (in USD per share) $ 3.68 $ 6.43 $ 13.94

Options | 2007 Equity Incentive Stock Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Options expiration period 10 years

Restricted stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 1,015,000 $ 4,199,000 $ 8,656,000

Shares issued in period (in shares) 2,000 270,000 570,000

Weighted average fair value of restricted shares issued (in USD per share) $ 5.78 $ 5.64 $ 20.61

Restricted shares, cancelled (in shares) 39,000 97,000 177,000

Total fair value of vested restricted stock awards $ 300,000 $ 1,300,000 $ 7,300,000

Number of shares vested (in shares) 83,000

Restricted stock units (RSUs)

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares issued in period (in shares) 20,000 187,000 46,000

Weighted average fair value of restricted shares issued (in USD per share) $ 4.97 $ 5.35 $ 15.70

Restricted shares, cancelled (in shares) 0 0 13,000

Total fair value of vested restricted stock awards $ 800,000 $ 200,000

Number of shares vested (in shares) 187,000 0

Long Term Performance Awards

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 2,800,000

Number of shares vested (in shares) 200,000

Vesting period 3 years

Long Term Performance Awards, With Market Based Performance Goals

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation expense $ 0 $ 600,000 300,000

Long-Term Performance Award, total grant-date fair value $ 3,600,000 $ 3,600,000

Long-Term Performance Award, incremental grant-date fair value $ (1,000,000) $ 1,800,000 $ 800,000

Nonemployee Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Unvested options to acquire shares of common stock, outstanding (in shares) 4,400 11,000

X

- Definition
Share based compensation arrangement by share based payment award, equity instruments other than options, grant date fair value.
+ References
No definition available.
+ Details

Name: ctic_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Describes the treatment of share-based compensation on basic and diluted earnings per share computations.
+ References
No definition available.
+ Details

Name: ctic_ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted

Namespace Prefix: ctic_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation expense related to nonemployee stock options and restricted stock awards.
+ References
No definition available.
+ Details

Name: ctic_ShareBasedCompensationExpenseRelatedToNonemployeeStockOptionsAndRestrictedStockAwards

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of share instruments newly issued under a share-based compensation plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=ctic_TwoThousandAndSevenEquityIncentiveStockPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ctic_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ctic_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ctic_VestedRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ctic_LongTermPerformanceAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ctic_LongTermPerformanceAwardsWithMarketBasedPerformanceGoalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ctic_NonemployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Weighted Average Assumptions (Detail) - Stock Options
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Risk-free interest rate 1.90% 1.20% 1.70%

Expected dividend yield 0.00% 0.00% 0.00%

Expected life (in years) 5 years 2 months 15 days 4 years 5 years 3 months 20 days

Volatility 83.00% 75.00% 80.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Weighted Average Exercise Price

Weighted Average Exercise Price, Exercisable (in USD per share) $ 12.58 $ 25.71

Stock Options

Options

Options, Beginning Balance (in shares) 2,806,000 1,559,000 492,000

Options, Granted (in shares) 4,450,000 1,511,000 1,149,000

Options, Exercised (in shares) 0 0 (8,000)

Options, Forfeited (in shares) (378,000) (128,000) (62,000)

Options, Cancelled and expired (in shares) (210,000) (136,000) (12,000)

Options, Ending Balance (in shares) 6,668,000 2,806,000 1,559,000

Options, Vested or expected to vest (in shares) 6,410,000

Options, Exercisable (in shares) 2,500,000 1,913,000 436,100 317,400

Weighted Average Exercise Price

Weighted Average Exercise Price, Beginning balance (in USD per share) $ 11.44 $ 17.45 $ 31.39

Weighted Average Exercise Price, Granted (in USD per share) 3.68 6.43 13.94

Weighted Average Exercise Price, Exercised (in USD per share) 0.00 0.00 13.98

Weighted Average Exercise Price, Forfeited (in USD per share) 6.27 9.07 21.70

Weighted Average Exercise Price, Cancelled and expired (in USD per share) 24.33 25.58 242.92

Weighted Average Exercise Price, Ending balance (in USD per share) 6.15 $ 11.44 $ 17.45

Weighted Average Exercise Price, Vested or expected to vest (in USD per share) 6.26

Weighted Average Exercise Price, Exercisable (in USD per share) $ 9.83

Weighted Average Remaining Contractual Term, Outstanding at end of period 7 years

Weighted Average Remaining Contractual Term, Vested and expected to vest at end of period 6 years 10 months 24 days

Weighted Average Remaining Contractual Term, Exercisable at end of period 3 years 2 months 12 days

Aggregate Intrinsic Value, Outstanding at end of period $ 0

Aggregate Intrinsic Value, Vested and expected to vest at end of period 9

Aggregate Intrinsic Value, Exercisable at end of period $ 0

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-Based Compensation - Summary of Status of Nonvested Restricted Stock Awards (Detail) - $ / shares
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Restricted stock

Nonvested Shares

Nonvested Shares, Beginning balance (in shares) 183,000

Nonvested Shares, Issued (in shares) 2,000 270,000 570,000

Nonvested Shares, Vested (in shares) (83,000)

Nonvested Shares, Forfeited (in shares) (39,000) (97,000) (177,000)

Nonvested Shares, Ending balance (in shares) 63,000 183,000

Weighted Average Grant-Date Fair Value Per Share

Weighted Average Grant-Date Fair Value Per Share, Beginning balance (in USD per share) $ 12.76

Weighted Average Grant-Date Fair Value Per Share, Issued (in USD per share) 5.78 $ 5.64 $ 20.61

Weighted Average Grant-Date Fair Value Per Share, Vested (in USD per share) 9.43

Weighted Average Grant-Date Fair Value Per Share, Forfeited (in USD per share) 14.39

Weighted Average Grant-Date Fair Value Per Share, Ending balance (in USD per share) $ 15.93 $ 12.76

Restricted stock units (RSUs)

Nonvested Shares

Nonvested Shares, Beginning balance (in shares) 187,000

Nonvested Shares, Issued (in shares) 20,000 187,000 46,000

Nonvested Shares, Vested (in shares) (187,000) 0

Nonvested Shares, Forfeited (in shares) 0 0 (13,000)

Nonvested Shares, Ending balance (in shares) 20,000 187,000

Weighted Average Grant-Date Fair Value Per Share

Weighted Average Grant-Date Fair Value Per Share, Beginning balance (in USD per share) $ 5.35

Weighted Average Grant-Date Fair Value Per Share, Issued (in USD per share) 4.97 $ 5.35 $ 15.70

Weighted Average Grant-Date Fair Value Per Share, Vested (in USD per share) 5.35

Weighted Average Grant-Date Fair Value Per Share, Forfeited (in USD per share) 0.00

Weighted Average Grant-Date Fair Value Per Share, Ending balance (in USD per share) $ 4.97 $ 5.35

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1

Employee Benefit Plans (Detail) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Retirement Benefits [Abstract]

Maximum Annual Contributions Per Employee, Percent 80.00%

Discretionary matching contributions $ 0.3 $ 0.2 $ 0.2

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of discretionary contributions made by an employer to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 83 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1

Shareholder Rights Plan (Detail) - Rights plan
1 Months Ended

Dec. 31, 2009

$ / shares

$ / right

shares

Class of Stock [Line Items]

Conversion rate of right (in shares) 1

Percentage of rights held by single shareholder 20.00%

Market value of rights 200.00%

Redemption price of rights (in USD per right) | $ / right 0.0002

Series ZZ Preferred Stock

Class of Stock [Line Items]

Conversion rate of right (in shares) 0.0002

Warrant exercise price (in USD per share) | $ / shares $ 16

X

- Definition
Class of Warrant or Right, Market Value of Warrants or Rights, Upon Merger
+ References
No definition available.
+ Details

Name: ctic_ClassofWarrantorRightMarketValueofWarrantsorRightsUponMerger

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Stockholder Rights Plan, Redemption price per right payable at the election of the board of directors.
+ References
No definition available.
+ Details

Name: ctic_RedemptionPriceShareholderRightsPlan

Namespace Prefix: ctic_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage of common stock held by a single holder triggering the exercisability of the shareholders rights plan.
+ References
No definition available.
+ Details

Name: ctic_RightsPlanTriggerPercentage

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=ctic_RightsPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesZZPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 84 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1

Customer and Geographic Concentrations - Product Sales by Major Customers (Detail) - Sales Revenue, Goods, Net - Customer Concentration Risk
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Customer A

Revenue, Major Customer [Line Items]

Percentage of product sales 61.00% 60.00% 41.00%

Customer B

Revenue, Major Customer [Line Items]

Percentage of product sales 24.00% 27.00% 42.00%

Customer C

Revenue, Major Customer [Line Items]

Percentage of product sales 13.00% 0.00% 0.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorCustomersAxis=ctic_CustomerAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=ctic_CustomerBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=ctic_CustomerCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1

Customer and Geographic Concentrations - Long-Lived Assets (Detail) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Revenues from External Customers and Long-Lived Assets [Line Items]

Total long-lived assets $ 2,365 $ 3,023

United States

Revenues from External Customers and Long-Lived Assets [Line Items]

Total long-lived assets 2,365 2,990

Europe

Revenues from External Customers and Long-Lived Assets [Line Items]

Total long-lived assets $ 0 $ 33

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 86 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1

Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Earnings Per Share [Abstract]

Net loss attributable to common shareholders $ (14,266) $ (11,974) $ 1,048 $ (19,828) $ (6,372) $ (29,183) $ (19,766) $ 3,312 $ (45,020) $ (52,009) $ (122,622)

Basic and diluted:

Weighted average shares outstanding (in shares) 36,569 28,198 19,324

Less weighted average restricted shares outstanding (in shares) (124) (250) (487)

Shares used in calculation of basic and diluted net loss per common share (in shares) 36,445 27,948 18,837

Net loss per common share: Basic and diluted (in USD per share) $ (1.24) $ (1.86) $ (6.51)

X

- Definition
Weighted average number basic and diluted, shares outstanding.
+ References
No definition available.
+ Details

Name: ctic_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesRestrictedStock

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 87 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1

Net Loss Per Share - Additional Information (Detail) - shares
shares in Millions
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from computation of let loss per share (in shares) 5.2 2.7 1.5

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 88 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1

Related Party Transactions (Detail)
1 Months Ended 12 Months Ended

Feb. 28, 2018

shares

Jun. 30, 2017

shares

Mar. 31, 2017

USD ($)

Dec. 31, 2015

member_of_board

shares

Sep. 30, 2015

shares

Dec. 31, 2017

shares

Dec. 31, 2015

shares

Dec. 31, 2016

Related Party Transaction [Line Items]

Conversion of preferred stock to common stock (in shares) 14,600,000

Series N-2 Preferred Stock

Related Party Transaction [Line Items]

Stock Issued (in shares) 55,000

Number of shares converted (in shares) 55,000

Conversion of preferred stock to common stock (in shares) 5,000,000

Series N-3 Preferred Stock

Related Party Transaction [Line Items]

Stock Issued (in shares) 22,500

Number of shares converted (in shares) 21,925

Affiliated Entity | BVF Partners, L.P.

Related Party Transaction [Line Items]

Stock Issued (in shares) 1,000,000

Common stock owned by others, percentage 20.00% 15.90%

Right to elect members of the board | member_of_board 2

Threshold for voting in board members 11.00%

Ownership threshold for resignation from board 5.00%

Beneficial ownership threshold for resignation from board 50.00%

Affiliated Entity | BVF Partners, L.P. | Series N-2 Preferred Stock

Related Party Transaction [Line Items]

Stock Issued (in shares) 30,000

Number of shares converted (in shares) 30,000

Conversion of preferred stock to common stock (in shares) 2,700,000

Affiliated Entity | BVF Partners, L.P. | Series N-3 Preferred Stock

Related Party Transaction [Line Items]

Stock Issued (in shares) 6,750

Number of shares converted (in shares) 6,175

Conversion of preferred stock to common stock (in shares) 4,100,000

Affiliated Entity | BVF Partners, L.P. | Series N-3 Preferred Stock | Maximum

Related Party Transaction [Line Items]

Conversion threshold 9.99%

Affiliated Entity | BVF Partners, L.P. | Series N-3 Preferred Stock | Minimum

Related Party Transaction [Line Items]

Conversion threshold 5.00%

Aequus Biopharma, Inc | Affiliated Entity

Related Party Transaction [Line Items]

Percentage of ownership in subsidiary 60.00%

Aequus Biopharma, Inc | Affiliated Entity | License And Promissory Note Termination, And Note Cancellation Agreements

Related Party Transaction [Line Items]

Amount funded to subsidiary | $ $ 347,500

Percent of milestone payments to be received 0.2

Milestone payments to be received | $ $ 20,000,000

Percentage of royalty payable to net sales 5.00%

Period from first commercial sale 10 years

Aequus Biopharma, Inc | Executive Vice President | Jack W. Singer, M.D.

Related Party Transaction [Line Items]

Percentage of ownership in subsidiary 4.30%

Aequus Biopharma, Inc | Member of Board | Frederick W. Telling, Ph.D.

Related Party Transaction [Line Items]

Percentage of ownership in subsidiary 3.80%

License And Promissory Note | Convertible Debt | Aequus Biopharma, Inc | Affiliated Entity

Related Party Transaction [Line Items]

Debt cancelled and terminated | $ $ 13,700,000

Common Stock

Related Party Transaction [Line Items]

Stock Issued (in shares) 1,000,000

Common Stock | Series N-2 Preferred Stock

Related Party Transaction [Line Items]

Conversion of preferred stock to common stock (in shares) 5,000,000

Common Stock | Series N-3 Preferred Stock

Related Party Transaction [Line Items]

Conversion of preferred stock to common stock (in shares) 14,616,000

Subsequent Event | BVF Partners, L.P. | Series N Preferred Stock

Related Party Transaction [Line Items]

Number of shares converted (in shares) 575

Subsequent Event | BVF Partners, L.P. | Series O Preferred Stock

Related Party Transaction [Line Items]

Conversion of preferred stock to common stock (in shares) 12,575

Subsequent Event | Common Stock | BVF Partners, L.P.

Related Party Transaction [Line Items]

Stock Issued (in shares) 6,300,000

Number of shares converted (in shares) 8,000,000

Common stock owned by others, percentage 11.95%

X

- Definition
Conversion Of Stock, Conversion Threshold
+ References
No definition available.
+ Details

Name: ctic_ConversionOfStockConversionThreshold

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners, Common Stock, Threshold for Resignation Requirement, Maximum
+ References
No definition available.
+ Details

Name: ctic_NoncontrollingInterestOwnershipPercentagebyNoncontrollingOwnersCommonStockThresholdforResignationRequirementMaximum

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners, Common Stock, Threshold for Resignation Requirement, Minimum
+ References
No definition available.
+ Details

Name: ctic_NoncontrollingInterestOwnershipPercentagebyNoncontrollingOwnersCommonStockThresholdforResignationRequirementMinimum

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners, Common Stock, Threshold for Voting Rights
+ References
No definition available.
+ Details

Name: ctic_NoncontrollingInterestOwnershipPercentagebyNoncontrollingOwnersCommonStockThresholdforVotingRights

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period From First Commercial Sale
+ References
No definition available.
+ Details

Name: ctic_PeriodFromFirstCommercialSale

Namespace Prefix: ctic_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Related Party, Agreement, Ability to Nominate Board Members, Maximum
+ References
No definition available.
+ Details

Name: ctic_RelatedPartyAgreementAbilitytoNominateBoardMembersMaximum

Namespace Prefix: ctic_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Related Party Transaction, Maximum Amount Of Milestone Payments To Be Received
+ References
No definition available.
+ Details

Name: ctic_RelatedPartyTransactionMaximumAmountOfMilestonePaymentsToBeReceived

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Related Party Transaction, Percentage Of Milestone Payments To Be Received
+ References
No definition available.
+ Details

Name: ctic_RelatedPartyTransactionPercentageOfMilestonePaymentsToBeReceived

Namespace Prefix: ctic_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Related Party Transaction, Percentage of royalty payable to net sales.
+ References
No definition available.
+ Details

Name: ctic_RelatedPartyTransactionPercentageOfRoyaltyPayableToNetSales

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross amount of debt extinguished.
+ References
No definition available.
+ Details

Name: us-gaap_ExtinguishmentOfDebtAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of transactions with related party during the financial reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNDashTwoPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesN3PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_BVFPartnersL.P.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_AequusBiopharmaIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ctic_LicenseAndPromissoryNoteTerminationAndNoteCancellationAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ExecutiveVicePresidentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_JackW.SingerM.D.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_FrederickW.TellingPh.D.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ctic_LicenseAndPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesOPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 89 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1

Legal Proceedings (Detail)
€ in Millions
1 Months Ended 12 Months Ended

Jul. 26, 2017

USD ($)

Mar. 29, 2017

USD ($)

Jan. 01, 2017

Jul. 31, 2014

grant

shares

Mar. 31, 2014

EUR (€)

Mar. 31, 2014

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2017

EUR (€)

Dec. 31, 2017

USD ($)

Loss Contingencies [Line Items]

Reverse stock split ratio 0.1

Securities Litigation

Loss Contingencies [Line Items]

Settlement amount $ 20,000,000

Insurance Recoveries $ 18,000,000

Derivative Lawsuits

Loss Contingencies [Line Items]

Settlement amount $ 800,000

Settlement expense $ 2,200,000

2007 Equity Incentive Plan

Loss Contingencies [Line Items]

Number of common stock transferred (in shares) | shares 4,756,137

Number of common stock transferred, adjusted for reversed stock split (in shares) | shares 475,613

Types of grants authorized by plan | grant 6

Non-employee director annual compensation $ 375,000

Additional compensation for board chairman $ 100,000

Payments for attorney fees $ 300,000

VAT Assessments

Loss Contingencies [Line Items]

Taxes paid € 0.4 $ 600,000

Estimate of possible loss € 3.9 $ 4,700,000

X

- Definition
Officers' Compensation, Board Chairman, Additional Amount
+ References
No definition available.
+ Details

Name: ctic_OfficersCompensationBoardChairmanAdditionalAmount

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award number of types of grants authorized by plan.
+ References
No definition available.
+ Details

Name: ctic_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTypesOfGrantsAuthorizedByPlan

Namespace Prefix: ctic_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Adjusted For Reversed Stock Split, Gross
+ References
No definition available.
+ Details

Name: ctic_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAdjustedForReversedStockSplitGross

Namespace Prefix: ctic_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
VAT deposit paid.
+ References
No definition available.
+ Details

Name: ctic_ValueAddedTaxDepositPaid

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InsuranceRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount awarded to other party in judgment or settlement of litigation.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349
+ Details

Name: us-gaap_LossContingencyEstimateOfPossibleLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for fees classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LitigationCaseAxis=ctic_SecuritiesLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=ctic_DerivativeLawsuitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ctic_TwoThousandAndSevenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=ctic_ValueAddedTaxAssessmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 90 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Additional Information (Detail) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Income Tax [Line Items]

Reduction in deferred tax asset due to tax reform $ 41,300,000

Net operating loss carryforwards 74,800,000 $ 305,400,000

U.S. federal tax credits 1,300,000 7,300,000

Increase (decrease) in valuation allowance (123,800,000) $ 23,200,000 $ 38,700,000

Unrecognized tax benefits 0

Accrued interest or penalties related to unrecognized tax benefits 0

Reserves for uncertain income tax positions 0

United Kingdom

Income Tax [Line Items]

Net operating loss carryforwards $ 31,200,000

X

- Definition
Income Tax [Line Items]
+ References
No definition available.
+ Details

Name: ctic_IncomeTaxLineItems

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense
+ References
No definition available.
+ Details

Name: ctic_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount recognized for uncertainty in income taxes classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilityForUncertainTaxPositionsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_GB

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 91 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Loss Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Net loss before income taxes, United States $ (40,180) $ (51,856) $ (110,831)

Net loss before income taxes, Foreign (651) (1,097) (9,932)

Net loss before noncontrolling interest $ (40,831) $ (52,953) $ (120,763)

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 92 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Reconciliation Between Effective and Income Tax Rate (Detail)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Federal income tax rate 34.00% 34.00% 34.00%

Research and development tax credits 3.00% 1.00% 3.00%

Non-deductible executive compensation 0.00% 0.00% (1.00%)

Valuation allowance 304.00% (33.00%) (32.00%)

Foreign tax rate differential 0.00% 0.00% (3.00%)

Impact of tax reform (101.00%) 0.00% 0.00%

Expired tax attribute carryforwards (240.00%) 0.00% 0.00%

Other 0.00% (2.00%) (1.00%)

Net effective tax rate 0.00% 0.00% 0.00%

X

- Definition
Effective Income Tax Rate Reconciliation, Expired Tax Attribute Carryforwards, Percent
+ References
No definition available.
+ Details

Name: ctic_EffectiveIncomeTaxRateReconciliationExpiredTaxAttributeCarryforwardsPercent

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective income tax rate reconciliation nondeductible expense executive compensation.
+ References
No definition available.
+ Details

Name: ctic_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation

Namespace Prefix: ctic_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 93 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Deferred tax assets:

Net operating loss carryforwards $ 21,005 $ 108,372

Capitalized research and development 27,540 43,768

Research and development tax credit carryforwards 1,347 7,253

Stock-based compensation 12,842 19,288

Intangible assets 8,117 14,525

Depreciation and amortization 472 626

Other deferred tax assets 2,279 3,721

Total deferred tax assets 73,602 197,553

Less: valuation allowance (73,310) (197,131)

Deferred Tax Assets, Net of Valuation Allowance, Total 292 422

Deferred tax liabilities:

Deductions for tax in excess of financial statements (292) (422)

Total deferred tax liabilities (292) (422)

Net deferred tax assets $ 0 $ 0

X

- Definition
Deferred tax assets capitalized research and development.
+ References
No definition available.
+ Details

Name: ctic_DeferredTaxAssetsCapitalizedResearchAndDevelopment

Namespace Prefix: ctic_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPrepaidExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 94 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1

Unaudited Quarterly Data (Detail)
$ / shares in Units, $ in Thousands, € in Millions
1 Months Ended 3 Months Ended 12 Months Ended

Dec. 31, 2016

EUR (€)

Dec. 31, 2016

USD ($)

Dec. 31, 2017

USD ($)

$ / shares

Sep. 30, 2017

USD ($)

$ / shares

Jun. 30, 2017

USD ($)

$ / shares

Mar. 31, 2017

USD ($)

$ / shares

Dec. 31, 2016

USD ($)

$ / shares

Sep. 30, 2016

USD ($)

$ / shares

Jun. 30, 2016

USD ($)

$ / shares

Mar. 31, 2016

USD ($)

$ / shares

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Quarterly Financial Data [Line Items]

Total revenues $ 462 $ 1,705 $ 22,225 $ 754 $ 9,136 $ 4,433 $ 7,361 $ 36,475 $ 25,146 $ 57,405 $ 16,116

Product sales, net 0 0 227 626 1,015 914 975 1,223 853 4,127 3,472

Gross profit (84) (69) 149 493 151 751 815 1,033

Net income (loss) attributable to CTI (14,266) (11,974) 5,398 (19,828) (6,372) (29,183) (19,766) 3,312 (40,670) (52,009) (119,422)

Net income (loss) attributable to CTI common shareholders $ (14,266) $ (11,974) $ 1,048 $ (19,828) $ (6,372) $ (29,183) $ (19,766) $ 3,312 (45,020) (52,009) (122,622)

Net income (loss) per common share—basic (in USD per share) | $ / shares $ (0.33) $ (0.28) $ 0.03 $ (0.71) $ (0.23) $ (1.04) $ (0.71) $ 0.12

Net income (loss) per common share—diluted (in USD per share) | $ / shares $ (0.33) $ (0.28) $ 0.03 $ (0.71) $ (0.23) $ (1.04) $ (0.71) $ 0.12

License and contract revenue 24,293 53,278 12,644

Milestone payment received $ 0 $ 32,000 $ 0

Collaborative Arrangement Product Agreement | Servier

Quarterly Financial Data [Line Items]

License and contract revenue $ 11,800

Milestone payment received € 7.5 $ 8,000 $ 8,000

Collaborative Arrangement Product Agreement | Teva

Quarterly Financial Data [Line Items]

Milestone payment received $ 10,000

Baxter

Quarterly Financial Data [Line Items]

Milestone payment received $ 32,000

X

- Definition
Quarterly Financial Data [Line Items]
+ References
No definition available.
+ Details

Name: ctic_QuarterlyFinancialDataLineItems

Namespace Prefix: ctic_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_ServierMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ctic_TevaPharmaceuticalIndustriesLtd.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ctic_AgreementOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1

Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended

Feb. 13, 2018

Feb. 28, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Jan. 31, 2018

Subsequent Event [Line Items]

Series N preferred stock authorized (in shares) 33,333 33,333

Proceeds from common stock offering, net of issuance costs $ 0 $ 0 $ 15,147

Subsequent Event

Subsequent Event [Line Items]

Common stock par value (in USD per share) $ 0.001

Preferred stock, par value (in USD per share) $ 0.001

Series N Preferred Stock | Subsequent Event

Subsequent Event [Line Items]

Series N preferred stock authorized (in shares) 575

Leerink Partners LLC | Subsequent Event

Subsequent Event [Line Items]

Common stock par value (in USD per share) $ 0.001

Stock Issued (in shares) 20,000,000

Shares issued in public offering (in USD per share) $ 3

Option to purchase additional shares (in shares) 3,000,000

Proceeds from common stock offering, net of issuance costs $ 64,200 $ 64,200

X

- Definition
Shares Issued During Period, Shares, Additional Shares Issued
+ References
No definition available.
+ Details

Name: ctic_SharesIssuedDuringPeriodSharesAdditionalSharesIssued

Namespace Prefix: ctic_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ctic_SeriesNPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=ctic_LeerinkPartnersLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1

Schedule II Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Reserve for excess, obsolete or unsalable inventory:

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at beginning of period $ 1,510 $ 1,265 $ 0

Charged to costs and expenses 0 692 1,326

Charged to other accounts 204 (19) (25)

Deductions (347) (428) (36)

Balance at end of period 1,367 1,510 1,265

Allowance for doubtful accounts:

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at beginning of period $ 0 0

Charged to costs and expenses 1,735

Charged to other accounts 0

Deductions (1,735)

Balance at end of period $ 0 $ 0

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInValuationAllowancesAndReservesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to accounts other than costs and expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesDeductions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 98 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 312 438 1 false 114 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://ctibiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://ctibiopharma.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://ctibiopharma.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://ctibiopharma.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://ctibiopharma.com/role/ConsolidatedStatementsOfComprehensiveLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://ctibiopharma.com/role/ConsolidatedStatementsOfShareholdersEquity CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://ctibiopharma.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - Description of Business and Summary of Significant Accounting Policies Sheet http://ctibiopharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies Description of Business and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Inventory Sheet http://ctibiopharma.com/role/Inventory Inventory Notes 9 false false R10.htm 2103100 - Disclosure - Property and Equipment Sheet http://ctibiopharma.com/role/PropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 2104100 - Disclosure - Accrued Expenses Sheet http://ctibiopharma.com/role/AccruedExpenses Accrued Expenses Notes 11 false false R12.htm 2105100 - Disclosure - Leases Sheet http://ctibiopharma.com/role/Leases Leases Notes 12 false false R13.htm 2106100 - Disclosure - Other Liabilities Sheet http://ctibiopharma.com/role/OtherLiabilities Other Liabilities Notes 13 false false R14.htm 2107100 - Disclosure - Long-term Debt Sheet http://ctibiopharma.com/role/LongTermDebt Long-term Debt Notes 14 false false R15.htm 2108100 - Disclosure - Preferred Stock Sheet http://ctibiopharma.com/role/PreferredStock Preferred Stock Notes 15 false false R16.htm 2110100 - Disclosure - Common Stock Sheet http://ctibiopharma.com/role/CommonStock Common Stock Notes 16 false false R17.htm 2110100 - Disclosure - Other Comprehensive Loss Sheet http://ctibiopharma.com/role/OtherComprehensiveLoss Other Comprehensive Loss Notes 17 false false R18.htm 2111100 - Disclosure - Collaboration, Licensing and Milestone Agreements Sheet http://ctibiopharma.com/role/CollaborationLicensingAndMilestoneAgreements Collaboration, Licensing and Milestone Agreements Notes 18 false false R19.htm 2112100 - Disclosure - Share-Based Compensation Sheet http://ctibiopharma.com/role/ShareBasedCompensation Share-Based Compensation Notes 19 false false R20.htm 2113100 - Disclosure - Employee Benefit Plans Sheet http://ctibiopharma.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 20 false false R21.htm 2114100 - Disclosure - Shareholder Rights Plan Sheet http://ctibiopharma.com/role/ShareholderRightsPlan Shareholder Rights Plan Notes 21 false false R22.htm 2115100 - Disclosure - Customer and Geographic Concentrations Sheet http://ctibiopharma.com/role/CustomerAndGeographicConcentrations Customer and Geographic Concentrations Notes 22 false false R23.htm 2116100 - Disclosure - Net Loss Per Share Sheet http://ctibiopharma.com/role/NetLossPerShare Net Loss Per Share Notes 23 false false R24.htm 2117100 - Disclosure - Related Party Transactions Sheet http://ctibiopharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 2118100 - Disclosure - Legal Proceedings Sheet http://ctibiopharma.com/role/LegalProceedings Legal Proceedings Notes 25 false false R26.htm 2119100 - Disclosure - Income Taxes Sheet http://ctibiopharma.com/role/IncomeTaxes Income Taxes Notes 26 false false R27.htm 2120100 - Disclosure - Unaudited Quarterly Data Sheet http://ctibiopharma.com/role/UnauditedQuarterlyData Unaudited Quarterly Data Notes 27 false false R28.htm 2121100 - Disclosure - Subsequent Events Sheet http://ctibiopharma.com/role/SubsequentEvents Subsequent Events Notes 28 false false R29.htm 2122100 - Schedule - Schedule II Valuation and Qualifying Accounts Sheet http://ctibiopharma.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II Valuation and Qualifying Accounts Uncategorized 29 false false R30.htm 2201201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) Sheet http://ctibiopharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Description of Business and Summary of Significant Accounting Policies (Policies) Uncategorized 30 false false R31.htm 2301302 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables) Sheet http://ctibiopharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables Description of Business and Summary of Significant Accounting Policies (Tables) Uncategorized 31 false false R32.htm 2302301 - Disclosure - Inventory (Tables) Sheet http://ctibiopharma.com/role/InventoryTables Inventory (Tables) Uncategorized 32 false false R33.htm 2303301 - Disclosure - Property and Equipment (Tables) Sheet http://ctibiopharma.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 33 false false R34.htm 2304301 - Disclosure - Accrued Expenses (Tables) Sheet http://ctibiopharma.com/role/AccruedExpensesTables Accrued Expenses (Tables) Uncategorized 34 false false R35.htm 2305301 - Disclosure - Leases (Tables) Sheet http://ctibiopharma.com/role/LeasesTables Leases (Tables) Uncategorized 35 false false R36.htm 2306301 - Disclosure - Other Liabilities (Tables) Sheet http://ctibiopharma.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Uncategorized 36 false false R37.htm 2310301 - Disclosure - Common Stock (Tables) Sheet http://ctibiopharma.com/role/CommonStockTables Common Stock (Tables) Uncategorized 37 false false R38.htm 2310301 - Disclosure - Other Comprehensive Loss (Tables) Sheet http://ctibiopharma.com/role/OtherComprehensiveLossTables Other Comprehensive Loss (Tables) Uncategorized 38 false false R39.htm 2311301 - Disclosure - Collaboration, Licensing and Milestone Agreements (Tables) Sheet http://ctibiopharma.com/role/CollaborationLicensingAndMilestoneAgreementsTables Collaboration, Licensing and Milestone Agreements (Tables) Uncategorized 39 false false R40.htm 2312301 - Disclosure - Share-Based Compensation (Tables) Sheet http://ctibiopharma.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Uncategorized 40 false false R41.htm 2315301 - Disclosure - Customer and Geographic Concentrations (Tables) Sheet http://ctibiopharma.com/role/CustomerAndGeographicConcentrationsTables Customer and Geographic Concentrations (Tables) Uncategorized 41 false false R42.htm 2316301 - Disclosure - Net Loss Per Share (Tables) Sheet http://ctibiopharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Uncategorized 42 false false R43.htm 2319301 - Disclosure - Income Taxes (Tables) Sheet http://ctibiopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Uncategorized 43 false false R44.htm 2320301 - Disclosure - Unaudited Quarterly Data (Tables) Sheet http://ctibiopharma.com/role/UnauditedQuarterlyDataTables Unaudited Quarterly Data (Tables) Uncategorized 44 false false R45.htm 2401403 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://ctibiopharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Uncategorized 45 false false R46.htm 2401404 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://ctibiopharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Description of Business and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Uncategorized 46 false false R47.htm 2402402 - Disclosure - Inventory (Detail) Sheet http://ctibiopharma.com/role/InventoryDetail Inventory (Detail) Uncategorized 47 false false R48.htm 2403402 - Disclosure - Property and Equipment (Detail) Sheet http://ctibiopharma.com/role/PropertyAndEquipmentDetail Property and Equipment (Detail) Uncategorized 48 false false R49.htm 2404402 - Disclosure - Accrued Expenses (Detail) Sheet http://ctibiopharma.com/role/AccruedExpensesDetail Accrued Expenses (Detail) Uncategorized 49 false false R50.htm 2405402 - Disclosure - Leases - Additional Information (Detail) Sheet http://ctibiopharma.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Uncategorized 50 false false R51.htm 2405403 - Disclosure - Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) Sheet http://ctibiopharma.com/role/LeasesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) Uncategorized 51 false false R52.htm 2406402 - Disclosure - Other Liabilities (Detail) Sheet http://ctibiopharma.com/role/OtherLiabilitiesDetail Other Liabilities (Detail) Uncategorized 52 false false R53.htm 2407401 - Disclosure - Long-term Debt (Detail) Sheet http://ctibiopharma.com/role/LongTermDebtDetail Long-term Debt (Detail) Uncategorized 53 false false R54.htm 2408401 - Disclosure - Preferred Stock (Detail) Sheet http://ctibiopharma.com/role/PreferredStockDetail Preferred Stock (Detail) Uncategorized 54 false false R55.htm 2410402 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://ctibiopharma.com/role/CommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Uncategorized 55 false false R56.htm 2410402 - Disclosure - Other Comprehensive Loss (Detail) Sheet http://ctibiopharma.com/role/OtherComprehensiveLossDetail Other Comprehensive Loss (Detail) Uncategorized 56 false false R57.htm 2410403 - Disclosure - Common Stock - Summary of Common Stock Reserved for Issuance (Detail) Sheet http://ctibiopharma.com/role/CommonStockSummaryOfCommonStockReservedForIssuanceDetail Common Stock - Summary of Common Stock Reserved for Issuance (Detail) Uncategorized 57 false false R58.htm 2411402 - Disclosure - Collaboration, Licensing and Milestone Agreements - Additional Information (Detail) Sheet http://ctibiopharma.com/role/CollaborationLicensingAndMilestoneAgreementsAdditionalInformationDetail Collaboration, Licensing and Milestone Agreements - Additional Information (Detail) Uncategorized 58 false false R59.htm 2411403 - Disclosure - Collaboration, Licensing and Milestone Agreements - Allocated Arrangement Consideration (Detail) Sheet http://ctibiopharma.com/role/CollaborationLicensingAndMilestoneAgreementsAllocatedArrangementConsiderationDetail Collaboration, Licensing and Milestone Agreements - Allocated Arrangement Consideration (Detail) Uncategorized 59 false false R60.htm 2412402 - Disclosure - Share-Based Compensation - Expense by Types of Awards (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationExpenseByTypesOfAwardsDetail Share-Based Compensation - Expense by Types of Awards (Detail) Uncategorized 60 false false R61.htm 2412403 - Disclosure - Share-Based Compensation - Summary of Expense (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationSummaryOfExpenseDetail Share-Based Compensation - Summary of Expense (Detail) Uncategorized 61 false false R62.htm 2412404 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Uncategorized 62 false false R63.htm 2412405 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetail Share-Based Compensation - Weighted Average Assumptions (Detail) Uncategorized 63 false false R64.htm 2412406 - Disclosure - Share-Based Compensation - Stock Option Activity (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationStockOptionActivityDetail Share-Based Compensation - Stock Option Activity (Detail) Uncategorized 64 false false R65.htm 2412407 - Disclosure - Share-Based Compensation - Summary of Status of Nonvested Restricted Stock Awards (Detail) Sheet http://ctibiopharma.com/role/ShareBasedCompensationSummaryOfStatusOfNonvestedRestrictedStockAwardsDetail Share-Based Compensation - Summary of Status of Nonvested Restricted Stock Awards (Detail) Uncategorized 65 false false R66.htm 2413401 - Disclosure - Employee Benefit Plans (Detail) Sheet http://ctibiopharma.com/role/EmployeeBenefitPlansDetail Employee Benefit Plans (Detail) Uncategorized 66 false false R67.htm 2414401 - Disclosure - Shareholder Rights Plan (Detail) Sheet http://ctibiopharma.com/role/ShareholderRightsPlanDetail Shareholder Rights Plan (Detail) Uncategorized 67 false false R68.htm 2415402 - Disclosure - Customer and Geographic Concentrations - Product Sales by Major Customers (Detail) Sheet http://ctibiopharma.com/role/CustomerAndGeographicConcentrationsProductSalesByMajorCustomersDetail Customer and Geographic Concentrations - Product Sales by Major Customers (Detail) Uncategorized 68 false false R69.htm 2415403 - Disclosure - Customer and Geographic Concentrations - Long-Lived Assets (Detail) Sheet http://ctibiopharma.com/role/CustomerAndGeographicConcentrationsLongLivedAssetsDetail Customer and Geographic Concentrations - Long-Lived Assets (Detail) Uncategorized 69 false false R70.htm 2416402 - Disclosure - Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) Sheet http://ctibiopharma.com/role/NetLossPerShareCalculationOfBasicDilutedNetLossDetail Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) Uncategorized 70 false false R71.htm 2416403 - Disclosure - Net Loss Per Share - Additional Information (Detail) Sheet http://ctibiopharma.com/role/NetLossPerShareAdditionalInformationDetail Net Loss Per Share - Additional Information (Detail) Uncategorized 71 false false R72.htm 2417401 - Disclosure - Related Party Transactions (Detail) Sheet http://ctibiopharma.com/role/RelatedPartyTransactionsDetail Related Party Transactions (Detail) Uncategorized 72 false false R73.htm 2418401 - Disclosure - Legal Proceedings (Detail) Sheet http://ctibiopharma.com/role/LegalProceedingsDetail Legal Proceedings (Detail) Uncategorized 73 false false R74.htm 2419402 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://ctibiopharma.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Uncategorized 74 false false R75.htm 2419403 - Disclosure - Income Taxes - Loss Before Income Taxes (Details) Sheet http://ctibiopharma.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails Income Taxes - Loss Before Income Taxes (Details) Uncategorized 75 false false R76.htm 2419404 - Disclosure - Income Taxes - Reconciliation Between Effective and Income Tax Rate (Detail) Sheet http://ctibiopharma.com/role/IncomeTaxesReconciliationBetweenEffectiveAndIncomeTaxRateDetail Income Taxes - Reconciliation Between Effective and Income Tax Rate (Detail) Uncategorized 76 false false R77.htm 2419405 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) Sheet http://ctibiopharma.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) Uncategorized 77 false false R78.htm 2420402 - Disclosure - Unaudited Quarterly Data (Detail) Sheet http://ctibiopharma.com/role/UnauditedQuarterlyDataDetail Unaudited Quarterly Data (Detail) Uncategorized 78 false false R79.htm 2421401 - Disclosure - Subsequent Events (Details) Sheet http://ctibiopharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Uncategorized 79 false false R80.htm 2422401 - Schedule - Schedule II Valuation and Qualifying Accounts (Details) Sheet http://ctibiopharma.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II Valuation and Qualifying Accounts (Details) Uncategorized 80 false false All Reports Book All Reports ctic-20161231.xml ctic-20161231.xsd ctic-20161231_cal.xml ctic-20161231_def.xml ctic-20161231_lab.xml ctic-20161231_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 103 0000891293-18-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000891293-18-000043-xbrl.zip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�ZBO+XM5E(8$$S",!C=T]K^6: M*YGZ:XXNK-/([:.$ TU=UE.A4_8A%7[)VL^O^?F'#UGR_@[CZ<=K?TR"+"1? M1]=CS,@I3DAP%D^F)$IP2N/H.HW]O[Y.Q8_)T$_I/4UG-^*K;KA<3D/^QY_^ M\3\_;+K;-SR;D"@=/F 6+-_M=QQF\BN&29)-\M^MWIFO3"3$?T5&/[Z[/!>N MU:_M/V_.WR$:\%]@/WUO#\^]MNLZ%Z?MLW-[>-'IVK9[X=F=TU-WT&F?O_OI MV7(N+\T-G9 $?2$/Z"J>X->):^GRD$;D_9A(GG1<^[M/4CUHQ'DO_>CU.&Y4 MZLH3LQ=@)E MB%W]YD*\H[LL1 MA.^XP_NT2!\WJND]+]CEC$K;TW@>,2Y;_RO<$_G9AD-_G3VZVH M.S<%*6
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
9!>+QWEB/Y1I9RC-CX#^&J5&3G-[5C@6%965IT>F M?Z-)FA0[,AXGT>2VBL^LNZ25RBQ8H(_JV"L=\T!RZ\,V;YK;AW_F=GV_K M=MC?#GS$VX=/Q?I0MUDTRK?;8@-_D'S]]?RS*S<+8.+!V'41C8 /2!;Y RX0 M0Z'61O.A,;Z)8O>-_:VVLSPO5[*WWIKCFK")PKR#!'=:6.4;R>T8'#MW1H^( M*8#38KIQ.@OX[XXV.)T1SOT/AYOQXF_-O'EC*O'7=GC,YE0[RA0SVOM\K\C, M3$LFPI^93'TIZF.;B)4;)&$2)4&< HJ"$ 9)ZO;#10E)A/K33A[$L%R?MTRI MNSSG:[%M'_VFW'W9%IUJ?ZVV;&8JY8@*S$IETV9)54^L>US.$=A<]"EEVV9I M5$N\/W\M^+G7DREZULEGF*CY,%6[6>KL.U/XWDW>'ZOXSKZB;+J*Z _^+?RG M)].Z&6:^W@S_!:-O)_OJ3K J[Y]@QNNO %-Y$6MCRB-4-42HJHLZO^;UOXI] M>^QV_%73_Z[Y_:EB;RS M/[@^!A29EIQ&72 05JQA7UM^W_OD'X-/!OSC1YH;A]O@=$98XRR9SJJV.$VQ MYZIYYPEV7)W XZ78-HMO+ A^\]A9S3WKI6[4VA2/[FK-EOJGIR\U41+B^^@^GT@P7Q2*\] ME:D9*Q%?P'I='XH-8K\OU_GV_>X;/Y#PA5/<7V35K"* ? ( C7FO+^>\=X>%>* 8NM_+Q02--(LMML_+L%Q4&+"] M&[@\07?C]/CF72)_DZXK2^#ZJ+9CB5NC/96I22ES7T"^.SSDZ_V!KV>-*@H] M0"(:@#CPTPR$ 0B9HO8#!0B*)[IJ7V]\'>$$E$KZJDB:0,)JGB\Y,3JG2B$E M5:1*YF( XY0IW@KPZBR;?"/ :]9>2BRG46-!*CG1@$K;-)%+%_M$]:ZN'HJ& M[U;,M[0XRGA&,!N0L"&IAS*,@!N#85 W#J6:Q$P 4F<.A+90#7B?J2@*HB6$[LC]=QE1&9J%\N?-3L=V>Z.$P8 HSE$9> M2B@$04IP%M)@&-"CH= ])1J&,:Q./:H)!4Q5^L1+ES,PIZ9+ WD#LC=523N) M\H7*&]WS:'F M]POVHX'=YC=&0C\THC0*O8R *'"#- M2'&?]T%&40J%MY5H'-*SA(SCGH=RQ M?_]_U5W;4N,X$'V?K_ 'P*XODB\O4R5+\A15U$ -X6D>4F9C,JD-]JQCV.'O MU]>0,(E1RY+M?:& (G3W:>FHI6ZI^][^U(@J*-@<#U Y:M_K-TF$V8O.QW&F M&G!G%6TJ,NETS*D2+TCD>966LSW9%?NMN,M2OR1#8ILB/J<=\/.<,6Y31TPBY5CD/$ M,"14'"A*,_76VL'"PJ'8B06$(\(&H^!:,:.CD>DST/U ]42%BA">1SRHRIA, MRRB4VLV>D$<(I8QS/R2,>XZ+N&]U.1EL1Y:_++(BWH*VL!)20)2T5TAX@BVJ MCQAQ.\$^# EU;KA \VDXH/.82@KL.+V?&HR,Z 2ZSM+U(LF?6/)0'+R>RQ"+ M2FDTP)%).(FP@]TPL$S;=YEE@AXEEY.@.Z58*G59?N[)J-2"+>J2D(FMY?K1 M@BWAQT 9WR=[\_4D,#T4,PS(>=#+0!LRE4-+NB5"6X]VE^0OW4V,,-XE*WI0 M]4FV-=3E=S>/U;/>Z[1J]7Z;Y)NL_+M=T3P0N^2.;0:!YW#. TP1XA9VZW=A M?>0%/ *]8C6-AKISD=U#SC>/QKZ\MK6KN7AFU)89AZ89;[95GWNSSFC,,VK[ MVD>?!9_@FW@OSAT?R;O?MV=&]1YJ&?1F'9$ MS&/1F1B#\TT@)O.(Z*+7=*>X*^(BJ0Y;KUM-R*_-;FER)S)10&U:QN^AXQ 6 ML$ZB8]J@#A!#Y&A/3]2=8/:Z&9URL&5C$))BY#\6B# */XN?\;W2;&3Z[<&H MAT15(#L/*E1B2:9^W"FA)98]Q9MTB4*,&+4M%-G4Y=SW79=W,K%E"Q7IJ9'T MOZ8F430'D9,&()714Z/;/ BJT05.44!\9TU24%O$:$H*(5&B^I;LDO)O?Y!T MQ9*79)O]K$2WZIIDVYV11Y7O0V[,HY6!V1;W',"3GS&2VTX8I&WWZ*2 M -8#7*EDW6>8C;(7QKI1MYZK\9'"P#-(M;@+GBU.!CGPS+!#^\L!VL>ZOEW. MF(8=05#V'>YI<\/XS0B"'U$9=@QX/4F3:[*T':WI YEONV:*.38 M=4)4[K/#3DO/I*#ZM;%UT\S$RC-(E65&;1HPC32ZT\5(?L[^!BX#9[)#!JE> M9UTWF_V'UZ,LTFW\6O^:_!OGJXOCCU6&B?E;ZU,SBAS3LZA,-03FL>Q,9OV9 M1V^F\0*\*.);N?-(GY-=5"+*?Y74G,9;^KPKLJ>2I:O6N%FZOBY7U%73++=) M6B$KLK#O.QQ1*Z2F[?O8;)3R0COT0"N59E5&+'/H]#F U@QX'0LL6)O>=?'W"WFV/9]P6MVZ[!+E-513_AY!Y?2A;>'K?IYNB;N$<%\*7[ !X]).C)B!@!'?_]6K!F7&W( M^ M)\-1N^2O/];9RY^M-0U%M3^\9ZM0BR!.+R92(TAZM-5<'M]6DWM:3.J[Q'W<>]T'4 M,U>5(#N/^:C&E$S#R'L_KPY'1CE+__[\J?M-^:4Z$?[\Z3]02P,$% @ M[HMG3 0:$3?:R 1_8) !4 !C=&EC+3(P,38Q,C,Q7W!R92YX;6SLO5F3 M&S>V+OI^?H6OS[/;F(<=N\\)C'T5(:MT)75[OV509%85MUG,:@ZR:O_Z"Y!, MUL0A2>14E+O#ME0%(+&^]0%K 5A8^,__^_UN\M.W?#8?%].__PS_!G[^*9\. MB]%X>O/WG__Y^1?UV;Q[]_/__3__ZS__GU]^^2_]Z?U/MA@N[_+IXB+ M?/33G^/%[4^_C_+Y'S]=SXJ[GWXO9G^,OPU^^65=Z:?5'R;CZ1__$?_U=3#/ M?_H^'__'?'B;WPW>%\/!8O7MV\7B_C]^_?7//__\V_>OL\G?BMG-KP@ _.NV MUMX2\6^_E,5^B3_Z!:)?,/S;]_GHYY^"A-/YZML5/E(6__ZJ_)]X51I**7]= M_79;=#[>53 T"W_]K]_>?U[)^?0Y5A$!PRB-9B_^\]Q1#\>3$+CVOU$S' MO@R^3D[&ZGFEFCIFBLED\+68K=C^?CP,7PIC3$U'OXW#QQ;%-%3.+7E(S6;#:8WJQ^:(E08 MY;.F@#CMDQV 4FTXGM]B;2+=W173SXMB^,?QOKXJ6G\GD@;2*:W4W_7/R[N[ MP>SAZOK)SS[E\WSV+1_Y8O9N/E]&JWBR,&>U6[]X50F]IT)M'9K.B\EX%,>^ M'DRBX)]O\[R*(3E2L>D.?AS,PBB^S4//!A74?THK#73]\R+\>S7M!-X-YK=^ M4OQY$L8'&VBZP\7=_2R_C9/IM_Q],3^_X_L::EB J_N-&3N[YZ];:+C+GT.Y M_+:8! ,\=_]>CA!Z*.U'P>IHJ*AB:QW?;$^S@K1LOAXO,@6!7]\-O@OXM96:L^ M6:M_I#W!*UK>4QNJ20";SX>S\7W\P-6U7@;_-9_/0R>V;LOG\#(>K!N( M'E/\)]J_;V$NBDO>Z2AX_8O9>!CL9?S=6H,-HU5#QWH!<+4YM,YOU"7V9@\Z M],*%KRT>GHSAH^)4J%M3-UVH7SSDNKUE3 M%]]-PQ_S+X/OQ^FYHVC]G4@P4Z>U4G_7XPI-Y^%S^9,?5IPF3VRF_LX_GVEU MOO@SSZ?N^CH/-;_E80AORWX*:Z63%9+2?/W"/IE'XQJ[F*Z7?C:_SF>S?!3* MK-<:H5_OQX.OH=N+<=6SEYH_4[_PU6S1W@JU=>A;0*.8'5VGORI8=P>JJG5G M\;H[4U4Y.XO7U)GW^:#"L>?S4K5^.L$&5&Z@U@[[Y6(YRW\;3\=WR[O5CSX. M'E;[2?^K.N>HI8M7VF5N&K4797V=JZ<3.8?)P5 MPSR/T105NK*[?$/=J:KA0[7JZEHQO?F2S^YL_G5QM$,[RC;0C8KH[*U14Y<^ MY(OH=WW,9ZO]WV/]V5.\FGM]2,"&8P&2XGFT6\'LS'0SN>+,."?5/N M+&E.:[09P:I-?@HVVLUJ&JY2M\YN/EDO M5.K:CO(-=><$M3:]Z'GYD1-4N;=635W[.-LL BO%ONPNW4A7JJGO4)W:NE4$ M%W;Q$')OW'H^AU)' R_Y(^U2@(U5R**G4; M[>;O^?CF-H;J?\MG@YM?+N_L3K'E:JW6*M@Y*_!0_/(\'PI5ZOJ]2DQT[ M =C#5>OJY/+K//_W,CBS[EN56S_[RC?4G:J^S>%J-77NG]/!,MCP/#I-LT4^ MFSS8P6)PK&^':S7:M6IDJU*WT6Y6FRVKU#VYFR_O8,IU/Z?Y35RFO!]\S5_ MMZO>9#9[5BU>_I3Q\B=DJY[O:JWFGL9=U%H[^[+!FOO[,9^-BY&;U@SQ[F8; MZ7OP.68U8[ZOX9K[_R6?S?-Z>_ZZR;K[7"P&DYK[_*K)^OI\!C$6K[M9D07W MLWP>C-[FHN+TCTWYV.YYM[G77\J_+_+I*!^M[HJ7WYH4PUU"K02Z'LR_KJ1: MSG^Y&0SN R*0_YI/%O/R)W%"Y[\ N+D5_[\W/\X^#AY6T[B:CE9=&DSFZFOP MX ?#[1;E)$+Q]Y_#][,*M3*"""1<24(]<\9"SBED6D* %*(8JN>BKFZL%K,- MJLW*6FZS;'J_4<&3/?4@SJL3@/%\."GFRUENEK-XR^Q+4(Z>/-GOW@%/O1_* M(# :4BD)APY9)RF"J$34$F6K(/J4J6HV_*F8!0?W[S_#GW^Z+S?-WZ\%V9LB M8<7;Q9/IYC[,F;.P4O_[SZCLPF V?$;^UZUL2OQZO[JS]\OP=CP9E;5C^H@& MB%;T2#M!_'(&^77G%-+ Y+++GWS34XS54G+@$&8*>68!$(HP09QEFE#,T#E3 MS&NO-_XDVT!I0LEXN?3=:I=C?!,;?#EW/Q&B:M6,*H.<4IXA*J@7W!'N2DFX M!I4FRPLIDS.=59IO#%3/I;)#4 M!5D]--(:!9@JI06,R 0^D1^(3XV@??8\L^G%YWPR><+L_5PY7BD36AI!H7!> M*RR?]Y-PXHJW@W8]#9@$F\+5)V%#E;/C/>4 M0.D4Q0 +B85E?M;W\;%2$.A-#!.<@.#(I'#0'''N-:5SC6: MD;4,V+VZ?DV8E1JJG )5;R2SA-DPD7&CJ"38"^B4+Y$(,UG**'_CV\#5"%*T MA'PKP_[\[,Z59H,]/O6SKQX:V0=*9X1QH)7G#EM& 6=$ LF\1<$R0V!]I?V? M9D9T3,$Z7JPP>SS+JS**#U?,".((2V:XUT ;2ADTN)08*\TO<.360H"B091[ M-THKWS_H? ;A9%%0%,,O6!*6XB$<]H+X801X*R3U;I-\I.N?\N?I#J?;_8B M]OSZZ9VGE1&H9+KK^EB&&*? 6>L-D, "[(V');(@V)VN)HKVYH;*W-IKS3M2 M1ELKQWB7)[@LCQU7W\>[-K4.EL_"E.B;FOT2CP;1%QWZ@]RKO#%3-/N'9 . LYD% 9)!392AN N S;VS@77OGL M-8+>-<4V*IE5 !#G17(,0.$4L$=\67_C>$IL39)L5MODT1- M8'[^^7;,O_HI7RQGT\$TWO"Y&T_7.JK&G:KU,QV<6F2UH4("*4D0@F_' /"( M=!6O]88YU!#VYW.I_.SG_%L^/<*;'64S%GKFJ)2QFU89Z^TC"HCS%(XDQ6J] M98ZDX]R>O[2,(1WW,6O0A\%=?F1+8E?Q3%+AE8 (6LTE,$1ZC;>2"95RNI7D M^US\)D0-VFB+9Y_R^^5L>#MX8G-?]MX6=X/Q] #Y*K>1(4!6D4C(&:F-8EJ* M[=K$*),RI_5P09A&@Z(=D,\V<)_SV;=Q/CMLV9X5RB #%C)/#3*0*8LY#J)O M>D:ET6VJ_UL^^UHT3( &=%;4!.YI\\L\'_[MIOCVZR@?QZF%Q#]$2I G,TKX M4;9*6^U6K[OL,5@[2F6 .:\ID!!QZ P@5MMRFI72TI0CFK[?ANF!T4K72#-< M6G=GK_%Y6213QB-DH89"* 8\-O%6<+F%:\PEQO(DJ:ZH!<P_D*V6\;3D/N;)V:_/YV,"FF[Z;#PWI]53"#DC"N M@V]D./<((*[L=A46_I>BV[[NT]:CZ%0HSU:V'GQ?'!N_3\MDVGD>7%]IK0ES ME.04,;K=>)$NY6)07\U\/2I.0/%L[7XHO@47=3Q?72Q9;Z0-)A]7L5C#?+EZ M\/O]8G18^Z>T$=Q7JX%SECA((?'Q"'9[ NL)]EUMB?:>'0VB?#9[_O$PS8/' M6MR,AU?3U1\>_C$KEO>'^7*X5F9=W,.P&'EN/7"4L<>#30>!Z6I#M/<,J177 M\P_D_O'EO]X?.7M[+)()ZYV!4F O.&(Q)IR@QWT2F!([T-=KI/5H^WP0SS<6 MT=D<3(O?\E&<;CX/Q_ETF.\/6SI>*7,.>2VT4)0K)!57BFS-G L9377USNB M-9F#&F%M:Q.Z? +S4SR663[;W@C].'+T<;QR!BSFGGHF-<:6>ZY.@M] M2KJ5OOH6/=I@:DQ1_:#GT>.1*M4S''PQ;RTST''OE!$. 5+269AZ"Q2M MDQXLZ-LBW3_O_:R8+C9/>IX2E'FD9F8\"-(* X!&@C#*'2H/"GR0/<6/ M?MM4.Y4/19.XG^V,V2#;I%@]UK1Z2?J4X+BY MDBD!<'W=JFN4/TTA?S:#-E\_3)5GA3(7.@2YU! 9X+C&4.AR#>DM)2D7"OJZ MM]<\)U(@KF/Z6)TA'%W'[:T05I]*>^RQ,@82Z4!@[..$IR"X8+>[E8DB">[V MG.>OBW?3^6*VK'"S[G7AC"+$B414"84@(4I)6)YF>*V3KM7U, RR5\NU1%UT MP[!*$6O[JF0!*$J594@($D:2B-=F2PD1ZBZM0%.SU/DJ/LB6LQ$]_S2RF,V* M/V,F@/F\&(YCAN#?QXO;T]S?DQK)!"#* ,.LEQ)ZH3QF9FN0-4A)8]=[KIRC MX*(EI-N:=S;WFZYF&SM\Q+;M*IY!@ZTCBC&!/8$QJ-UOG3H:?M?5*P]GK30U[^9,,JBI M"_-JZ[*=A3/EI(\\(V%YX 0Q6./M5(J=[6SSKU'UIVALQX(\"=*SE;]*REE- M]3N*9L2&]2$&5!!$.;?.\&T6&*^"I]?5KMV;4'PZH&T9B_@N\/JBP60PG\=W M@N-CP(<]D[UU,D2#XV6#3^=AL*V.8B#1=C6 34H01E]/X7OHJ]2EG];N+C[I MYE%/Y77A+%AF)%"02SNJ)--"PNT0A12DA +V_8"J!E6_O(N8BF]*A/\XGW\8 M3_-%GD\_EK"O>G(T[/](S4P:RC726%AAE 2"(K\]"@$@Z09]WSF2HM&B293/ M#PU<6^O/^(])3,#L6=,:DNH4F$L(&C**"G/ 4J)G.A[[O<>V*AZM%(3 M<_8:F[UE,Z,!1=QC[)3QV$*!E=RN!0E*R0_4UWDD667[57\6J*G*GYLC4<7/ MBV56"B0L)#@&5S(/' 2;!" >*'&YJ8/35+5#Z6G[/$1;6_HNO\[S?R^#K.Y;M=#A/34R(I2"VB'D MC&&!P)(R4,H7($N9(4Y__.-'VI6O1R$=$N[HGSXB?'0^C?9Y^3L+9T%G0'!)D% 2.!EL MA]].!%33SF)RVM@6[$3C1WQ>AY@?_9 M2<3S&\NTD@HPZCWWP3X%@(RE6X!1TB6ESU.A73I56U-:RCRX& >9@T-2 M]FASJ>A+H?,*$V.%VAE1#&-$+ 6>,J:Y[SC%3UJ^CAOGV M*;]93B()'M*8]]A.AC1A4E(LO4(L](MJZ4OY'+ I^RP]3(/]5FAWMH(:)N#G MP63_6^,G-)%)X2MT.XLE+:(>'6_VOR9WKCO]S%0_I"]?%4V0U0S$4.SM5N_Q 'M M=MM=V:0MD1Z>NO:":*E*J#/+P'[K>*1&AIQRPDJ@O4-$&TD$W&[+$)X4 9AV MRG#I9K)>Q;1W1:(8_O%N/E_F([N1O\:3);YA_S/U6\.7Y>H4#]C MB#)!L.)2 R>-%(C ;8R,(TGW[/XZBJ@PMS6AIO-W. ;SV]..M_95R(! U@)B M)#0,AR4.P6([J+!P23?X>GB3J_L)KBY5M#6_;6XI'C"H>TIF'&C,&/1,*BD1 MA0SX;1PG%"PE3R;\ZU"@PIR5II"S9Z=/066A\FT0]8DU_Q1EO+K^6,SGXZ^3 M_,EO-M[B;X/OX[OEW;XI+*W5S!ED%'4X"FH(I$*B[>"B"B?%CO0]?53WDUZK MRNLF4Y ?#'-U%]_C.K@_LKM*9@$S@&#)@$42!*& WJ[ "3(IYZ?PKU.$??LB MM2BC94/\Y YZ99/\NDYF)9*0(N854D 81XEYC$ID/.E]J[\.%@[:XV1MM,6X M?PS&T_=AW[GC-#(2^ RCC.\[ *D0%Y=L1)%3::VY]O[C;O7]7 MNX(2%A^3F/[M8WP1]8F '_/9,*HV^IN?BH?!9/$0.AACHK\4'_+%P6"0A"8S M3:6P4%J.&50*0\3$)IN/A]2*I O!2<<0/P0MV]/<^;=0G_0E;B(.IL-5P/_= M73%=[3GZ8O9R3.W/9W!.8YFV4D.+E+84$RIP +<,M<359,R4=/8'NVG6[SQ6 \>2Y%_GV13T?YZ.>SO-8G MG9NKK_.5^[S?4]U5.M-(VKAOY:4W''M!&??(8:"X:F>N>56KCU\D2S:V62WB1S[WW@0=%71IIADONR?N)>XCTM$AF MK$?(6Q!?1;14(VR-*?M, +A$%B6IKJ@%Q[-=W6>OVN^SZ,\*91IKY@.IF72& M4VN ,W#3,V\D33JGZ;&&S]-.41.,?^5$V+\X@/&)A)B&"0/$@$=&$5TB*<-" M(665U1__IT>VJ@=:['_HC[*&$\VXQ@11JPA6C);R$"R30G]^K/OHE9EQ)/;G M-(V4$TXIS+F(./8@#6F"DK"*QV0 M5UU7'??27J=+68'V)<"DPU?^V+L:2V\ZL](YY@"4GC/CJ;60\!()8D1GJ1&; MSN":2HRB4SVT-,JW9W!G#-]ZO&[W[V7<2-D_RG<7S# (YI1"9Z$17G/+M45K M. F0!%>*JZH\(6UALN/Y<%+,E[/C8_=PK6@X&-06"\6E%\9Q7.YC$Q L0-*] MNYX.RU1-%DVAV_9@4Z/1:H883-Y-KXM0*NDDK]MQ",)\JC&U A/)$,7.":JA M\!@!#[SO\*QO\]3'[X,X2R^N9I_&-[>+8V=V^RME4@@:A/(20^:$]XH@4$K* M$;K$U/>I.M_]G$XZN.VEKMD94377#T]_O5&,BPQ$=Y)0 UUG&I&&2E1 M".N""TMC70<=7B6S:0CK+AAW-!_ZZ\(9D YR@3"/K]@S+C%5J)0*07YA2:V; M4/CU\=71K.B[*V0J^$K*:(6MD"SX9HP1L1UZD*:\ MJIRXF=T\ATY5<-$ HNT=_RVG883>1[GCB^1'K-BNXID(WK1&P H#H7$2$2RV MT[36.H4K/3R.:\!>U8!J>Y;I?CD;W@Z>O##_LO<5#%;%-C*+*<#&$XXLE S& MU.U;# 1WG3G;36U)I]#@E<5J!N2S#RCTOWR<7:?'8D]>ELMH6&B(,'J$-E1B M8YG56YOM$.TLP*@I0U2[WHKZT&TOP=#F$=?UFM,4=_?%='4Z4_$=YEWU,@&\ MY5)I8+6"EBCOF2ME-09>=,+N^JU6G5BWQ:L773UJJG:6SSS TEL$,?/>04@9 MAX^NG$J*/^K['E!-2B_JA[DM"FV&T-&%U;-R&6.*"X516'="[J0P&&^1D4"T MNI[J9-OP;.46]<':VJ)JUV1[;&6UKT[&'58""N>P850@QR5[] !ATEONO4_B MT\!:JR:<.^724;MUH%:F$&50&2DT4$Y0J W VWT-I"_Z@:=TY5>ATUE GQ]^ M.!D,5R99K7(1''[8=T?9# $. 3.6"Z+"PH$!).6ZGQ! G):W[XJ MF>>:4DBX=TP+C %&$I82:D!2WF/HX6Y.BHH/LN5L1,\V,U]NQ[.1"M\>W1TU M,[O*9D83+A$3PEI"F/38&57VDT/;F9EI0_/GJ*NH%]!.'=;W5:Z(':R8 >65 M%MI#@RE1&$A$:2EMH&K*"CHI=]\%+8/.!;N]P\IM\-SGVX#<7"T7MP'\PT^+ M'J@5W'XH#&0Q]R5'- CK'N745B=E4.O?G%27TE\=7]8%<'O'"SL3VZ][G_" MP8L&LB RYQ@SX[P0\6:(!5O'WVN>XNR\E9/Q='HU@G5K3!O$^P(K$3[.QL,\ M]'W5\4/T::'GWP:+?+O9<(!-U1K(K&2<24&PI-01(+146SBY<2F'['U\1[89 M;C6"=:=^^X=E7&F$\9(/P]2[&.=S,YA,\I%^V)2;;PJ>[-A7;SG##EAOG02, M:J>%,1KH#5X08)9R )*TT=25YU^#Q]:J1CIEL/N>SX;C>;Z:[+>_W(IRZ&'' ML]K++/#!R67&:ZJI!=HK8TML'$PZ7GF3Z]2&V%JS'CKEZ-5R,5\,IJ/@VYY* MQR=5,V<\C-?GF.>:(>48=N5^$&0VZ1RGCSGF6R3;^2BW?:GP\_+N;C![>)99 M-SY$,ULGJBB]DC=ZS5 [:&C,HF4]D0@%[08E1.RA54*)2EYJ0^N\[=WP%>3Z M8<6CZKE!7]7*O-#:Q<>X-254<0:Y J6L7JD+2?*9JNB]^3U3 6UM@3<93"M< MO'A:+ M3#L$Z;O1R%)"Q %%42H*M27H8L^<$, M X^8@(9(":D&0C#+2FD,EY<5O=0XRPXSSYJ74^&[Z8Q8?[X6]PYF,X/ M'[CNKY%YHK5 CM!/1146+B)R0U]!HI=M59B M-'8^G6\4M\U?]/MXH7QIJ]T;02I*GB;P>)2T? MCYOO%Z_B-:(Z/I)I8['AB%# 00.6[4)'PHH,M:=[]]4%%5/.+GSPE('"FUM M6#PU;U?WL;]';SSMK9-I0)'D@K,P 0&K@:12;V&F:0]1]S&;1!?T>,G0FI31 M%N&^C!?1G#U"=,2?V%D^$XA:R2RP0)JPWD,FOA:VD0W*2PN1:,(+J /7SC@3 M[<$JDTM,_W,[OO]2N,.OF9S94D8\Q %>A 6T!"$55H);=$GXT659X41.'&-8 MK5BW=I!W.\ZOW?=\N(S; E?7U^/A@#KLO(VFR3,IH0E]/T6<1-FLDZP MWUCRB^ C$J@I19PR$2^= %C*YNU%O@95L]*K);\X">9^)[_PGA/@N=,:,ZN] M5DZ:4A;'DA+$]9TRBWC)N%%+E8AMRQ%RZZ3N%?-#:P75B,[@?+S8G2/,G\;)^N5C.\C)J]A"?3FTKVM78/MS=9_^KMJI;68JK.^M-]AC"K@12F'O2]F1 M=9WEL6G_'9C*+-CWEEK#V+Q;3_>C")G?Y\F^>+[@;U=F5P=>W' MT]"A\6#RL9BOGIRJ,-2K5,^LY4!RA8F4WFEGM73Q$,@+16%P$"OY2\U(K^;S M 'X%.9\7S"S7CF,#F528$6D5%5N)C$_:;^C[L*Y7XR\?Q4B!N2V'<-U)LYQ% MN"ISYT7YC!,,8GP%#QX,=#H@9M56-FTNF4+G:GDG6=)P;6T1,9C?JNDH_B?: MQ6^#R>I 8&$&L]G#>'KSK\'DX"ORE>IG+%@Y9BP.;E%PBVTP=)*5LD/-\<5S MZFPRO%PY- !W6U0+[M%B-AX&#R-V?X/( 6KM+)\A0+$SCC.,F*'$[#[C3$/EP3KH M9R6I)4GYK/K^@$:]1*H1Y;.WVQ^_';HQOONZG,WC7]SW&(*:[WOB>M]B^KS6 M,J,L(DA*P8BB#$.NC2AE51"GA+/W,.]0/21J#^^VYJIWTV^A<\7L(8R" W/3 MTV*951XB:)$E2FDED:1V*XE1+"4.I>]9@>J=BQ)0;2\+6GX_&(\VY [^V]7B M-I\]@^$ ;2K4SA V5#+C'!18,Q8?"H<;N9'R.H5-?<_:4R^;Z@>[D]5_U55_ M9JP)@#!FH>#(*>:Q]:4L'B6]SG)ZTIUB,9B\5>*DP-K>/%32&I 2K]+W>]@U;1?5"&];1'HR M*7XHIL.C<\[.\IEGB @+7!ABW$1OCDA4RD;#VN'BEV/)U*D#UW;MTU'#E$G* M'3>&Q1?6'*<> K+M/89)-X1/7U)U89%JVG\^$EM,@GKFE8_QJS:108\YH(H;&!_'$L&:&U BX A->>*G[[:IT=.PAA30 06K M'Y;MKY0QR 7!@@,@M/=,&0^WZP'-R"5?*:F?"?NIE@9[V_O6'P4TMH$L<)\374IG<'DDB^=U*'S/1O622"W2*'9,JCF%0R'6;2[ M3D8@"7Z$EA1#2IBU['%!BP3@*;-3WXU@,T2J!>>V,V9]RK_ETV6%Z6AWA8Q) M@@ /(\1+))S7 3E22@=04KJUOJ_5&F!1+2"WYBX5TYLO^>PN/@EWG#\[2F=* M$.$HT=QJ@R7D7G"W79 *FA)2U/?+VPV0)QWA5K>)3C)C>VIDQA++!, ^2"2! MH]"R[>3JI;ODT[(&&%0/RMTMUTY:IF4V+&\Q]2Q(1HS2!,=U[D8JR9EK]6RL MW0VE)F:?5( [\GPJ[5/OK9,YBI245J,@JF8 :ZJWZU?M74H$XQORHIM9X]>% M>A<.425:[:X0CQJC@)90Z)CU8:SP[1#$2J>X16_(IVYHWZ@.R+ORDZJ?J>VL ME&G."7# .!_CI<*H"8.GE)*'L=2FO_W\XO@E4*LVX#MPH*IY3AG0R%"K@$&( M8(Z#!-QLAPE#*8&RI[O;G;E,C>]HGXASFQ?+QXM5RM=XUZ"8+L;3FWPZ/,R? M [4RYVB QSJAB5/!GA-)M\M3A'#*(PY]#T]KG$_UX=Y>BJ67(+R;#B?+^#S9 MQV*VTN]B,1M_72Y6]V:+.,'&A,/%)'3EYMTT:#"?5SFSJ_=#&3&>,\PPMDYK M#IFB8AO4I81,V81(>J#N$EC"] R3@*=U%I6'%M@;S"]X9Z0G_&Q072T>>2_OEI.8?F*UO(H9)V?Y M;3Z=C[_E0:;B+G]?S.TE F'E/&"$JV01\03H;9X8*I2 MDJSU?1.F)_1M5F/MW6Y>#,;3?.0&LVE 9_Y$*IM?CX?CPU>=CU7.C XFQV@A M/$ ,>1[6A^7.%::0I4RS?3]#[0E/:U=2=^NMD]9,F<.*$XZHQ 1(+!P/(ZZ4 MBH,A(A+1H]Y(I+%+ MF>'ZODG4$YHEJN1M[1\UOF^4>6XI44$13F"B@"<2TZTU,#8E16;?[U;VA-"= M*+(O-VD2;M!D,<,",(H'&Q/F (&5PF5(!R8&I80[B)Y3M\T#H#K ?Z1;%_DA M/ZXPO,EP9)RR!C ;3R#3&Q@=5$7A6MMB:I5_E&:TB MYSI)MH,QP,]Z$_X -=).255*9"FZL%?@ZE7ROE0 MHE!C*@D5)53:ZJ0@DSZSYT0%5W[-Y#0X6SM02'S-Q")/PM)!>(B0DEIJ:G4I ME8+^AWG-I+)VC[]F.NXT51XKK9C04M_8=-+BKH/ M1C%43PAW.4I^77^?#V?A^]<#S:?/4LZH9\# ,(P6!@4AR M "CDL)08(YURSI$4#:3S".)$^3VIFUB"I+88N+#\]L]PY3$IY!9&IEV 2RF)7(&.DBA08)N1XI3*8>,?;]/T22#SD*W,_94LV>' MJF4*$R(4I)Y"89 62C!72AJ 3+FM>/IA]>7PZ'R(6S^2WL(PO[J.3]OX2?%G M+YXNW';FM%/H5]4R:8'B7E)JL&%((:AIW$!F8<%C-7>5-D7[=?IL)51A3<8L MHL (#Z17N)2(4];9^6&[R5D3-'WX"/HT>-_F$;2!%FI"% ?"88PL 5R5,H8I ML+, AC8I=**V*Y]'GX;M6SF/CLF.$?&0,>4H#\-):5M*A;#^(1ASOJJ/'TZ? MAF_BX?27/X,T#U?3_/0SZH-5 R T@L D !P)Z0"0NI2"!6_Z@EF2HM/7Y]9U MPIP:R6"#I3V+*X=J9E@H)[SQRFDCM53*>[8%Q_.4":6'A]7ULJ-&8.L@QY<_ MBS/)L:=F!J6R#BI*O#36&J[\HRN'"4V91WIXTM, .>H!MC\Q4*''''LEC'*6 M&(EC"H&RW] FA5C6.?NJ9,$W M,T)RJ!3!7/(P+^JM;^\I3#FKZ:&)J6EA4Q.:7?+E?=ROFAU=Y1RKFBFI#=* M<8Z09V&X6 JW(P2YSEZ2:(8_Z8JOP*0$?,\V1GKP?3!9# Y;GV>%,F^$$)I+ M1Q&35DD47T5=]\Q1AU(B3=Z(YL]35%$3HN<['J'SPV+ZK\%DDC_HP?28S[&[ M>$:<9Q*%Z9-"%TAO RDW_36&M79TQ]O2?_U8'LV$_[??#9<3O+Y80(\+Y5Y M934SW#E-&.;,(*3(MF^PVE6UM[/N:$;O29"^E5![J "B2%BI(-, :F"@W4I% M:&>AB&]P _U<4-NBRH=\$<^:/LZ*;^-1/M(/_YSGHW?3J_M\-H@90U5@_;=U M6O]5"M%E^-GFE\6TRO%E/1_(J)44,*$QEE! C%U8)&[12WMHJ.][KRE<*GJ@ MC/;"(HOK\2+F!#L8 5D6RCP583@C X7PW",G0]]+*;QV*4'\?:=4VSQX_;3U M>4IHBTIJ]-_+^3IY\I?B4QX _Y &UQ[QS7XJ*"%:8(YOX7.:\(]HY!!"T M#AIGF2QWP!R72?<)^IZ LV-Z]T"=;0V4S=LL4V8T MD-1(26@II[(PY4RQ[VOX7M&P/AVUQ<5_#,;3>00IGU]-W?>(QW(\OUT'IL:' MLPXP\FC=3"M."3 * A4&HG3??B'Y%$]&FEQ5^C;>!X4[(N9+99? M%]?+B1H.BV7 \/ ^T=YJ&9<<2F\D5) (""%RR#S.VZZS=ZLNF'0-Z*4M!KZ; MA@50(,##[\'OR6WQYR&7[G7A#%HJ+##$2H, \K8X-5J8^BK+!=9/C^'%%_FY:/EX0 M<#Y SAJ_DCDCM)5AZ:4 9QQBA8TO<932=78[\P=@=7=J;&W__LDJ:YO7=7IC MBOGJ-40[GA]U *HVD0E$$6-:*6V44Y1R"[8(6(]3,HS)OQ;:U5G=D,+.7MW$ MI/%!]$\!'9U/\^N=+_WL*9DY1A&W@G+%$)1($P^V(%BBD]+6@;^6-T>7-\DJ M:6NF\V'>7F5.>\3NZOKWP6PV.#R]':R7028,YUI"(S@/?S;:/&Z20L52Z-?W ML_%>D+ )-;7JBVX&T!HS]SWNOQ]* K"W3@8QQH*+&)\GG00L.!@EKG*<]GPA^4C'4IJ;V%]W 6]ZALOO[O$U0VSUY6B,VHWD@&J%*8:H4%D,ZZ8VZYQQ6@SVBJHVD4F(A85>*QC$%T(2 MQ?@: 4D$U"G7T,XU[\TO=#JA7RT*Z(Z"Y5YL,! G\>Y)O8Q@:?0JFS2R6'B* MI#.EK-AJE4"VZ@;ZAYKSSD>_.Z9]G.7W@W%\O7>ES8V3JZ;K=ZC5?)X?7%J? MUV 67S!T!"&DM38:>A#3[VS0 8*D3(3G!D9<.#<;4$N'2YMR<;:<1<#/8.G. M%C)HB:$.4D<%Y( HJ?Q6?J:2\O&=&V=QX;2L0P_=+U0^#A[.7J5LZF;("&\] M<411$#P4'LR'+&5VP*28Z[[GDNYT@7(>_IUR;K8,>GQ\0?54VKVHGCD#P]-TRN*X[SFHNV)>F@JZ(U_I/FSN.9S$O!=U,QT67\0 Y51P M-TR8[S5G6V>#N!3:]3UE=2>T2\._8V=OB\^Y\][>5C*#H9; >T-BTD]KG43; MB9]RG\+#OL'J6O78?K^_5Z4R'6NU?5HT#[*_>2&84- 8)H1CRGH:E(GI$(5BTE+VCTP\> MVZ5VQW>]&U-2QU1=1X VF #FQ _$Q%H4: 2E(9H98S3FM$2/:-7..=&E)H!I M5AFM7?49/&RLBAK^>SF>Y4',T/?%P\?)8+I0TY$+/[V/10Y=_*G<2%@M6(>" MIP<@$%YBAQG9&$!)C67MY%'L:FNT;2:]O ?4E)K:)JLO9J'KPSP?S7T >;42 MV %B!<96;"D+4/BPPN4B7O#43$C,2LC#&D:T\Y#Z#T[;9G35/Y^A%K\@,P)@ MXW%88!CK AK&;L_@J."VW83YO7!OV^)K8TKJF*K;ZR%-N;0$(#D$YG]A:4K[XB43:FC"PI^RN\W;O;1?$6' MJF7>A]'ED(2:20R\0$B24E* =,K4V'>;W",6)JJEO4R8C]U\7TQOON2SNR/D MVUN& MN=YR@HD2RE(<5X]:;&4FFEQFDJVNY[Z:M=(V$S_EDY6>BB^#[[^/%[>WQ22^ M%>^+V=NPLKIP*)_LVJYV M:G= 6M''K-!2AID&&G)%O2%82VN4W2H 0I%RTMGWV-.N*=RHIOJWY5G+MF:& M1<#4,X&$X, H;8W;CE^%8;N9O'JQ.]\67QM34EM4==?7^7!Q=>V^#V\'TYO\ M4[ <5],H4_PG'N%^&TS61B5 -1X&NQ)_H::CYS]X4O( IQOX6B:4DL)81W2P M6Y !A,%6=4C:E#V"I*=[W]:^??>::8OQ23)]S(-61Z_#AX>3972QGJ*W1O3 M8&BW(QDSG%&-B%5$24NTQ%!MIS@F4K8TJJ\DNS$2-8Z37BOM30RAID9$9K$, MUA7JH$+A3,P1][B*D0RD>$$GWU6\7VDZ\&ZV^/%H?J(F?FS6$@ 4%T0C1HA' MS"._C4FFAI,4]^7DM>::M6XZ:G27I#7E_/UGA,YC$'OM)\>>[ MZ74QNUOK]WA 3,46,JBIA@A8[!6(.$!&'\\1;=*$V?>[CC5RL!FTV[O9&) / M(^3C8'SH8;BGQ3(6UL8,"*HLTQQ)S03TVS@S@%-XT_> E=J5_>IBXMDXMVE& MH]C;-)1E(.)TM&/;(R9]GA3SY2RO,'&E-IUAA E%R"@E EZ>$BU*=YD!G+3& MZ?NMV9JM:HMJ:(VX11!D-E\E)U\%TJB[F&MC_>/@'L!#S#Q6-Q/2>\,<<\XC MY V"')6#E6&LDQ(V]YQZ[?'E)5%KULK9<:3;D(4@\F/,UI[@DR,U,@8]%H)A MXSQV4&CF@2C[+#!MYW9(:]%VK9.G7OC/ILQ+>0<[Y=V^Y*I&WV(?-V=B^UB5 MU&BFC5:0*X.9X,I2JRTOHQH8,RCE8<"D:+M+(EZ;&DH(BW\:!/TL_GF]61G/ MN%ZDJHHO:ZY3"&VR^!T(DZ^C]8P) 0%1P:\A D$3_!Q8;C(QZF [V1HOG*V= MJ.J1MO_YZRLM!>_VC]6O=OYFT\XSY(,@7\?%_>T@K-'^-BSNUAH+/L*\F(Q' M,5!FZSK/5W'6H=';T._QMV\;2W\5M%#.R2/ M75[=\/DR^+[[:*["X$IO/)/&.88<18Y'_)&DX6\;U(" *9=KWTQBC88YVKJ6 M^L!M7\SR\9!D_0SZZF^3-5^VZ:!**,[D^_D?S,)*BVH# M#;%.!Z\;;N< MA7^O%9,P;FK\>@8TE0)XXXA&$ *%#%0E[M[#E*#['NX<]7#<=*?,K@=1E.93 M/IP,YO/Q]7CX8F:(X=SJRKP+^*S><1X5?\8MVWP8!(_KU42[D_[A#"KF(.)0 M&<BQ#Z-&?1N,)W'C)-[/&4SR1Z%J\\M. M^43FJ4:&>@@0E5I;IJS>&F\M9,I(Z'L\=4^'18/JZ\, 2"3WH\%4!G.)>'S3 MB"--@&)@:S E3=GLZ7N Z9JV@L(>-7KLL?;F.R/\4GSP(7%8C;^NES$ M4?BEB)OP\2FW8A+Z=%/&[!P,'ZCU2_'98>6D],PBY@RU+FIH@Z?$1+?JK704 MR]_PCE&W*NO!$&B.\I7PL_BF)TY.7L M7<4S[;CB$AK@D8FOK5B%3"D9I#8EM+SOK#E?RR^ORJ0#VQ9EWH^'FZ=H/^>S M;^$O\^.OR^VMDTDB@9?64V2!XBB&8+E2QF D4V[,]/V$OS;RU(5N>^D(UX)7 M,$V9L-0;QKCT*GA)!@ J="D!M[3=R-MV_7P58Q,46>4Z MU)XJF=)"2*Q9=+21E*!BXY"SCZ3K>09KSL6W/ ,WS\*UX!]Z&N7%2 MK![CV8#@OF_V,#>/]XS>35>YU^;S*-Q!FW5VJW%O@&JM :$* D\H0X\X27/1 M;E#M'&Q/#ZVMTO+5YN(_\FD^&TSB-8+1W7@ZCC@MQM_RC6B'UFV5&LBTQ@)H MXZ#S06P-PL*C=!KQ%EG8".2M'DIOWXE<>Q:;'A_>(#A<,?/<2<:Q M$T)3ZKD'3NFMM&&UV\'1Q9_*Y3_!U<^,%=(XBB$R'$F%)6&\E(A+ ME6(J^W[BT(B[E@!N:]/16THW0&&99.04(-X1Z1>$"BML/ VI1D\7W? M1JA[79@.;UNT^5!,BYT38Y6GTX[5S3@QF'/*O0TFQ1+"@-W.K,K(=FS996PU MU UVVRFBCCO@+TIF4F"G8K9CSI57A.BP&-[.LXZVULB%X>T1K"ORT&[K^-4]Z_T?EU*',X+NB$5C+O!;&(2>L4L=XH+M$6!\IU MRGOD?=]::(Z%S2F@U8V&O0 =VVC86S$SU#*I%800\; ",DH^(@H 2IGV^NZ< M-4>W6C'O?!%PCO.?6>\QT52%=;8-"V+&C,>EC$[C2PYW;(Y7=<'=%J5.S;4B M5$2%0.*0EI JZ>#CP!#:7S!IZEXIGHUJ:]--OGAR/2WMHL#);67&.TZ9-E(X M(XTWV#Z.0(=DBI=U[MMR;Y=K3SL.#[:-1W%M>S*ZWN\3GO8YE5M).-A\G8ZYMD3 MU!!/0 "C1 $[DD*OZAGV+V6F:@SW;JQF>:G[2V$>WW:/3W6&A90>S,?#RC;S M:$L9)5)9YB&BA&%$N/"NW"%$'.-V\Z)?T#17._1M4=$-9M-@T^.+5.6;L./A M:DMOL@R3Q 'J':D9#\D(1M!K1:!'3 GB^7;H<99TNP;T?%.B;J[5BW5;W/H] M']_Y-_6-Y]S6=7URL)KI:+^6(PC:%IU2EW7H-QZ82MP 8!;8P' MGE.Z'7F6)KWB"_L>\EHW$UM10:<7-U>B;&;N^$C4XN%YY[K)_/O4GJQ[=5J^ MW_WU,P65%D'OA$MOM#<06*:A\!A)9*VM=#C;L/Q?HFFM(NBJ8":(<(#%QW(P M4]1S (DI)>*0IWC;?1_O-:O\991G"LZMA0^7G30QAUCY(,CW\:&EW-XZF0Y& ME0+#(6-*:03"W+B%"@:1&Q;B]9\TDU;W W&TT/QFJ\*9\X) M$VR=P@H(ZAAQQ. M3LREW.%[,XPY7]4O0S93\3W.FCUO7WS.9S&?H!W,;Z^F M^?,]A]_RZ/;LH$7%FID $@''1?"Y*'4:I?!L@1SW II(#GT&+G74R MCXER%AG$ K>#"(897O;;$-Y9:-&;($0=D+;NQZZ=]Y@7J9C&-6I57W97O4Q3 M3P!U' HD&":"$^.WZ'&5XL_V_>IEW?YL#?BVMLW[O*M'W=J=Y;.8V4T:+[T@ M%"HKB=.BE VD92_IN]=2D])?[NO6 ',W1Z9[#=BAXAGSU'@KH5"2,T"9]%9O M),/8@91TI7TG4**J#QZ!GH5N>Y.^AZ!7R]Q:L&WM;M&P^'R;CF)9SK[\I$?)53E-C(C/')2AM6"%P%3Z*2% M)08&B11SUO>P^WHYUA3D+4;=[PB0/,JT0]4R *T,"USF-& &*X(,!:6D 8.4 M;>33PZC?,KEJ1+GUI?_[,/.^"W^LM-[?%LZ@E,@%4 C42@)B@TM(2JF 3'HY MON_&K^Y%_KF@MG'#1W6Y P[PZ@Q"OKFTW"71K:L/,M^O'L0)"IXM6@W,:H8$+R>R1.C;,WDOI:_YZ9UZ/I!)%;S, MX'MZPIR'VE/'Y-8!53[E=MO)&Q*73=PN]-4JV]_-Y\M\]/3-S_5@_9#_N?K5 M8:>O2@.9 890;0BQ'E/+@P8X+:6/@9<7[ BVRM.Z-=$Q#_\UF"SS!!H^KY]! MQ570H!$0(\0 AT)N]XJ@]:WNDWS+9U^+'XB'2:KHQ71HBFE0VGR5>F;]Y\7X MZ]/'+\^=)H\VG#G+I52>2TL9]0(" AYWFSB_Y#V87DR?=6NH#]-J W2NUFY& MM#948(8\MR*,>TA9>4J-K6 I*?RJ7Y?_(=G;J6N?3_'H\' \F MCSWS^6"QG(5?/C]@WA>H=GI+F0H2A>6G1)H&F8 /$F[]<:AE2N3KZ1?M+XN$ M[:CD;-H].8%VW^_'LX?B^N-R-KP-2/P^F,T&,6E]/AN.Y_G'V7@8_E5\&S_I M]JYYL99V,X\U%L(X3 SE\21<>+8] X!)C^Y4OYS?VD9F*RQL62>MVG4U'6UD MF.^9Z9^/KR?ECYGVA*8S@ZS#@L=KP 8" "T06T$<=#NU?XWS^*.U-*+!5=Y MQ3Q?O>^:3^^K"@JHNN!QH+Y@@:: "VBF&(/0N#NKPA0'A:]O.WD$*@\[53+6KIQ^0: M?WEUOWH9NO2!#IW*G]Y8%G" BB!K@=54(&*!*??XB$0FZ0)JWX-F^S&UUJ"6 M7LRL]7!U?UN9I%AXR(CPA'HM#&"XM#8$(9Q$U;\.J-K12EM,_6T\7:FD/-I= MB_$2Q0/TK-9 1J6AP:A8):GD &B+^':< @F2.-GWL-ZV.-F(*LZ_H[O=I]@Q M1/9M.QVLE EHK+0T.B8@_!E(O4XI(HP5"E$(=?&'$9+E51K U2:%T;R(-AWJ?OK MZ*,Q1;R-BS6<(*J]T4 I3 D HGR5C\1&,$4;'F,GG;A;H>R=YD0N_@F(89?A9_'FOVLSDG=]$G_E3?A\QGMY42=Z]ITH&$(+>>1^? M '..6N6DX@"&#X=_A7^JC)1VI(SOPDZ*^7*6?PE8Z\GN2-(3:F<2"ZD8L)0! M1#P@EII'V;5/+^8V9K"97,38 MUXX##;1PFA)FD+:&0^0P4()K[6FE?;B&I!S>YJ/E)+^Z_I1_RZ?+?.X#A5V M>38=3$JEQ7V$%]HYFML_J>&,0 ^I$-@1 [4)CKZ@H$0,Z:0K/&]VQJC,HI3<>ZMT[F",+,$H,Q@=I9I:!6I8R&P91T!+WG6[KB=WM$ MR3"?1J5Y/OS;3?'MUV&Q#![,PYI)F[^$-'FQ]D_/^\*2]C^,E/,2LZHX93; ML#YT5,#M# ^U;36]2NLWKFM08Y&(:%N3B5O.BOOC*0V?%LL$1$)+SR61GBK$ M,,"ZE,0BEQ)YW_?HT/J840.R;7'D1&O\OD+*N7.;S(SQSI!5[*LUD!*/O-L: M>:D[>\WBMJ>M?E)@>B&!+" ML1&$00B%F&VY!\]6M9_&\S_T@\ZGP]N[P>S8 ^K'JF90,<6P M!AI(":BS/N!7PJ:]N>1IHTO7M&:]=,?$LM/'7V0_4C5CF KAJ*%*(R*%!1IN MIUDCDB:ROCLN];'A*,V20&_M+#[NV&V&XC^*8A2O!AP]3-M?*3,PGC5KJ)WP M#G@O+-^N 1@"E^P3U\> E[L]=<'=H17]$CIPN@$M:V64&L(A1\ J* 75P%I6 MRBE<4O:IOB=)Z9GM/%,EG5$O]O=TB_E8*P/:.H&)L(@9J97'FO+M6I3!5@-) M.I_1SE#_,4J=#75KE"I7+B][?OPQW\,U,QE63\IRKS@% E(7T"P-@A;(7'*H M9"TT>$FM6N%N+8#IY:S^;$Y_7R$6I6(+&3>*$FJ$\1@9!RTF2&WD-Q@FO:?9 M]ZQ.71K19M33F4']F,_B#P8W.3S%HCZIEC&NC(%$&^Z,%]+;,EJ]%W&Q<4P;5C-N1+4:R6AIHS+57 /%YI85JT M6.E>8W+CF9+ >N6<9-A9P) ERI3(&2E2+O7W?_C&-.V_N/#:71OOAN9 M)59RK3$7#C@26&!CH/5:$QXDY83J_:E"Y<*^N]7(> MO)%YC(#]O+R[&\P>KJX_!YG&U^-AC%L=KJZ&K)(F3,;#<8<6^G57*MCH_94R M)F%\(=5AI"T34&(+-YKQ@BI4Z7BD&4E+G3Q15%#/:U&JS%(GMY4Y1914F!LL M /%6,*ZWN'C!+OFF71UL*=K%_PW,&&HT&L>J@\F[Z741&HY_Z3ATK+F$4IH+EXB&%&1P\&7Q?/*+& *"2\ M858+SK52NI0,2]O9@K!>2K6F_U?;2,F0MW>Y\W[SKIZZF>6KZ_ O>W_T_*]R M&YF&!(1U+]%"2P444HZX$H.8"NPR:%6G&$^9Q01@)[T%[5Z?;)Y4C2@QZ)^E-N:?N*YY=6U MBF\=WJRP.&+,=I;/D(F'Z ) "[W#U$&J:2F;]=6\Q"9V<2[#FM6!>5M\>M++ MB,J'L#IZ_,F7\*=Y\"/CLVQ(-*=6&F+9$3 M19M8M^>73P*/BGCN]BU_(M+F=O=VNC\>^')20YE3T&BGL28!;D8I]$9M9W:< M%)C00^8UQI57/GR#2FCM2&?Y=9[_>QFZZ;Y%>(Z'D>ZID3D2$+1*",QY.7)7:5S[B3R!,7IE84IEU,%9+;1;1EU=+8OFG. MG*KCPZPY"]6S-P[*;#?K\^<]]FA/R2STA!@<#+?F&@'NB,1RTT?O6=)LD12% M^;;M4#UHU\2(O;9D;]E,8&N8@AHJ93AG&*VNUJ[[23E+>1&G1_-!LI;V:_LL M'%/U/3^R8_BB6":IM 89+I%6!@GG*"M=>0\=OY!9OP;M[-#SF2">YA:4F6A' M^3AZ!"3^(:J?/'$$PH^R]_G-8+(.$MHS_>\HE6'# !>< @X<%1H32L"6YM:E M[/+U]47?K MK*@?T?-SRN3APY-B>E3UKPIF#'D4UBT&A46S5\8@XNF6Y%(G/5C7'Z^@'C6G MHM=>5,(DOHX;3S$?GN[IQM#ZQ]\-:Z8*;%4)C7A;.XD/'\9%'(; "FE%MP-:+-P)<CP9Q[ZNI_7C!]([*V1&0.[C0/164:H($6P+%/-)JZ*W1*=3=?WR M!+H.<-NBSOLP35]=FZ"5\<(/AJ'C1VWAOBH9U-(JBX!W1"GEB5?X44(C4CQF MWA_OJ2MC5Q/L71+K?;PZ<#S+[[&J&9=$"6:Y@-AR$H\3'AU- NF%1?FE*[X" MDQ+P/7NA]CE\>5A,_S683/('/9CN3^-RJ'@65I+."R>HDAAJ*VS2*J@Q]QC#Q1T6X PO9#K4?6H]=4;F&E@MD60V,%W MT_EBMJQP[>!UX4Q3' 03T :3&H-+X\OIVW-4C5-R:LK^4*0K>Y0,>#>&IFUDE1\4&VG(WH^5?ABD',/K": M^J*-/1KI7Z%6!K$2&$OF)+>4&QR#RLN^$P N;,&!_5&95VV"[MJY)Y[Q!6"$'DXSO#P8!C44KHN'$IY $]W1;NRE;5I(0N M:7;49NVOE%F%,?9(2R/#.'6,:V2V@TF*SN:I%@X@TC5?@4IGP=P6F:X6M_GL M0S$-\VP$;)W*Z^B"ZT"M3!LFPDJ#,QI$8T128ETI)V/FDE_7J$/[15-(M\6H MC[/\?C >N>_W^72>QZE[)8,YB6#5&\DT,5HZ&Y:DWEGBK ^>W=:_,$G35]\S M #; M\: ;VW?*&AQY2H^9BL<3([=F=Q7)^,"".29<MXM-B&;;1X$-#/>;Q"23LT!8;JG1G)[#M9;Y- M4>_+1PK.1_:\"Q/#=3[<-44V?WG)CLV/LW=?=NU ;7^9<2.5]AK'9/;<$:XA M5MM1 GS*R6K?/:#ZF' VGJV%K<8$%L-RY-2&?' &X^-)"*^:8ZH4H]R0'.)UZ\2E+F+#F%8N"U@(9Z0@BG% %(&>ND>S>)%W\I)46M0'9FO$&'RO M1HRGY3+#!!-24.<5!(X@C!#;R (UUY>\ U,+,1+ ;&]3+[C'L\7#QTFTG].1 M^_=R?!\]KTI/FU:HG5D-@2+8&DM=0$Y;0%$I-X=IIZ5]?>.T*X>E?GUTSL-* M.:PJU,ZLM I) *UEE"H<0 5X._XD2UE,]=W*U4J+JI0[&_KS+ZNO-K%7V]I? M;@?3]_E@GM\6D]&[N_M9\6V=F/#(]?7*+63>0"?CG0&NI41><^[H%B^9]#[1 MFZ73.2HOVH"_M6LZ98_C/'\:_TYM(D,JN)>,20J$HA!("*$M$; @:3X[V3G[ MEL^^%F^=@@UKX.QI[2P_XOV!]W5K:#43U #@57")M1&. D65+&7WVB9%1/;U MT=U.$VE(->V%&Q3#/^+$'_H=K7=EU$J)E&5U=;=2KGDWS6]BU[Y<)/UJUT5K]XP'\]OX M3YRVOPTF<3WV*7@8L_$P=#W^(F#W_ =/2AX@9U*[64P.SYG1V# .@QJ@%-O1 MZO#_S]Z;+;FQ(UNB_](?4 ?S8-8O&,O4K:W4E52[K)]@5&9(XBDF0\5!VCI? M?P&2P9PX! ,Q)55M7?M(J0 26+[@@#L<[BIGR\Y*@7H]A.U3/CUZO6^+XF[I M(\)OELMU"OJ]^6+*^_MROMD63ON\3[<-T$E$>#Q10Z.00M@XNY\SBRL[@Y-9 MN?.NAY-MRZ"_7?Q',5\7'XK;,N*34/MC.HMKIYP7?Q2K;^7=TP_^I[@[N:M? MVEG@D#J&.(F(6TL)BV9?\H0H(V2J?==K;JNGOLOKX6;G8NESPW^DRM7*3!:+ M7Q&K/R>S]:$2S_4:!FN)U51CQK0 BBEI_?YX@Q'..6I>1=Z:=K;LU@30&]W* M^_1$9I*@V+W#4?<)FE-,.]8F0(.0 58Z JC0DC%N]\XMX'W.H[FK2$;1 LE: MPK[',]^/:?(L^7)AR_7GU9?U;(?+F5";H\T"H8 9[YAR2F#M*2$/O@)I3%:) MRXL?E5_KAMJB!)J'.,QFY<]$\2\OQQ W\B*JVL^SN*5/[S^O%\OTY]V#OV-% M$X]&0K3]BU+P/8&>(:<8C>I><$RKAXL(J;PRK"-*FS$$0T)G9"=1YI$6PZ<1!GN9!: LY%*KJSFQ^+YMI_GE*TJT#;D]L4;$XJS[Z.N+BNV,>XTE,C +35,*[AH& M0:+9!3 @VC*-5#R[5,7&$+(Z+YG']<7O=,:_9N)H?'Q\](OCIE]L:CR\+R+B MA_Q[9UI$\UU[3:7AW"A)/?96X_V"H21+A5U?V;?,TUUK)7 M8OY&OA^BJ!<_BE-&[O%&05-OB46"4B\L]S2%6U:S!#COL/:?VXQVT1_\T<@_ MED6T?MY.OYPR"VJT#DA[P+0FB'I.A!$*VOW:DLAE/1K)JL)Q93JN.YGTQ45? M+HJ(S79#OWU<1.GOD^G\;;E<_F.^*":S,Y=IEW03E/52&::0E40;C0G;)[-# M$?VLIW7_N<+H6A[]7?8>K.UEUT6ZMOY4/O[W6M9MLPZ#1U(H9R!0QCL$N5-J M[TXR@&<]&?C/74A_DGG@[?_^KQ="B7/XU^:?#O[+KI\G.,<1?JZJF_[MMKS? MRNG8X+JE^XY3? MTAJH5+1Y)6<:4F2JV2@>#YI7^!BC31D?>1[4&N#]W;3/EW&@=QL9GB=8G6;! M$^DV^U% T+6^^N.5J M>A_/1J>\4T\_#( *J@SQ%$2TJ-%$<5O-1IFL8E5C]:!WJ&JRP&VL7$RQ2,\@ M/DR7_TJGRW_,;[<_6%6'R/-:YH(N J$(82P,Y08@8CS7AE>S,E+E).\;J\>\ M*W73'>Q]QK7&D9][T_#LW[=S.Q/UVK3;D/(E8(:I=I8P%DU/1_?+CGJ96+?QE1=):0M=H'[ZD#!@AJ"0+6D@BYWZ]1( 9)_[]9KN\R.-8D&&BM\TPZ(U/IRVC.@KT-Z^.Z&"H\_W4QJ668![\^KD^LNET$ M(:PQS&.N-%62426,JQ# P&;EV!UKV;<.F=81[KVIL/OOD^DBC?=F8:?+[^5R M,KOY\K:;M'HU/"PU6@6'(67(*LN4 ME7%Q6ZQ!-<^4;OD:P_@[I&)[4/<6>A.7SN8<^T<<]'I1/.P#]0E6NX_ &2'. M&T.]\#!.FT&W=V)#KJXR^GJTU:T.37*3?H%//;6@[DRSL) MUD,#,?:46 :DBX<:NU^"BI"LN_/?\-JA,^2'2^51GW9GVP8?%3Z$3!@:];VS ME%O_:,W1K#*)O]&-15> ]Z?D#C\1?0;1R6N)FET$1R%R3#OO!;/<(A:/L7NG M$\XK491U!_$Z*=<1[OTQ;[FZ^?)Q,KML.SW6*'A@I%+"6N^Q1LI9PU$U2\!= M5LCT;WC/T!K2_6V7RR+^KG0'9Z,RGI4;K]'N)?Q9)5:C=6"<&*^C#K="^+6O>SYYH$"W24$8GV.2+2*02(K<(8 MM (DYWH6_89W'2WAW!>3JH3"[XO%)JEU?4*=:1DPQ@(3(2F3EGC%A';5+:*. M>.98!N@WO'-H%^Z^Z/6N^/D(BT4YCW^\W9;EN=3G>VE703$N$'?$2*B-41AX M4=VH:$]]%@%_PYN&CO'O+XP@@K_-Q?"AN)U-ELO-N[2-@._^>[W<>!3:W)^.YU-)]L. M#F1=?Y%GW:92 K/K>6R)'/?*4.N%%=&:U% HXJ!F/EU^ ETK2K\C;]C!Z.'+ M,B*?;1]LM$@ )S+.'WK()-5$Q_GS.'=B',_RD;VJ(/#:1*@5!)X'L8/?!X 8]1)@P76T3314DN,T-^L(4USDO/4?406K#BG4!JQ]/F097T46 M1[AR'#H?CXQ,.B@,LQ$KP0S&%ON%Y/8<< MX)SW5!G!/#/$(:R9XVC24KC[LTL,5P)H0>K_]V[>JE-I'*LPNE'^92W MZ\V]^_S.12!3:=0O9?SBL4?@ J5R+'G+B=]R0E_4;ANBL*E6A$:;6F,J&*<2 M(X>!XDYY@&J%GYU2D,OB]F]?RQ__=5=,DVXDZ0]IGN212HP_V@\VU?L^,*'G MGP05#TF" *8YAX0*""@GU;@QAUF)_$;J)^E J&4KZ%YV+JW+"!5'3 M0Y5/7WP39#3 +*<>1MU%XBF%0Z;VT_8^)Y1RK-[<;CF1 V\WI*BFNO7IN?F= MG:S.Z8LGWP:47CTJZQ@'1E"C'<&PF@41("=EPU@=K/THCAR8NR6+GRYO)[/_ M5TP6/O[DD(5ZXNM !'2$0(X,%T12!*77U4PH@SDALV.-S^Z','E ]T&9+:7K MD^;1]T%QK:70.M)>$AG-? MR]D1LCSY)FP "*E1$+<.@B\X-6HN3 Y5WUC#8ONEB Y\'9#BNW\/A1?IVE: M\]6[R?VQP\JA3P,%TB# TH9II/-1*7I:S8%%>SR#(F.-;>Z6(BV@W"533)SS M8C)[,[\K_OJ_Q:' Y:/?!L2A)RK"H*+Q)IU VNYG0:(-E\&5L48I]\&5/)B[ M(1 6.R@=$0A1!&AB.X-.H193G*PL480=TN9EI#N4L7\ MLYC-_N^\_#G_6$R6Y;RX2V7.B\5)57.D3= *&:@E2#.2D1+SU5S MLLSF;%NCS3O2R[[5!MQ=4NC/W#9R[9,MF0"9NI5_+Q>ES\9,O W9>*2X51YA39)V&UEWY?SCZOR]E^;-Q#+F_5JN9K,DV/@]/9THF%( MP34IU%BF LKP1@IQ0RI%V2&F. MM8?&^EK'KVZPL%$H\V*39FPQ_;S>)("*(OIC\M?T?GVOYO/U9/;X']/;W$JD M\8^WQE!X3;JF-L7*H474UR.0(S/; M#3XEM;U-6K6<3Q:_'G^D[E-@\>6LKMEQT%1AJ#RE%$&#.19,X HMKUG.G>A8 M73\C('0WTNEE"]VGVQCPL<=^#!?MD2=:!48-45)AAR/>5ED,+=R<59A5$I!: M\<^]S?6B[#.'3F82&PX%)%A):J"AFB-4S=;:K PT8]_%6B'!L0PT^5CWO835 MW=TFSV:ZDM_[%08^$;>_NI5V4D+$'2/6"N8E=E3K:)<(9!CEM=S6-5^8[(>Q M>7)S["W)TZ\"D%RGY'\8:80-\$YS78U/,91U ?.*UV-ML95M0=O7:3!='VZ. M&G\ORJ^+R?=OT]O)3/TU/?7<]VB;H!VAD*;L0Y9;0)*75U5SE"XO=]U(Z9,E MZK(;8'LC3_'U^6AM>3^9GLJ<<[1-B*!3P+0EWCEE):>(N&J.3F2]\ADK>5H4 M_',JM01SL^N7S1O4Q:\MDW9_>4ZBW8_#W_6AO6G_C\%B@QF1VG%@XI =CV>7 M:KP0BJP[NK'3(E^(92:>Y^5_[O@13X3%F\CN0SO*D2\#I=IKJJ$06EF*)*-P MKT %<]?H"VAC'VD'SL8BC[_3K#=II_Y/^7FI;E^ 8]3PZC00?V8'R];4FUYLSL76T>V+0VG]1)E,5X\' M>]89?Z)5,")B9ZE BGL/-8F+Q5?SY$[FI(W+"IT;-W':0[0OYJ3L=5L!S6;E MS\G\]H5&K13N63I=VE6 S"FLG:=0&B258(:Q"A%*LYX0C#JPKD7"=8QY7RS\ MQWRQK:+T/YN!5W$:)\AVI$7@1% )B4+Q?Y(2*.,!M)J?X2#'NS3JR+L6.=4. MM -3YR'/?A&/@JN4XVI^]V8>15(L4SZXQ;JXNYQ>=7H-Q%B(/<4(,:BLAI+X M_1%!L'IQ<*_Q;7?W%.P _KYH^G8Z^3R=I>#YMVT4 P# @K(O3C6<,*256HD(@6N,Y^^JH7XZW2,".L.[[PC39+[J(Y]#B MT0^'SO#=_HVI$U$&$B/@#&(*$\W=+F.9<@*"6A$"7N **X[\[QI-49M"!Z,I^A!% M7SM5@QGMZF>UR]A=IT%J2JQ2D,.H7(E 1#-6H:2!SWG%-U9_UL@(VTP2??'U M_:*,9\,TH5//-?8?!8(1C%L_ULQ3AXAR@.R!XUCF7"&/,)5X%Q1J#&;?QY^G MZ8AUL?I9%'/WY4MQNZF?FVR'W;?;JX0K"R3SW$&,J3?&"0"MX\*X>!3V&#!L MF:]U$]#-7/"* I^)2*U_$5369;;(7Q)']>O+Q"4Q:Z#U(Y5.--*2Y\5I8 M28D3%79.@6L.-&F%4L_+T_4NDKZVGSHSVU\++*L"N)GL?=EA\$((AI6&%AJF MF8%:\@H=@ #NY9@DMX2=%U_CD.^NG[+9G[KM7QY,9:I>,=%] M9XD_-5NFL6$2S71R*/=PF]T'&T5()/$T2HMIA^->1RKDO,?7F-=Z:&*W+),Q ML;E:LVX^2<6 VC'L#G<:/$3("DYDM"*T$PAB%X]EQF-!J-329C WZU+VNLC: M"OB=GHGC.6BZVQY6V_?+Q9, O^.)&=K^%4$C1"3&0#"M/8G6K$4^F@V8E4B];V-GV@7CCE,>:"R^5I=1Q^##_O&#R MUWQA4YL6S^M%=P!ZC]FKGHZWT1.K"WH)\9@(!4="$22 XU)["RH<@,]R;8^= M?"T3Y65&JHZ$T-C*?#$D,_D^C<>!%*M4^!>681 M1QAXAZ@DW!)MJSEBD)59>.S!4-T0K1]!#*;Y#CY(JW,+?6%/\1@*)((&IJ0W MV)$( X,5'D;8G"B]L5_N]:P!6Q7$D,2L?K:[FGR6X+!Z\[')#:\GRY26\.$# M4R[/I)EL_=<%3;"7ABKA.=:"X7BFHA6REMJ<37[LMWK]4[QG:0VV#OY>EG<_ MI[/9]B'39/XU7=9O_^D2?I_H)A@JM3'8,J61(4)+ZE"%!(%9Q0''?FG7,V_; MD\)@?'R_*.,)>_4KY7W=E''X]WIZ[!![>2I\HPBG7 "/M/=)Z[ZP$!JO!;M6NCV%- M\!YNGUV,8L8]AA14P17 QO_U>OW5[Z5#WWMG [P'8]-% MT85U0M(\ 5@K3B6(\(&HD#%T^WDSE1-85?]R:ZCH[9Z9E@W_8+1[5UQT#(N? M!RF-DU"2] S>"PD Q:B:&74XJQ39Y65ZKUJ#70[W $1Z= 5:X^KM=,.@,'/& M.F6M%-A(AZ6I7N0 GN?T&[LWNHL[MU;1'I9;[Q?%]\FT\M[4/'@=;Q^@I=+' M)<04B78STL"C*@0&, 2SU-CH]\>V>%&+;GG(]\VZ1RE?]C.H0;9#S0*"P*>$ MH%0[A3'V&J+]V=-1FA/JUO0%W:=^-\R.B=8"ZH,=O1X-^<)3V-.6 6&2(J@0 M-<@*);!$M'H?& ^>."?_2E;Z@=>_9[8 =]^Q:YL4WM>4B4DJZ"G'4AME(>;. MIU#J33X(#8D9LEKCQ]MOQ=UZ5MQ\V8[_69:3*BF/FM_M7MQL9%.G>%5FST'; MJ%6-3?_?(Z9E7O*?K%=+V\V\ M<4XB N)_J+# V0<)&9F5/._!CQY[49PX\8P^X M;H4$+Y("MH9UOPMX\&<\;2]C1; &AB %(&;1/H6.J!W8U E<:]/J>*Y^.I\N MXUZ0HIU..=L.-P@".02,0DG]@WC@%A2!W0P9H>*Z$]"V(/AC2S<'Y;X.A_O! M_K-<_.O-_/VBO"U.AF4<;A!5DL1**R@%D<@0S+FI]!QCG%]CC:->.)2#]KAS1I FCO]-B'>:2G$8L? M)^^%CC<*#GBN.5%2(,@ 1BE'6C7+:'CGW#S6C_I_=BO4@Y.N0_;D8MP[DTY? M^#S^+ C C(0II3LS6E$35T)U5F8 HGYC[?N^W>F0,Y=CVZ\=,OA%3MMV"*$F M4L!*"*P6#B"FC-N"385UOI:!W?U%SF[\NV(LC6YL3G41'+8*"4JHB[-F'F!N M384",#;'A?B:;97:Y#AQ3],B[KTL];?%9#G@"M_^^AJ+^NF'@0B+.'$& ZBP MX,A9J)F.DDO%_U2]"YLN9W3SY6TT-8KB,M_@V;;I&:S0Q &N(",F[A#8B6K> M3+%KK@C?E '/2V"UC'&/JU3=W6VJ=*4:T%_*^$'ZR\"NPJ8+&'&(L86$*"I< M5(&.^I2#"<13$Y-0U3I1=KT1/R3E2&._JQ[Q1I5>:Q,^WCQX[2&UEEE"/.>. M.RED-7N+1(ZC9X2Q$4U%?W2;;0W9OFRNS3C58I'2B*;'BI_B;U=_34_9[L>: M!( ]A88BQ#QVUD @K*IF*&B]\B>OASOM"OW07I"/\9 LLN7]9'JJ1-GQ1H%( MS*"!3D(*.(<6"\-WL^3(ZQRK?H1,RA=V#?8T0K9QSJ:/Z\C^.(@_BOO/!Q\5 M'_@J( *IM$X#H)$GA E'0#4V0_!@2;WZD_JE0BK; K,O17%05;ZMJL>>4!:G M&P9K-608"N,C8@PIQ8BM9JLLS@E/R+J?>H5;3ZM(-U8@V]7Q=5%LUH9:%)-C M2N3EET%Z+G \PR%-+ <2:,8KOVB7!_QY!D.:?A1@ >J=;E M4U26GXK%_<1=O?(XVI@,#[O>Y5Q.7P;^RWY2WSKU=! M-%96-]\WT<*EVW@W-B/Y?\5D<6@_._E]L-X29;1!QAG/%8@HP?UX?=;C\;%' MT':AN%K">6SJZT,Q+WY.9HGK+>BN1[T%CM)=,- 8">HPI BFBX8M+E!?=1VM M@157+CO]<1.E^61Q/J7M!% MP-8S+YV6*4I6:XDUV"/HO,W9%,>>%:\+W=8=]!G;X!-*^_5JO2C^F,ZG]^O[ MW<#LNG@S]],?Q1]QB_YV8H.\M*<0C5UMH")<$XHDQPKJ_1RI=CE;Y]@3W76S M=78L@<8LVY40FJ2R5[>+S>C>S#=#F/U*2V RVXWO&+EJ=Q D0!PSQ[%!6G ; MP7.ZFA$ 69'38T]MUP6GN@*^,94^%?/)?/7F_ONB_+'=E4^E%SO7)'BBO$N% MK9B4VB-&I7+[44N0HX+&7KJI"[JT!W6V&WO[O._MX?#G(U\&P"C0\11'8#RV M"4RUM-5MHI JZQ(C,\7'WTM'<7K7?J8N1PBT"\ M)1I #P15A-@X/[A?)A2*+ *-\#:M(P*U@^Y0['E7SF\O)M!#H\ 495@AGJIT M"H(M5ZQ"36B+LNY1+G9D_R@6G\OK8%%CB(>YIDW.J=4N/UVU(6_/ZTM8^\KV M5"=!,.:M9 XPZZDT(N[LU5VEX$B:'*)E.;Y?%\VZ GQXVIU^$72R78 <8"0@ M]0PCK*")O[NZ!!+$,YU#KM_4J]TFX#V&*3_Q8FU^5/E+_S&/\DQJ.5F7LQ0_ M\6R*KS28&1C%N?:*,4@I41@H['<1XT!)/N!KA!H.QJ5=UWE5=6%/@8MX]-?: M*&J)H>F)-60[3"#P66Z:L4>'-&7'Z>7?,N(#[3;'9E'#!+NHHP !I0I;9)B0 M)BI=([6IT(!"3A5"'JM$C0[3(C,\E]F&G^_'T\;BV5\5(V_]6AT5$9O@0 =C1C!(48$ M*(B-(]6S.\@AR5&K%YN0_Z%K8\&,CK"^7"]:X^N^LQ!11]1(CV% I$T93J@A&*JM!$.L;B;&!"Q M8/*X>U?\M?KTLYB=B.+.[3(P;H"Q MD'"%$?5."*<@T]K%OR"-AG/2=T7%#CET 5];%,G82%O#17II5P$JS8!B'##" MK-.IFBE+B%#GA(,F)UO=*/7E^$C:4!2C(V<=I^CEG06,D68,$2(CWHYX([#9 MH.(A5GEF^PC#:D9)T*;"&!M%Z[A!+^XK4*<=X49A KQ-)2U=7,0;3##G5N0X M[;-"CX67%?0:2*24AQ 5&T#*TF*<_B!A,&K?/]II?^/?G9 M4!9CXVNK$D7/HHXRT"FF E<^SV+"_G[T/'"T70Y6O_Y&Q][D8X',F=V6.P M$!)./15:6P.TD3S:@]J!>&QQT3#,25PRPEHSF9[+?L'NFF /H5'YU'K25X!> M>ZDYU7%8--IH$]R=X*H1[W%JR1PN&X9@@G MD#$BF09IKH8X;I')R2B15:[F&BB5 73WI-J;V6UPZG%GP2K@E%(">BPP1-1H M3^-,E9$*"B)[#7>X,DIEX-P#HRK#N!5&/>HLQ.W<(4^,DR8N'N.-HVFF.BTI MYK.<.3; :.;3!F\HEDC&M9/! MI\OSXEP3GW)@[M[NR[?S4BT=&)>"]=0+BY2S#$4@XYR<4=@"EG->JI]#YQJI M8%4K709PWH *V=5[<)^ M>1T'[2A "D0S#T2;SV%.$&91>TFM+7 M:*PG:0&7_OFTEPTJ4&;T'W@4%*?>:B>DIU89Z$3$#CD1Z6!)3BJ)L2=V;XF\ M0\BAIYWK:YQ *N1>W,5A#[=[F?+^?KK:YDN50Q%U!.L# ;'KM2^&013#P)EDAE$/7(-XON"*8&XX M4L)":IRPR@H(+;:UKH4[4@_E3B^6#UKW?I.%YLB]-L?_SK7*'-VIT$360\"$&/ M .$0$:- MK.;ID?^MR-4"&TX2+@?YQB[=/R>S=:'NX@'DT^2OE"-PN=QH\]/5.T^W"H9# MRZ0 RCIMC2>&N#T>VN3ZA%J-(*S\2;SZ6?YZ5NY7D[F=]%*^)@R\KM_KR-<;^:I*LST M1Y'&=7K+N:2/8$DJ?,R%DA 9 !1 T%?S4@CFZ)+70I-+)5SV@W5O1^'I:OIU M(SLS69[;AUY^' AC&'JC4A51H 0D1NQU+U+JVIY/MFQ(Y>(Y#$L>RK#7YLJC MRNV<6N"04X!X#3EG'L65MYLAR\PU/D+&9(CX)%L:(]IX=_I8W*;+TLCZAY&< MWHN.MPC>*T[C<9PCY0"00F%+JC$3A;+*&8R=!4U$5W8!:V,JV&(Q_3%)&]S; MR<]EW/'.V,''O@_*Q7.9Y0YYCE!4H9#)_5I@NEX\R"M*#]$J#5H"=3!_[]NJ MQL(E_MU]HX"=3(0TBSIC+UG1M3^W*-=L\;U<3E?O M)]-#SRU/?A\X$%8[0C#GFF"98O2J8SRBFN>DFQF[0=.&%(\ZU)IC/)!/WRU7 MT_O)JKCY\C[^PS0NCR.E*2]J'XQFFD"2MEABN6< BLJ?@"S)\O._.N=;67*GE(\+(Q=7;5I!&^:V<1;$OM_[?=^6J>!A[ MA#Q-)\[X0P+H5$'(2[L*RB#!H8< >8T 8I SM=\I MY":[R;MU<@+7-E^T:4^O5M[BE_D]QIW^E.XF3"KBSWQJW,T8I=A!% M[ !60B' ]J:#]#G9D[,R,;VN \?X)-67IKWY\F5Z&^7V>,HGM.FASP/"1A&, MH8Y;B1.2.*:JX$KD;%88^N5/MU^CQFP!U>8O:P_\;EU&5IMOD^GB?C)7=W?3 M],/)3-V7ZX,U"9MU% G0GBHM!4,4LFY 'LS%.BL/(>7/]%^3;SI!>_> G(> MWE_YHC@9M/7TR^ 9Z?]FOC3#J#]7Y5_+%:K MV68KWC)ZL_L6=Y_*3:W[]Y/%ZE>M^_,:_00@J)04">\@Y!8:J/4>"QSQS?%[ M@]^"75WBW1?WWLR7ZT4JS_VAN"VCU3(]J: .?!T,)$!3A)7VC!A*'=*BFI=6 M(HM'8[R7;Y]'^:@.J:EV)>HOU$N[5H''A6 YAQ(RHB*EH/?&PWQYUD/O,9X MG=^/%FJ&;C\/-\OYUT_%XMX6GU=/?WV/SS73+[_H7>;A!L%:[X!@0"(AD'#& M$F^WN60$DPH/^@#S >9:[[$/?1^8)=8;ZXRD'B@73TY5V4[!+ 37_/PR5^(O M[BWS\>U]?0[\J+JM50H@T4 QP@!$4;\*"\E."TH#N:AU:]G=#./NOUJLD]8^ M]T;ZP-?!8.^TM<(S*MPFOYU3U=R\ONI7A+G2+MM&MZ]3F(D"F:[\Y'8Z2RG0 M3P?@O_PX2*&,,P1&K:.HV=@DJ)J5$/3:.=-8R&7+R [#E[-A^(<^#Y*FZ@M4 M1X,$2A]GIPW?KRIGK_G93XZ<3U*F$;2]W5"GB/'B+BV8HX':1[\-T!@?[9AH MPD9P*-*(&5_-21)US0?'/!D_OVK.1+8OMCS5JV>VI)SPI[F/&L?>Y!DFUM2-K+#\*76<^5C38*-&"GF.)'.1Q.,,6!V#UBD!=;F M9+,=NZ[)D?=)ZC2&M_$U[=MR,M^\B+W=%O;YNB@VKJS3KX1.MPJ48<(4-A@[ MRZQSP-)*65JIL@K8C- UG2_"LBMHF]_>+Z9?I_/)+(WF-!5>?ADX0'&OC+:@ M46GBTB%JJS&2N(7^-KM*+A>RL6TL?W6_\3;5I\'1!@$RS3WEF#KF@-. U)M MJA83GA.-D?7N_-6QH2V(FR>]^#9=W&U&<7Z'./1MD!JSN#$Z91!WV&.I%*S& MZ8S,24$PPACN=J7? J"-!9]*QZR^U93\P8^#EY0H!(415"N(H .X<@]:RMF5 MU9YM5_1M(-I8]KI<+,J?T_E7M5R6M]/)JKC[YW3U[>WT-EUUUCPO7M1)8)QB M9ZP10D6-1J@6KK+:K799=<5&6 6V7:YTB71?5NJ?D\4TV>,?XNC/^#2>?QH@ M1EK&64B*F:(I'RN4>]"@[K=V9L_?APBSYE2 %(OO5#1 M9.(<[0_0T;*Z+MNTN5!/L*,1DKV%_2ZF]YM1GG6?/_LR6!2[C,:48Y![ @V3 M'-ZF;Q8?KUVSF7^=$V@1B. M7=2P7ED?5Q!VA.S],$*(G/=1HS=E,N]O6\)T4-Z4J"2J21 M$B&5P*W=:9\68^74TG,_=7L;B=+H^?3B[O)!#$ MM3*>*.DB4AYB@<5^WS8NY]9_A+'92/IQF;3O45 MO%42::BP,01Y1!.TU3P-SXI6&Z$AW1NI6L2\,;?^F,Z*Y:J<[PLMZE_['Z6W MYD<.Q;7;!BX<5418(+T!$%MGV/X^0EF6DS)T],[>9H?CKK#MC"-'#\ 7M Z. M20PB1!IP*X717-#]RHHVXV!5-=KE20>RO80UC;!NS!NW7I3?BW0S>1?5W[Q8 MJJV"JT9T>J>JUSH BJ114D$!HEZTD@F\=U08BZ^DTFXGTBV[1KOYB2?E[EFN M4$VJ'/D\0(854T1Y!U3<2K6+PZQ&RRT=K.C**^-&._#V]T!VGHI87?) XUB3 M0*VS5 M("?>&>,65K>Q$IV%6I8W1WS[F>?9:@G1(TKQ-(3:+&B433C<-CE.& M&3*8F/0V(6*H*IWIQ0[0F^!I,R\&V\)WV,O_FVG/\YF9 M*@J'/P]<.P<03!&;%G@ 0=R/UJ+V3JVS<-@)G]-9JO)F_EM MN?A>+E)\3G"8D^-T1&>7 M;GG2"=3#O,]X6Z/LPI$6@2.!A>;<>($B/4TQ+N_47?E+=%<;?T$:PTG64UGY-Q.$?:! H<@I!$:U4S1PGFA.^/CY#I MG""+U_60))];;8$\I"K[4*1C05P$N$?!Z,V+*B20 ]!JI(#?+ZODX+BN M:Z\^-%AK8/<6\+-/?!K'/)FE#'%',]2>;1.T-10JP; 6#L8Y2<3H?HZN7A:< MM@+%GM;N>!V4:@O9QI;?TPE]*+YOG:TI6=,Q<^]$DX"YQ$0@+8U#@%#IC=^K M6P=E3H#ZZ.]&F[.A95A;(L.;>42P6*YNYK-?V\H8]1CQLETPRDD,XFF.2\V!/@')QD .?[($2;2;_ODTA',PQ"M6BAIQ!]7R:L:5\EM$NS7^KD33W42 MN'.808.9^6;"T"W=)VZ(O=L?TD;>HU#$YSP(1$ M!&D$E8'4^^KA@#/.9OD<1YA#O\/]+Q_=8=31?MRU=<^^14#:>VXYUA!13@Q6 M>O\\S5&9E8H@+W/^*W0KMH/QH$^YJBI;NXQ+TV)ITAWSG?ZU^VZY^_#BAX+U M>PY" &^BD<(0U5I:3YG8'P&T<#G7=7GY^%\A)_N5Q:#LPA[I_ MS"?WY6*5:ENF!/,7'>\.M W2>,.-H-X!H"S4\412*7*O65YH0I:O_14JJ[;1 M[HMACT>:IK!KRR2N@PE8.H] MXB2> 9V1"&M,]A4WO" PYQ8'9;GF7[W*:A/W(:,X37E_/UW5=>+7["% CZS MP%&&&*,(%"H_PC54?@9OY,&=DO]E$=MU\V8_EVV1Q_,;PR.?! M1!VLO7<>&D.E\PQ9LA^MPEGOJ7X7KWJ+ #>FPQ%/Z??I8B.6TU%5M1H'B@F, M2E-!(XS T#J#JK1.'@F9197?Q;'=&=S]'9<6TQ]QF#^*M]/)YT3T=$^T7B00 M3YZ/CC<+U*< ,F*) 5(;;24"56$@+V56+B24Y<]^1<3J .B^*/7WR72^3.7' MB^7-W/V5HMC7T^6WK39]7(S[ *_.M@W4"(@DH- XEI*16U#*T]WIP M;7)2$J K#CAO"<_^[*]MV8=43VSQ(_YE^:'X40^55 M^LN^((6WPF;96+^%^[H=8!_(TV$]^G?%*FG$>%S[&/^E>#J"'HO1N\DBO1W< M#Z1&.?IC30+F E AA<604.3V9OYES)^ MF?YBB]5D.KN*]>P\0MP9SX5GS$I'N69(:8ZUY1@.N9[5?#6]F\[6R51YB#AT M?]W.UA'F] 8_/6M=;V5\\^7%#,]Y15OI/V!A=#3 (VGC*5;QE-585/AY.EPI MG"'U1&U.E<-+9 B=8B:SV_5L-XOTING6IED7=[OOKDB]Q .9,5)C#@5U3#OA MD64:8V.H]E+7"A_K9I81ZY3?ZKY(B*L?$?#TF.Q3F3SVY?SC*FY/W\I97(C+ MC81.3/["GH(VPC)'N(%*:$,IIMA4F BHL\*>7JO*J,V3LD_L&SO;_UDDCVUQ MIWX4B\G78ALXOQE!M%QVBWT#P/)FO5JN)IM<]B?667ZGP1$63VO"&V40I=)9 MPL0>8>RSG!6_"^MZ%T-?/HZ#<[KYLIU&BB4L[LYIP;I=! LAM15 MZ%"OD^EP]TS*51#66"L*P0!%CSHC=SY>I MK$HC%Y.R]Q#LUBV>=M$>POVQR2:\?#J.5^K>2$FQ(K+>"@88P)!%Y8$PSIE@\X1J2,QK=D7#$@*XR0 M1(,E[A]R\=?F33F$#'I1"C>K;\4B^7,7Q;>4,NS'QH4SG%;X]SH%@M?0!4\^ M#!PBYZQ$%&-K@-4$<[]%EB .3:VGUMW,Z FV6R?9NW)5:ZF?:QHH8LK+:"XGX@[=[H^)/W6]>T$VP5!NB,':>>T\\ M1L+OT8":Y(0EO;(%79L7SR\ONX.[+Q-PD^4NQ6EM(4DS*.E0S]:*._A]$!!8 MX01R&J:R"Y BYZNY48)JJ?!7RJR6A/[E>L_C%?%)-9RG[Q M9OZC6&Y>W*60]+2\CI85:]I5\%(:Z8UT &JNC87$F!TBS"!US<3+I,CQ3;,+ MY ?@XJ?%9+[;R=Q"0-/=! HQ]!J+*+)[CD&TF(+J]DKQ.TUW^%W MQ;OV\&X<+?+ >U\NBNG7N?OK]MMD_K6HR'\SWR0CCN>%[Y/YKUT%C]/5$G/Z MC$<1@(F40',!"4'*2(RJ>4.054-QA 5\VJ%6WZ@/H-M.G6'?UJBS>&E789/F M-J4H8LQ(PB%1J=C$%A&O1-;3O)'KNUY,AXX%TM\;OMOT8'KZ97J[$7.*%*XQ MM=VCU^UKZGC\N/GR:?)7#4=2%[\N:,*D]40H#"6WED!A5(4L]6ZP./)!V=V M>"_>& XNJY$IZFHV^7JZZBENE<@0"9SVS*5[9X@TJ?!P(NN"_V+N?M^(+)K' MBU5_RGI8EC53Z@VEUQ>;,RE<:^8: :8@!< C3"F*1B7=SURKK#)R%Q\O>@], M&15G.Q#7]:M=CZQGBG,JF.81%NNUK?#@ME\K;:MVW;R'2-51$KA;V8U!Z3Z' M^\%9L@'^QKR))N\_H\R+N_+G_'&1B$QUG?^+@[<,1)-=0V:-]LI:""M_.+/. M#.8W>^6'ZU%)K:\U\GY1?)],[W:)M=5\B[%:+HM5C317-5H'#Q7EUEOAI!92 M(ZGTWL<-..RU?'8?U8Y[XVO[X \8=C-T%&W#L!OJ4E9#B:3VR/$H2"(A\Q9I MK#D$M%9>C:XC9B_QO5T6.=NHY\ ) ,H#"KFP1GD"H39[S!#^C8)S:K/G:-QL M'Q+H3RL\2N$WF"9X/I!4S&16+M>U(NO/-T[7(LY K!# A!HIHMW'F)80(&$! M,[6\2WW/O(Y6J-$Z,(\D-Y1QJ3BC7,7_JFKNA&55-!_[RF^3&8?.K:TB/\B* M'SCPMNMUSSP7#@I)N9=.* @P TR0>.H3SALS8(!N51_L0Y3C-MWWNW)^6R/% M[?%F07'$L#.,H$A=XBW 2E6SY2:K&OT5K/3:7#A2R:T%R'OUP7Q6THL&@0NAF(0$44"U($J).-7=[!#/RYG\^Q*J%;![I=*C8=;24L<;!>>\ M=Q(CQ&TTN+ESUKIJEDR;'#MDK*_+^Z)4&X#WE^&]4JJ;S*MOB\FR6/Y]D=S; MEVV#QYL'X8DPT!I/L(<20R3B 4Q0$0]B%!*8<_ =80'37G; UM#NCV>/
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end

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Feb. 28, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	CTIC
Entity Registrant Name	CTI BIOPHARMA CORP
Entity Central Index Key	0000891293
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		57,982,860
Entity Public Float			$ 88,062,209

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 27,218	$ 44,002
Restricted cash	16,000	0
Accounts receivable	4	378
Receivable from collaborative arrangements	1,278	7,778
Inventory, net	550	1,525
Prepaid expenses and other current assets	1,874	2,141
Total current assets	46,924	55,824
Property and equipment, net	2,365	3,023
Other assets	5,597	4,996
Total assets	54,886	63,843
Current liabilities:
Accounts payable	2,588	7,227
Accrued expenses	13,890	24,765
Current portion of deferred revenue	912	103
Current portion of long-term debt	444	7,949
Other current liabilities	1,424	602
Total current liabilities	19,258	40,646
Deferred revenue, less current portion	494	514
Long-term debt, less current portion	13,575	11,311
Other liabilities	5,469	3,615
Total liabilities	38,796	56,086
Commitments and contingencies
Shareholders' equity:
Preferred stock, no par value: Authorized shares - 33,333, Series N-3 Preferred Stock, $2,000 stated value per share, 22,500 shares designated, 575 and 0 shares issued and outstanding as of December 31, 2017 and 2016, respectively	1,090	0
Common stock, no par value: Authorized shares - 81,500,000 and 41,500,000 at December 31, 2017 and 2016, respectively, Issued and outstanding shares - 42,969,494 and 28,228,602 at December 31, 2017 and 2016, respectively	2,222,341	2,170,300
Accumulated other comprehensive loss	(6,272)	(6,655)
Accumulated deficit	(2,195,346)	(2,150,326)
Total CTI shareholders' equity	21,813	13,319
Noncontrolling interest	(5,723)	(5,562)
Total shareholders' equity	16,090	7,757
Total liabilities and shareholders' equity	$ 54,886	$ 63,843

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
N-3 Preferred stock authorized (in shares)	33,333	33,333
Common stock authorized (in shares)	81,500,000	41,500,000
Common stock issued (in shares)	42,969,494	28,228,602
Common stock outstanding (in shares)	42,969,494	28,228,602
Series N-3 Preferred Stock
N-3 Preferred stock stated value (in USD per share)	$ 2,000	$ 2,000
N-3 Preferred stock designated (in shares)	22,500	22,500
N-3 Preferred stock issued (in shares)	575	0
N-3 Preferred stock outstanding (in shares)	575	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product sales, net	$ 853	$ 4,127	$ 3,472
License and contract revenue	24,293	53,278	12,644
Total revenues	25,146	57,405	16,116
Operating costs and expenses:
Cost of product sold	364	1,377	1,940
Research and development	32,866	64,961	76,627
Selling, general and administrative	31,435	45,306	53,962
Other operating (income) expense, net	0	(5,077)	253
Total operating costs and expenses, net	64,665	106,567	132,782
Loss from operations	(39,519)	(49,162)	(116,666)
Non-operating expense:
Interest expense	(1,872)	(2,614)	(2,104)
Amortization of debt discount and issuance costs	(163)	(214)	(390)
Foreign exchange gain (loss)	817	(484)	(703)
Other non-operating expense	(94)	(479)	(900)
Total non-operating expense, net	(1,312)	(3,791)	(4,097)
Net loss before noncontrolling interest	(40,831)	(52,953)	(120,763)
Noncontrolling interest	161	944	1,341
Net loss attributable to CTI	(40,670)	(52,009)	(119,422)
Deemed dividends on preferred stock	(4,350)	0	(3,200)
Net loss attributable to common shareholders	$ (45,020)	$ (52,009)	$ (122,622)
Basic and diluted net loss per common share (in USD per share)	$ (1.24)	$ (1.86)	$ (6.51)
Shares used in calculation of basic and diluted net loss per common share (in shares)	36,445	27,948	18,837

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest	Series N-1 Preferred Stock	Series N-1 Preferred Stock Preferred Stock	Series N-1 Preferred Stock Common Stock	Series N-2 Preferred Stock	Series N-2 Preferred Stock Preferred Stock	Series N-2 Preferred Stock Common Stock	Series N-3 Preferred Stock	Series N-3 Preferred Stock Preferred Stock	Series N-3 Preferred Stock Common Stock
Beginning Balance (in shares) at Dec. 31, 2014		0	17,676,000
Beginning Balance at Dec. 31, 2014	$ 38,478	$ 0	$ 2,023,949	$ (1,975,695)	$ (6,499)	$ (3,277)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued (in shares)			1,000,000					50,000			55,000
Stock Issued	15,147		$ 15,147				$ 46,611	$ 46,611		$ 52,409	$ 52,409
Conversion of preferred stock to common stock (in shares)								(50,000)	4,000,000		(55,000)	5,000,000
Conversion of preferred stock to common stock							0	$ (46,611)	$ 46,611	$ 0	$ (52,409)	$ 52,409
Value of beneficial conversion features related to preferred stock	3,200		3,200
Expiry of exercise price provision features related to common stock purchase warrant	150		$ 150
Equity-based compensation (in shares)			393,000
Equity-based compensation	14,828		$ 14,828
Stock option exercises (in shares)			8,000
Stock option exercises	156		$ 156
Noncontrolling interest	(1,341)					(1,341)
Expiry of mezzanine equity	1,445		$ 1,445
Other (in shares)			(31,000)
Other	(595)		$ (595)
Deemed dividends on preferred stock	(3,200)			(3,200)			$ (3,200)
Net loss for the year ended	(119,422)			(119,422)
Other comprehensive income (loss)	(453)				(453)
Ending Balance (in shares) at Dec. 31, 2015		0	28,046,000
Ending Balance at Dec. 31, 2015	47,413	$ 0	$ 2,157,300	(2,098,317)	(6,952)	(4,618)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation (in shares)			207,000
Equity-based compensation	13,324		$ 13,324
Noncontrolling interest	(944)					(944)
Other (in shares)			(24,000)
Other	(324)		$ (324)
Deemed dividends on preferred stock	0
Net loss for the year ended	(52,009)			(52,009)
Other comprehensive income (loss)	297				297
Ending Balance (in shares) at Dec. 31, 2016		0	28,229,000
Ending Balance at Dec. 31, 2016	7,757	$ 0	$ 2,170,300	(2,150,326)	(6,655)	(5,562)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued (in shares)														22,500
Stock Issued													$ 42,669	$ 42,669
Conversion of preferred stock to common stock (in shares)														(21,900)	14,616,000
Conversion of preferred stock to common stock													0	$ (41,579)	$ 41,579
Value of beneficial conversion features related to preferred stock	4,350		4,350
Issuance of warrants	470		$ 470
Equity-based compensation (in shares)			150,000
Equity-based compensation	5,746		$ 5,746
Noncontrolling interest	(161)					(161)
Other (in shares)			(26,000)
Other	(104)		$ (104)
Deemed dividends on preferred stock	(4,350)			(4,350)									$ (4,400)
Net loss for the year ended	(40,670)			(40,670)
Other comprehensive income (loss)	383				383
Ending Balance (in shares) at Dec. 31, 2017		600	42,969,000
Ending Balance at Dec. 31, 2017	$ 16,090	$ 1,090	$ 2,222,341	$ (2,195,346)	$ (6,272)	$ (5,723)

Long-term Debt	12 Months Ended
Long-term Debt	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	7. Long-term Debt Silicon Valley Bank In November 2017, we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, for a senior secured term loan of up to $18.0 million. The first $16.0 million of the term loan was funded in November 2017, and the remaining $2.0 million is available at our option at any time from the occurrence of the Milestone Event (as defined below) through July 31, 2018, subject to the satisfaction of certain conditions. The loan proceeds were used to repay in full all outstanding indebtedness under the Loan and Security Agreement with Hercules as discussed below and to fund our general business requirements. We were required to maintain unrestricted and unencumbered cash in an amount equal to at least $16.0 million under the terms of Loan and Security Agreement, and as such, $16.0 million of our cash was legally restricted as of December 31, 2017 and held as a compensating balance against the term loan. The restriction was subsequently removed in January 2018. See Note 1. Description of Business and Summary of Significant Accounting Policies for further details regarding restricted cash. The Milestone Event is defined as our receipt of evidence satisfactory to SVB, in its sole but reasonable discretion, that we have received a positive opinion from the EMA for our pacritinib product. The term loan is repayable over 36 months after an initial interest-only period of at least 12 months after closing, which will be extended to 18 months upon the occurrence of the Milestone Event. The interest rate on the term loan floats at a rate per annum equal to the greater of 2.5 percent above the prime rate and 6.75 percent. We may elect to prepay some or all of the loan balance at any time subject to a prepayment fee. A fee in the amount of 9 percent of the total principal amount funded to us is payable to SVB on the date on which the term loan is paid or becomes due and payable in full. Such fee in the amount of $1.4 million was included in Other liabilities in the consolidated balance sheet as of December 31, 2017. The loan obligations are secured by a first priority security interest on substantially all of our personal property except our intellectual property, and subject to certain other exceptions. In addition, we issued warrants to SVB and Life Science Loans II, LLC, pursuant to a participation arrangement among SVB, Loan Manager II, LLC and Life Science Loans II, LLC, to purchase up to 190,140 shares of our common stock. Warrants underlying 169,014 shares of our common stock are initially exercisable at any time prior to November 28, 2027. Warrants underlying 21,126 shares of our common stock will become exercisable when the remaining $2.0 million of the term loan is funded to us. The initial exercise price of the warrants is $2.84 per share of our common stock. In connection with the Loan and Security Agreement, we recorded debt discount and debt issuance costs of $1.9 million and $0.1 million, respectively, of which $1.9 million and $0.1 million was unamortized as of December 31, 2017, respectively. The outstanding principal balance on the term loan was $16.0 million as of December 31, 2017. Hercules In March 2013, we entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules, providing for a senior secured term loan of up to $15.0 million. In March 2014, we entered into a First Amendment to the Loan Agreement, which modified certain terms applicable to the loan balance then-outstanding of $15.0 million and provided us with the option to borrow an additional $5.0 million. In June 2015, we entered into a Third Amendment to the Loan Agreement, or the Third Amendment. Under the Third Amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million, inclusive of the principal balance outstanding immediately prior to closing of the Third Amendment of $13.8 million, or collectively, the Term Loan Borrowings. We drew $6.2 million upon closing of the Third Amendment, resulting in a then-outstanding principal balance of $20.0 million under the Term Loan Borrowings. The remaining $5.0 million was available for borrowing at our option through June 30, 2016, subject to certain conditions. In connection with the Third Amendment, we paid a commitment fee of $15,000 and a facility charge of $0.3 million. The provision under the Loan Agreement requiring us to pay a fee to Hercules of $1.3 million on the date of repayment of the borrowings thereunder was amended pursuant to the Third Amendment, such that the fee was paid in October 2016. In connection with the Third Amendment, we issued a warrant to Hercules to purchase shares of common stock. The warrant is exercisable for five years from the date of issuance for 29,239 shares of common stock at an initial exercise price of $17.10 per share. The warrant did not meet the considerations necessary for equity classification under the applicable authoritative guidance. As such, we determined that the warrant was a liability instrument with changes in fair value recognized through earnings at each reporting period. The warrant was categorized as Level 2 in the fair value hierarchy as the significant inputs used in determining fair value were considered observable market data. As of the issuance date, we estimated the fair value of the warrant to be $0.4 million. Upon expiry of the exercise price adjustment provision in December 2015, the then-estimated fair value of the warrant of $0.2 million was reclassified from liability to equity. The modified terms under the Third Amendment were considered substantially different as compared to the terms of the Loan Agreement immediately prior to the Third Amendment, pursuant to ASC 470-50, Modification and Extinguishment. As such, the Third Amendment was accounted for as a debt extinguishment, resulting in a loss on debt extinguishment of $1.2 million, which is included in Other non-operating expense for the year ended December 31, 2015. In December 2015, we entered into a Fourth Amendment to the Loan Agreement, or the Fourth Amendment, pursuant to which Hercules funded the remaining $5.0 million term loan available under the facility, resulting in a then-outstanding principal balance of $25.0 million. In November 2017, we repaid the then-outstanding principal balance of $14.3 million in full, using the proceeds from the the Loan and Security Agreement with SVB as discussed above. Accordingly, among other things, (1) all obligations under the Loan Agreement and all related documents have been paid, satisfied, released and discharged in full, (2) all unfunded commitments to make credit extensions or financial accommodations to us or any other person under the Loan Agreement have been automatically and irrevocably terminated, and (3) our obligations under the Loan Agreement and all related documents have been automatically and irrevocably terminated (other than with respect to customary provisions and agreements that are expressly specified to survive the termination). Upon full repayment of the principal in November 2017, we wrote-off the then-unamortized debt discount balance of $0.1 million to a loss on debt extinguishment, which was recorded in Other non-operating expense for the year ended December 31, 2017. Baxalta In November 2013, we entered into a Development, Commercialization and License agreement, or the Pacritinib License Agreement, with Baxter International Inc., or Baxter, for the development and commercialization of pacritinib for use in oncology and potentially additional therapeutic areas. Baxalta has been assigned Baxter’s rights and obligations under the Pacritinib License Agreement. In June 2015, we entered into the First Amendment to the Pacritinib License Agreement, or the Pacritinib License Amendment, pursuant to which two potential milestone payments in the aggregate amount of $32.0 million from Baxalta to us were accelerated from the schedule contemplated by the Pacritinib License Agreement relating to the following: the $12.0 million development milestone payment payable in connection with the regulatory submission of the Marketing Authorization Application, or the MAA, to the EMA with respect to pacritinib, or the MAA Milestone, and the $20.0 million development milestone payment payable in connection with the first treatment dosing of the 300th patient enrolled per the protocol in PERSIST-2, or the PERSIST-2 Milestone. Under the Pacritinib License Amendment, each of the two milestone advances bore interest at an annual rate of 9% until the earlier of the date of the first occurrence of the respective milestone or the date that the respective advance plus accrued interest was repaid in full. In January 2016 and February 2016, we successfully achieved the $20.0 million PERSIST-2 Milestone and the $12.0 million MAA Milestone, respectively, which were recorded in License and contract revenue for the year ended December 31, 2016. See Note 11. Collaboration, Licensing and Milestone Agreements for further details regarding our agreements with Baxalta.

Preferred Stock	12 Months Ended
Preferred Stock	Dec. 31, 2017
Equity [Abstract]
Preferred Stock	8. Preferred Stock Series N-1 Preferred Stock In October 2015, in an underwritten public offering, we issued 50,000 shares of Series N-1 convertible preferred stock, or Series N-1 Preferred Stock, for gross proceeds of $50.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $3.4 million, including $3.0 million in underwriting commissions and discounts. Each share of Series N-1 Preferred Stock was convertible at the option of the holder and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-1 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-1 Preferred Stock. The Series N-1 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-1 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law. In October 2015, all 50,000 shares of Series N-1 Preferred Stock were converted into 4.0 million shares of common stock at a conversion price of $12.50 per share. During the year ended December 31, 2015, we recognized $3.2 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-1 Preferred Stock. Series N-2 Preferred Stock In December 2015, in an underwritten public offering, we issued 55,000 shares of Series N-2 Preferred Stock for gross proceeds of $55.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.6 million, including $2.2 million in underwriting commissions and discounts. Each share of Series N-2 Preferred Stock was convertible at the option of the holder (subject to a limited exception) and was entitled to a liquidation preference equal to the initial stated value of $1,000 per share of Series N-2 Preferred Stock, plus any declared and unpaid dividends, and any other payments that would have been due on such shares, before any distribution of assets would have been made to holders of capital stock ranking junior to the Series N-2 Preferred Stock. The Series N-2 Preferred Stock was not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-2 Preferred Stock had no voting rights, except as otherwise expressly provided in the amended articles or as otherwise required by law. In December 2015, all 55,000 shares of Series N-2 Preferred Stock were converted into 5.0 million shares of common stock at a conversion price of $11.00 per share. There was no beneficial conversion feature on Series N-2 Preferred Stock. Series N-3 Preferred Stock In June 2017, in an underwritten public offering, we issued 22,500 shares of Series N-3 Preferred Stock for gross proceeds of $45.0 million before deducting underwriting commissions and discounts and other offering costs of approximately $2.3 million. BVF Partners L.P., or BVF, an existing shareholder of the Company, was one of our investors in this offering. See Note 17. Related Party Transactions for further details. Each share of Series N-3 Preferred Stock is convertible at the option of the holder (subject to a limited exception) and is entitled to a liquidation preference equal to the initial stated value of $2,000 per share, plus any declared and unpaid dividends, and any other payments that may be due on such shares, before any distribution of assets may be made to holders of capital stock ranking junior to the Series N-3 Preferred Stock. The Series N-3 Preferred Stock is not entitled to dividends except to share in any dividends actually paid on common stock or any pari passu or junior securities. The Series N-3 Preferred Stock has no voting rights, except as otherwise expressly provided in the articles of amendment to amended and restated articles of incorporation of CTI or as otherwise required by law. In June 2017, 21,925 shares of Series N-3 Preferred Stock were converted into 14.6 million shares of common stock at a conversion price of $3.00 per share. For the year ended December 31, 2017, we recognized $4.4 million in deemed dividends on preferred stock related to the beneficial conversion feature on our Series N-3 Preferred Stock. There were 575 shares of Series N-3 Preferred Stock outstanding as of December 31, 2017. In February 2018, 575 shares of Series N Preferred Stock owned by certain affiliates of BVF Partners L.P., or collectively, BVF, along with 8.0 million shares of our common stock owned by BVF were exchanged for 12,575 shares of Series O Preferred Stock. See Note 17. Related Party Transactions for further details.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2017
Retirement Benefits [Abstract]
Employee Benefit Plans	13. Employee Benefit Plans Our U.S. employees participate in the CTI BioPharma Corp. 401(k) Plan whereby eligible employees may defer up to 80% of their compensation, up to the annual maximum allowed by the Internal Revenue Service. We may make discretionary matching contributions based on certain plan provisions. We recorded $0.3 million related to discretionary matching contributions during the year ended December 31, 2017, and $0.2 million during each of the years ended December 31, 2016 and 2015.

Shareholder Rights Plan	12 Months Ended
Shareholder Rights Plan	Dec. 31, 2017
Equity [Abstract]
Shareholder Rights Plan	14. Shareholder Rights Plan In December 2009, our Board approved and adopted a shareholder rights plan, or Rights Plan, in which one preferred stock purchase right was distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI’s common stock outstanding as of, and issued subsequent to January 7, 2010. In 2012, 2015 and 2017, our Board approved certain amendments to the Rights Plan. The Rights Plan expires on December 2, 2018. Each right, if and when it becomes exercisable, will entitle the holder to purchase a unit consisting of two ten-thousandth of a share of Series ZZ Junior Participating Cumulative Preferred Stock, no par value per share, at a cash exercise price of $16.00 per unit, subject to standard adjustment in the Rights Plan. The rights will separate from the common stock and become exercisable if a person or group acquires 20% or more of our common stock. Upon acquisition of 20% or more of our common stock, our Board could decide that each right (except those held by a 20% shareholder, which become null and void) would become exercisable entitling the holder to receive upon exercise, in lieu of a number of units of preferred stock, that number of shares of our common stock having a market value of two times the exercise price of the right. In certain circumstances, including if there are insufficient shares of our common stock to permit the exercise in full of the rights, the holder may receive units of preferred stock, other securities, cash or property, or any combination of the foregoing. In addition, if we are acquired in a merger or other business combination transaction, each holder of a right (except those held by a 20% shareholder which become null and void) would have the right to receive, upon exercise, common stock of the acquiring company having a market value equal to two times the exercise price of the right. Our Board may redeem the rights for $0.0002 per right or terminate the Rights Plan at any time prior to an acquisition by a person or group holding 20% or more of our common stock.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions Aequus We have a majority ownership interest in Aequus. In May 2007, we entered into a license agreement with Aequus whereby Aequus gained rights to our Genetic Polymer™ technology. We also entered into an agreement to fund Aequus in exchange for a convertible promissory note. In March 2017, we and Aequus entered into a License and Promissory Note Termination Agreement and a Note Cancellation Agreement, pursuant to which (1) all of the then-outstanding principal, plus all accrued and unpaid interest, approximately $13.7 million in total, was cancelled and terminated, (2) our license agreement with Aequus was terminated, (3) all obligations to Aequus were terminated with the exception of providing additional funding of up to $347,500 to Aequus, and (4) Aequus agreed to pay us a) 20% of milestone and similar payments, up to a maximum amount of $20.0 million, and b) royalties, on a product-by-product and county-by country basis, of 5% of net sales of certain ACTH Products being developed by Aequus. The additional funding of $347,500 had been provided in full as of September 30, 2017. Payments from Aequus are due the later of (1) expiration of the last to expire valid patent claim that claims the ACTH Product, or (2) ten years from the first commercial sale of the applicable ACTH Product. We have the right to terminate the License and Promissory Note Termination Agreement and require Aequus to assign all ACTH Product related assets to us if Aequus does not file an Investigational New Drug Application for an ACTH Product with the FDA by September 6, 2019. Jack W. Singer, M.D., our Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer, and Global Head of Translational Medicine, and Frederick W. Telling, Ph.D., a member of our Board, are minority shareholders of Aequus, owning approximately 4.3% and 3.8% of the equity in Aequus as of December 31, 2017, respectively. Dr. Telling is the Chairman of Aequus' Board of Directors. Dr. Singer and Richard Love, a member of our Board, are also members of Aequus’ Board of Directors. BVF Partners L.P. In September 2015, as discussed in Note 9. Common Stock, we entered into a subscription agreement with BVF pursuant to which we issued 1.0 million shares of our common stock. Further, as discussed in Note 8. Preferred Stock, we completed underwritten public offerings of 55,000 shares of our Series N-2 Preferred Stock, no par value per share in December 2015 and 22,500 shares of our Series N-3 Preferred Stock, no par value per share in June 2017. BVF purchased 30,000 shares of our Series N-2 Preferred Stock and 6,750 shares of our Series N-3 Preferred Stock in such offerings. BVF converted 30,000 shares of our Series N-2 Preferred Stock and 6,175 shares of our Series N-3 Preferred Stock into approximately 2.7 million shares and 4.1 million shares of our common stock, respectively. Primarily as a result of these transactions, BVF beneficially owned approximately 20.0% and 15.9% of our outstanding common stock as of December 31, 2017 and 2016, respectively. Matthew D. Perry, a member of our Board, is the President of BVF and portfolio manager for the underlying funds managed by the firm. In connection with the Series N-2 Preferred Stock offering, we entered into a letter agreement with BVF, or the First Letter Agreement, pursuant to which we granted BVF a one-time right, subject to certain conditions, to nominate not more than two individuals to serve as members of our Board, subject to the Board’s consent, which is not to be unreasonably withheld and which consent shall be deemed automatically given with respect to two individuals specified in such Letter Agreement. One of such nominees (the “Independent Nominee”) must (1) qualify as an “independent” director as defined under the applicable rules and regulations of the SEC and the NASDAQ, and (2) must not be considered an “affiliate” of BVF as such term is defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have agreed, for the period hereinafter described and subject to a limited exception, to include the nominated directors in the slate of nominees for election to the Board at each annual or special meeting at which directors are to be elected, recommend that shareholders vote in favor of the election of such nominees and support such nominees for election in a manner no less favorable than how we support our own nominees. This obligation will terminate with respect to: (1) the Independent Nominee, and such Independent Nominee must tender his or her resignation to the Board, if requested, promptly upon BVF ceasing to beneficially own at least 11% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), and (2) each of the Independent Nominee and the other individual nominated by BVF, and each such nominee shall tender his or her resignation to the Board promptly upon the earlier to occur of (a) BVF and its affiliates ceasing to beneficially own at least 5% of the issued and outstanding common stock or voting power of the Company (determined on an as-converted basis that gives effect to the conversion of all outstanding preferred stock), (b) BVF ceasing to beneficially own at least 50% of the shares of the common stock beneficially owned by BVF immediately after consummation of the Series N-2 Preferred Stock offering (on an as-converted basis), (c) the continuation of such nomination right would cause any violation of the applicable listing rules of NASDAQ, (d) such time as BVF informs us in writing that it wishes to terminate the foregoing nomination right, or (e) any breach of the Letter Agreement by BVF. In connection with the offering of Series N-3 Preferred Stock, we entered into a letter agreement with BVF, or the Second Letter Agreement, and pursuant to the First Letter Agreement and the Second Letter Agreement, we agreed to, upon BVF’s election and subject to any board and committee approvals, exchange shares of common stock purchased by BVF directly from us or underlying convertible preferred stock purchased by BVF directly from us, including the shares of common stock underlying the Series N-3 Preferred Stock, into shares of a convertible non-voting preferred stock with substantially similar terms as the Series N-3 Preferred Stock, including a conversion “blocker” initially set at 9.99% of our common stock. Such right would terminate if at any time BVF’s beneficial ownership of our common stock falls below 5%. In February 2018, in connection with the public offering of common stock as discussed in Note 21. Subsequent Events, BVF purchased 6.3 million shares of our common stock. In addition, BVF exchanged 8.0 million shares of our common stock owned by BVF and 575 shares of our Series N Preferred Stock owned by BVF for 12,575 shares of our Series O Preferred Stock, pursuant to the letter agreements discussed above as well as an additional exchange agreement executed in February 2018. As a result of these transactions, BVF beneficially owned approximately 12.0% of our common stock as of February 28, 2018.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events Reincorporation Merger In January 2018, CTI BioPharma Corp., a Delaware corporation ("CTI DE" or, after giving effect to the Reincorporation Merger (defined below), the “Company”), a wholly owned subsidiary of CTI BioPharma Corp., a Washington corporation (“CTI WA”), entered into an Agreement and Plan of Merger, or the Merger Agreement, with CTI WA, pursuant to which CTI WA would merge with and into CTI DE for the sole purpose of reincorporating CTI WA in the State of Delaware (the “Reincorporation Merger”). The Reincorporation Merger and the Merger Agreement were approved by the Board of CTI WA and by a majority of the votes actually cast by the shareholders entitled to vote at CTI WA’s Special Meeting of Shareholders held on January 24, 2018, or the Effective Date. On the Effective Date, CTI DE and CTI WA effected the Reincorporation Merger, thereby changing the state of incorporation of CTI BioPharma Corp. from the State of Washington to the State of Delaware pursuant to the Merger Agreement. As a result of the Reincorporation Merger, CTI WA ceased to exist as a separate entity. CTI DE’s common stock, par value $0.001 per share, or the Common Stock, will continue to trade on the NASDAQ. The Company’s trading symbol remains as “CTIC.” In accordance with Rule 12g-3 under the Exchange Act, the shares of Common Stock of the Company were deemed to be registered under Section 12(b) of the Exchange Act as a successor to CTI WA. The Delaware Charter authorizes the same number of shares of the Common Stock and each class of preferred stock of CTI WA, except that all subseries of Series N Preferred Stock are eliminated and reclassified as Series N Preferred Stock and the number of authorized Series N Preferred Stock is reduced to 575. In addition, each share of CTI DE common stock and preferred stock has a par value of $0.001 per share. The Reincorporation Merger changed the legal domicile of CTI WA, but did not result in any change in the principal offices, business, management, capitalization, assets or liabilities of the Company. By operation of law, the Company succeeded to all of the assets and assumed all of the liabilities of CTI WA. The officers and directors of CTI WA are the officers and directors of the Company. As a result of the Reincorporation Merger, the Company has assumed all of the CTI WA employee benefit plans and stock incentive plans in effect at the Effective Date, including CTI WA’s 2017 Equity Incentive Plan, 2015 Equity Incentive Plan, 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan, or the Stock Plans, and any and all stock options, restricted stock and restricted stock unit awards, and other equity-based awards that are outstanding under any of the Stock Plans or any individual award agreements outside of the Stock Plans. The Company has also assumed CTI WA’s rights plan with Computershare Trust Company, N.A., as rights agent, dated as of December 28, 2009 and amended on August 31, 2012, December 3, 2012, December 1, 2015 and September 22, 2017. Public Offering of Common Stock In February 2018, we entered into an underwriting agreement with Leerink Partners LLC acting as sole book-running manager and as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the offer and sale (the “Offering”) of 20.0 million shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Offering closed on February 13, 2018. The price to the public in this Offering was $3.00 per share of Common Stock. The Underwriters exercised in full their option to purchase an additional 3.0 million shares. The net proceeds from this Offering, after deducting underwriting discounts, commissions and other estimated offering expenses, were approximately $64.2 million.

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) € in Millions			1 Months Ended	12 Months Ended			31 Months Ended
	Feb. 13, 2018 USD ($)	Jan. 01, 2017 shares	Feb. 28, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)
Description Of Business And Significant Accounting Policies [Line Items]
Reverse stock split ratio		0.1
Preferred stock outstanding (in shares) \| shares		0
Accumulated deficit									$ 2,195,346,000			$ 2,150,326,000
Available cash and cash equivalents						$ 128,182,000			43,218,000			44,002,000	$ 70,933,000
Proceeds from common stock offering, net of issuance costs				$ 0	$ 0	15,147,000
Milestone payment received				0	32,000,000	0
Cash equivalents									0
Bad debt expense				0	1,735,000	0
Allowance for doubtful accounts from collaborative arrangements									0			0
VAT receivable									4,800,000			4,400,000
Reserve for inventory									1,367,000			1,510,000
Unrealized foreign exchange gain (loss)				$ 4,300,000	(1,200,000)	$ (2,600,000)
Intercompany balance, due from CTILS, noncurrent								€ 26.2	31,400,000		€ 29.7	31,200,000
Minimum \| Assets Other Than Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life				3 years
Maximum \| Assets Other Than Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life				5 years
Maximum \| Leasehold Improvements
Description Of Business And Significant Accounting Policies [Line Items]
Property and equipment useful life				10 years
Europe \| Minimum
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, collection period				3 months
Europe \| Maximum
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, collection period				5 years
ITALY
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable									4,800,000
ITALY \| Minimum
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, collection period				3 years
ITALY \| Maximum
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, collection period				5 years
Other Assets
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, non-current									4,700,000			4,100,000
Prepaid Expenses and Other Current Assets
Description Of Business And Significant Accounting Policies [Line Items]
VAT receivable, current									100,000			$ 300,000
Silicon Valley Bank \| Secured Debt \| Loan and Security Agreement
Description Of Business And Significant Accounting Policies [Line Items]
Unrestricted and unencumbered cash required to be held per agreement									$ 16,000,000	$ 16,000,000
Aequus Biopharma, Inc \| Affiliated Entity
Description Of Business And Significant Accounting Policies [Line Items]
Interest in majority-owned subsidiary								60.00%	60.00%
Collaborative Arrangement Product Agreement \| TRISENOX \| Cephalon, Inc
Description Of Business And Significant Accounting Policies [Line Items]
Milestone payment received				$ 10,000,000	$ 0		$ 40,000,000
Collaborative Arrangement Product Agreement \| Subsequent Event \| TRISENOX \| Cephalon, Inc
Description Of Business And Significant Accounting Policies [Line Items]
Milestone payment received			$ 10,000,000
Leerink Partners LLC \| Subsequent Event
Description Of Business And Significant Accounting Policies [Line Items]
Proceeds from common stock offering, net of issuance costs	$ 64,200,000		$ 64,200,000

Description of Business and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Cash and cash equivalents	$ 27,218	$ 44,002	$ 128,182
Restricted cash	16,000	0	0
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 43,218	$ 44,002	$ 128,182	$ 70,933

Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 394	$ 477
Work-in-process	1,523	2,558
Inventory, gross	1,917	3,035
Reserve for excess, obsolete or unsalable inventory	(1,367)	(1,510)
Inventory, net	$ 550	$ 1,525

Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	$ 9,929	$ 11,828
Less: accumulated depreciation and amortization	(7,564)	(8,805)
Property and equipment, net	2,365	3,023
Depreciation expense	717	831	$ 990
Furniture and office equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	4,552	6,521
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	5,168	5,106
Lab equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	$ 209	$ 201

Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Clinical and investigator-sponsored trial expenses	$ 5,019	$ 7,303
Employee compensation and related expenses	4,432	6,364
Manufacturing expenses	2,637	7,616
Legal expenses	537	1,037
Selling expenses	143	136
Insurance financing	575	888
Interest expenses	93	2
Other	454	1,419
Total accrued expenses	$ 13,890	$ 24,765

Leases - Additional Information (Detail) ft² in Thousands	1 Months Ended		12 Months Ended
Leases - Additional Information (Detail) ft² in Thousands	Dec. 31, 2017 USD ($) ft²	Jan. 31, 2012 USD ($) ft² Option $ / ft²	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Lease agreement area (square feet) \| ft²	44	66
Lease term		120 months
Number of options to extend the term \| Option		2
Extend option term		5 years
Initial annual rent payments per square foot \| $ / ft²		27.00
Rent payments due in initial five months	$ 0	$ 0	$ 0
Percentage of annual rent increase		3.00%
Allowance for tenant improvements		$ 3,300,000
Sublease loss	1,600,000		1,584,000	$ 0	$ 0
Deferred liability	1,600,000		1,600,000
Other current liabilities	1,424,000		1,424,000	602,000
Other liabilities	5,469,000		5,469,000	3,615,000
Sublease income			100,000
Rent expense, net facilities charges and sublease income			1,600,000	$ 2,000,000	$ 2,000,000
Sublease
Operating Leased Assets [Line Items]
Other current liabilities	800,000		800,000
Other liabilities	$ 600,000		$ 600,000

Leases - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Operating Leases Future Minimum Payments
Operating leases, 2018	$ 2,487
Operating leases, 2019	2,532
Operating leases, 2020	2,584
Operating leases, 2021	2,580
Operating leases, 2022	868
Operating leases, Thereafter	0
Operating leases, Total minimum lease commitments	11,051
Sublease Rentals Future Payments Receivable
Sublease rentals, 2018	771
Sublease rentals, 2019	1,365
Sublease rentals, 2020	1,410
Sublease rentals, 2021	1,454
Sublease rentals, 2022	499
Sublease rentals, Thereafter	0
Sublease rentals, Total minimum lease commitments	5,499
Operating leases, net, 2018	1,716
Operating leases, net, 2019	1,167
Operating leases, net, 2020	1,174
Operating leases, net, 2021	1,126
Operating leases, net, 2022	369
Operating leases, net, Thereafter	0
Operating leases, net, Total minimum lease commitments	$ 5,552

Other Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Deferred rent, less current portion	$ 3,050	$ 3,011
Other long-term obligations	2,419	604
Total other liabilities	5,469	$ 3,615
Deferred liability related to sublease execution	600
Silicon Valley Bank \| Secured Debt \| Loan and Security Agreement
Debt Instrument [Line Items]
Fee amount on term loan	$ 1,400

Long-term Debt (Detail) - USD ($)	1 Months Ended					12 Months Ended
Long-term Debt (Detail) - USD ($)	Nov. 30, 2017	Feb. 29, 2016	Jan. 31, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	May 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Debt Instrument [Line Items]
Loss on debt extinguishment						$ 163,000	$ 0	$ 1,211,000
License and contract revenue						24,293,000	$ 53,278,000	12,644,000
Borrowing Associated With License Agreement
Debt Instrument [Line Items]
Debt instrument stated interest rate percentage					9.00%
Borrowing Associated With License Agreement \| Baxalta
Debt Instrument [Line Items]
Debt face amount					$ 32,000,000
Borrowing Associated With License Agreement \| EMA Milestone \| Baxalta
Debt Instrument [Line Items]
License and contract revenue		$ 12,000,000
Borrowing Associated With License Agreement \| Persist2 Milestone \| Baxalta
Debt Instrument [Line Items]
License and contract revenue			$ 20,000,000
Secured Debt
Debt Instrument [Line Items]
Debt instrument unamortized discount	$ 100,000
Debt face amount										$ 15,000,000.0
Repaid principle face amount	14,300,000
Secured Debt \| Loan and Security Agreement \| Silicon Valley Bank
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity	18,000,000
Proceeds from line of credit	16,000,000
Remaining borrowing capacity						2,000,000
Legally restricted cash	$ 16,000,000					16,000,000
Repayment term	36 months
Interest only period	12 months
Interest only extension period	18 months
Debt instrument stated interest rate percentage	6.75%
Fee payable when loan is paid or payable in full	9.00%
Fee amount on term loan						1,400,000
Debt issuance costs	$ 100,000
Debt instrument unamortized discount	$ 1,900,000					1,900,000
Debt instrument unamortized issuance cost						100,000
Outstanding principal balance						$ 16,000,000
Secured Debt \| Loan and Security Agreement \| Participation Arrangement \| Silicon Valley Bank
Debt Instrument [Line Items]
Number of warrant issued (in shares)	190,140
Warrant exercise price (in USD per share)	$ 2.84
Secured Debt \| Loan and Security Agreement \| Participation Arrangement, Initial Exercise \| Silicon Valley Bank
Debt Instrument [Line Items]
Number of warrant issued (in shares)	169,014
Secured Debt \| Loan and Security Agreement \| Participation Agreement, Loan Funding Contingency \| Silicon Valley Bank
Debt Instrument [Line Items]
Number of warrant issued (in shares)	21,126
Secured Debt \| Loan and Security Agreement \| Prime Rate \| Silicon Valley Bank
Debt Instrument [Line Items]
Interest rate above prime rate	2.50%
Secured Debt \| Original Loan
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity											$ 15,000,000.0
Secured Debt \| Amended Original Loan
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity										$ 5,000,000.0
Secured Debt \| Third Amendment
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity					25,000,000
Proceeds from line of credit					6,200,000
Fee amount on term loan					$ 1,300,000
Number of warrant issued (in shares)					29,239
Warrant exercise price (in USD per share)					$ 17.10
Debt instrument, outstanding amount					$ 20,000,000				$ 13,800,000
Debt instrument unused additional borrowing capacity					5,000,000
Commitment fee					15,000
Facility charge					$ 300,000
Warrant exercisable period					5 years
Warrant liability				$ 200,000	$ 400,000			200,000
Loss on debt extinguishment								1,200,000
Secured Debt \| Fourth Amendment
Debt Instrument [Line Items]
Proceeds from line of credit				5,000,000
Debt instrument, outstanding amount				$ 25,000,000				$ 25,000,000

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Sep. 30, 2015	Dec. 31, 2017	May 31, 2017	Apr. 30, 2017	Dec. 31, 2016	Apr. 30, 2016	Mar. 31, 2016
Class Of Warrant Or Right [Line Items]
Common stock authorized (in shares)		81,500,000	81,500,000	41,500,000	41,500,000	41,500,000	31,500,000
Warrants outstanding		29,239
Common stock purchase warrants \| Third Amendment
Class Of Warrant Or Right [Line Items]
Number of warrant issued (in shares)		29,239
Warrant exercise price (in USD per share)		$ 17.1
Common stock purchase warrants \| Placement Agent
Class Of Warrant Or Right [Line Items]
Number of warrant issued (in shares)		190,140
Warrant exercise price (in USD per share)		$ 2.84
Warrants outstanding		190,140
Affiliates \| BVF Partner
Class Of Warrant Or Right [Line Items]
Stock issued, purchase price (in USD per share)	$ 15.70
Proceeds from issuance of private placement	$ 15.1

Other Comprehensive Loss (Detail) - USD ($)	3 Months Ended	12 Months Ended
Other Comprehensive Loss (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Changes in AOCI [Roll Forward]
Beginning Balance		$ (6,655,000)
Current period other comprehensive income (loss)		383,000	$ 297,000	$ (453,000)
Ending Balance		(6,272,000)	(6,655,000)
Other-than-temporary impairment on available-for-sale securities	$ 500,000	0	520,000	$ 0
AFS included in prepaid expenses and other current assets		1,874,000	2,141,000
Net Unrealized Gain (Loss) and Impairment on Available-For-Sale Securities
Changes in AOCI [Roll Forward]
Beginning Balance		(6,000)
Current period other comprehensive income (loss)		7,000
Ending Balance		1,000	(6,000)
AFS included in prepaid expenses and other current assets		0	13,500
Foreign Currency Translation Adjustments
Changes in AOCI [Roll Forward]
Beginning Balance		(2,902,000)
Current period other comprehensive income (loss)		(3,927,000)
Ending Balance		(6,829,000)	(2,902,000)
Unrealized Foreign Exchange (Loss) Gain on Intercompany Balance
Changes in AOCI [Roll Forward]
Beginning Balance		(3,747,000)
Current period other comprehensive income (loss)		4,303,000
Ending Balance		$ 556,000	$ (3,747,000)

Common Stock - Summary of Common Stock Reserved for Issuance (Detail) shares in Thousands	Dec. 31, 2017 shares
Class of Stock [Line Items]
Total common stock reserved (in shares)	7,826
Series N-3 convertible preferred stock
Class of Stock [Line Items]
Total common stock reserved (in shares)	383
Common stock purchase warrants
Class of Stock [Line Items]
Total common stock reserved (in shares)	219
Options \| Chief Executive Officer
Class of Stock [Line Items]
Total common stock reserved (in shares)	1,120
Equity incentive plans
Class of Stock [Line Items]
Total common stock reserved (in shares)	5,920
Employee stock purchase plan
Class of Stock [Line Items]
Total common stock reserved (in shares)	184

Collaboration, Licensing and Milestone Agreements - Additional Information (Detail)		1 Months Ended											3 Months Ended									12 Months Ended			31 Months Ended
	Jan. 01, 2014 USD ($)	Feb. 28, 2018 USD ($)	Sep. 30, 2017 EUR (€)	Sep. 30, 2017 USD ($)	May 31, 2017 EUR (€)	May 31, 2017 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2016 USD ($)	Feb. 28, 2015 EUR (€)	Feb. 28, 2015 USD ($)	Jan. 31, 2014 USD ($)	Nov. 30, 2013 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2015 USD ($)	May 31, 2012 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received																						$ 0	$ 32,000,000	$ 0
Total revenues													$ 462,000	$ 1,705,000	$ 22,225,000	$ 754,000	$ 9,136,000	$ 4,433,000	$ 7,361,000	$ 36,475,000		25,146,000	57,405,000	16,116,000
Purchase of preferred stock																								15,147,000
License and contract revenue																						24,293,000	53,278,000	12,644,000
Servier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue						$ 11,487,000
Collaborative Arrangement \| Servier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Consideration received \| €					€ 12,000,000
Milestone payment received			€ 1,000,000	$ 1,200,000	2,000,000
Contingency milestone payment to be received \| €					76,000,000
Potential regulatory milestone payment \| €					36,000,000
Potential sales based milestone payment \| €					€ 40,000,000
Total revenues						$ 12,800,000
Collaborative Arrangement \| Servier \| License Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenues																						11,500,000
Collaborative Arrangement \| Servier \| Other Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue													1,400,000									1,400,000			$ 1,400,000	$ 1,300,000
Other services consideration																						500,000
Collaborative Arrangement Product Agreement \| Servier
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received							€ 7,500,000	$ 8,000,000									8,000,000
Operating expenses																							800,000	300,000
Development services revenue																						100,000	500,000	0
License and contract revenue															11,800,000
Collaborative Arrangement Product Agreement \| Servier \| Up-front Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Consideration received									€ 1,500,000	$ 1,700,000
Collaborative Arrangement Product Agreement \| Cephalon, Inc \| TRISENOX
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received																						10,000,000	0		40,000,000
Contingency milestone payment to be received													100,000,000.0									100,000,000.0			100,000,000.0
License revenue																								10,000,000
Collaborative Arrangement Product Agreement \| Cephalon, Inc \| TRISENOX \| Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received		$ 10,000,000
Collaborative Arrangement Product Agreement \| Baxter
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue								$ 0					0				$ 0					0	0		0
Development services revenue																							1,000,000	800,000
Maximum amount allowed for the development costs	$ 96,000,000
Collaborative Arrangement Product Agreement \| Baxter \| Up-front Payment Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Consideration received												$ 60,000,000
Collaborative Arrangement Product Agreement \| Baxter \| Up-front Payment Arrangement \| Series 19 Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Purchase of preferred stock												30,000,000
Collaborative Arrangement Product Agreement \| Baxter \| License and Development Services Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash consideration received												30,000,000
Collaborative Arrangement Product Agreement \| Baxter \| License
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue												27,300,000
Collaborative Arrangement Product Agreement \| Baxter \| Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue												$ 2,700,000
Collaborative Arrangement Product Agreement \| Novartis \| PIXUVRI
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingency milestone payment to be made											$ 16,600,000.0
Percentage of royalty payable to net sales											10.00%
Collaborative Arrangement Product Agreement \| Gynecologic Oncology Group
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones obligation paid															$ 500,000
Collaborative Arrangement Product Agreement \| PG-TXL
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingency milestone payment to be made													14,400,000.0									14,400,000.0			14,400,000.0
Collaborative Arrangement Product Agreement \| Nerviano Medical Sciences
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received																					$ 0
Contingency milestone payment to be made													80,000,000.0									80,000,000.0			80,000,000.0
Pacritinib License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and contract revenue																							32,000,000
Pacritinib License Agreement \| Borrowing Associated With License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Debt outstanding																											$ 32,000,000
Pacritinib License Agreement \| Baxter
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development services revenue																						0	11,400,000	$ 0
Asset Return and Termination Agreement \| Borrowing Associated With License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gain on termination of agreement																							$ 5,900,000
Contingency milestone payment to be made													$ 10,300,000									$ 10,300,000			$ 10,300,000
S_BIO Asset Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingency milestone payment to be made																												$ 132,500,000.0
Milestone payments through the issuance of stock													50.00%									50.00%			50.00%

Share-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended					12 Months Ended
	Mar. 31, 2017	Dec. 31, 2015	Sep. 30, 2015	Jan. 31, 2014	Mar. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense						$ 5,746,000	$ 13,324,000	$ 14,828,000
Effect on basic and diluted net loss (in USD per share)						$ (0.16)	$ (0.48)	$ (0.79)
Unrecognized compensation cost						$ 9,900,000
Recognition period						2 years 3 months 10 days
Tax benefits attributed to share-based compensation expense						$ 0	$ 0	$ 0
Shares of common stock reserved for future issuance (in shares)						7,826,000
Weighted average exercise price of options exercisable (in USD per share)		$ 25.71					$ 12.58	$ 25.71
Weighted average fair value of options granted (in USD per share)						$ 2.47	$ 3.01	$ 9.17
Unvested options to acquire shares of common stock, outstanding (in shares)		0						0
Compensation expense related to nonemployee stock options and restricted stock awards						$ (8,000)	$ 16,000	$ 0
2007 Equity Incentive Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance (in shares)						8,300,000.0
Shares available for future grants (in shares)						24,000
Employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)						184,000
Options \| Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)						1,120,000
Options granted in period (in shares)	1,200,000.0
Exercise price of options granted (in USD per share)	$ 4.24
Options \| Chief Executive Officer \| Stock Option Plan, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted in period (in shares)	80,000
Employee stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)			200,000
Employee stock \| Employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance (in shares)						200,000
Shares authorized for issuance (in shares)						200,000.0
Shares issued in period (in shares)						4,000	10,000	700
Vested Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Repurchased shares of common stock (in shares)						21,000	35,000	32,000
Repurchased shares of common stock						$ 100,000	$ 400,000	$ 600,000
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense						$ 4,731,000	$ 8,550,000	$ 3,017,000
Weighted average exercise price of options exercisable (in USD per share)						$ 9.83
Exercise price of options granted (in USD per share)						$ 3.68	$ 6.43	$ 13.94
Options \| 2007 Equity Incentive Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options expiration period						10 years
Restricted stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense						$ 1,015,000	$ 4,199,000	$ 8,656,000
Shares issued in period (in shares)						2,000	270,000	570,000
Weighted average fair value of restricted shares issued (in USD per share)						$ 5.78	$ 5.64	$ 20.61
Restricted shares, cancelled (in shares)						39,000	97,000	177,000
Total fair value of vested restricted stock awards						$ 300,000	$ 1,300,000	$ 7,300,000
Number of shares vested (in shares)						83,000
Restricted stock units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued in period (in shares)						20,000	187,000	46,000
Weighted average fair value of restricted shares issued (in USD per share)						$ 4.97	$ 5.35	$ 15.70
Restricted shares, cancelled (in shares)						0	0	13,000
Total fair value of vested restricted stock awards						$ 800,000	$ 200,000
Number of shares vested (in shares)						187,000	0
Long Term Performance Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense								$ 2,800,000
Number of shares vested (in shares)			200,000
Vesting period		3 years
Long Term Performance Awards, With Market Based Performance Goals
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense						$ 0	$ 600,000	300,000
Long-Term Performance Award, total grant-date fair value		$ 3,600,000						$ 3,600,000
Long-Term Performance Award, incremental grant-date fair value		$ (1,000,000)		$ 1,800,000	$ 800,000
Nonemployee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested options to acquire shares of common stock, outstanding (in shares)						4,400	11,000

Employee Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
Employee Benefit Plans (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Retirement Benefits [Abstract]
Maximum Annual Contributions Per Employee, Percent	80.00%
Discretionary matching contributions	$ 0.3	$ 0.2	$ 0.2

Shareholder Rights Plan (Detail) - Rights plan	1 Months Ended
Shareholder Rights Plan (Detail) - Rights plan	Dec. 31, 2009 $ / shares $ / right shares
Class of Stock [Line Items]
Conversion rate of right (in shares)	1
Percentage of rights held by single shareholder	20.00%
Market value of rights	200.00%
Redemption price of rights (in USD per right) \| $ / right	0.0002
Series ZZ Preferred Stock
Class of Stock [Line Items]
Conversion rate of right (in shares)	0.0002
Warrant exercise price (in USD per share) \| $ / shares	$ 16

Customer and Geographic Concentrations - Long-Lived Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 2,365	$ 3,023
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	2,365	2,990
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 0	$ 33

Net Loss Per Share - Calculation of Basic & Diluted Net Loss (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net loss attributable to common shareholders	$ (14,266)	$ (11,974)	$ 1,048	$ (19,828)	$ (6,372)	$ (29,183)	$ (19,766)	$ 3,312	$ (45,020)	$ (52,009)	$ (122,622)
Basic and diluted:
Weighted average shares outstanding (in shares)									36,569	28,198	19,324
Less weighted average restricted shares outstanding (in shares)									(124)	(250)	(487)
Shares used in calculation of basic and diluted net loss per common share (in shares)									36,445	27,948	18,837
Net loss per common share: Basic and diluted (in USD per share)									$ (1.24)	$ (1.86)	$ (6.51)

Related Party Transactions (Detail)	1 Months Ended					12 Months Ended
Related Party Transactions (Detail)	Feb. 28, 2018 shares	Jun. 30, 2017 shares	Mar. 31, 2017 USD ($)	Dec. 31, 2015 member_of_board shares	Sep. 30, 2015 shares	Dec. 31, 2017 shares	Dec. 31, 2015 shares	Dec. 31, 2016
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock (in shares)		14,600,000
Series N-2 Preferred Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)				55,000
Number of shares converted (in shares)				55,000
Conversion of preferred stock to common stock (in shares)				5,000,000
Series N-3 Preferred Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)		22,500
Number of shares converted (in shares)		21,925
Affiliated Entity \| BVF Partners, L.P.
Related Party Transaction [Line Items]
Stock Issued (in shares)					1,000,000
Common stock owned by others, percentage						20.00%		15.90%
Right to elect members of the board \| member_of_board				2
Threshold for voting in board members						11.00%
Ownership threshold for resignation from board						5.00%
Beneficial ownership threshold for resignation from board						50.00%
Affiliated Entity \| BVF Partners, L.P. \| Series N-2 Preferred Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)				30,000
Number of shares converted (in shares)				30,000
Conversion of preferred stock to common stock (in shares)				2,700,000
Affiliated Entity \| BVF Partners, L.P. \| Series N-3 Preferred Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)		6,750
Number of shares converted (in shares)		6,175
Conversion of preferred stock to common stock (in shares)		4,100,000
Affiliated Entity \| BVF Partners, L.P. \| Series N-3 Preferred Stock \| Maximum
Related Party Transaction [Line Items]
Conversion threshold		9.99%
Affiliated Entity \| BVF Partners, L.P. \| Series N-3 Preferred Stock \| Minimum
Related Party Transaction [Line Items]
Conversion threshold		5.00%
Aequus Biopharma, Inc \| Affiliated Entity
Related Party Transaction [Line Items]
Percentage of ownership in subsidiary						60.00%
Aequus Biopharma, Inc \| Affiliated Entity \| License And Promissory Note Termination, And Note Cancellation Agreements
Related Party Transaction [Line Items]
Amount funded to subsidiary \| $			$ 347,500
Percent of milestone payments to be received			0.2
Milestone payments to be received \| $			$ 20,000,000
Percentage of royalty payable to net sales			5.00%
Period from first commercial sale			10 years
Aequus Biopharma, Inc \| Executive Vice President \| Jack W. Singer, M.D.
Related Party Transaction [Line Items]
Percentage of ownership in subsidiary						4.30%
Aequus Biopharma, Inc \| Member of Board \| Frederick W. Telling, Ph.D.
Related Party Transaction [Line Items]
Percentage of ownership in subsidiary						3.80%
License And Promissory Note \| Convertible Debt \| Aequus Biopharma, Inc \| Affiliated Entity
Related Party Transaction [Line Items]
Debt cancelled and terminated \| $			$ 13,700,000
Common Stock
Related Party Transaction [Line Items]
Stock Issued (in shares)							1,000,000
Common Stock \| Series N-2 Preferred Stock
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock (in shares)							5,000,000
Common Stock \| Series N-3 Preferred Stock
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock (in shares)						14,616,000
Subsequent Event \| BVF Partners, L.P. \| Series N Preferred Stock
Related Party Transaction [Line Items]
Number of shares converted (in shares)	575
Subsequent Event \| BVF Partners, L.P. \| Series O Preferred Stock
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock (in shares)	12,575
Subsequent Event \| Common Stock \| BVF Partners, L.P.
Related Party Transaction [Line Items]
Stock Issued (in shares)	6,300,000
Number of shares converted (in shares)	8,000,000
Common stock owned by others, percentage	11.95%